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Summary
The known somatic (N>4000) and germline (N>4000) cancer-associated mutational 
spectra (viz. missense and nonsense mutations; micro-deletions, micro-insertions and micro- 
indels <20bp) of 17 human tumour suppressor genes (viz. APC , ATM, BRCA1, BRCA2,
CDH1, CDKN2A, NF1, NF2, PTCH, /T£W, £ 5 7 ,5 7 ^ / ,  7555, 7SC7, 7SC2, F77I and 
WT1) were compared in order to identify similarities and differences. Analysed parameters 
included the recurrence status of mutations, CpG mutability; Grantham difference; 
evolutionary conservation of affected codons; role of nonsense-mediated mRNA decay and 
co-location with repetitive sequence elements.
Only a small proportion of the mutations (-5%) were found to be shared between the 
germline and soma, although the proportions varied between different types of mutation 
(from 11% for missense mutations to -1%  for micro-indels). Shared mutations are unlikely to 
be coincidental and are probably indicative of underlying shared (and endogenous) 
mutational mechanisms. Shared missense mutations were found to be more likely to be 
drivers of tumorigenesis than either exclusively somatic or exclusively germline missense 
mutations.
Shared micro-lesions combined for all genes occurred disproportionately within 
repetitive elements by comparison with both somatic or germline micro-lesions, consistent 
with an endogenous mutational mechanism. For some genes (e.g. TP53), shared CpG- 
dinucleotide mutations evidenced the action of an endogenous mutational mechanism (viz. 
methylation-mediated deamination of 5-methylcytosine) in both the soma and the germline.
Differences between mutational spectra were also noted. Germline missense 
mutations were found to be more likely to bear relatively more drastic functional 
consequences by comparison with somatic missense mutations, but also more likely to be 
truncating mutations. Germline micro-lesions (combined for all genes) were also found to be 
more likely to be co-located with repetitive elements than somatic micro-lesions. This could 
be due to the germline being relatively more protected from the action of exogenous 
mutagens by comparison to the soma.
This study of 17 human tumour suppressor genes has therefore provided a first 
glimpse of the similarities and differences between germline and somatic mutational spectra.
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1. General introduction
1.1. Cancer genes
‘Cancer is, in essence, a genetic disease’ (Vogelstein and Kinzler 2004), in which 
DNA sequence and epigenetic changes are considered causative of neoplasms. Generally, 
there are three types of ‘cancer’ genes that when mutated can promote or substantially 
contribute to tumorigenesis: oncogenes, DNA repair/genome stability genes and tumour- 
suppressor genes (Vogelstein and Kinzler 2004).
Oncogenes can promote tumour development via mutations that render the genes 
continually active. For example, the BRAF oncogene encodes a serine/threonine protein 
kinase that when activated, e.g. via phosphorylation of amino-acids at positions 598 and 601, 
phosphorylates downstream targets, such as the extracellular signal-regulated kinase 
(Robinson and Cobb 1997). Thus, missense mutations, mostly affecting the kinase domain 
(Wan et al. 2004) render the BRAF oncogene constitutively active in the absence of wild-type 
activating signals. Thus, mutations in one allele of the oncogenes are generally sufficient to 
promote cell proliferation and confer a growth advantage.
DNA repair/genome stability genes on the other hand are responsible for the repair of 
subtle DNA sequence changes. These genes are involved in DNA repair mechanisms, such as 
mismatch repair, nucleotide-excision repair and base-excision repair (Vogelstein and Kinzler
2004). Mutations in the coding sequences of these genes result in cells being deficient in 
certain repair mechanisms. For example, skin cells from Xeroderma pigmentosum patients 
exhibit increased mutation frequency, due to defective nucleotide-excision repair (Friedberg 
2003; Masutani et al. 2000). Mutations in the DNA repair genes give rise to an increased 
mutation frequency in all genes and therefore indirectly promote or contribute to tumour 
development. In addition, bi-allelic inactivation of both alleles of the DNA repair genes is 
required for a ‘physiological effect’ (Vogelstein and Kinzler 2004).
Tumour suppressor genes (TSGs) are responsible for a variety of cell functions that, 
as suggested by their name, suppress tumour development. These include pivotal functions, 
such as regulation of cell proliferation, maintenance and surveillance of the human genome, 
cellular response to DNA damage and ubiquitination of proteins (Sherr 2004). TSGs are 
defined as ‘genes that sustain loss-of-function mutations in the development of cancer’
(Haber and Harlow 1997). Following Knudson’s ‘two-hit’ hypothesis (Knudson 1971, 1978), 
generally a bi-allelic inactivation is required for a phenotypic effect. Thus, one inherited
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(germline) hit and subsequent somatic inactivation o f the hitherto unaffected allele, or 
alternatively somatic bi-allelic inactivation is required for tumour initiation and/or 
development. However, a number of studies have suggested that some tumour suppressor 
genes may not conform to Knudson's two-hit hypothesis. Reports, suggest that gene dosage 
(Fodde and Smits 2002), in heterozygous carriers of mutations, could confer increased cancer 
susceptibility (e.g. BRCA2 gene, Howlett et al. 2002; TP53 gene Venkatachalam et al. 1998). 
Nevertheless, the commonly accepted model of TSGs is that, in contrast to oncogenes, bi- 
allelic inactivation of tumour suppressor genes is sufficient to promote tumour development 
and/or progression.
1.2. Importance of the mutational spectrum in the development of 
cancer
Cancer, being a disorder of the soma, arises as a consequence of somatic DNA 
sequence and/or epigenetic changes (Stratton et al. 2009). Cancer cells also frequently exhibit 
genetic and genomic instability and abnormalities (e.g. chromosome (CIN) and microsatellite 
instability (MSI); Charames and Bapat 2003). As a consequence of genetic instability, 
somatic cells can acquire anywhere between <1000 to >100,000 DNA sequence changes 
during tumorigenesis (Stratton et al. 2009). However, it is generally considered that between 
5 and 7 and up to 20 mutations are responsible for tumour initiation and development 
(Beerenwinkel et al. 2007). Thus, it can be seen that not all sequence changes contribute 
equally towards cancer development. Some of the changes do not confer a selective (growth) 
advantage upon the cells harbouring them and these changes have been termed ‘passenger’ 
mutations, whereas other mutations are more likely to be ‘drivers’ of tumorigenesis 
(Greenman et al. 2007; Thomas et al. 2007). Therefore, a great deal of effort has been put 
forward, to distinguish mutations that drive tumorigenesis from those that are mere 
‘passengers’.
Mutations can be placed into numerous categories, based on the number of affected 
nucleotides, the functional consequences of the mutant product, the transmission ability to 
descendants, the recurrence status, the location in the genome, etc. With respect to 
inheritance, germline mutations can be transmitted to descendents, whereas somatic 
mutations are confined exclusively to the soma. In addition, the genome of a cancer cell 
exhibits a diverse range of mutations, from single base-pair substitutions to gross genomic 
rearrangements (Stratton et al. 2009), in terms of the size of mutated or affected DNA
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sequence. Germline intra-genic single base-pair substitutions along with micro-deletions and 
micro-insertions of <20bp, are by far the most frequent types of mutations logged in HGMD 
(The Human Gene Mutation Database; http://www.hgmd.org: Stenson et al. 2003). 
Furthermore, small intra-genic mutations (missense and nonsense mutations and micro­
lesions) represent the bulk of mutations in the COSMIC database (The Catalogue o f  Somatic 
Mutations in Cancer,; http://www.sanger.ac.uk/genetics/CGP/cosmic/: Bamford et al. 2004; 
Forbes et al. 2006; Forbes et al. 2008).
Missense mutations are defined as intra-genic single base-pair substitutions (e.g. 
CAC->CAA; histidine->glutamine) that lead to a non-synonymous change of the wild-type 
amino-acid encoded by a specific codon. Based on their functional consequences (in terms of 
an increase in susceptibility to developing or directly causing disease), missense mutations 
could be categorised as being neutral, deleterious, and beneficial or of unknown clinical 
importance (Chan et al. 2007; Strachan and Read 2004). Following this classification, the 
functional importance of some of the missense mutations during the development of cancer is 
somewhat unclear. Such missense mutations are of unknown functional and clinical 
importance. Because, functional assays are difficult to perform or do not exist for every 
single missense mutation that turns up during clinical diagnostic procedures, numerous in 
silico algorithms have been proposed to try to assess the functional significance of missense 
mutations (Chan et al. 2007; Miller and Kumar 2001; Vitkup et al. 2003). Most of these 
algorithms rely on datasets of mutations with already known functional consequences. 
However, by definition, these training datasets do not comprise all observed missense 
mutations. Thus, chance variation is likely to influence the outcome of these in silico 
algorithms. Indeed, it has been estimated that the overall predictive accuracy of these 
algorithms ranges from -70% to -90% (Chan et al. 2007). Despite difficulties in quantifying 
the relative functional/clinical importance of some missense mutations, studies have shown 
that some missense variants are very likely to significantly contribute towards tumour 
development. For example, a number of mutations in the BRCA1 gene have been shown to 
display a significantly negative effect (as compared to wild-type product) on the function of 
the protein (reviewed in Carvalho et al. 2009). More detailed description and analysis of the 
functional consequences of missense mutations are presented in Chapter 4.
Nonsense mutations are defined as single base-pair substitutions that lead to the 
introduction of nonsense or premature termination (stop) codons (e.g. CAG->TAG; 
glutamine->stop codon) within the coding regions of genes. Generally, the functional 
consequence of the majority of nonsense mutations is abrupt translational termination.
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Nonsense mutations are important because in the majority of cases they are ‘equivalent to 
nonsense sequences’ (Kuzmiak and Maquat 2006), and if translated (assuming stable and 
functional mRNA to support translation), it is very likely that such mutant products could 
have either very limited or no function at all. Such an assertion is supported by an estimation 
that inherited nonsense mutations are twice as likely to come to clinical attention as 
compared to the most extreme missense mutations (extreme in terms of the chemical 
difference between the substituted wild-type and substituting amino acid residues; Krawczak 
et al. 1998). Thus, nonsense mutations are frequently selected for their likely ‘loss-of- 
function’ effect during tumour development or clonal expansion (e.g. APC  gene in colorectal 
cancer; Beroud and Soussi 1996; Feamhead et al. 2001). A more detailed description and 
analysis of some of the functional consequences (i.e. the role of the nonsense-mediated 
mRNA decay) of nonsense mutations are presented in Chapter 5.
Micro-lesions, viz. micro-deletions, micro-insertions and micro-indels in this PhD 
project were defined as intra-genic (although some micro-lesions extended into the intronic 
parts of the genes) deleted and/or inserted nucleotides (nt) of length <20nt. When the length 
(in base-pairs or nucleotides) of the affected DNA coding sequence is not divisible by three, a 
frameshift occurs and premature termination of translation is to be expected, due to the triplet 
nature of the genetic code (Crick et al. 1961; Yanofsky 2007). Such micro-lesions are very 
likely to result in similar functional consequences as the abovementioned nonsense 
mutations. On the other hand, micro-lesions with length (in base-pairs) of affected bases 
divisible by three (i.e. in-frame), would be expected to have relatively less severe functional 
consequences, as only a few amino-acids would be lost. Indeed, a comprehensive meta­
analysis of micro-insertions and micro-deletions in inherited human genetic disease (Ball et 
al. 2005) has revealed that such in-frame micro-lesions (i.e. length of affected nucleotides- 
3bp and 6bp) exhibit a markedly decreased frequency. Therefore, these micro-lesions are less 
likely to come to clinical attention, most likely because of less severe functional 
consequences. A more detailed description and analysis of micro-lesions are presented in 
Chapter 6.
The functional importance of single base-pair substitutions is exemplified by the 
mutational spectrum in the TP53 gene. The TP53 gene has been referred to as ‘the guardian 
of human genome’ (Lane 1992). The latter assertion is supported by the fact that mutations in 
the TP53 gene are observed in >50% of all human cancers (Soussi and Beroud 2001; Toledo 
and Wahl 2006). Furthermore, the majority of mutations found in TP53 are indeed single 
base-pair substitutions, and in particular missense mutations (>80%; the p53 database,
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http://p53.free.fr/ Soussi and Beroud 2001). Some missense mutations, part of the mutational 
spectrum in the TP53 gene, are likely to have additional functional consequences, such as a 
ioss-of-function’ effect. Others are selected for their likely ‘gain-of-fimction’ effect during 
clonal expansion (Blagosklonny 2000; Glazko et al. 2006; Glazko et al. 2004; Koonin et al.
2005).
1.3. Somatic and germline mutations
Cancer predisposition genes can exhibit either somatic or germline mutations (Futreal 
et al. 2004; Kinzler KW 2002; Vogelstein and Kinzler 2004). A major distinction to be made 
between somatic and germline mutations is that the former occur during meiosis, whereas the 
latter are generally meiotic in nature. Both germline and somatic cells divide mitotically, 
whereas meiotic division is exclusively confined to the germline cells. However, a hallmark 
of meiotic division, recombination, is not exclusively confined to germline cells. Somatic 
mitotic recombination has also been reported (LaFave and Sekelsky 2009), albeit a rare event 
per cell division (Dong and Fasullo 2003).
Despite the relative scarcity of reports on the comparative analysis of germline and 
somatic mutations, some similarities and differences have been observed. Out of the -22,000 
protein-coding genes in the human genome, -350 have been found to contribute significantly 
to oncogenesis (Futreal et al. 2004; Stratton et al. 2009). The majority of mutations found in 
these cancer genes (-90%) are somatic mutations as compared to -10%  germline mutations 
(Futreal et al. 2004; Stratton et al. 2009). These observations clearly demonstrate that human 
cancer is a disorder of the soma. Despite their relatively lower frequency of occurrence, 
germline mutations have been shown to play an important role in the process of 
tumorigenesis by conferring cancer susceptibility. For example, the lifetime risk (by the age 
of 70) of breast cancer carriers of inherited (germline) mutations in the BRCA1 gene is 
estimated to be -50% and for germline carriers in the BRCA2 gene -35%  (Antoniou et al. 
2002; Ford et al. 1998). Even although these estimations suggest that several common low 
penetrance genes other than BRCAJ and BRCA2 may account for the residual risk (Antoniou 
et al. 2002), germline mutations in these two genes are responsible for the majority of 
familial cases of breast and ovarian cancers (Ramus et al. 2007). Despite the relatively high 
risk associated with germline BRCA1 and BRCA2 mutation carriers, the underlying 
mechanisms responsible for the increased risk are still unclear. To account for the increased 
risk, research has suggested a potential disruption of hormone-signalling pathways (Mote et
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al. 2004) and deficiency in DNA repair through homologous recombination (Barwell et al. 
2007; Stefansson et al. 2009). In addition,4radiosensitivity’ (repair deficiency following 
ionizing radiation) has been shown in heterozygous carriers in BRCA1 and BRCA2 genes 
(Buchholz et al. 2002). Therefore, potential mechanisms that could account for the increased 
risk include a gene-dosage effect and haploinsufficiency, whereby one functional allele of the 
genes is insufficient to suppress tumour development (Buchholz et al. 2002; Meric-Bemstam 
2007).
Germline mutations have also been shown to play an important role in shaping the 
somatic mutational spectrum. Thus, germline and somatic mutations in some genes are not 
just two separate mutational events, but intricate germline-soma interplay is evident. The 
position of germline mutations in the APC gene has been shown to have the potential to 
influence the position and type of the second (somatic) hit in familial adenomatous polyposis 
coli (Albuquerque et al. 2002; Feamhead et al. 2001; Lamlum et al. 1999; Latchford et al. 
2007). Similarly, inherited variation (i.e. haplotype block) in the JAK2 gene has been 
proposed to either confer a somatic hypermutability at the JAK2 locus, or a stronger selective 
advantage over the somatic cells in myeloproliferative neoplasms (Campbell 2009; Jones et 
al. 2009; Kilpivaara et al. 2009; Olcaydu et al. 2009). On the other hand, germline mutations 
in the CHEK2 gene have been associated with a decreased risk of lung and upper aero- 
digestive cancers (Cybulski et al. 2008), although the mechanism to account for the decreased 
risk remains elusive.
Some remarkable differences and similarities have been shown between the germline 
and the soma. DNA mismatch-repair-deficient C. elegans mutants have been found to display 
similar germline and somatic repeat instability (Tijsterman et al. 2002). The frequency of 
somatic micro-indels in mice have been shown to be similar to the human germline micro- 
indels (i.e. TP53 micro-indels; Gonzalez et al. 2007). A similar age-related shift has been 
noted in the frequencies of human somatic and germline mutations (Evans et al. 2005), 
although the frequency of somatic micro-indels in mice has not been shown to display any 
age-related difference (Gonzalez et al. 2007).
However, mutation rates in the soma and the germline may also display some 
differences. Thus, the germline mutation rates are suggested to be lower as compared to the 
soma (Azad and Woodruff 2006; Drake et al. 1998; Neel 1983; Walter et al. 1998). The 
highly variable minisatellites show extreme germline instability, whereas somatic mutants 
have been shown to be rare (Buard et al. 2000; Stead and Jeffreys 2000).
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Research has shown that the mutational spectrum of tumour cells is influenced by the 
action of both endogenous mutational mechanisms and exogenous mutagens. The positional 
occurrence of micro-lesions (viz. micro-deletions, micro-insertions and micro-indels) is likely 
to be influenced mainly by endogenous mutational mechanisms, such as ‘slipped-mispairing’ 
and ‘strand-switching’ mechanisms (Cooper and Krawczak 1993; Efstratiadis et al. 1980; 
Krawczak and Cooper 1991; Ripley 1982). These mutational mechanisms have been shown 
to be often promoted by numerous repetitive elements, such as direct, inverted and mirror 
repeats; runs of mononucleotides; various non-B DNA secondary structures (e.g. C/G- 
quartets); sequence motifs, etc. (Bacolla et al. 2004; Bacolla and Wells 2009; Chuzhanova et 
al. 2003; Cooper and Krawczak 1993; Efstratiadis et al. 1980; Krawczak and Cooper 1991; 
Ripley 1982; Wells 2007), although Cheung et al. (2007) have noted no overrepresentation of 
repetitive elements around the breakpoints of deletions and insertions in the BRCA1 and 
BRCA2 genes. In addition, environmental mutagens (e.g. mitomycin C, cyclophosphomide 
and radiation) could induce slippage in repetitive elements (i.e. tetranucleotide repeats; 
Lyons-Darden and Topal 1999; Niwa 2006; Pineiro et al. 2003). Then again, the mutagenic 
effect of low doses of radiation in mice has been shown to be very similar in both the soma 
and the germline (Vilenchik and Knudson 2000). In addition, environmental agents can 
directly cause DNA damage, such as double and single DNA-strand breaks, abasic sites, 
oxidised bases, etc. (Breen and Murphy 1995; Sankaranarayanan and Wassom 2005).
Spontaneous deamination of 5-methyl cytosine in the context of CpG-dinucleotides 
resulting in C->T (on the coding DNA strand) and G->A (on the non-coding strand) 
transitions, is largely responsible for the increased mutation rate (estimated transition rates - 5 
times the base mutation rate; Krawczak et al. 1998) at CpG-dinucleotides (Pfeifer 2006). 
Consequently, differences or similarities in the frequency and positional occurrence of CpG- 
located mutations are dependent of the methylation status of CpG-dinucleotides.
Furthermore, epigenetic silencing of gene expression, via hypermethylation of promoter 
regions, has been shown in a number of human cancers (Nagarajan and Costello 2009; Schulz 
and Hoffmann 2009; Tost 2009) and CpG-dinucleotides have been shown as a mutational 
hotspot for a number of tumour suppressor genes (e.g. RBI, APC, BRCA1, BRCA2, TP53; 
Cheung et al. 2007; Farrell and Clayton 2003; Radpour et al. 2009; Soussi and Beroud 2003). 
However, mutations at CpG-dinucleotides (viz. C->T and G->A) are also thought not only to 
result from endogenous mutagenesis (i.e. spontaneous deamination of 5mC) but also to the 
action of carcinogens (e.g. benzo[a]pyrene and cyclic aromatic hydrocarbon) at least in the 
TP53 gene (Pfeifer and Besaratinia 2009). For a more detailed description and analysis of
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mutations within CpG-dinucleotides, see Chapter 4 (Missense mutations) and Chapter 5 
(Nonsense mutations).
Therefore, it is evident, from past research, that somatic and germline mutations arise 
from the action of endogenous mechanisms and/or the influence of exogenous mutagens. 
However, the relative contribution of exogenous mutagens and exogenous mutational 
mechanisms is often difficult to quantify.
1.4. How could the comparative analysis of somatic and germline 
mutational spectrum help us to better understand tumorigenesis?
As pointed out above, somatic and germline mutations, amongst other genetic and 
epigenetic changes, contribute or play an important role in tumour development and/or 
initiation. Understanding the mutational mechanisms that predispose or directly contribute to 
the process of tumorigenesis is pivotal in trying to assess the clinical significance of DNA 
sequence changes, such that a better understanding of these mutational mechanisms is likely 
to lead to a better risk assessment, cancer treatment and prevention therapies. A key 
component is the relative contribution of endogenous mutational mechanisms and exogenous 
or environmental mutagens (e.g. carcinogens).
It is surprising that relatively few studies have attempted a formal comparison of 
germline and somatic mutations. Tumour suppressor genes, being subject to bi-allelic 
inactivation, could potentially provide an appropriate model system to study not only the 
relative contribution of somatic and germline mutations, but also the relative contribution of 
endogenous mutational mechanisms and environmental mutagens in both the soma and the 
germline, in the process of tumorigenesis. Furthermore, a potential elucidation of the relative 
contribution of exogenous mutagens and endogenous mutational mechanisms is likely to help 
the understanding of mutagenesis in other types of genetic disorders (Elespuru and 
Sankaranarayanan 2007).
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1.5. Objectives of this PhD project
The current PhD project is a formal attempt to try to shed some light upon the 
mutational mechanisms that operate to influence the known mutational spectra in both the 
soma and the germline in 17 human tumour suppressor genes. Several key objectives were 
defined at the beginning of this PhD project (the end of 2005). These objectives comprised 
several general key questions:
How do germline and somatic mutational spectra for each of the studied human 
tumour suppressor gene compare with respect to the relative proportions of each type of 
mutation (i.e. missense and nonsense mutations, micro-deletions, micro-insertions and micro- 
indels)?
What proportion of the observed mutations (viz. missense and nonsense mutations and 
micro-lesions) is found in both the soma and the germline (i.e. shared)?
Are shared mutations merely coincidental and what is their relative functional 
importance with respect both to exclusively somatic and exclusively germline mutations?
Do specific DNA sequence features account for both single base-pair substitutions 
(i.e. missense and nonsense mutations within CpG-dinucleotides) and micro-lesions (e.g. co­
localisation of repetitive elements and micro-deletions, micro-insertions and micro-indels) for 
their mutability and in particular recurrent somatic mutations?
In addition, specific questions were also asked with respect to different types of mutations.
How do somatic and germline missense mutations compare to each other (for each 
tumour suppressor gene and the combined mutations for all 17 genes) with respect to 
nucleotide substitution rates derived from non-disease and disease-associated substitution 
rates; physicochemical difference between wild-type and mutant amino-acids; degree of 
evolutionary conservation; co-localisation within CpG-dinucleotides?
How do somatic and germline nonsense mutations compare to each other (for each 
tumour suppressor gene and the combined mutations for all 17 genes) with respect to the 
potential involvement of nonsense-mediated mRNA decay?
How do somatic, germline and shared micro-lesions (viz. micro-deletions, micro- 
insertion and micro-indels) compare to each other with respect to their occurrence in the 
vicinity of repetitive elements?
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2. G enera l m ateria ls
2.1. Sources o f m u ta tion  da ta
Germline mutations were obtained from the Human Gene Mutation Database 
(HGMD; http://www.hgmd.org; Stenson et al. 2003), a collection of >90,000 germ-line 
mutations in >3500 nuclear genes underlying or associated with human inherited disease. The 
HGMD data were privately communicated with Peter D. Stenson and Andrew D. Philips. 
Only one example of each reported mutation is present in HGMD, a policy designed so as to 
avoid confusion between recurrent and identical-by-descent lesions.
Sources of somatic mutation data included various somatic mutational databases, 
PubMed-based literature searches and data privately communicated by Gareth Evans (NF2 
gene) and Eamon Maher ( VHL gene). The sources of somatic mutation data, used to extract 
mutations at the beginning of the PhD project (October 2005) are summarised in Table 1.
Table 1 Sources of somatic and germline mutational data
Name Source Data obtained
Human Gene 
Mutation Database 
(HGMD)
http://www.hemd.org Germline mutation 
data
Catalogue of 
Somatic Mutations 
in Cancer 
(COSMIC)
http://www.saneer.ac.uk/cosmic Somatic mutation data 
for RBI and PTEN
Breast Cancer 
Information Core 
(BIC)
http://research.nheri.nih.eov/bic/ Somatic mutation data 
for BRCA1
RBI Gene 
Mutation Database
http://rbl-lsdb.d-lohmann.de Somatic mutation data 
for RBI
International NF2 
Mutation Database
http: /neurosurgery .mgh.harvard.edu/NFclinic/NFresearch.htm* Somatic mutation data
for NF2
Gareth Evans Privately communicated; University Department o f Medical 
Genetics, St. Mary’s Hospital, Manchester M13 OJH, UK
Somatic mutation data 
for NF2
VHL Mutation 
Database
http:/'www .umd.be/VHL Somatic mutation data 
for VHL
Eamonn Maher Privately communicated; Section o f Medical and Molecular 
Genetics, University of Birmingham, School o f Medicine, B15 
2TT, UK
Somatic mutation data 
for VHL
CDKN2A Database https://biodesktop.uvm.edu Derl/ol6 Somatic mutation data 
for CDKN2A
International 
Agency for 
Research on 
Cancer (IARC) 
TP53 Mutation 
Database
http://www-p53.iarc.fr/index.html Somatic mutation data 
for TP5 3
PubMed http://www.ncbi.nlm.nih.iiov/sites/entrez Somatic mutation data 
for A PC, ATM, 
BRCA1, BRCA2,
11
CDH1, NF1, PTCH, 
STK11, TSCl, TSC2
__________________   and WTl___________
* no longer existing link
Obviously, incorrect, incomplete or ambiguous data were disregarded irrespective of 
whether they were derived from databases or the original literature.
In order to avoid the repetition of analyses on multiple regularly updated mutational 
datasets, the collection of mutations was deemed to be complete by October 2005. Six 
different categories of germline and somatic micro-lesions were collated for 17 different 
human tumour suppressor genes (Table 2).
Table 2 The 17 human tumour suppressor genes studied
Gene symbol'' Gene ID' Chromosome Official name'
A PC 324 5 Adenomatous polyposis coli
ATM 472 11 Ataxia telangiectasia mutated
BRCA1 672 17 Breast cancer 1, early onset
BRCA2 675 13 Breast cancer 2, early onset
CDH1 999 16 Cadherin 1, type 1, E-cadherin (epithelial)
CDKN2A 1029 9 Cyclin-dependent kinase inhibitor 2A (melanoma, p i 6, 
inhibits CDK4)
NF1 4763 17 Neurofibromin 1
NF2 4771 22 Neurofibromin 2 (merlin)
PTCH1 5727 9 Patched homolog 1
PTEN 5728 10 Phosphatase and tensin homolog
RBI 5925 13 Retinoblastoma 1
STK11 6794 19 Serine/threonine kinase 11
TP53 7157 9 Tumour protein p53
TSC1 7248 6 Tuberous sclerosis 1
TSC2 7249 17 Tuberous sclerosis 2
VHL 7428 3 Von Hippel-Lindau tumour suppressor
WTl 7490 11 Wilms tumour 1
’Gene symbol, Gene ID anc Official name were derived from Entrez, NCBI's gene database,
available at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene.
The categories of mutations comprised: single base-pair substitutions that introduced 
missense and nonsense mutations in the coding regions of the 17 tumour suppressor genes; 
intra-genic micro-deletions, micro-insertions and micro-indels involving <20bp either deleted 
and/or inserted.
2.2. Collection policy
To allow ready comparison with the HGMD data, the somatic single base-pair 
substitutions (i.e. missense and nonsense mutations) were collated as triplet changes with an
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additional flanking base (shown in lower case) included when the mutated bases occurred in 
either the first or third positions in the triplet (e.g. gATG-TTG, ATGt-ATC).
Micro-deletions, micro-insertions and micro-indels of <20 bp were augmented with 
lObp genomic DNA sequence flanking both sides of the lesion (e.g. 
CCAAGAAAAACagGGGCCCGAAA). The ‘A’ symbol indicates the start of an amino-acid 
codon, such that it is not part of the deleted or inserted sequences and the deleted and/or 
inserted nucleotides are indicated in lower case. In addition, where deleted/inserted 
nucleotides or the lObp flanking sequences extended into an intron of a gene, the position of 
the intron/exon boundary was also recorded (e.g. 
GAAG_I25E26_GATTTTTccTTGATATAGC,
CC AAAATC AC Agttatttcttaa_E 19bl 19b_gtaaattTC AGTC ACC A).
The clinical phenotype (histological clinical phenotype of the tumours of associated 
mutational data), mutation sequence (triplet changes for nonsense and missense mutations 
and deleted/inserted nucleotides with corresponding 1 Obp flanking sequence for micro- 
insertions, micro-deletions and micro-indels), amino-acid position (referring to the amino 
acid immediately following the symbol ‘A’ for micro-deletions, micro-insertions and micro- 
indels), reference (author, journal, volume, page and year) were also collected. Examples of a 
logged missense mutation and a micro-deletion are provided in Table 3 and Table 4.
Table 3 An examp e of a logged somatic missense mutation in the NF1  gene
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Table 4 An example of a logged somatic micro-deletion in the NF1 gene
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To be regarded as bona fide  somatic mutations, and therefore suitable for inclusion in 
the analysis, reported lesions had to have been found in tumour tissue but also to have been 
shown to be absent from a non-tumorous tissue from the same patient. Thus, mutation data 
derived from “sporadic” patients were not included, unless non-tumorous tissue had also been 
examined in order to exclude the possibility that they were constitutional mutations.
Only one example of each somatic lesion was selected, although individual examples of 
independently recurring somatic lesions in each dataset were noted and marked accordingly. 
Thus, mutations with more than one, but fewer than ten, independent examples were marked 
with a symbol **’, whereas examples of mutations that recurred more than ten times were 
marked with the symbol
Mutational data were stored in the form of plain text files (tab-delimited format), 
separately for each gene and for each mutational type (viz. germline and somatic). A 
summary of the numbers of collected mutations is presented in Table 5. In addition, a 
graphical overview of the collected somatic and germline mutations is presented in Figure 1 
and Figure 2.
Table 5 Summary of numbers of collected mutations in the 17 human tumour 
suppressor genes studied_______________________________________________
Missense Nonsense
M icro­
deletions
M utations
M icro­
insertions
M icro-
indels Total
Somatic 38 3 137 44 3 225
Germline 22 64 284 115 36 521
APC Shared 1 4 15 0 0 20
Recurrent 4 2 33 4 0 43
Total 61 71 436 159 39 766
Somatic 11 4 4 1 0 20
Germline 75 69 122 35 14 315
ATM Shared 0 2 0 0 0 2
Recurrent 1 0 0 0 0 1
Total 86 75 126 36 14 337
Somatic 5 3 6 3 0 17
Germline 169 109 255 83 12 628
BRCA1 Shared 1 4 3 2 0 10
Recurrent 0 0 2 0 0 2
Total 175 116 264 88 12 655
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Somatic 20 1 7 2 0 30
Germline 85 75 244 88 10 502
BRCA2 Shared 1 0 1 2 0 4
Recurrent 2 0 1 0 0 3
Total 106 76 252 92 10 536
Somatic 14 5 13 2 0 34
Germline 18 9 12 8 1 48
CDH1 Shared 1 2 0 0 0 3
Recurrent 0 0 0 0 0 0
Total 33 16 25 10 1 85
Somatic 170 13 76 24 8 291
Germline 34 1 10 6 2 53
CDKN2A Shared 28 5 1 1 0 35
Recurrent 6 3 9 3 0 21
Total 232 19 87 31 10 379
Somatic 2 4 13 3 0 22
Germline 83 105 218 105 8 519
NF1 Shared 0 10 3 0 0 13
Recurrent 0 0 1 0 0 1
Total 85 119 234 108 8 554
Somatic 23 24 176 28 6 257
Germline 20 25 50 16 2 113
NF2 Shared 0 18 5 0 0 23
Recurrent 3 18 8 2 0 31
Total 43 67 231 44 8 393
Somatic 13 7 14 6 1 41
Germline 23 25 42 32 8 130
PTCH Shared 1 2 0 0 0 3
Recurrent 0 0 0 0 0 0
Total 37 34 56 38 9 174
Somatic 201 39 145 47 4 436
Germline 23 15 23 18 3 82
PTEN Shared 22 12 6 4 0 44
Recurrent 47 17 45 16 0 125
Total 246 66 174 69 7 562
Somatic 22 12 30 12 2 78
Germline 34 61 112 53 10 270
RBI Shared 3 15 4 0 1 23
Recurrent 1 9 2 0 0 12
Total 59 88 146 65 13 371
Somatic 17 7 3 1 0 28
Germline 27 23 45 24 2 121
STK11 Shared 3 3 2 0 1 9
Recurrent 2 1 1 0 0 4
Total 47 33 50 25 3 158
Somatic 1138 87 504 234 0 1963
Germline 6 1 8 3 3 21
TP53 Shared 88 9 8 4 0 109
Recurrent 781 85 162 57 0 1085
Total 1232 97 520 241 3 2093
TSC1 Somatic 2 1 1 0 0 4
Germline 7 37 53 25 4 126
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Shared 0 0 0 0 0 0
Recurrent 0 0 0 0 0 0
Total 9 38 54 25 4 130
Somatic 0 0 3 2 1 6
Germline 87 72 110 46 3 318
TSC2 Shared 2 1 0 0 0 3
Recurrent 0 0 0 0 0 0
Total 89 73 113 48 4 327
Somatic 43 3 171 38 1 256
Germline 98 8 55 31 5 197
VHL Shared 45 6 8 6 0 65
Recurrent 5 2 14 2 0 23
Total 186 17 234 75 6 518
Somatic 1 0 4 3 0 8
Germline 39 11 8 4 1 63
WTl Shared 0 3 0 0 0 3
Recurrent 0 0 0 0 0 0
Total 40 14 12 7 1 74
Somatic 1720 213 1307 450 26 3716
Germline 850 710 1651 692 124 4027
ALL Shared 196 96 56 19 2 369
Recurrent 852 137 278 84 0 1351
Total 2766 1019 3014 1161 152 8112
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Figure 2 A graphical representation of the somatic and germline mutations in 9 of the 
17 human tumour suppressor genes studied (PTCH , PTEN, R B I , TP53, TSC1, TSC2, 
fT /I , JfT/ and STK11)
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3. General methods
3.1. Program implementation and computer specifications
All custom-built computer programs were created using the ‘Practical Extraction and 
Reporting Language’ (Perl; version 5.8). Those programs were the result of my own design 
and implementation, unless stated otherwise. Certain Perl packages were used to perform 
specific functions and those have been explicitly acknowledged, either as a literature 
reference or internet link. All algorithmic steps of these programs have been described, where 
appropriate.
All programs used in this PhD thesis were executed on a personal computer (PC) with 
the following specifications:
Operating System (OS): Microsoft Windows XP Professional 
Processor: single-core Intel Xeon at 2.8 Giga Hertz (GHz)
Random Access Memory (RAM): 1 Giga Byte (GB)
Hard-Disk Drive: 150GB
3.2. Data integrity
A computer program was devised in order to check the accuracy of the manually 
extracted/curated mutational data. Where errors in these data were discovered, they were 
manually corrected. This minimised the chance of having inaccurately annotated (in terms of 
position of mutation and type of sequence change, flanking genomic sequence for the micro­
lesions) mutations included in the analysis.
3.3. Labelling of mutations
Some of the mutations in the 17 tumour suppressor genes under study were found in 
both the soma and the germline. In order to identify such mutations that were shared (i.e. 
mutations that were reported in both the soma and the germline), I devised a computer 
program that made possible the automatic recognition and labelling of mutations that were 
shared. For each gene and for each type of mutation (viz. missense and nonsense mutations 
and micro-lesions) found in both the germline and the soma, they were removed from the list 
of mutations and a new single entry with the label ‘shared’ was created. Thus, mutations were 
labelled somatic (when they were found exclusively in the soma), germline (i.e. when they 
were found exclusively in the germline) or shared (when they were found in both the soma
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and the germline). A graphical representation of the labelling of mutations is given in Figure 
3.
Figure 3 A graphical representation of labelling of mutations
Non-recurrent mutations
Recurrent mutations
Somatic mutations
Germline mutations
Shared mutations
Germline non-shared 
mutations
3.4. E xtended cDNA sequences
Some of the analyses performed in this PhD project required extended cDNA 
sequences for all 17 tumour suppressor genes under study. In order to acquire such extended 
cDNA sequences, genomic DNA sequences (sequence contigs) for each gene were collected. 
A sequence contig encompassing the gene sequence was identified via a link in NCBI’s 
GenBank http://wAVAv .ncbi.nlm.nih.gov/sites/entrez?db=Nucleotide. For every gene, the 
genomic sequence was stored in a text file (FASTA format). In order to find the positions 
where the cDNA mapped to the genomic sequence, the Spidey program (Wheelan et al.
2001) was used. It allows alignment of spliced sequences (i.e. cDNA) to genomic sequences. 
The PC executable form of the Spidey program available at
http://www.ncbi.nlm.nih.gov/spidev/spidevexec.html was used locally to obtain the exact 
positions where the cDNA mapped to the genomic sequence with the following parameters:
-i (file name, containing genomic sequence in FASTA format)
-m (file name, containing cDNA sequence in FASTA format)
I devised a computer program that took Spidey’s output (text file) and extracted the 
extended cDNA sequence (i.e. 85bp around every exon) as well as the positions of splice
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junctions. For every gene, the program outputted a text file with the extended cDNA 
sequence (FASTA format) as well as a mapping file that mapped the exact positions of the 
beginning and end of every exon and intron to the extended cDNA. The cDNA and extended 
cDNA sequences for all 17 tumour suppressor genes studied could be found in the 
supplementary materials.
3.5. Identification of potential missense and nonsense mutations
Every codon within the coding regions of all 17 human tumour suppressor genes 
under study was examined in order to determine all potential missense and nonsense 
mutations that could arise through a single base-pair substitution. Thus, at position 1 of the 
codon, all possible combinations of nucleotides were introduced (3 possible combinations 
excluding the existing nucleotide) and keeping the nucleotides at positions 2 and 3 unchanged 
(i.e. simulating a single base-pair substitution in position 1). After each change of nucleotide 
in position 1, the new codon sequence was examined to see if it changed the wild-type amino 
acid (i.e. missense) or it could potentially give rise to a stop codon. This process was repeated 
for positions 2 and 3, where nucleotides 1 and 3 respectively were kept unchanged (i.e. 
change in position 2) and positions 1 and 2 were kept unchanged (i.e. change in position 3). 
An example is shown in Table 6.
Table 6 Identification of potential missense and nonsense mutations through a single 
base-pair substitution_____
Position
Codon
Possible
change
G
Codon
CGA
TGA
AGA
CGA
CTA
CAA
CCA
CGT
CGG
CGC
Amino acid
Arginine (R)
Stop
Arginine (R)
Arginine (R)
Leucine (L)
Glutamine (Q)
Proline (P) 
Arginine (R) 
Arginine (R) 
Arginine (R)
S y m b o l " indicates that corresponding position within the codon is unchanged
All calculations of potential missense and nonsense mutations were performed 
according to the canonical open reading frame (ORE). I devised a stand-alone computer 
program in order to define, codon-by-codon, all potential single base-pair substitutions
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leading to a non-synonymous change (missense and nonsense mutations) of the wild-type 
amino acid within the coding sequences of the genes, thereby minimising manual 
intervention and maximising error-free definitions of potential missense and nonsense 
mutations.
3.5.1. Iden tification  o f po ten tial m issense and  nonsense m uta tions in 
C pG -d inucleo tides
In order to recognise all missense and nonsense mutations that could arise in CpG 
dinucleotides, a slight modification to the algorithm, described in 3.5, had to be applied in 
order to include exon-intron junction-spanning CpG dinucleotides. Generally, the coding 
sequences of human genes are split by introns, the exception being a few intronless genes. 
Let us take an example of a TCC codon (encoding the amino acid serine) that is split by an 
intron after the first C nucleotide. Since the nucleotide sequence for the splice donor site of 
the intervening intron invariably starts with a G nucleotide, a C->T transition in the CpG 
dinucleotide in the last base of the exon in the gene's genomic sequence would generate a 
missense mutation (i.e. TTC) after exon-exon splicing. The above example is shown in 
Figure 4.
Figure 4 A single base-pair substitution (missense mutation) in a CpG dinucleotide at 
exon-intron boundary
DNA
__ l__
exon in tro n ex o n
c g tg c  cgcag CA.. -3'
CpG d in u c le o t id e  
C->T in CpG d in u c le o t id e
5'-  t f ^ g c g t g c l l cgcag CA. 3'
exon in tro n ex o n
cDNA
- i _
5'-
Ser
.TCC. -3'
C->T
n o t  in CpG d in u c le o t id e
5'- .TTC.
P h e
-3'
Similarly, if we take an example of a CAA codon (encoding the amino acid glutamine) 
that is split by an intron after the C nucleotide. Since the nucleotide sequence for the splice 
donor site of the intervening intron invariably starts with a G nucleotide, a C->T transition in 
the CpG dinucleotide in the last base of the exon in the gene’s genomic sequence would
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generate a nonsense mutation (i.e. TAA) after exon-exon splicing. The above example is 
shown in Figure 5.
Figure 5 A single base-pair substitution (nonsense mutation) in a CpG dinucleotide 
(exon-intron boundary )
DNA
__I__
exon in tron exon
5'-  Ck tg c g tg c  cgcag AA -3'
CpG d inucleo tide  
C->T in CpG d inucleo tide
5'- c  cgcag AA  l3'
exon in tron exon
5'-
5'-
cDNA
i
Gin
.CAA. -3 '
C->T
n o t in CpG d inuc leo tide
 TAA -3'
Stop codon
These special cases (arguably could be classified as splice site mutations, although the 
mutations are exonic in location) would however have been missed, if the analysis had 
employed cDNA (rather than genomic DNA) sequence to identify single base-pair 
substitutions leading to missense and nonsense mutations in CpG dinucleotides (i.e. if the 
analysis had been based on cDNA sequence, the TCC->TTC and CAA->TAA substitutions 
would not have been counted as a missense and nonsense mutation in CpG dinucleotides, 
because they would not obviously have occurred in a CpG).
In addition, not all splice sites contain the canonical GT-AG consensus splice site 
sequence. Indeed, a very small proportion of introns possess AT-AC splice sequences instead 
of the usual GT-AG consensus splice site sequence (reviewed in Mount 2000). Therefore, in 
a very similar way (as described above and shown in Figure 4), if an ATG codon, encoding 
the amino acid methionine, were to be split by an intron after the T nucleotide and the 
consensus acceptor splice site ends with the nucleotide C, a potential G->A substitution 
would create a AT A missense mutation (as shown in Figure 6).
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Figure 6 A single base-pair substitution (missense mutation) in a CpG dinucleotide at 
intron-exon boundary
DNA 
___1__
ex o n in tro n ex o n
5'- .AT g tg c g tg c  cgcac ¥■ -3'
CpG d in u c le o t id e  
G->A in CpG d in u c le o t id e
5'- .AT g tg c g tg c .~ c g c ^ c -3'
ex o n in tro n exon
cDNA
i
5'-
M e t
.ATG.. -3"
G->A
n o t in CpG d in u c le o t id e
5'- .ATA.
lie
-3'
Similarly (as described above and shown in Figure 5), a TGG codon, encoding the 
amino acid tryptophan, were to be split by an intron after the T nucleotide and the consensus 
acceptor splice site ends with the nucleotide C, a potential G->A substitution would create a 
TAG nonsense mutation (as shown in Figure 7).
Figure 7 A single base-pair substitution (nonsense mutation) in a CpG dinucleotide 
(intron-exon boundary )
exon intron exon
DNA
(-------------------------1------------------------- 1
exon in tron exon
5'->.......T gtgcgtgc......cgcac[<3G........
/CpG dinucleo tide 
G->A in CpG d inucleo tide
t
5'- T gtgcgtgc......cgcacjAG.........
-3 '
-3'
5 '-
cDNA 
___l___
Trp
..TGG. -3'
G->A
no t in CpG dinucleo tide
5 ' -  .TAG -3'
Stop codon
Again, as described above, these special cases (arguably they could be classified as 
splice site mutations, although the mutations are exonic in nature) would be missed, if the 
analysis were to have been solely based on cDNA sequence to identify single base-pair 
substitutions leading to missense and nonsense mutations in CpG dinucleotides (i.e. the G->A 
substitutions giving rise to TGG->TAG and ATG->ATA are not in a CpG dinucleotide when 
the cDNA is considered).
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Taking these special cases into consideration, in order to examine whether such cases 
exist in the 17 tumour suppressor genes, ‘extended cDNA sequences’ that include exon- 
intron junction sequences, were required. Detailed description of the generation of extended 
cDNA sequences is given in 3.4.
I developed a computer program to determine if such special cases of CpG 
dinucleotides, discussed above, exist in the 17 tumour suppressor genes and could be 
converted into missense and nonsense mutations through a single base-pair substitution in the 
17 tumour suppressor genes examined. For each gene, the program took an extended cDNA 
sequence file, a mapping file (as described in 3.4) and produced any of these special cases of 
single base-pair substitutions in CpG dinucleotides that could lead to a missense and 
nonsense mutation.
After running the program sequentially for each gene, such special cases (i.e. 
missense mutations) of CpG dinucleotides were indeed noted. These special cases included, 
TC|g...|C->TTC, AC|g...|A->ATA and AT|...c|G->ATA (|g...| denotes the first nucleotide of
an intron and | c| denotes the last nucleotide of an intron) in the ATM, CDH1 and STK1J
genes respectively. Having found such special cases of substitutions in CpG dinucleotides 
leading to missense mutations, extended cDNA sequences were used in the subsequent 
analyses (i.e. analyses in Chapter 4; Missense mutations) for the abovementioned genes.
In addition, such special cases of CpG dinucleotides were also noted for the potential 
nonsense mutations, although none of the potential single base-pair substitutions (i.e. C->T or 
G->A) led to the introduction of a stop codon. Having checked in this way that the use of 
cDNA rather than genomic sequence would not cause errors, cDNA sequence from each gene 
was used in order to make the subsequent algorithms more efficient (i.e. analyses in Chapter 
5; Nonsense mutations). Certainly, if this analysis were ever to be extended to a wider range 
of genes, genomic DNA sequence should be employed because non-canonical splice 
sequences do occasionally occur.
3.6. Statistical methods used
3.6.1. Hypothesis testing
3.6.1.1. Association testing
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When analysing a binary or categorical variable, the distribution of the variable can 
be represented as a contingency table (Table 7).
Table 7 Distribution of a binary variable, represented as a contingency table
In repeats Not in repeats Marginal totals
Number somatic mutations 
Number germline mutations 
Marginal totals
a b a+b
c d c+d
a+c b+d n=(a+b+c+d)
In order to assess the association or relationship between different type of mutations 
(e.g. somatic and germline in the example given in Table 7) and the binary variable in 
question (e.g. status of the mutations with respect to its occurrence in repeats), i.e. the non- 
random distribution of the status of mutations with respect to its occurrence in repeats in the 
two samples of mutations, a Pearson's test with 1 degree of freedom ( d f )  can be 
calculated (Altman 1991). The test compares observed frequencies with the expected 
frequencies (see Equation 1), under the assumption of independence (i.e. repeats are not 
associated with the positional occurrence of mutations and the distribution of the repeats is 
similar in both types of mutations).
Equation 1 Pearson's ^  statistic (after Field 2005)
? A  (Observed. -  Expected )2
X  -  ? -----------------------------—, where~  Expectedi
Expected^ m ^ ow -  t()tah- where n is the total number of observations (i.e.
n
n - a  + b + c + d  in Table 7); i is the number of the cell in the contingency table; m is the total 
number of cells within the contingency table
The y? statistic is an appropriate statistical measure, when 80% of the cells in the 
contingency table have expected counts >5, but also when all of the cells show expected 
counts >1 (Altman 1991). In the case of small expected frequencies, Fisher's exact test or 
simulation-based tests should be used. The small expected frequencies would inflate the x 1 
statistic. Furthermore, when the observed counts are small, then the x* statistic tends to be 
overestimated, because the assumption of a continuous y£ distribution introduces some bias.
The calculation of the x* statistic was performed using the formulae given in 
Equation 1. Those calculations were mainly incorporated into Perl programs. Some of the 
calculations were performed using the chisq.test function in the R statistical language
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(http://cran.r-proiect.orgA. The chisq.test function in R was only used for the calculation of 
the statistic in Chapter 6 for the combination of micro-lesions.
The associated p-values of the x 2 statistic were calculated either within a Perl program or 
within R. Within a Perl program, the p-values were calculated using the chisqrprob function, 
which is a part of the Statistics::Distributions package, available at
http: search.cpan.org/-mikek/Statistics-Distributions-l .02/Distributions.pm. Within R, the 
chisq.test function (see above) outputs include both the x 2 statistic and the associated p- 
value.
3.6.1.2. N o n -p a ram etric  tests
Most of the statistical tests rely on parametric assumptions about the data, most 
notably- normally distributed data (Field 2005). In addition, for non-normally distributed 
data, it is not always possible to correct for an unknown distribution. Such was the case with 
the analysis of a number of parameters detailed in Chapter 4. Therefore, a non-parametric test 
was used, i.e. Wilcoxon rank-sum test (Wilcoxon 1945).
Non-parametric tests are usually known as assumption-free tests, because they make 
fewer assumption as compared to parametric tests (Field 2005). The Wilcoxon rank-sum test 
compares whether two independent samples have come from the same distribution, but is 
also known to be used for testing differences between medians (Field 2005).
I created a computer program that, when supplied with two sets of data (e.g. somatic 
and germline substitution rates), calculates the Wilcoxon rank-sum statistic (i.e. Ws statistic), 
the mean of the test statistic ( Ws ) and the standard error ( SEWs). The calculations of the
Wilcoxon rank-sum statistic comprised the following algorithm: the values in two datasets 
under investigation were combined into one dataset, but keeping a record to which dataset 
they belong. Those values were sorted in ascending order and assigned a potential rank, 
ignoring the dataset to which they belong. If two values have the same number (i.e. tied 
ranks), they were assigned ranks that were the average of the potential ranks. The W statistic 
is calculated by adding up all the ranks in each dataset and choosing the lowest of the two 
sums to be the test statistic (Field 2005). Based on these values, the W statistic could be 
easily converted into a z -score using the following formula:
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Equation 2 Converting Wilcoxon rank-sum statistic into z -score (Field 2005)
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Then, by using the properties of the normal distribution with mean 0 and variance 1 
( /J. -  0, a  -1 ) , the z -score is easily converted into a p-value in order to assess the statistical 
significance of the results at the chosen alpha level of significance (i.e. a  -  0.05).
3.6.2. Multiple hypothesis testing
The difference between two groups is considered as statistically significant if the 
corresponding p-value is smaller than the significance level alpha ( a )  chosen for the 
particular experiment. The commonly accepted significance level is a  -  0.05 (Fisher 1990). 
The significance level a  indicates the probability of observing a difference between two 
groups by chance under the null hypothesis of no difference. Thus, when more than one 
(N  > 1) hypothesis is tested, each hypothesis has a probability a  of being falsely determined 
as being significant and therefore the expected number of (false) significant findings, 
assuming the null hypothesis in each test, is equal to N a  and the probability of finding at 
least one significant difference by chance if the tests are independent is p  -1  -  (1 -  a)  * N  
(e.g. if N  -  200 this probability equals to 0.99996).
Correction for multiple hypothesis testing attempts to maintain the probability p  at 
the chosen significance level a . The most widely used method of multiple hypotheses 
correction is the Bonferroni correction, where the a  is simply divided by the number of tests 
performed, and the overall chance of finding any false positive remains the same as in a 
single hypothesis experiment. The Bonferroni correction assumes that the tests are 
independent, and is considered to be a conservative adjustment when tests are dependent 
(Sokal and Rohlf 1995).
The way the data were split, many comparisons were found to have strong 
correlations with one another within a gene, and the use of the Bonferroni adjustment would 
therefore be likely to be a conservative correction. I implemented a permutation-based 
correction, which computes p-values that are adjusted for the number of tests undertaken but 
in a way that is less conservative than the Bonferroni method. The permutation-based
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methods are often (and successfully) used in the context of microarray expression data 
(Olshen and Jain 2002). At each permutation, the label (i.e. somatic, germline, shared and 
potential, where applicable) is randomly reshuffled, ensuring that the number of each type of 
mutation (viz. somatic, germline, shared and potential, where applicable) is the same and that 
the differences between groups occur purely by chance while preserving the correlation 
structure between the tests.
The algorithm of the permutation method used is as follows:
1) Compute y? statistic (original statistic) for every possible comparison in a particular 
gene or the combination of mutations in all genes;
2) Randomly permute the label (i.e. somatic, germline, shared and potential), thereby 
breaking the relationship between the studied variables and the observed mutations;
3) Compute the same x 2, statistic as in (1) using the permuted labels. Save the maximum 
statistic;
4) Compare the maximum statistic with every original value of statistic (see 1) and 
record a success, if the maximum statistic is greater or equal than original value of 
statistic
5) Repeat (2) and (3) 10,000 times*;
6) For each test the permuted p-value is derived by dividing the number of successes 
recorded in (4) by the number of permutations performed (i.e. 10,000).
* It is not feasible to use all possible permutations, as the number of combinations is 
computationally expensive or time-consuming.
The permutation-based method used here, only tries to maintain the probability of 
falsely finding any significant hypothesis at the a  value for each gene or the combination of 
mutations in all genes, but does not account for the tests performed in different genes. It is 
computationally expensive to use permutation-based method to account for the tests 
performed for all genes. If it were to be performed, the permutation method (described 
above) used for each gene had to be performed 10,000 times. Instead, Bonferroni correction 
for multiple testing was applied which is always valid as a conservative estimate. The new a  
value for each gene was obtained after dividing the permuted critical value by the number of 
genes tested (i.e. 17).
29
Due to the nature of the permutation method applied to correct for multiple hypothesis 
testing, if the original statistics is very large, the statistics obtained at a particular permutation 
sometimes never reached the observed one. In this case the corrected p-values were reported 
as < \ I M , where M  is the number of permutations performed (in all cases this was 10,000).
All p-values reported in the Results section of the individual chapters are corrected for 
multiple testing as described above.
3.6.3. Calculation of statistical power
3.6.3.I. Type I and type II errors
Generally, statistics deals with a subset or a subsample of the population of interest. 
Thus, statistics uses statistical tests to determine if an effect or a phenomenon (e.g. difference 
in proportions, difference in the distributions, etc.) exists in the studied population. Normally, 
the true state of the population is unknown, i.e. it is unknown whether an effect exists or not. 
Therefore, a test statistic and associated probabilities could indicate which is more likely. In 
this process, one could commit two types of errors.
Type I error, also called the false positive error (Figure 8), is the probability of falsely 
rejecting the null hypothesis, when there is no true effect in the population. The most 
commonly accepted Type I error rate is a  -  0.05 (Fisher 1990). Therefore, there is only a 
small, i.e. 5% chance, of the result occurring by chance alone.
Type II error, also called the false negative error (Figure 8), is the probability of falsely 
accepting the null hypothesis, when in fact there is a true effect in the population. Cohen 
(1988) has suggested that the maximum acceptable probability of the Type II error should be 
P -  0.2 or 20% (Cohen 1988; Field 2005). Thus, there would be a 20% chance that an 
existing genuine or true effect/phenomenon in the population would not be detected by the 
statistical test.
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Figure 8 Type I and Type II errors
Actual phenom enon in the population
Present Absent
£  a  True positive
3 2
Type I error
Type II error True negative
3.6.3.2. E ffect size
The effect size or an observed effect size is the strength of the relationship between 
two variables being measured. For the test ofx* statistic, the effect size was calculated by 
using the ES.w2 function in the PWR package, part of the R statistical language (http://cran.r- 
proiect.org/) that utilizes the following formula (Cohen 1988):
Equation 3 Effect size for statistic
where PQi is the proportion in cell i posited by the null hypothesis (e.g. a/n in Table 7), 
and P and P are the proportions of the marginal totals in the contingency table (i.e.
Pt  -  (a + b)/n  and Pu = {a + c) /n  in Table 7); Pu is the proportion in cell i posited by the 
alternative hypothesis.
It is generally considered that an effect size of 0.10 represents a small effect, 0.30 a medium 
effect and 0.50 a large effect.
3.6.3.3. Pow er
The power of a statistical test represents the probability to detect an effect size of a 
particular magnitude (w or r) with a specified Type I error rate (a) and a particular sample 
size, power - 1 - /5  (where /5 is Type II error rate). The power analysis requires an 
assumption that a true effect exists in the population under study.
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Power calculations for the x2 tests were performed using the pwr.chisq.test package, part of 
the R statistical Language (http://cran.r-proiect.orgA. The following parameters were 
supplied to the pwr.chisq.test package: the effect size w (calculated using Equation 3), the 
total number of observations#, the number of degrees of freedom d f(  for all tests performed, 
d f  -1 ), and the significance level a .  In order to keep the overall a  at the 0.05 level, as 
multiple statistical tests were performed, the value of a  used in the power calculations was
set to — ( #  is total number of tests performed, e.g. 374 tests performed in Chapter 6,
N
therefore, the Bonferroni-adjusted a ,  to account for multiple testing, was a  -  0.05/374, or 
0.0001336898). The number of tests (N )  is explicitly given in each of the results chapters 
(i.e. Chapters 4, 5 and 6). Since Bonferroni correction is considered to be a conservative 
correction for multiple testing, the power calculated for the x statistical tests is a 
conservative estimate.
For power calculations, with respect to Wilcoxon rank-sum tests used, a data-based 
simulation method for statistical inference was used (Walters 2004). The simulation method 
involved repeatedly drawing random sub-samples from the original data, with replacement, 
thereby generating the non-standard distribution of the observed data. For power analysis, the 
following algorithm was used, based on Walters’ Method 4 (Walters 2004):
For each test, calculate observed difference of means S « x  -  y , where x  is the mean in the 
first sample ( )  and y  is the mean in the second sample ( S 2)
1) Draw two random samples ( Sx andS2) from the combined mutational data, with Nx 
and N 2, where N { and N 2 are the observed number of mutations in the two original 
datasets.
2) Add S to each of the samples in Sv
3) Calculate the Wilcoxon rank-sum test statistic and associated significance (p-value).
4) A success is recorded, if p js (two-sided test, thus a  / 2 -  0.025)
} 2N
5) Steps 1-4 are repeated 10,000 times and power is calculated by the proportion of 
successes among the 10,000 simulations.
3.7. Supplementary Data
Owing to the immense volume of data generated during this project, only the most 
interesting (i.e. the statistically significant) results are presented in paper format.
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Nevertheless, comprehensive results from the analyses are presented in the form of 
supplementary tables, and are supplied on a CD at the back of the thesis. The supplementary 
CD comprises: cDNA and extended cDNA sequences, comprehensive results for the 
missense, nonsense and micro-lesions mutational analyses, somatic and germline mutations, 
repetitive elements, properties of corresponding types of mutations (i.e. disease and non­
disease nucleotide substitution rates, Grantham difference values, CpG-located mutations, for 
missense mutations; predicted NMD status and CpG-located mutations for nonsense 
mutations; location within repetitive elements for micro-deletions, micro-insertions and 
micro-indels), for each of the 17 human tumour suppressor genes studied.
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4. Missense mutations
4.1. Introduction
4.1.1. The importance of missense mutations
Missense mutations (i.e. nonsynonymous mutations) are defined as single base-pair 
substitutions in the coding regions of genes that lead to a nonsynonymous change of the wild- 
type amino acid encoded by a specific codon. For instance, a single base-pair substitution C- 
>A in the third position of the codon CAC (i.e. CAC->CAA), would change the encoded 
(wild-type) amino acid histidine to glutamine. Missense mutations could be classified into 
several different categories with respect to their functional importance. These include neutral, 
deleterious and beneficial missense variants and missense variants of unknown clinical 
importance (Chan et al. 2007; Strachan and Read 2004).
4.1.1.1. Deleterious effect of missense mutations
Proteins often contain domains of relatively high functional importance. These 
domains themselves contain key amino acid residues, responsible for DNA-binding, 
transactivation, oligomerization, promotion or suppression of cell division, etc. Thus, 
substitution of these amino acids is likely to alter or abrogate the function of the 
domain/domains affected. Generally, deleterious missense mutations are defined as missense 
variants that have a significantly negative impact on the function of a protein as compared to 
the wild-type product (Carvalho et al. 2009), hence the term deleterious. Various estimations 
have shown that -20%  of all de novo missense substitutions are likely to be strongly 
detrimental - indeed, these mutations may predispose an individual to a disease state 
(Kryukov et al. 2007; Yampolsky et al. 2005).
Numerous research groups have performed functional assays to determine if certain 
missense variants impair either critical regions or the overall function of an affected gene 
product. For example, certain missense variants in the BRCA1 gene (e.g. V1833M) have been 
shown to reduce transactivation activity to -30%, as compared to the activity of the wild-type 
protein (Carvalho et al. 2009). Further, a number of missense variants have been shown to 
negatively affect the function of the BRCA1 protein (reviewed in Carvalho et al. 2009).
Missense mutations in other well studied human tumour suppressor genes have also 
been shown to abrogate crucial functions of the affected proteins. For example, these affect
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the kinase activity of the ATM  gene (Mitui et al. 2009), the DNA-binding domain of BRCA2 
(Farrugia et al. 2008), the calcium-binding domain responsible for cell-cell adhesion of 
CDH1 (Corso et al. 2007), the CDA'-interacting domains of CDKN2A (Ruas et al. 1999), the 
GTPase-activating protein related domain of NF1 (Upadhyaya et al. 1997), the phosphatase 
domain of PTEN (Han et al. 2000), the DNA-binding domain of TP53 (Khromova et al.
2008), the tuberin-binding domain of TSC1 (Mak et al. 2005), the p domain of VHL (Li et al. 
2007), and the DNA-binding domain of WTJ (Little et al. 1995).
Additionally, genes/proteins with several functionally important domains could 
exhibit deleterious (as defined above) missense mutations in different domains. Such is the 
case with the human mismatch repair gene MSH2, where mutations in the amino-terminal 
and lever domains affect protein stability whereas mutations in the ATPase domain affect 
mismatch binding or repair (Ollila et al. 2008).
On the other hand, missense variants could indirectly exert their negative effects on 
the function of a protein by altering the splicing phenotype. Examples are a germline 
missense mutation (R141S) which results in the skipping of exon 4 in the APC gene (Aretz et 
al. 2004) and a germline missense mutation (D153Y) in the CDKN2A gene which results in 
an alternatively spliced product, comprising either a 75bp deletion or the complete skipping 
of exon 2 (Rutter et al. 2003). Both missense variants lead to a nonsynonymous change of the 
wild-type amino acid, but also affect normal splicing. In the case of APC R141S, the 
observed clinical phenotype and the segregation patterns within families indicate that the 
altered splicing is disease-causing (Aretz et al. 2004). In the case of D153Y, exon 2 has been 
reported to be required for nucleolar localisation; therefore exon skipping could potentially 
have a negative effect on the function of the protein (Rutter et al. 2003; Zhang and Xiong 
1999).
4.1.1.2. Neutral effect of missense mutations
Generally, missense variants that have been shown to have no negative impact on the 
function of proteins are classified as neutral and are likely to be of little clinical importance 
(Abkevich et al. 2004; Carvalho et al. 2009). These variants are termed neutral because they 
are associated with little or no disease risk, although the definition of ‘no negative impact’ 
varies from study to study. Thus, Carvalho et al. (2009) suggests using a tentative criterion of 
>50% intact product activity in comparison to the activity of the wild-type protein, in order 
for a variant to be classified as neutral. By contrast, Mitui et al. (2009) regard a variant as
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being neutral or ‘operationally neutral’ if >36% of the activity of the wild-type protein 
remains intact. Nevertheless, missense variants have been invariably shown to have no or 
very little effect on the function of a mutant protein and estimations show that -27% of all de 
novo missense substitutions are effectively neutral (Kryukov et al. 2007; Yampolsky et al. 
2005). Analysis of a germline missense mutation (S1613G) in the BRCA1 gene indicated no 
change in the activity (i.e. quantitative transcription assay Carvalho et al. 2009) of the mutant 
product in comparison with the wild-type activity. This substitution has been confirmed to be 
a neutral polymorphic variant (Friedman et al. 1994; Tavtigian et al. 2006). Similarly,
R841W (BRCA1 gene), Y42C and P655R (BRCA2 gene) have also been shown to be 
probably neutral missense variants (Goldgar et al. 2004).
4.1.1.3. Unknown effect of missense mutations
Despite numerous classification procedures, classifying the functional effect of some 
missense variants remains elusive. For example, Alter et al. (2007) reported 5 different 
missense variants in the BRCA2 gene which are of unknown clinical significance (Alter et al. 
2007). In addition, other gene products harbouring missense mutations show intermediate 
activity (viz. somewhere between neutral and deleterious), with respect to wild-type activity 
with the functional consequences not being readily determined (e.g. K1487R in the BRCA1 
gene Carvalho et al. 2009). Moreover, some 50% of all unique variants in the BRCA1 and 
BRCA2 genes are classified as being of unknown effect (Breast Cancer Information Core 
(BIC) database, http://research.nhgri.nih.gov/bic/: Goldgar et al. 2004) and 13% of the 
variants detected in 7461 individuals sequenced for the BRCA1 and BRCA2 genes are also 
classified as being of uncertain clinical significance (Frank et al. 2002).
Kryukov et al. (2007) have estimated that -50%  of all de novo missense substitutions 
are mildly deleterious. Mildly deleterious mutations are defined as mutations that are neither 
neutral nor strongly deleterious (i.e. mutations subject to purifying selection). Therefore, the 
majority of de novo missense mutations described in human genes are effectively of unknown 
status. The effect of a given missense mutation may be unclear for a number of reasons. In 
general, there might be insufficient evidence to determine the functional consequences. Some 
variants could be benign polymorphisms, whereas others might simply co-segregate with 
known deleterious variants within families.
4.1.1.4. Beneficial effect of missense mutations
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Interestingly, some missense mutations in certain genes appear to display a protective 
effect, or selective advantage, on the individual carrying those mutations. Cellular chemokine 
receptors act as co-receptors for the entry of pathogens (i.e. CCR5 for M-tropic strain of HIV  
and DARC for the malarial parasite Plasmodium vivax; Tamasauskas et al. 2001). A germline 
missense mutation (R89C) in the DARC gene results in a reduced level of the associated 
protein (i.e. ZX4/?C-negative) and confers resistance to infection by the malarial parasite 
(Miller et al. 1976; Pogo and Chaudhuri 2000; Tamasauskas et al. 2001). Similarly, the R60S 
germline missense change in the CCR5 gene reduces the ability of HIV-1 entry (72% entry 
efficiency compared to that of a wild-type product Tamasauskas et al. 2001) and has been 
shown in an unaffected yet HIV-1-exposed individual (Carrington et al. 1997). Low 
frequency germline missense mutations in the CHEK2 gene (e.g. I157T) have been shown to 
be associated with a significantly lower incidence of lung cancer (Brennan et al. 2007; 
Cybulski et al. 2008), although the underlying mechanism remains unknown. Likewise, a 
germline missense variant (S408N) in the CSNK1E gene, which plays an important role in the 
regulation of circadian clock rhythms, has been found with reduced frequency in cases of 
Delayed Sleep Phase Disorder, as compared with healthy controls, but also has much higher 
functional activity than the wild-type protein (Takano et al. 2004). Takano et al. (2004) have 
speculated that the aforementioned allele may play a protective role in the development of 
Delayed Sleep Phase Disorder.
4.1.2. The challenge of classifying the functional consequences of 
missense mutations
The optimal means of identifying the functional consequences of missense mutations 
is a reliable in vitro functional assay that would measure not only the activity, but also the 
properties of the mutant product (i.e. the protein harbouring the missense mutation), long­
term effects and interaction with other gene products. For a limited number of disease-related 
genes, such functional assays exist, but for many others they are costly to construct, 
unreliable or difficult to perform. Even for a relatively small gene, such as CDKN2A (156 
codons in total), there are 2945 possible missense variants, but for only 100 (<3%) of these 
have functional assays been performed (Chan et al. 2007). Therefore, in the absence of in 
vitro assays, a variety of in silico algorithms have been developed to aid in the classification 
of missense mutations. Computational methods are relatively cheap and allow for an 
unlimited number of variants to be tested. These methods rely on various sources of data
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including the biochemical and physicochemical properties of amino acids; known secondary 
and tertiary structure of affected proteins; evolutionary conservation data and mutation rates.
4.I.2.I. Biochemical and physicochemical properties of amino 
acids
Some amino acids are very similar to each other with respect to their chemical and/or 
physicochemical composition, whereas others are extremely different. One of the most 
widely used scores for measuring the chemical and physical differences between amino acids, 
is the so called ‘Grantham score’ or ‘Grantham difference’ (Grantham 1974). This measure 
describes the difference between the side chain composition (i.e. weight ratio of noncarbon 
components in end groups or rings to carbons in side chains), polarity (i.e. basic, acidic or 
nonpolar depending on the side chain charge) and molecular volume of two amino acids.
Even although numerous other measures of amino acid difference have been devised (Clarke 
1970; Epstein 1967; Miyata et al. 1979), the Grantham difference is useful because it is a 
continuous measure and most importantly helps to quantify the ‘severity of amino acid 
changes’ (Miller and Kumar 2001).
Some amino acid residues play a crucial role in proteins and therefore could not be 
easily substituted by others without drastically altering protein structure and/or function. For 
instance, cysteine could form disulphide bridges and plays an important role in formation of 
the secondary structure of proteins (Grantham 1974). In addition, cysteine is also a unique 
amino acid, as it is the only one with a sulfhydryl group in its side-chain. By contrast, 
isoleucine and valine, or serine and threonine, have very similar side chains (shown as R in 
Figure 9); therefore the physicochemical difference between them is one of the lowest 
(Grantham 1974). The chemical composition of the above-mentioned amino acids is shown 
in Figure 9.
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Figure 9 Chemical composition of some amino acids (adapted from Strachan and Read 
2004)
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Although Grantham differences range from 5 to 215, Tavtigian et al. (2008) have 
suggested that Grantham differences of 5-60 are to be considered ‘conservative’, 60-100 
‘non-conservative’ and >100 ‘radical’. Disease-associated germline missense mutations in 7 
human genes (CFTR, TSC2, G6PD, LI CAM, PAH, RSI,  PAX6) exhibit a greater average 
chemical difference than the average difference observed in interspecific comparisons of 
missense changes in orthologous proteins (Miller and Kumar 2001). In addition, Miller and 
Kumar (2001) have also noticed fewer ‘radical’ disease-associated amino acid changes (i.e. 
Grantham difference >100), than ‘non-conservative’ (Grantham difference 60-100). A similar 
result has been reported by Notaro et al. (2000) for the G6PD gene. These authors suggested 
that ‘radical’ mutations are likely to be lethal, hence relatively fewer radical changes are 
observed. Thus, there is strong, negative purifying selection pressure acting on those ‘radical’ 
amino acid changes. Furthermore, Krawczak et al. (1998) have shown that the Grantham 
difference is positively correlated with a measure which they termed the ‘relative clinical 
observation likelihood’; thus, germline missense changes that give rise to a greater difference 
in terms of chemical composition are more likely to come to clinical attention.
These results indicate that non-conservative (with respect to the amino acid difference 
between the wild-type and mutant amino acids) disease-associated mutations are more likely 
to lead to an observed disease phenotype in patients, in comparison to less radical changes.
4.1.2.2. Relative mutability rates
DNA in living organisms comprises 4 basic nucleotides (viz. A, C, G and T). At the 
mRNA level, a set of three nucleotides forms a codon, which encodes a specific amino acid. 
Strings of amino acids (i.e. amino acid sequences or polypeptides) define proteins. As a 
consequence, there are 43 (i.e. 4 possible nucleotides in each of the three positions in a 
codon), or 64 different codons (i.e. different set of trinucleotides), but only 20 standard amino
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acids. Therefore, different codons can encode the same amino acid, known as codon 
degeneracy (shown in Figure 10).
Figure 10 Codon degeneracy (adapted from Ellington and Cherry 2001)
For example, the codons CGA, CGC, CGG and GCU all encode the same amino acid, 
arginine. In addition, the last position of the CG- codon is said to be fourfold degenerate, as 
all possible nucleotides (viz. A, C, G and T) at this position encode the same amino acid (i.e. 
synonymous substitutions). There are also twofold (i.e. when 1 out of the 3 possible 
substitutions is a synonymous change) and non-degenerate sites (i.e. when all 3 possible 
substitutions are non-synonymous). Interestingly, for some amino acids that are encoded by 
more than one codon, there is a bias in the usage of synonymous codons (Irwin et al. 1995; 
Tats et al. 2008). As a result, some codons are preferred over others. Studies have suggested 
that preferences in the use of the genetic code may be due to different rates of translation 
efficiency and accuracy (Bossi and Ruth 1980; Irwin et al. 1995; Stormo et al. 1986).
The physicochemical differences, the design of the genetic code, and codon usage 
differentially affect amino acid mutability (defined as relative rates of amino acid 
substitutions). Thus, some substitutions will be observed more frequently than others. The 
relative rate of mutability in an evolutionary context has been defined as the rate of change of 
an amino acid in a pair of aligned sequences (i.e. the number of changes divided by the total 
number of occurrences of a particular amino acid (Collins and Jukes 1994; Dayhoff et al. 
1978). These relative rates of substitution are usually portrayed as substitution matrices, such 
as PAM (Dayhoff et al. 1978) and BLOSUM (Henikoff and Henikoff 1992). The term PAM
t in t  poi t o r  >n coeon
inird pouticn in codon
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matrix stands for Point Accepted Mutation and measures the probability or rate of 
substitution of one amino acid by another over time. It is calculated from the sequence 
alignments of closely related protein families. Thus, PAM1 is 1 substitution per 100 amino 
acids or 1% and is usually used for closely related sequences. For othologues from more 
distantly related species, PAM matrices are extrapolated from PAM1 matrix, by multiplying 
PAM1 by itself. On the other hand, BLOSUM matrix (Henikoff and Henikoff 1992) stands 
for BLOcks of amino acid Substitution Matrix and is mainly used for relatively divergent 
sequences. In contrast to PAM matrices, BLOSUM is derived from local sequence 
alignments (i.e. blocks of protein alignments without gaps), without extrapolation. Numerous 
BLOSUM matrices have been devised, according to the relatedness of the sequences used, 
e.g. BLOSUM80 for relatively closely related sequences and BLOSUM45 for more divergent 
sequences and the number represents clustering of the blocks at certain percentage level. 
Others have used a different approach to calculate substitution rates. For example, Hess et al. 
(1994) have shown a strong neighbour-dependent bias of the substitution rates using -20,000 
point substitutions in aligned human gene/pseudogene sequences. In addition, the 
substitutions rates estimated by Hess et al. (1994) have been derived from sequences that are 
no longer under evolutionary pressure.
Despite the differences in the methods used in calculating substitution rates, it is clear 
that relative substitution rates are not uniformly distributed between different amino acid 
changes. Estimates show that, in an evolutionary context, one of the least mutable amino 
acids is cysteine, whereas serine and threonine are among the most mutable ones (Collins and 
Jukes 1994). The latter findings are not surprising bearing in mind that cysteine, as described 
above, is the only amino acid with a sulfhydryl group and serine and threonine are quite 
similar, with respect to their chemical composition.
At the nucleotide level, transitions are single base-pair substitutions of a pyrimidine 
for another pyrimidine (T^>C) or a purine by a purine (G<=>A), while transversions are 
substitutions of a pyrimidine by a purine and vice versa (depicted in Figure 11).
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Figure 11 Transitions and transversions (after Strachan and Read 2004)
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As shown in Figure 11, there are twice as many possible transversions than 
transitions. Therefore, based purely on their frequencies, transversions are expected to be 
twice as frequent compared with transitions. However, in an evolutionary context, studies 
have shown quite the opposite, with transitions being found more frequently observed than 
transversions. Collins and Jukes (1994) have calculated that the ratio of transversions to 
transitions for nonsynonymous changes is 1.2 as compared to 2.4 expected from the genetic 
code. Thus, there is an excess of transitions over transversions (almost 2 times), even with a 
correction for the use of genetic code. To a large extent, this transitional bias is due to the 
spontaneous deamination of 5mC in the context of CpG dinucleotides, resulting in C->T 
(coding DNA strand) and G->A transitions (non-coding DNA strand) in a CpG dinucleotide 
context (Coulondre et al. 1978; Grippo et al. 1968). As is evident from numerous studies, this 
spontaneous deamination of 5mC is also largely responsible for a highly increased mutation 
rate at CpG dinucleotides (Cooper and Youssouflan 1988; Gaffney and Keightley 2008; 
Krawczak et al. 1998).
Other authors have derived mutability rates from disease-associated single-base pair 
substitutions. Thus, Krawczak et al. (1998), employed single-base-pair substitutions 
associated with inherited disease that were logged at that time in the Human Gene Mutation 
Database (HGMD, Stenson et al. 2003). These substitution rates therefore represent 
mutability rates associated with inherited disease.
Comparison of relative mutability rates derived from disease-associated mutations 
with those derived from the interspecific comparison of orthologous protein sequences, could 
indicate patterns of specific amino acid exchanges or the severity of the amino acid 
exchanges associated with disease. It is expected that on average the physicochemical 
difference of amino acid exchanges, over evolutionary time, will have been relatively small. 
By contrast, disease-associated mutations are expected to have been much more drastic with
42
respect to the physicochemical differences of the amino acids involved. Indeed, a number of 
studies have revealed the similarities of amino acid substitutions between orthologous 
proteins, with respect to physicochemical properties (Clarke 1970; Epstein 1967; Miyata et 
al. 1979; Zhang 2000). Therefore, whilst amino acid substitutions will be very similar 
between orthologous proteins (in terms of their physicochemical properties), drastic changes 
are likely to be under negative purifying selection (Miller and Kumar 2001) and hence are 
rarely going to be observed. Indeed, both the type and frequency of amino acid exchanges 
greatly differ, between disease-associated mutations and the exchanges observed between 
orthologous proteins (Miller and Kumar 2001). Most importantly, disease-associated changes 
are more radical overall than changes observed in orthologous sequences (Miller and Kumar 
2001; Vitkup et al. 2003). In contrast to the strong nearest neighbour-dependent substitution 
rates reported by Hess et al. (1994) for evolutionary substitutions, disease-associated 
substitution rates exhibit a very limited nearest neighbour effect (Krawczak et al. 1998).
4.1.2.3. Evolutionary data
DNA sequence is said to be evolutionary conserved if the orthologous sequence is 
similar or nearly identical in multiple organisms. Under natural selection (genetic variations 
that confer an advantage or disadvantage upon the organism in terms of its ability to survive 
and reproduce), changes in the DNA sequence (e.g. mutations) would be neutral or nearly 
neutral (i.e. silent mutations), deleterious or advantageous. Mutations are said to be neutral if 
they neither confer an advantage nor a disadvantage to an organism. Some amino acid 
residues frequently vary between orthologous proteins, indicating that they are tolerated by 
natural selection and might be under less stringent selection pressure (Miller and Kumar
2001). On the other hand, some amino acid residues are virtually invariant (i.e. they exhibit a 
high degree of evolutionary conservation), when orthologous sequences are compared in 
different species. Many authors have suggested that some amino acid residues could play a 
relatively more important role than others, with respect to protein function. Assuming that 
such sites are susceptible to mutation, the fact that they are found to be virtually invariant 
among different species suggests that mutations at these sites might exert a detrimental effect 
on the function of the protein product. Therefore, these sites will have been under negative 
selection pressure via natural selection. Nevertheless, evolutionary conserved sites are not 
necessarily under strong purifying selection pressure. Indirect evidence comes from a 
phenomenon, termed ‘pseudogeneralization’ (Wang et al. 2006), which represents the loss of
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a gene (through deactivating mutation and independently from other species) during human 
evolution, since divergence from the chimpanzee lineage. This gene loss has been the basis 
for the ‘less is more’ hypothesis (Olson and Varki 2003). It suggests that the loss of specific 
genes in humans, since divergence from the chimpanzee lineage, may have allowed brain size 
expansion (Stedman et al. 2004). Thus, Stedman et al. (2004) have suggested that loss of 
masticatory muscle strength may have relaxed the evolutionary constraints on 
encephalisation. In addition, a nonsynonymous mutation that leads to sickle cell anaemia 
confers resistance to malaria in heterozygotes (described in more detail in 4.1.1.4). Thus, 
even though some mutations at evolutionarily conserved sites confer a negative effect on the 
function of the protein, they may nevertheless be tolerated by natural selection.
Nevertheless, it is commonly accepted that drastic amino acid exchanges (in terms of 
the physicochemical difference between substituted and substituting amino acids) during the 
evolution of species, would be subject to strong negative selection. In addition, studies 
suggest that the majority of changes are neutral or nearly neutral with respect to selection 
pressure (Kimura 1991; Kimura and Ota 1974). There is evidence to show that drastic amino 
acid changes are depleted in the genomes of higher organisms (Kimura 1991) and that the 
majority of changes are physicochemically similar or effectively neutral. On the other hand, 
disease-associated missense changes are much more drastic. Significantly more disease- 
associated mutations are observed at invariant or highly conserved amino acid positions than 
would be expected by chance alone (Abkevich et al. 2004; Miller and Kumar 2001; Walker et 
al. 1999).
During tumour development, pathological amino acid changes occurring in the soma 
are generally considered to abrogate the function of tumour suppressor genes (Tavtigian et al.
2008), whereas gain-of-function mutations are associated with oncogenes, such as the KRAS 
and HRAS genes (Schubbert et al. 2007). Tumour suppressor genes are responsible for key 
processes, such as response to DNA damage (e.g. ATM), inhibit cell proliferation (e.g. TP53), 
responsible for DNA repair (e.g. BRCA1, BRCA2), etc. (Sherr 2004). Therefore, tumour 
development and progression require the elimination of key tumour suppressor genes. 
Nevertheless, some tumour suppressor genes have been suggested to ‘evolve’ via positive 
selection, during tumorigenesis (Glazko et al. 2006; Glazko et al. 2004). Since, the majority 
(>80%) of tumour-associated TP53 sequence changes are missense mutations (The p53 
database, http://p53.free.fr/ Soussi and Beroud 2001) and a significant excess of non­
synonymous mutations is observed as compared to neutral expectations (Glazko et al. 2006), 
the mutant TP53 gene could acquire new functions during tumour development. Indeed,
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various studies have suggested that, unusually, TP53 is not a simple tumour suppressor gene, 
but may also possess some properties of an oncogene (Blagosklonny 2000; Pugacheva et al.
2002). In other words, during tumour development, at least for the TP53 gene, there is a 
preferential fixation of missense mutations over nonsense or silent mutations. Thus, nonsense 
mutations, which are generally considered to abrogate gene function, are likely to be 
eliminated, possibly via negative selection, whereas missense mutations are preferentially 
acquired and may result in gains of function (i.e. oncogenic properties). Despite nonsense 
mutations being generally considered to abrogate gene function, several studies have shown 
that mutant TP53 proteins retain specific wild-type functions, such as an ability to induce 
apoptosis (Rutherford et al. 2002) or are as abundant as the wild-type protein (Anczukow et 
al. 2008). Thus, considerable variation could exist between different nonsense mutations, 
with respect to functional consequences. As mentioned above, in general the majority of 
pathological missense mutations are found at evolutionarily conserved positions. The TP53 
gene is no exception to this rule. These key positions are located in several functionally 
important domains responsible for DNA binding, conformation, transactivation and 
tetramerization (Glazko et al. 2004; Joerger and Fersht 2008). Thus, these observations 
strongly suggest that missense changes in the TP53 gene at key amino acid positions, could 
promote tumour development or progression, through the acquisition of new gene functions. 
Similar findings, although with a relatively smaller effect, has been reported for other tumour 
suppressor genes, such as the BRCA1, BRCA2 and CDKN2A (Glazko et al. 2006).
4.1.2.4. Hotspot analysis
The mutational spectra of both the soma (i.e. tumours) and the germline contain 
examples of mutations, which frequently re-occur at particular positions (i.e. hotspots) in a 
number of different tumour suppressor genes. This observation suggests that mutations are 
not randomly distributed along the gene sequence, but rather can occur at hotspots due to the 
action of both exogenous mutagens and endogenous mutational mechanisms. Carcinogens are 
responsible for some of the mutational hotspots (Besaratinia and Pfeifer 2006). For example, 
sunlight (UV light) and aflatoxin B(l) exposure are both associated with specific mutational 
spectra in the TP53 gene in skin and liver cancer respectively (Pfeifer et al. 2005). UV 
irradiation is usually characterized by C->T or CC->TT transitions at dipyrimidine sites 
(Drobetsky et al. 1994; Sage et al. 1996), whereas aflatoxin exposure is strongly associated 
with G->C and T->A transversions, predominantly in CpG dinucleotides (Besaratinia et al.
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2009; Hussain and Harris 1999). It has however also been shown that endogenous 
mechanisms also play an important part in shaping the mutational spectra associated with 
tumour development. These endogenous mechanisms include methylation-mediated 
deamination of 5-methylcytosine in CpG dinucleotides, slippage of the complementary DNA 
strands, post-replicative mismatch repair, exonucleolytic proofreading mechanisms, etc 
(Krawczak et al. 1998; Wells et al. 2005).
Furthermore, only 19% (73 hotspots) of TP 5 3 codons account for 88% of all reported 
TPS3 mutations whilst just 6 codons account for 25% of all somatic point mutations in this 
gene (Walker et al. 1999). Walker et al. (1999) have reported that these hotspots are situated 
at evolutionarily conserved codons thereby indicating a relationship to functionally important 
amino acid residues.
4.1.3. Accuracy of existing methods to classify the functional 
consequences of missense variants
In the absence of reliable functional assays to determine the functional importance of 
missense variants, numerous in silico methods and algorithms have been proposed. These 
methods take into consideration important factors that contribute to, or play an integral part in 
mutagenesis. In order to predict the pathogenicity of missense mutations, these methods rely 
on evolutionary conservation, based on multiple sequence alignments, amino acid physical 
and chemical composition, structural properties of wild-type and mutant proteins, amino acid 
substitutions matrices, nucleotide mutability rates, etc (Tavtigian et al. 2008). The prediction 
accuracy of these algorithms is relatively high. For three algorithms (SIFT, PolyPhen and A- 
GVGD), Chan et al. (2007) have reported an overall prediction accuracy of 73-82% when 
missense variants are scored with each of the programs. Similarly, several other tools reach 
an accuracy of prediction which ranges from 75% to 95% (Tavtigian et al. 2008). Further, the 
combination of the three algorithms tested by Chan et al. (2007) increases the overall 
predictive ability to -88% and up to -96% for mutations at invariant amino acids with 
respect to evolutionary conservation.
Comparison of these methods indicates that all algorithms, which use evolutionary 
conservation, are superior to those methods, which only use structural information (Chan et 
al. 2007). In addition, predictions are less accurate when the degree of evolutionary 
conservation is not used (Goldgar et al. 2004).
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Even although these methods achieve a relatively high degree of prediction accuracy, 
the parameters used are only proxies for the quantity of interest, i.e. pathogenicity (Kryukov 
et al. 2007; Tavtigian et al. 2008). Most of these algorithms rely on training sets, usually 
based on recurring mutations (i.e. hotspots). However, there are some indications that the 
majority of rare missense alleles (usually not included in the training sets) are in fact 
deleterious (Kryukov et al. 2007). Furthermore, even although these rare missense alleles 
may be subject to purifying selection (i.e. since they are likely to be deleterious), some could 
predispose to disease. Indeed, if the ‘common disorder, rare allele’ hypothesis (Kryukov et al. 
2007) turns out to be correct, some of these deleterious alleles may play an important role in 
the development and/or initiation of a disease phenotype. Nevertheless, there is no single test 
that is capable of achieving 100% accuracy and unequivocally determining the pathogenicity 
and functional importance of missense variants. Thus, further effort is required to improve 
the predictive accuracy of these algorithms.
4.1.4. Could the comparison of somatic and germline mutational 
spectra help to improve the accuracy of pathogenicity 
prediction?
It is already known that the mutational spectra of both the soma and germline exhibit 
similarities, but also differences. For example, in response to ionizing radiation dose, both the 
germline and the soma show similar damage rates (Vilenchik and Knudson 2000). On the 
other hand, it has been shown that the germline exhibits extreme minisatellite instability, 
whereas this is rarely observed in the soma (Buard et al. 2000).
Research suggests that an interaction between germline and somatic mutations could 
play an important role in the aetiology of familial adenomatous polyposis (Latchford et al. 
2007). This interaction is evident from the observation that germline mutations can predict or 
even direct the type and position of subsequent somatic mutations with respect to tumour 
development. In addition, germline inherited susceptibility not only has the potential to 
influence the somatic mutation rate directly, but could also confer a stronger selective 
advantage upon the cells. Hence, these cells might be more likely to undergo clonal 
expansion and subsequent tumour development. Evidence for such interplay between the 
soma and the germline comes from the analysis of myeloproliferative neoplasms (Campbell
2009). These neoplasms are associated with somatic mutations in the JAK2 gene. Three 
independent studies have shown that these somatic mutations are preferentially acquired
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within a particular inherited haplotype within the JAK2 gene (Jones et al. 2009; Kilpivaara et 
al. 2009; Olcaydu et al. 2009). These authors proposed two hypotheses to account for the 
preferentially acquired somatic mutations. Firstly, inherited variants could confer a selection 
advantage and secondly, the inherited variants could promote an increased somatic mutation 
rate. Additional research is required to ascertain which hypothesis is valid (i.e. selective 
advantage or increased mutation rate), but these findings clearly put the differential selection 
advantage of somatically acquired mutations with respect to inherited variants in perspective. 
To speculate further, if the stronger selection advantage hypothesis is valid, a somatic 
mutation might or might not promote tumour development, based on inherited (i.e. germline) 
mutation or variation (e.g. a specific haplotype). Therefore, interplay between germline and 
somatic variants could well be very important when assessing the functional importance of 
missense variants.
Based on the importance of somatic and germline mutational spectra with respect to 
tumour development, it is quite surprising that relatively few studies have attempted to 
compare and contrast mutational spectra in the soma and the germline. Potential differences 
in the mutational mechanisms operating in the germline and the soma could influence the 
overall accuracy of any prediction algorithm, with respect to the pathogenicity of missense 
variants. On the other hand, different selection constraints could also distort the overall 
prediction accuracy. Therefore, studying mutational mechanisms, with regard to the germline 
and soma, should not only serve to contribute substantially to improving our understanding of 
tumour development, but could also help to improve the accuracy of in silico algorithms to 
predict the pathogenicity of missense variants.
4.1.5. Aims of the analysis
The main objectives of the analysis here were to explore any similarities or 
differences that somatic and germline missense mutations might exhibit with respect to 
nucleotide substitution rates derived from disease-associated mutations and nucleotide 
substitution rates derived from non-disease-associated mutations. The main objectives also 
included exploring similarities and differences between the soma and germline with respect 
to amino acid physical and physicochemical differences and the degree of evolutionary 
conservation. To accomplish these objectives, a number of tasks were performed and a 
number of parameters or properties were addressed in this analysis.
• Definition and calculation of potential missense mutations
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For every tumour suppressor gene examined, all possible single base-pair substitutions were 
calculated (described in 4.2.2.5). Those mutations that were not part of the observed somatic 
and germline mutational spectra were termed ‘potential missense mutations’. As the potential 
missense mutations in these particular tumour suppressor genes have not so far been 
associated with any disease phenotype, they were used as a “control set” to draw inferences 
about the non-randomness of various parameters observed in somatic or/and germline 
missense mutations. The following parameters were assessed:
* Non-disease-associated single base-pair substitution rates
For every missense mutation, observed or potential, non-disease-associated nucleotide 
substitution rates were derived from Hess et al. (1994).
* Disease-associated single-base pair substitution rates
For every missense mutation, observed or potential, disease-associated relative nucleotide 
substitution rates were derived from Krawczak et al. (1998).
* Degree of evolutionary conservation
In order to estimate the degree of evolutionary conservation at every codon in each gene, 
orthologous gene sequences were derived from a number of vertebrate species. They were 
used to produce codon-by-codon multiple sequence alignments. These alignments, allowed 
the estimation of the degree of evolutionary conservation at each amino acid position.
* Degree of physical and physicochemical difference of amino acid 
substitutions
For every amino acid substitution (observed or potential), the physicochemical difference 
between wild-type and mutant amino acids, calculated by Grantham (Grantham 1974), were 
used.
These tasks were performed to provide meaningful answers to the following 
questions:
Are there any differences/similarities between somatic, germline, shared and potential 
missense mutations for each tumour suppressor gene and all genes combined in terms of 
disease and non-disease-associated nucleotide substitutions rates, evolutionary conservation 
or physicochemical difference?
Is there any difference/similarity between the combination of somatic, germline and shared 
missense mutations (henceforth called observed mutations) and potential missense mutations 
for each tumour suppressor gene and all genes combined in terms of disease and non-
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disease associated nucleotide substitutions rates, evolutionary conservation or 
physicochemical difference?
Are there any differences/similarities between CpG- and non-CpG located missense 
mutations between somatic, germline, shared and potential missense mutations for each 
tumour suppressor gene and all genes combined?
Are there any differences/similarities between CpG- and non-CpG located missense 
mutations between observed and potential missense mutations for each tumour suppressor 
gene and all genes combined?
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4.2. M ateria ls and m ethods
4.2.1. M ate ria ls
4.2.1.1. G enera l defin ition of m issense m uta tions
A missense mutation is defined as a single base-pair substitution responsible for the 
non-synonymous change of the wild-type amino acid encoded by a specific codon. This 
definition excludes single base-pair substitutions that lead to the introduction of a stop codon 
within the coding region of a gene (these are termed nonsense mutations). Employing this 
definition, there are 392 different possible single-base pair substitutions in 61 codons that 
could lead to a missense mutation. These single base-pair substitutions are listed in Table 8.
4.2.1.2. L abelling  of som atic, germ line  and  sh a red  m issense 
m uta tions
For detailed description of labelling of mutations, see 3.3. A summary of the studied 
missense mutations is given in Table 9 and Table 11.
4.2.1.3. G enera l defin ition o f single base-p a ir substitu tions 
g enera ting  m issense m u ta tions in C pG  dinucleotides
CpG missense mutations were defined as C->T transitions found in the context of 
CpG dinucleotides. In addition, all observed missense mutations were logged according to 
the coding strand of DNA. Hence, single base-pair substitutions in CpG dinucleotides on the 
non-coding DNA strand would appear as G->A transitions (as shown in Figure 12).
Figure 12 Single base-pair substitutions in CpG dinucleotides
change in coding s tran d  C->T
coding s trand  5 '.......
non-coding s tran d  3 '.......
3' ob served  change 
, in coding strand  
5 C->T
coding s tran d  5' 
non-coding s tran d  3'
C-G -3 ' 5 '....... C-A.........-3 ' observed  change
in coding strand  
G->A
change in non-coding s tran d  C->T
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4.2.2. M ethods
4.2.2.1. Iden tification  of po ten tial m issense m uta tions
The identification of potential missense mutations and potential missense mutations in 
CpG-dinucleotides was accomplished as described in 3.5.
4.2.2.2. C alcu la tion  of degree o f evo lu tionary  conservation
In order to assess the degree of evolutionary conservation at the codon level for each 
of the 17 tumour suppressor genes under study, multiple sequence alignments were required. 
For each gene, several sequence orthologues from vertebrate species were obtained (cDNA 
and protein sequence). Detailed information on species and sequences used is given in Table 
10. Research suggests that the disease-associated mutations tend to occur at evolutionarily 
conserved sites (Abkevich et al. 2004; Miller and Kumar 2001; Tavtigian et al. 2008; Walker 
et al. 1999). In the majority of cases when a disease-associated mutation is found at an 
evolutionarily variable position, substitutions have occurred in phylogenetic lineages least 
related to humans (Miller and Kumar 2001). While inclusion of a wide variety of species 
could protect from chance variation (i.e. an amino acid position may be evolutionarily 
invariant due to the limited number of sequences used Tavtigian et al. 2008), amino acid 
variation may be correlated with functional differences of the associated products (Miller and 
Kumar 2001). Therefore, only orthologous sequences from vertebrate species were used. 
Orthologous sequences were retrieved from NCBI’s Entrez Gene database 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene Maglott et al. 2005). The aim was to 
include as many orthologous sequences from vertebrate species as possible. At the time of 
conducting the analysis (beginning of 2006), there were on average 6-7 vertebrate species 
available for each of the 17 studied human tumour suppressor genes (detailed information is 
given in Table 10). In addition to the orthologous sequences listed in the NCBI’s Entrez Gene 
database, for each gene the genomic DNA was used to find orthologous sequence from 
vertebrate species, using the ‘Basic Local sequence Alignment Search Tool’, BLAST, 
available at http://blast.ncbi.nlm.nih.gov/Blast.cgi (Altschul et al. 1990). In order to be 
included as an orthologue, the sequence (for each species) had to have been completely 
sequenced. Therefore, sequences that were partially sequenced were not included.
In order to align the orthologous sequences codon-by-codon, the CLUSTALX 
software package (Thompson et al. 2002) was used. Multiple alignments of orthologous
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protein sequences, for each gene, were generated using the default parameters in 
CLUSTALX. In order to generate cDNA codon-by-codon multiple sequence alignments, I 
created a computer program that took the output of CLUSTALX (i.e. multiple protein 
orthologous sequence alignments) and consecutively, for each of the codons and for each 
species, generated multiple orthologous cDNA sequence alignments. These multiple cDNA 
sequence alignments were then used to assess the evolutionary constraints at codon level.
In order to estimate the evolutionary constraints acting upon each of the 17 human 
tumour suppressor genes and to estimate how fast each gene has been evolving, 4 different 
algorithms were employed. The most common measure used to estimate sequence diversity is 
the Ka/Ks  ratio (Yang and Bielawski 2000). Ka represents the number of non-synonymous 
substitutions per non-synonymous site and Ks is the number of synonymous substitutions per 
synonymous site. Each site (i.e. position 1, 2 or 3 within a codon) could thus be synonymous, 
non-synonymous, or partially non-synonymous. A comprehensive example is given in Figure 
13.
Figure 13 Example of synonymous and non-synonymous sites
non -  non-synonymous 
syn -  synonymous 
N -  number
position 1 2 3
synonymous site 0 0 2/3 -------► total N synonymous sites 2/3
non-synonymous site 1 1 1/3  ► total N non-synonymous sites 22A
Generally, the algorithms for calculating the Ka/Ks ratio contain the following steps. 
The numbers of synonymous and non-synonymous sites are counted, then for each pair of 
aligned (codon-by-codon) sequences, the number of synonymous and non-synonymous 
changes is determined. If two aligned codons differ by more than 1 substitution, depending
possible substitutions 
position 1 position 2 position 3
lie He lie
(Aft T A ® r  A T ®
non © T  T Leu 
non ® T T  Phe
non ® T T  Val
non A A T  Asn syn A T ®  lie
non A C T  Thr syn A T ©  lie
non A © T  Ser non A T ©  Met
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on the number of different substitutions (i.e. 1, 2 or 3), there are 2 or 6 different pathways to 
account for the substitutions. An example is given in Figure 14.
Figure 14 Example of number of synonymous and non-synonymous differences between 
two aligned codons
sequence 1 CTA
sequence 2 ATG
pathway 1 
ATA
CTA ATG
CTG ^  
pathway 2
Leu lie Met
pathway 1 CTA “► ATA ATG
pathway 2 CTA -► CTG -► ATG
Leu Leu Met
2 non-synonymous changes
1 synonymous, 1 non-synonymous changes
Number synonymous differences (s^  1 / 4 x 2 =  1/2 
Number non-synonymous differences ( s j  3 / 4 x 2 =  3/2
The proportions of synonymous and non-synonymous differences are then calculated 
from the total number of synonymous and non-synonymous differences. The numbers of 
synonymous substitutions per synonymous site, Ka and the number of non-synonymous 
substitutions per non-synonymous site Ks are then estimated, by using for example the Jukes- 
Cantor formula (Jukes and Cantor 1969).
Equation 4 Jukes-Cantor formula
< / - —- l o g , ( l - — )
4 3
P  Ln
where nd - number of nucleotide differences
n - total number of nucleotides compared
The algorithm, described above is the Nei and Gojobori (1986) unweighted pathway 
method for estimating synonymous substitutions. A plethora of methods and algorithms exist 
to account for multiple substitutions at two aligned codons, which take into account the 
transition/transversion bias, unequal base frequencies, varying substitution rates among sites,
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substitution rates between sites and substitution patterns among lineages (Kumar et al. 2004). 
As mentioned above, four of the most common methods were used to estimate, for each gene, 
the rate of synonymous and non-synonymous substitutions per site. These included the Li- 
Wu-Luo (Li et al. 1985) and Pamilo-Bianchi (Pamilo and Bianchi 1993) codon models, both 
part of the MEGA software package (Kumar et al. 2004). In addition, the Nei and Gojobori 
(1986) codon model and the Goldman and Yang (1994) maximum likelihood method were 
also used, both part of the PAML (CODEML program) software package (Yang 1997). For 
each of the methods, both software packages produce pair-wise Ka/Ks ratios between the 
orthologous sequences from two species. In order to calculate the overall Ka/Ks ratio for all 
pair-wise comparisons (i.e. for each gene, and for a pair of aligned codon-by-codon 
orthologous sequences), the average Ka/Ks ratio was taken for all pair-wise comparisons.
In order to estimate the evolutionary constraints acting at the codon level, a method 
described in Walker et al. (1999) was used. The program SUBROLL part of the SEALS 
software package (Walker and Koonin 1997) that was used in Walker et al. (1999), was not 
available. Therefore I created a program according to the method described in Walker et al. 
(1999) to estimate evolutionary constraints at the codon level. The program utilizes 
orthologous cDNA sequences, aligned codon-by-codon as described above. In a pair-wise 
fashion (i.e. comparing only two sequences at a time), for all combinations of pairs of aligned 
orthologous cDNA sequences and consecutively for each pair of codons, the numbers of 
synonymous (Ks) and non-synonymous (Ka) differences were counted. The pathway method 
of Nei and Gojobori (1986) was used to create all possible pathways between two codons. If 
two aligned codons differed by more than one substitution, the minimum number of 
substitutions was assumed and the most favourable path was determined using a PAM 100 
matrix. Gaps in the cDNA sequences of non-human species were treated as being equivalent 
to a non-synonymous substitution. Codons that were not present in human cDNA sequence 
were not taken into consideration. As a result, the evolutionary constraints acting upon the 17 
human tumour suppressor genes at codon level were inferred by calculating Ka/(Ka+ Ks) . 
The measure corrects for the fact that some substitutions occur at degenerate codons and do 
not change the amino acid.
4.2.2.3. Nucleotide substitution rates
Nucleotide substitution rates were taken from Hess et al. (1994) and Krawczak and 
Cooper (1991). Both substitution rates take into account the influence of nucleotide context
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(e.g. frequency of nucleotide triplets) on mutational bias. Thus, these nucleotide substitution 
rates take into consideration the effect of adjacent nucleotides, either side of the reported 
single base-pair substitution.
4.2.2.4. Amino acid difference between wild-type and mutant 
amino acids
For each amino acid change in all datasets (i.e. somatic, germline, shared and 
potential) and for every gene, a value corresponding to the amino acid difference between the 
wild-type and mutant residues, was assigned according to Grantham (Grantham 1974).
4.2.2.5. Comparisons and calculation of statistical significance
In order to answer the questions posed in the Aims of this analysis (Section 4.1.5), the 
following tests for each gene were performed:
Soma vs. potential (simulated spectra) missense mutations 
Germline vs. potential (simulated spectra) missense mutations 
Shared vs. potential (simulated spectra) missense mutations
Observed (the combination of numbers of somatic, germline and shared mutations) vs.
potential (simulated spectra) missense mutations
Soma vs. germline missense mutations
Soma vs. shared missense mutations
Germline vs. shared missense mutations
Recurrent somatic vs. non-recurrent somatic missense mutations
Recurrent somatic shared vs. recurrent somatic non-shared missense mutations
Non-recurrent somatic shared vs. non-recurrent somatic non-shared missense mutations
Recurrent somatic shared vs. non-recurrent somatic non-shared missense mutations
In addition, the numbers of mutations in all genes were combined only if missense 
mutations possessed the same label (i.e. somatic, germline or shared) to represent the 
combination of mutations in all genes. Each of these comparisons were performed with 
respect to nucleotide substitution rates (values derived from Hess et al. (1994) and Krawczak 
et al. (1998)), degree of evolutionary conservation at the codon level (as described in 4.2.2.2), 
Grantham amino acid difference (as described in 4.2.2.4) and CpG dinucleotide context
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(described in 4.2.2.1). All mutations were categorized into two groups, i.e. ‘within CpG
dinucleotide’ or not, and the tests with respect to CpG dinucleotide context were performed
• 2using a x  statistic (as described in 3.6.1.1). The rest of the comparisons (i.e. involving 
nucleotide substitution rates, degree of evolutionary conservation and Grantham amino acid 
difference) used continuous measures. Therefore, in order to determine what was the most 
appropriate test statistic, a normality test (to assess whether the data were drawn from a 
normally distributed population or not) was performed for each of the datasets (e.g. somatic, 
germline, shared, etc.). The normality tests were performed using the Shapiro-Wilk test for 
normality, part of the R software package (http://www.r-proiect.orgA. All of the datasets (e.g. 
somatic, germline, shared, etc.) for each gene were found to deviate significantly from a 
normal distribution (an example is given in Figure 15). As a result, the rest of the test was 
performed using the Wilcoxon rank-sum test (Wilcoxon 1945). Detailed description of 
Wilcoxon rank-sum test is given in 3.6.1.2
To allow for multiple hypotheses testing for the tests performed for each gene (listed 
at the beginning of this section), 10,000 resampling permutations were performed and the 
resulting statistic was termed ‘permuted’. To allow for multiple hypotheses testing for the 2 
separate tests performed in each gene (i.e. CpG-dinucleotide analysis and Wilcoxon rank-sum 
tests), a Bonferroni correction was applied and the resulting statistic was termed ‘gene-wise’. 
Therefore, each permuted p-value was multiplied by 2 (gene-wise a  -  0.05/2 or 0.025), to 
account for the different tests. To allow for multiple hypothesis testing, for the tests 
performed in all genes, a Bonferroni correction was also applied. Therefore, each gene-wise
p-value was multiplied by 17 (overall experiment-wise a  -  — or 0.0015).
2 17
I designed a computer program that automatically performs the x2 and Wilcoxon rank- 
sum statistics for each test along with the re-sampling permutations.
4.2.2.6. Calculation of power and effect size
Calculations of the power and associated effect sizes are described in 3.6.3. In order 
to keep the overall a  at the 0.05 level, as multiple statistical tests were performed, the value 
of a  used in the power calculations was set to 0.0001336898 (total number of tests 
performed 374; therefore, the Bonferroni-adjusted a ,  to account for multiple testing,
was a  -  0.05/374, or 0.0001336898 for r 2 test statistic and a  -  ^ (two-sided test) for
374*2
the Wilcoxon rank-sum test statistic). As Bonferroni correction is considered to be a
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0  •  •  •conservative correction for multiple testing, the power calculated for the x statistical tests is 
a conservative estimate.
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4.3. Results
The results are presented in comparison-wise fashion. Due to the overwhelming 
quantity of results that were generated during the work described in this chapter, only 
summaries of statistically significant results are discussed and presented in the form of tables 
(Table 9, Table 11, Table 12, Table 13, Table 14 and Table 15). These tables are to be found 
at the end of this chapter.
Nevertheless, the presented tables capture the results obtained for all comparisons 
performed, along with the directionality of the statistically significant results observed and 
power calculations. For further information, complete results for all comparisons performed 
are to be found in the Supplementary Tables.
In order to facilitate readability, whenever a comparison was statistically significant, 
it was substituted with the words “significant” or “significantly”; gene-wise statistically 
significant p-values were substituted with the symbol pG and experiment-wise statistically 
significant p-values were substituted with the symbol pE. In addition, whenever a 
comparison exhibited gene-wise and experiment-wise statistical significance, only the 
experiment-wise p-values were given and whenever a comparison exhibited only gene-wise, 
but not experiment-wise statistical significance, only the gene-wise p-value was listed. 
Additionally, all gene-wise and experiment-wise statistically significant results are 
graphically summarized in Table 13, along with the direction of the result and power 
calculations, but it was not referenced throughout the Results section, in order to reduce 
repetition.
4.3.1. Degree of evolutionary conservation
In order to estimate how fast each gene has been evolving and the degree of the 
evolutionary constraints acting upon the 17 human tumour suppressor genes, four different 
algorithms (detailed description is given in 4.2.2.2) for estimating the rate of evolution, 
namely Ka/Ks ratio, were performed. A summary graph of the results is presented in Figure 
16.
For all genes, the Ka/Ks ratio was smaller than 1. This indicates that over time 
natural selection has tended to eliminate deleterious mutations in these genes, thereby 
yielding highly evolutionarily conserved gene and protein sequences. The evolutionary 
divergence for most of the genes was well below the average rate of sequence divergence 
between human and rodent, Ka/Ks~0ASQ derived from 1880 human, rat and mouse gene
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orthologues (Makalowski and Boguski 1998). The TP 5 3 gene exhibited a rate of evolution 
that was similar to the average rate of gene evolution between human and rodent. In addition, 
the CDKN2A, BRCA1 and BRCA2 genes exhibited on average comparatively higher rates of 
evolution than the average rate of evolution between human and rodent. All of the genes 
showed Ka<Ks, indicative of the relative functional importance of these genes and that they 
might be under strong negative purifying selection.
4.3.2. Somatic vs. potential missense mutations
For a number of genes, it was evident that nucleotide context, measured in terms of 
both disease-associated and non-disease-associated mutability rates, significantly influences 
the occurrence of somatic, when compared to potential missense mutations. This was 
certainly the case for the APC, CDKN2A, PTEN and TP53 genes (p E<0.0034), with medians 
ranging from 4.6 to 8.4 and from 4.1 to 4.5 for the somatic and potential mutations 
respectively for non-disease-associated mutability rates and ranging from 0.5 to 1.1 and from 
0.38 to 0.5 for the somatic and potential mutations for disease-associated mutability rates. In 
addition, the STK11 gene showed experiment-wise significantly higher median relative 
disease-associated mutability rate (p E<0.0034; median 1.66 and 0.44 for the somatic and 
potential mutations respectively). On the other hand, two genes (i.e. BRCA2, RBI) did not 
exhibit significant results, but nevertheless showed >80% power to detect an experiment-wise 
significant difference. Thus, it is very likely that nucleotide context does not play a 
significant part in shaping the somatic missense mutational spectrum in these two genes, i.e. 
BRCA2 and RBI. These results indicate, that the somatic mutational spectrum in some genes 
is strongly influenced bv the nucleotide sequence context (i.e. APC. CDKN2A. PTEN and 
TP53), whereas for other genes (i.e. BRCA2 and RBI) nucleotide context plavs little or no 
role.
The RBI and CDKN2A genes exhibited significantly more somatic missense 
mutations located in CpG dinucleotides (13% and 15% for RBI and CDKN2A respectively), 
when compared to potential missense mutations (1% and 4%, pE <0.0034). In addition, 
several other genes (i.e. ATM , BRCA2 and STK11) exhibited only gene-wise statistical 
significance ( pG ranging from 0.01 to 0.03), indicating more somatic missense mutations 
located in CpG-dinucleotides (proportions ranging from 9% to 24%) than potential mutations 
(proportions ranging from ~0% to 3%), but did not reach experiment-wise statistical 
significance ( pE ranging from 0.170 to 0.510). These results indicate that for the RBI and
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CDKN2A genes, there is likely to be heavy intra-genic methvlation in the soma whereas other
genes are likely to be methylated to a relatively lesser degree (i.e. ATM. BRCA2 and STK11).
No individual gene showed significantly different median Grantham physicochemical 
difference, when somatic mutations were compared to potential missense mutations. 
Therefore, it is likely that the mutant amino acids that comprise part of the somatic missense 
mutational spectrum are not associated with a higher median Grantham difference, as 
compared to wild-tvne amino acids, although no individual comparison showed >80% 
statistical power. Thus, either no true difference between wild-tvpe and mutant amino acids, 
with respect to Grantham difference, and/or a paucity of mutations, may have contributed to 
these results.
The somatic mutations of the TP53 and VHL genes were found to preferentially target 
evolutionarily conserved sites (p E<0.0034; medians 0.14 and 0.17 for TP53 and VHL 
respectively), when compared to potential missense mutations (medians 0.29, 0.43 for the 
TP53 and VHL genes respectively). In addition, there was a trend in the CDKN2A gene 
(p G=0.006) for somatic missense mutations to target evolutionarily conserved codons 
(medians 0.38 and 0.46 for somatic and potential mutations respectively), but this result did 
not reach experiment-wise statistical significance ( pE= 0.102). On the other hand, the APC 
and PTEN genes, showed >80% power to detect an experiment-wise significance, but did not 
reach a statistically significant threshold (experiment-wise a  £ 0.05). Therefore, for these 
two genes, it is very likely that somatic missense mutations do not preferentially target 
evolutionarily conserved codons. Thus, for the TP53. VHL and to some extent the CDKN2A 
genes, somatic missense mutations are more likely to be found in functionally important sites, 
whereas for the APC and PTEN genes, evolutionary conservation does not seem to plav an 
important role.
4.3.3. Germline vs. potential missense mutations
In a similar pattern to the somatic mutational spectrum, it was evident that nucleotide 
context (measured by both disease and non-disease associated mutability rates) plays an 
important part in shaping the germline missense mutational spectrum in some genes, but not 
others, when compared to potential missense mutations. Seven genes (i.e. ATM, BRCA1, 
BRCA2, NFJ, RBI, TSC2 and WT1), showed significantly higher disease and non-disease- 
associated mutability rates ( pE<0.0034) with non-disease-associated medians ranging from 
7.2 to 10.1 and 4.1 to 4.5 and disease-associated medians ranging from 0.79 to 1.27 and 0.38
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to 0.43 for the germline and potential mutations respectively. Additionally, the CDH1 and 
PTEN genes showed experiment-wise significantly higher disease-associated mutability rates 
(p E<0.0034) for both genes; medians 1.27/0.41 and 0.92/0.38 for the germline/potential 
mutations in the CDH1 and PTEN genes. Some genes (i.e. APC, NF2 and PTCH) showed 
enough statistical power (i.e. >80%), but did not exhibit statistically significant results, for 
both disease and non-disease-associated mutability rates. Hence their germline missense 
mutational spectra are very likely not influenced by nucleotide context, with some other 
mechanism(s) influencing the occurrence of mutations. Therefore, for a number of genes (i.e. 
ATM. BRCAL BRCA2. CDHL NFL PTEN RBI. TSC2 and WT1\ the germline mutational 
spectrum was characterized bv a significantly higher median, with respect to disease and non­
disease-associated nucleotide substitution rates, but not for others, such as the APC. NF2 and 
PTCH. This is to be expected, since the disease-associated nucleotide substitution rates have 
been derived from germline missense mutations.
The ATM  and TSC2 genes showed significant co-localisation of germline missense 
mutations within CpG-dinucleotides (p E<0.0034; 8% and 15% within CpG-dinucleotides for 
ATM  and TSC2 respectively), as compared to potential missense mutations (1% and 3% 
within CpG-dinucleotides for ATM  and TSC2 genes respectively). In addition, a number of 
genes (i.e. APC, BRCA1, BRCA2, CDH1, NF1 and NF2) showed a trend (p G ranging from 
0.008 to 0.038 and pE ranging from 0.136 to 0.646) for germline missense mutations being 
preferentially found in CpG-dinucleotides (proportions ranging from 5% to 22% and -0%  to 
2% for the germline and potential mutations respectively). Thus, the germline missense 
mutations for the ATM  and TSC2 genes were much more likelv to be found in CpG 
dinucleotides than potential missense mutations, whereas for other genes (i.e. APC. BRCAL 
BRCA2. CDHL NF1 and NF2) only a trend was observed.
The wild-type amino acids in the NF1 and VHL genes were much more likely to be 
substituted by mutant amino acids, characterized by a significantly higher Grantham 
difference as a result of germline missense mutations (p E <0.0034 for both genes), with 
medians ranging from 98 to 99 and 71 to 76 for the germline and potential mutations 
respectively. In addition, the ATM  gene exhibited a trend in the same direction, i.e. 
significantly higher median Grantham difference (p G=0.04 and pE= 0.68) for the germline as 
compared to potential missense mutations. For the rest of the genes, no conclusions could be 
made, as there was not enough statistical power and none of the genes showed statistically 
significant results.
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The germline mutations for the ATM, BRCA1 and VHL genes preferentially targeted 
evolutionarily conserved codons (p E<0.0034), with medians ranging from 0 to 0.14 and 0.17 
to 0.54 for the germline and potential mutations respectively. In addition, the CDKN2A, TSC2 
and WT1 genes showed only a modest association of germline missense mutations and 
evolutionarily conserved sites ( pG ranging from 0.008 to 0.032), when compared to potential 
mutations (germline medians ranging from 0 to 0.29 and potential medians ranging from 0 to 
0.46). Conversely, the NF1 and PTEN genes showed enough statistical power, but did not 
exhibit statistically significant results. Therefore, in the ATM. BRCAL VHL and possibly 
CDKN2A. TSC2 and WT1 genes, germline missense mutations are much more likely to be 
found in evolutionarily conserved codons as compared to potential mutations, whereas for the 
NF1 and PTEN genes no such finding was evident.
4.3.4. Shared vs. potential missense mutations
The CDKN2A, PTEN and TP53 genes exhibited experiment-wise significantly higher 
nucleotide substitution rates, for both disease (medians ranging from 1.08 to 1.28) and non­
disease substitution rates (medians ranging from 8.9 to 11), when shared mutations were 
compared to potential missense mutations (p E<0.0034; medians ranging from 0.38 to 0.5 and 
4.1 to 4.5 for disease and non-disease-associated substitution rates). In addition, the VHL 
gene exhibited only a significantly higher median, with respect to disease-associated 
mutations (p E <0.0034; medians 1 vs. 0.44 for the shared and potential mutations), but not 
with respect to non-disease-associated substitution rates.
The BRCA2, CDKN2A, PTEN, RBI, TP53 and TSC2 genes exhibited a significantly 
higher proportion of CpG-located shared mutations (ranging from 14% to 100% of the 
mutations found within CpG-dinucleotides), when compared to potential missense mutations 
( pE <0.0034), with proportions ranging from -0%  to 4% of the mutations found within CpG- 
dinucleotides.
Only the TP53 gene exhibited a significantly higher difference between wild-type and 
mutant amino acids with respect to Grantham difference (p c=0.014; medians 98 and 74 for 
the shared and potential mutations respectively), but did not reach experiment-wise 
significance (p E=0.23 8).
Three genes (viz. CDKN2A, TP53 and VHL) showed significantly many more shared 
missense mutations found in evolutionarily conserved sites as compared to potential
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mutations ( pE <0.0034, medians 0 for the shared mutations and medians ranging from 0.29 to 
0.46 for the potential missense mutations).
From the results presented for the comparisons between shared and potential missense 
mutations, three genes (viz. TP53, CDKN2A and VHL) clearly stood out. The TP53 gene 
exhibited statistically significant results for all of the comparisons performed. Thus, it is 
evident that the shared mutational spectrum associated with the TP53 gene is strongly 
influenced bv nucleotide context, measured in terms of disease and non-disease-associated 
substitution rates: mutant amino acids exhibited a greater physicochemical difference as 
compared to wild-tvpe amino acids: shared missense mutations preferentially faceted 
evolutionarily conserved sites and CpG-dinucleotides.
Similarly, the CDKN2A gene showed exactly the same pattern, with one exception: 
shared missense mutations did not exhibit significantly higher Grantham difference.
The shared missense mutations in the VHL gene were found to be characterised bv a 
significantly higher median nucleotide substitution rate (disease associated) and preferential 
location within evolutionarilv conserved sites, as compared with potential mutations.
4.3.5. Somatic vs. germline missense mutations
Interestingly, not a single gene showed a statistically significant result for any of the 
comparisons performed, although it should be noted that only the CDKN2A and STK11 genes 
had enough statistical power to detect an experiment-wise significant difference, with respect 
to disease and/or non-disease-associated mutability rates. Thus, one could conclude for these 
genes that no difference exists between somatic and germline missense mutations, with 
respect to nucleotide context measured by both disease and non-disease associated 
substitution rates. It is clear that nucleotide context for these genes (i.e. CDKN2A and STK11) 
influences both the somatic and germline missense mutational spectrum in a very similar 
way.,.
In addition, the CDH1 and PTEN genes showed >80% statistical power for detecting 
an experiment-wise difference, with respect to disease associated substitution rates, but no 
significant differences were detected (both gene-wise and experiment-wise). Therefore, 
nucleotide context, measured in terms of disease-associated substitution rates, influences both 
the somatic and germline missense mutational spectrum for the PTEN and CDH1 genes in a 
very similar wav.
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One could conclude that nucleotide context strongly influences both the germline and 
somatic spectrum in a very similar wav for the CDHL CDKN2A. PTEN and STK11 genes.
When shared mutations were compared to potential missense mutations, with respect 
to evolutionarily conserved positions in the PTEN gene, there was enough statistical power, 
but the comparison did not reach a statistically significant threshold (both gene and 
experiment-wise). At least for the PTEN gene, the location of somatic and germline missense 
mutations did not differ with respect to evolutionarily conserved codons. Thus, it is very 
likely that somatic and germline missense mutations within the PTEN gene did not 
specifically target evolutionarily conserved sites.
4.3.6. Somatic vs. shared missense mutations
Clearly, only 4 genes (i.e. CDKN2A, PTEN, TP53 and VHL) had enough shared and 
somatic missense mutations that resulted in enough statistical power to derive any 
meaningful conclusions (Table 12).
The TP53 gene exhibited a significantly higher median substitution rate (p E<0.0034 
for both disease and non-disease-associated substitution rates) of shared mutations (medians
4.6 and 0.5), when compared to somatic missense mutations (medians 8.9 and 1.6). The 
proportion of CpG-located shared missense mutations was also found to be significantly 
higher than its somatic counterpart ( pE<0.0034; 3% and 23% missense mutations were found 
in CpG-dinucleotides for the somatic and shared mutations respectively). In addition, somatic 
missense mutations showed significantly higher median evolutionary variation, when 
compared to shared missense mutations (p E<0.0034; somatic median 0.17 and germline 
median 0) for the TP53 gene. These results indicate that shared missense mutations in the 
TP53 gene are much more likely to be influenced bv nucleotide context and to preferentially 
target evolutionarily conserved codons and CpG-dinucleotides. when compared to somatic 
missense mutations.
The PTEN gene showed only a modest statistical significance of disease-associated 
nucleotide substitution rates (p G=0.04, and pE= 0.68; somatic median 0.53 and shared 
median 1.23) and non-disease-associated substitution rates (p G=0.022 and pE=0.374; 
somatic median 5.6 and shared median 11). Thus, shared missense mutations within the 
PTEN gene were found to be associated with higher median substitution rates as compared to 
somatic missense mutations. Conversely, there was enough statistical power for the 
comparison of shared and somatic missense mutations, with respect to evolutionary variation,
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but the results were not found to be significant ( pG~\ and pE~ 1). Therefore, it is likely that 
both shared and somatic missense mutations do not preferentially target evolutionarily 
conserved codons.
Contrary to the TP 5 3 and PTEN genes, there was enough statistical power to detect an 
experiment-wise difference between the shared and somatic missense mutations for the 
CDKN2A gene, with respect to both disease and non-disease associated substitution rates, but 
no statistically significant difference was found. Thus, both somatic and shared missense 
mutations in the CDKN2A gene are equally strongly influenced bv nucleotide context. The 
CDKN2A gene exhibited a modest significantly higher median evolutionary variation of 
somatic missense mutations (median 0.38) when compared to shared missense mutations 
( Pg~®-034 aHd p£=0.578) with median 0. Therefore, to some degree, it is likely that shared 
missense mutations at least for the CDKN2A gene, targeted relatively more evolutionarily 
conserved codons than the somatic missense mutations.
4.3.7. Germline vs. shared missense mutations
As with the somatic vs. shared missense mutations comparison, four genes had 
enough germline and shared missense mutations to yield sufficient statistical power to detect 
an experiment-wise significant difference. The CDKN2A, PTEN, TP53 and VHL genes did 
not exhibit statistically significant results, with respect to nucleotide substitution rates, 
disease and/or non-disease associated mutability rates. Therefore, it is very likely that both 
the germline and shared missense mutations are equally strongly influenced bv nucleotide 
context as both the germline and shared mutations were separately found to be characterized 
bv significantly higher medians, when compared to potential missense mutations (Tor details 
see sections 4.3.3 and 4.3.4T
For the rest of the tests, there was not enough statistical power and none of the 
comparisons reached statistical significance.
4.3.8. Recurrent somatic missense mutations
Only two genes (i.e. PTEN and TP53) had enough mutations to permit further 
conclusions to be drawn. In fact, the number of recurrent somatic missense mutations in both 
genes represented 90% of the recurrent mutations observed in the 17 genes studied (Table 9).
Furthermore, for these two genes, all (100%) shared missense mutations that were 
found in CpG-dinucleotides were also found to be recurrent (66% for all genes combined). In
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addition. -27% o f all recurrent somatic missense mutations (the recurrence status of the
germline missense mutations could not be determined, since this information is not recorded 
in HGMD) that were found in CpG dinucleotides were also found in the germline (27%% and 
25% for the PTEN and TP5 3 genes respectively).
The results obtained for the TP 5 3 gene suggest that recurrent somatic missense 
mutations are significantly more strongly influenced by nucleotide context (medians 0.53 and
4.6 for disease and non-disease associated substitution rates respectively), than non-recurrent 
mutations (p E <0.0034 and medians 0.42/4.1 for the disease/non-disease-associated 
substitution rates respectively). Furthermore, the recurrent somatic missense mutations were 
also found to preferentially target evolutionarily conserved codons as compared to non­
recurrent mutations (p E<0.0034), with medians 0 and 0.36. Thus, somatic missense 
mutations that recur are influenced bv nucleotide context, but selection towards functionally 
important domains is also likely to plav an important part. Similarly, recurrent and shared 
somatic missense mutations were much more likely to be associated with a significantly 
higher median mutability rate, than both recurrent non-shared (p E<0.0034; recurrent and 
shared medians 1.19 and 9 for the disease and non-disease associated mutability rates 
respectively; recurrent non-shared medians 0.53 and 4.6) and non-recurrent and non-shared 
somatic missense mutations (medians 4.1 and 0.42 for disease and non-disease associated 
mutability rates respectively). In addition, recurrent and shared somatic missense mutations 
were disproportionately more likely to be found in CpG dinucleotides (25%), than both 
recurrent non-shared ( p E=0.0034; 3%) and non-recurrent non-shared mutations ( p E<0.0034; 
2%). Therefore, these results imply that recurrence status is heavily influenced bv nucleotide 
context. In addition, recurrent somatic mutations that are also found in the germline 
preferentially target CpG dinucleotides, as compared to recurrent somatic mutations not 
found in the germline or somatic mutations that do not recur and were also not found in the 
germline. Thus. CpG dinucleotides are mutational hotspots for both recurrent somatic and 
germline missense mutations. This is likely to result from heavy intra-genic CpG methvlation 
in both the germline and the soma for the TP53 gene.
In contrast to TP53, the PTEN gene possessed enough statistical power, but did not 
exhibit statistically significant results for either the recurrent vs. non-recurrent or recurrent 
and shared vs. recurrent and non-shared somatic missense mutations. As a result, and in 
contrast to 77*53. recurrent somatic mutations that are also found in the germline were 
unlikely to be influenced bv nucleotide context. Nevertheless, recurrent somatic missense
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mutations that are also found in the germline are more likely to be associated with higher 
median nucleotide substitution rates (p G=0.0360/0.002 and p£=0.612/0.034 for disease/non­
disease associated substitution rates respectively; medians 1.4, 12.7 and 0.43, 4.7 for 
recurrent and shared vs. non-recurrent non-shared mutations respectively) and were 
disproportionately more likely to be found within CpG dinucleotides (27% vs. 1% 
respectively), than somatic missense mutations that did not recur and were also not found in 
the germline (p G=0.004 and p£=0.068).
4.3.9. Combination of somatic, germline and shared vs. potential 
missense mutations for individual genes
The results for the combination of missense mutations in the individual 17 genes were 
very much dependent on the number of somatic, germline and shared missense mutations. 
Thus, the mutational spectra in the genes could be separated into several groups: 
predominantly somatic missense mutations (APC); predominantly germline missense 
mutations (ATM, BRCA1, BRCA2, NF1, PTCH, TSC1, TSC2 and WT1); similar proportions 
of somatic and germline missense mutations (NF2 and CDH1); predominantly somatic with a 
sizeable proportion of shared mutations (CDKN2A, PTEN and TP53); predominantly 
germline with a sizeable proportion of shared mutations (RBI, STK11 and VHL). The results 
exhibited very similar patterns (e.g. direction of results and statistical significance) to the 
comparisons of the largest proportion of mutations in the individual genes.
4.3.10. Summary of results
4.3.10.1. Disease and non-disease-associated substitution rates
The APC, CDKN2A, PTEN and TP53 genes exhibited significantly (gene-wise and/or 
experiment-wise) higher relative median values for both disease and non-disease- associated 
substitution rates for somatic mutations, when compared to potential mutations.
The A TM, BRCA1, BRCA2, NF1, RBI, TSC2 and WT1 genes exhibited significantly 
(gene-wise and/or experiment-wise) higher relative median values for both disease and non­
disease-associated substitution rates for germline mutations, when compared to potential 
mutations.
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The CDKN2A, PTEN and TP53 genes exhibited significantly (gene-wise and/or 
experiment-wise) higher relative median values for both disease and non-disease-associated 
substitution rates for shared mutations, when compared to potential mutations.
None of the individual genes studied exhibited significantly (gene-wise and/or 
experiment-wise) different relative median values for both disease and non-disease- 
associated substitution rates for somatic mutations, when compared to germline 
mutations, even though there was enough power to detect an experiment-wise significant 
difference for the CDKN2A and STK11 genes.
The PTEN and TP53 genes exhibited significantly (gene-wise and/or experiment- 
wise) higher relative median values for both disease and non-disease-associated substitution 
rates for shared missense mutations, when compared to somatic mutations.
Only the TP53 gene exhibited significantly (gene-wise and/or experiment-wise) 
higher relative median values for both disease and non-disease-associated substitution rates 
for recurrent somatic missense mutations as compared to non-recurrent somatic 
mutations: recurrent and shared somatic mutations as compared to recurrent non- 
shared somatic mutations; recurrent and shared somatic as compared to non-recurrent 
and non-shared somatic missense mutations.
It is interesting to note that all comparisons that showed a significant result with non­
disease-associated substitution rates, also showed a significant result with disease-associated 
substitution rates while a number of comparisons showed only significant results with 
disease-associated mutability rates. Therefore, it may be concluded that the majority of the 
spectrum of missense mutations in most genes are likely to be associated with disease- 
associated substitution rates, hence are more likely to be ‘drivers’ of tumour development.
4.3.10.2. CpG dinucleotides
The A TM, BRCA2, CDKN2A, RBI and STK11 genes exhibited a significantly (gene- 
wise and/or experiment-wise) higher proportion of somatic mutations, when compared to 
potential mutations, with respect to mutations found in CpG dinucleotides.
The APC, ATM , BRCA1, BRCA2, CDH1, NF1, NF2 and WT1 genes exhibited a 
significantly (gene-wise and/or experiment-wise) higher proportion of germline mutations, 
when compared to potential mutations, with respect to mutations found in CpG 
dinucleotides.
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The BRCA2, CDKN2A, PTEN, RBI, 77^55 and TSC2 genes exhibited a significantly 
(gene-wise and/or experiment-wise) higher proportion of shared mutations, when 
compared to potential mutations, with respect to mutations found in CpG dinucleotides. 
None of the genes exhibited a significantly (gene-wise and/or experiment-wise) different 
proportion of somatic mutations, when compared to germline mutations, with respect to 
mutations found in CpG dinucleotides.
Only the TP53 gene exhibited a significantly (gene-wise and/or experiment-wise) 
higher proportion of somatic vs. shared mutations: recurrent and shared vs. recurrent 
and non-shared somatic mutations: recurrent and shared vs, non-recurrent and non- 
shared somatic mutations, with respect to CpG-located missense mutations.
4.3.10.3. Grantham difference
None of the genes exhibited a significantly higher median Grantham difference 
between wild-type and mutant somatic missense mutations, when compared to potential 
mutations.
The ATM, NF1 and VHL genes exhibited a significantly (gene-wise and/or 
experiment-wise) higher median Grantham difference between wild-type and mutant 
germline missense mutations, when compared to potential mutations.
Only the TP53 gene exhibited a significantly higher median Grantham difference 
between wild-type and mutant shared missense mutations, when compared to potential 
mutations.
4.3.10.4. Evolutionary conservation
The somatic mutations in the CDKN2A, TP53 and VHL genes preferentially targeted 
evolutionarily conserved codons, when compared to potential mutations.
The germline mutations in the ATM, BRCA1, CDKN2A, TSC2, VHL and WT1 genes 
preferentially targeted evolutionarily conserved codons, when compared to potential 
mutations.
The shared mutations in the CDKN2A, TP53 and VHL genes preferentially targeted 
evolutionarily conserved codons, when compared to potential mutations.
The TP53 gene exhibited significantly (gene-wise and/or experiment-wise) lower 
median evolutionary variation for somatic as compared to shared missense mutations:
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recurrent as compared to non-recurrent somatic missense mutations: recurrent and
shared as compared to non-recurrent and non-shared missense mutations.
The CDKN2A gene exhibited significantly (gene-wise) lower median evolutionary 
variation for somatic as compared to shared mutations and non-recurrent shared as 
compared to non-recurrent non-shared somatic missense mutations,
4.3.11. Combination of missense mutations in all genes
Around 88% of the somatic mutational spectra for all genes combined were 
represented by 3 genes (i.e. CDKN2A- 9.88%, PTEN- 11.69% and TP53- 66.16%). In 
addition, -70% of the germline mutational spectrum for all genes was represented by 6 genes 
(i.e. ATM- 8.82%, BRCA1- 19.88%, BRCA2- 10.00%, NF1- 9.76%, TSC2-10.24% and VHL- 
11.53%) and >93% of the shared mutational spectrum for all genes was represented by 4 
genes (i.e. CDKN2A- 14.29%, PTEN- 11.22%, TP53- 44.90% and VHL- 22.96%). Therefore, 
the results for the combination of mutations in all genes were very much influenced by these 
genes. Detailed proportions are presented in Table 12.
Nevertheless, when each type of mutations, namely somatic, germline and shared 
missense mutations for all genes, were compared to the corresponding potential missense 
mutations combined for all genes, they were found to exhibit significantly higher median 
mutability rates (both disease and non-disease associated), preferential location in CpG 
dinucleotides, higher median Grantham difference between wild-type and mutant amino acids 
and higher affinity towards evolutionarily conserved sites (summary of results is given in 
Table 15). Clearly, the somatic, germline and shared missense mutations are influenced by 
nucleotide context, but nevertheless selection pressure in the form of the physicochemical 
difference of affected amino acids and functionally important codons/domains must also play 
an important role. Thus, codons susceptible to mutations (i.e. hotspots) are also selected on 
the basis of damage to the protein.
Clear differences and similarities between the somatic, germline and shared 
missense mutations for all genes combined were evident. Indeed, when somatic were 
compared to germline or shared missense mutations, they were significantly less likely 
to be influenced bv nucleotide context (measured bv both disease and non-disease- 
associated mutability rates'!, less likely to be located in CpG-dinucleotides« showed 
smaller Grantham differences and targeted relatively less evolutionary conserved sites. 
In addition* when germline were compared to shared missense mutations, the shared
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missense mutations exhibited a significantly higher median disease-associated 
substitution rate and were significantly more likely to be found in CpG dinucleotides. 
Furthermore, shared and germline missense mutations were equally likely to be found 
in evolutionarily conserved codons.
Therefore, these results suggest that a fine ‘ranking’ in the pathogenicity of missense 
mutations exists, with shared missense mutations being more likely to be ‘drivers’ of 
tumorigenesis, than pure somatic or pure germline missense mutations. Similarly, pure 
germline missense mutations are more likely to be associated with tumorigenesis, than purely 
somatic mutations.
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4.4. Discussion
Cancer is regarded as a genetic disorder on the basis that genetic and epigenetic 
modifications often contribute to neoplasia. The underlying mutations include DNA sequence 
changes, such as copy number variation, gross rearrangements, micro-lesions (e.g. deletions, 
insertions and indels), single base-pair substitutions, etc. (Loeb and Harris 2008; Stratton et 
al. 2009). Missense mutations are an important part of the mutational spectrum associated 
with tumour development. For some missense mutations, research has unambiguously shown 
their functional importance, but for others the degree of pathogenicity remains largely 
unknown. Therefore, numerous classification procedures have been developed and employed 
to try to predict the pathogenicity of missense mutations. These classification procedures 
involve sometimes costly and labour-intensive functional assays, but which nevertheless 
could be helpful in assigning functional significance (Chan et al. 2007). In addition, it may 
not be very practical to perform functional assays on every single variant that turns up during 
routine clinical screening, because for some variants, functional assays may not exist or may 
be very difficult to perform. As a result, a plethora of in silico algorithms, methods and 
procedures has been developed to facilitate the classification of functional importance of 
genetic variants, and missense mutations in particular (Miller and Kumar 2001; Tavtigian et 
al. 2008). Normally, variants such as deletions, insertions and nonsense mutations are readily 
classified as functionally important because they generally disrupt gene function and/or 
structure. Most of the unclassified sequence variants are missense mutations (Tavtigian et al.
2008). Thus, in silico algorithms for the classification of sequence variants are usually 
focussed on missense mutations. These procedures utilize numerous measures and 
parameters. Some of these measures include properties of amino acids, derived from 
substitution matrices, such as PAM (DayhofF et al. 1978) and BLOSUM (Henikoff and 
HenikofF 1992); physicochemical difFerences, e.g. Grantham (Grantham 1974); changes in 
protein structure (Goldgar et al. 2004), evolutionary conservation, disease and non-disease- 
associated nucleotide substitution rates (Hess et al. 1994; Krawczak et al. 1998); and many 
others. Usually, these procedures and methods rely heavily on training datasets. These 
datasets comprise classified, e.g. validated neutral/polymorphic, pathogenic/functional 
missense variants (Tavtigian et al. 2008). Because unclassified missense variants exist, these 
training sets would not encompass every single missense mutation; therefore, they are subject 
to chance variation.
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Furthermore, while cancer or tumour development is considered to be a disorder of 
the soma (i.e. phenotypic manifestation as somatic tumours), there is growing evidence that 
inherited (i.e. germline) variants may play an important role in the development of a disease, 
including cancer. Three recent papers (Jones et al. 2009; Kilpivaara et al. 2009; Olcaydu et al.
2009) have shown very strong association of a particular inherited haplotype in the JAK2 
gene and the preferential acquisition of a particular somatic mutation (V617F), considered 
causative of myeloproliferative neoplasms (Campbell 2009). This activating point mutation, 
has been found in >95% of the individuals with polycythemia vera and 50-60% of the 
individuals with essential thrombocythemia (Campbell 2009; Levine et al. 2007). Campbell 
(2009) has proposed two competing hypotheses that could potentially account for the 
inherited predisposition. The somatic missense mutation occurs with a rate independent of the 
inherited haplotype, but inherited variation confers a stronger selective advantage over the 
cells; thus, such cells are more likely to undergo clonal expansion. The second hypothesis 
considers the differential mutation rate of the causative variant with respect to the germline 
haplotype. Thus, cells that inherit the germline variant exhibit hypermutability of the gene 
locus and these cells more frequently acquire mutations and hence are more likely to acquire 
the causative variant and undergo clonal expansion.
Knudson’s ‘two-hit’ hypothesis (Knudson 1971,1978) provides a framework for 
understanding tumour suppressor genetics and the development of cancer. This hypothesis 
states that in addition to an inherited hit (e.g. a sequence alteration or modification), a second, 
somatic hit affecting the hitherto unaffected allele of the gene is necessary for the initiation 
and development of cancer. In addition, research on the genetics of tumour suppressor genes 
has indicated that there might be a complex interaction between the two hits. The APC gene 
is an example of such a tumour suppressor gene that has been shown to exhibit somatic- 
germline interplay. It is a tumour suppressor gene consistent with Knudson’s ‘two-hit’ 
hypothesis, in the sense that both inherited (i.e. germline) and acquired (i.e. somatic) 
sequence changes are required for tumour development (Miyoshi et al. 1992; Powell et al. 
1992). In their seminal paper, Latchford et al. (2007) have shown a positional non-random 
occurrence of somatic mutations, also shown by others (Groves et al. 2002; Lamlum et al. 
1999), but most importantly the position of the germline hit could direct the frequency and 
type of the second hit (i.e. somatic mutation). This ‘first-second hit’ relationship is held to be 
sufficient to maintain a ‘just right’ level of (3-catenin protein (Latchford et al. 2007), in order 
to manifest a selective advantage of the mutant APC protein. Even although the lesions found 
in the A PC gene are predominantly truncating mutations (nonsense mutations and
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ffameshifts), these examples indicate the important role of the relationship between germline 
and somatic genetic changes.
Therefore, it is clear that interplay, similarities and differences between the soma and 
germline in terms of genetic changes, have to be taken into consideration, when inferring the 
functional consequences of DNA sequence changes and in particular missense mutations. In 
addition, the anecdotal nature of reports of the relationship between the germline and the 
somatic mutation status does not rule out the possibility that this phenomenon could be 
relatively widespread. Usually, germline mutations are considered to increase the risk of 
developing cancer, but the mechanisms are still unclear. Thus, we may see an increasing 
number of reports suggesting a possible intricate relationship between the germline and the 
soma in the context of mutagenesis.
In the light of the relatively few studies that have compared and contrasted somatic 
and germline missense mutations, the analysis presented in this chapter represents an attempt 
to shed some light on differences and similarities in the germline and soma, with respect to 
missense mutations.
4.4.1. ATM  gene
The presented results for the ATM  gene are very much in agreement with other studies 
on the mutational spectrum of the ATM  gene. A number of studies have reported the absence 
of somatic missense mutations in breast cancer (Feng et al. 2003; Vorechovsky et al. 1996) 
and T-cell prolymphocytic leukaemia (Luo et al. 1998). The data presented in this chapter 
indicates that the missense mutational spectrum in the ATM  gene comprised predominantly 
germline missense mutations (-87% germline vs. -13% somatic missense mutations). In 
addition, studies have failed to show any association between germline missense mutations 
and loss of heterozygosity in breast cancer and ataxia-talagiectasia (Feng et al. 2003;
Liberzon et al. 2004); hence it is likely that germline missense mutations contribute 
significantly more to tumorigenesis than somatic missense mutations. Furthermore, to 
account for this, Feng et al. (2003) have suggested that germline missense mutations in the 
ATM  gene could exert a dominant effect, e.g. by inactivating a multiprotein complex. Indeed, 
a study by Scott et al. (2002) has identified a number of missense mutations (S2592C, 
V2716A, R2849P and G2867R) in breast cancer, using in vitro mutagenesis of full length 
ATM cDNA, that display dominant negative activity over the wild-type protein. Clearly, the 
mutational data from the ATM  gene strongly suggest that the germline missense mutational
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spectrum disrupts the function of the mutant proteins, predicting a major effect of germline 
missense mutations in driving tumorigenesis.
On the other hand, analysis of the mutational spectrum of the ATM  gene has revealed 
that -80-85% of all sequence alterations are truncating mutations (Lavin et al. 2004). The 
data presented here showed that 52% of the somatic sequence alterations are truncating as 
compared to 76% in the germline (data are presented in Table 16). These results suggest that 
germline mutations (truncating and non-truncating- i.e. missense mutations) in the ATM  gene 
predispose to tumour development to a relatively stronger degree as compared to somatic 
mutations. Based on the results presented in this chapter, one could conclude that somatic 
missense mutations present in the ATM  gene are more likely to be result of genomic 
instability, thereby constituting passenger mutations.
4.4.2. BRC A1  and  B R C A 2  genes
Germline sequence variants in the BRCA1 and BRCA2 genes have been shown to 
contribute significantly to the development of breast and ovarian cancers (Easton et al. 1993; 
Ramus et al. 2007; Szabo et al. 1996). About a third of all reported (Breast Cancer 
Information Core (BIQ  database: http://research.nhgri.nih.gov/bic/index.shtml) sequence 
changes in BRCA1 are missense mutations and >50% of those are reported only once (Szabo 
et al. 2004). Furthermore, -50% of all reported changes in BRCA1 (-1200, B1C) have been 
reported only once. Likewise, -11,000 mutations have been reported for the BRCA2 gene and 
-50% of these are classified as being of unknown functional consequence. These data 
indicate the highly variable nature of the mutational spectrum in the BRCA1 and BRCA2 
genes. Some authors have suggested that the relatively poor evolutionary conservation of 
BRCA1 across different species (Szabo et al. 1996) could indicate that most of the gene 
sequence might have relaxed functional and/or structural constraints. Therefore, numerous 
sequence variations could be relatively well tolerated, with respect to functional and/or 
structural characteristics. Indeed, the evolutionary conservation analysis performed in this 
chapter suggested that both the BRCA1 and BRCA2 genes are the two most variable genes 
from the 17 tumour suppressor genes studied, with respect to evolutionary conservation 
(Figure 16). Nevertheless, even although mutations in some regions of the BRCA1 gene could 
be of little functional importance to the function of the gene, germline missense mutations 
were very likely to have functional importance. This was indicated by the fact that BRCA1 
germline missense mutations were rather more likely to be found in evolutionarily conserved
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codons than potential missense mutations. Conversely, the paucity of the somatic and 
germline missense mutations in the BRCA2 gene precluded the possibility of inferring the 
evolutionary conservation of residues subject to mutations.
The BRCA2 gene showed a greater proportion of germline (-80%) as compared to 
somatic (-19%) missense mutations (Table 12). Over and above that, the BRCA1 gene 
showed an almost complete absence of somatic missense mutations (-3% of all missense 
mutations, Table 12). Due to the fact that both BRCA1 and BRCA2 genes are reported to be 
consistent with Knudsons's two hit hypothesis (Dworkin et al. 2009), different mechanisms 
could explain the dearth of somatic missense mutations, such as somatic abolition of protein 
expression through hypermethylation of the promoter region and protein truncation. Indeed, 
studies on methylation patterns in the BRCA1 promoter region have shown hypermethylation 
in breast and ovarian cancer tissues as compared to normal tissues from the same individual 
(Baldwin et al. 2000; Esteller et al. 2000; Radpour et al. 2009). The germline missense 
mutations in the BRCA1 gene showed, to some extent, a preferential location within CpG 
dinucleotides, implying hypermethylation of intra-genic CpG dinucleotides in the germline. 
On the contrary, promoter hypermethylation has been shown be an infrequent event in the 
BRCA2 gene (Dworkin et al. 2009; Hilton et al. 2002). Nevertheless, germline, somatic and 
shared missense mutations all showed preferential localization within CpG dinucleotides. 
Thus, one could infer that heavy intra-genic CpG methylation may be present in both the 
soma and germline in the BRCA2 gene.
Due to the lack of data on promoter hypermethylation, one could only speculate the 
possibility that the BRCA1 and BRCA2 genes could exhibit a reduction of protein expression 
in both the soma and germline through hypermethylation of the promoter region.
Alternatively, the lack of somatic missense mutations could potentially be explained by 
the predominance of truncating mutations. Around 79% of all somatic mutations in the 
BRCA1 gene are indeed truncating aberrations (nonsense mutations, micro-deletions, micro­
insertions and micro-indels; Table 16), comparable with the -70% value reported in the 
literature (Szabo et al. 2004). It is interesting to note that the proportion of truncating 
germline mutations was very similar (-73%, Table 16). Therefore, protein truncation in both 
the soma and the germline appears to be a common mutational mechanism in the BRCA1 
gene.
On the contrary, -61% of all somatic mutations within the BRCA2 gene are non- 
truncating (i.e. missense mutations), in contrast to -17% germline missense mutations. It has 
been suggested that BRCA2 may not be a classic tumour suppressor gene with respect to
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Knudson's two-hit hypothesis (Meric-Bemstam 2007), although heterozygous knock-out of 
BRCA2 in mice has not shown a "strong tumour predisposition phenotype" (Evers and 
Jonkers 2006; Meric-Bemstam 2007).
Therefore, it would seem that missense mutations in both the BRCA1 and BRCA2 
genes might not be severe enough to dismpt the function of the protein to such a degree to 
cause tumour development, but nevertheless could lead to a predisposition at least with 
germline missense mutations in the BRCA1 gene. This is further supported by the observation 
that germline missense mutations in both genes did not show significantly higher Grantham 
differences as compared to wild-type amino acids. It is likely that somatic and germline 
missense mutations in the BRCA2 and somatic missense mutations in the BRCA1 genes are 
disproportionately "passenger" mutations, whereas germline BRCA1 missense mutations give 
rise to predisposition to tumour development.
4.4.3. CDKN2A  gene
The mutational spectrum of the CDKN2A gene is predominantly described by whole- 
gene deletions and point mutations being uncommon in most common cancers, such as 
colorectal, breast and gynaecological cancers (The CDKN2A database: 
https://biodesktop.uvm.edu/perl/p 16. Murphy et al. 2004). Interestingly, the observed somatic 
and germline mutational spectra in the CDKN2A gene were described predominantly by non­
truncating mutations (-61% and -70% of all mutations for the somatic and germline 
mutations respectively, Table 12). Therefore, apart from the common whole-gene deletions, 
missense mutations are a relatively common event.
The majority of the missense mutational spectrum comprised somatic (-73%), 
followed by equal proportions of germline and shared missense mutations (-15% and -12% 
for germline and shared missense mutations). It has to be said that the CDKN2A is the 
smallest gene, with respect to number of nucleotides, as compared to the rest of the genes. 
Thus, one could argue that it is relatively more likely that mutations in the soma could be also 
observed in the germline just by chance alone, as compared to larger genes. Nevertheless, the 
results presented herein indicated that shared missense mutations within CDKN2A are not 
merely accidental. Shared missense mutations were indeed found to preferentially target 
evolutionarily conserved sites, despite the fact that the CDKN2A gene might have relaxed 
functional and/or structural constraints. Similar to BRCA1 and BRCA2, the CDKN2A gene 
showed relatively more evolutionary divergence as compared to the rest of the genes (Figure
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16). In addition, both the germline and somatic missense mutations were also found to some 
degree within evolutionarily conserved sites. Thus, shared missense mutations showed a 
stronger association with evolutionarily conserved codons than both the soma and germline 
and were more likely to be found in evolutionarily conserved sites than somatic missense 
mutations.
Furthermore, the somatic and germline missense mutations did not show preferential 
location within CpG dinucleotides, where the shared mutations were preferentially located in 
CpG dinucleotides. This is a potential indication of intra-genic hypermethylation in both the 
soma and the germline. Indeed, promoter hypermethylation has been shown to be a strong 
cancer predictor in the CDKN2A gene, for breast cancer and oesophageal adenocarcinoma 
(Radpour et al. 2009; Wang et al. 2009).
These results suggest that missense mutations in both the soma and the germline are 
very likely to be caused by the same mechanisms. This was further supported by the fact that 
direct comparison between somatic and germline missense mutations did not exhibit 
significant differences, with respect to any of the parameters studied. Both the somatic and 
shared missense mutations exhibited higher relative median values of both disease and non­
disease mutability rates, when each was compared to potential missense mutations.
Therefore, these mechanisms are very likely to be DNA-sequence dependent, i.e. endogenous 
mutagenesis, such as methylation-mediated deamination of 5-methylcytosine in CpG 
dinucleotides, post-replicative mismatch repair and exonucleolytic proof-reading (Cooper and 
Krawczak 1993; Krawczak et al. 1998).
4.4.4. NF1 gene
The NF1 gene is regarded as being a classic tumour suppressor gene; thus, bi-allelic 
inactivation is required for tumour development (Glover et al. 1991; Rasmussen et al. 2000; 
Upadhyaya et al. 2008). Most frequent somatic inactivation reported has been large deletions, 
frequently encompassing numerous genes (Upadhyaya et al. 2008). By contrast, the inherited 
hit comprises a more complex spectrum of sequence changes. These comprise ffameshifts, 
splice-site mutations, nonsense mutations, large deletions and infrequent missense mutations 
(Upadhyaya et al. 2008). It was not surprising that the majority of somatic (-94%) and 
germline (-84%) mutations in the NF1 gene were truncating mutations (Table 16). Moreover, 
a preponderance of germline missense mutations was evident, when compared to somatic 
missense mutations (-98% germline vs. -2%  somatic missense mutations).
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Therefore, at least with respect to inactivating mutations (e.g. micro-lesions <20bp), 
both the germline and the soma exhibit very similar frequencies. Nevertheless, it is clear that 
the germline mutational spectrum is more likely to comprise missense mutations, than the 
somatic mutational spectrum. These germline missense mutations are also likely to contribute 
significantly towards tumour development, as indicated by the higher median Grantham 
difference between mutant and wild-type amino acids, when germline were compared to 
potential mutations.
In contrast to the BRCA1 and BRCA2 genes, the NF1 gene was found to be the most 
evolutionarily conserved of the 17 genes studied. This is an indication that in the majority of 
sequence changes, selection eliminates deleterious mutations. Thus, it was not surprising that 
germline missense mutations were not preferentially found within evolutionarily conserved 
codons as compared to potential mutations, due to the fact that codons in the NF1 gene are 
evolutionarily conserved throughout.
It is interesting to note that the inherited lesions comprise a variety of sequence 
changes with a sizeable proportion of missense mutations that are also very likely to 
significantly impair the function of the protein, where such mutations are virtually absent 
within the soma. This is an indication of slightly different mutational mechanisms that 
operate in the germline and soma. Thus, it has been speculated before that germline allelic 
loss could confer a "significant selective disadvantage on many cells" (Upadhyaya et al.
2008).
4.4.5. PTEN gene
The PTEN gene is the second most frequently mutated gene, after TP53, in human 
cancers (Simpson and Parsons 2001). It’s mutational spectrum comprises ffameshifts, 
nonsense and missense mutations (Yin and Shen 2008). Thus, not surprisingly, missense 
mutations were a relatively frequent event (-46% and -35% for somatic and germline 
sequence changes respectively, Table 16), but those were predominantly somatic missense 
mutations (-82% somatic vs. -9%  germline and shared missense mutations).
Along with NF1, the PTEN gene is one of the most evolutionarily conserved gene out 
of the 17 tumour suppressor genes studied; hence most missense mutations are to be found in 
evolutionarily conserved sites. Thus, it is not surprising that neither germline or somatic, nor 
shared missense mutations showed preferential location within evolutionarily conserved 
codons, when compared to potential mutations. This notwithstanding, most of the missense
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mutations are likely to be found in evolutionarily conserved sites, just because PTEN is 
highly conserved for most parts of the gene.
On the other hand, both the somatic and germline missense mutations exhibited 
similar nearest neighbour-dependent mutability rates; thus, similar mechanisms contribute 
towards the mutational spectrum in both the soma and the germline. Furthermore, mutations 
found in both the soma and the germline were found to have significantly higher median 
mutability rate than somatic missense mutations. Hence, one could speculate that similar 
mechanisms in the germline and soma, quite possibly due to sequence-dependent 
mechanisms, result in missense mutations in specific codons that are shared between the 
germline and the soma. Such hotspots that were found to be significantly overrepresented, 
were CpG dinucleotides. As a result, it is very likely that intra-genic hypermethylation of the 
PTEN gene is present in both the soma and the germline. Somatic promoter hypermethylation 
has indeed been confirmed in familial cerebral cavernous malformations and acute 
lymphoblastic leukaemia (Montiel-Duarte et al. 2008; Zhu et al. 2009). Moreover, recurrent 
somatic missense mutations that were also found in the germline were more likely to be 
found in CpG dinucleotides, than non-recurrent somatic mutations found exclusively in the 
soma. This is likely to be a result of heavy intra-genic methylation in the soma, but crucially 
it is also likely to be the case within the germline.
4.4.6. TP53 gene
The TP53 gene is regarded as the "guardian of the genome" (Lane 1992), as it is the 
most frequently (>50% of all human cancers; Toledo and Wahl 2006) mutated gene in human 
cancers (Levine et al. 2004; Vogelstein et al. 2000) and plays a vital role in crucial functions, 
such as activating cell cycle inhibitors and triggering apoptosis in response to DNA damage 
(Efeyan and Serrano 2007). Therefore, it was not surprising that -66% of all somatic 
missense mutations for the 17 genes studied, were TP53 mutations. Even more, -45% of the 
combined spectrum of shared missense mutations in the 17 genes, were also TP53 mutations. 
The TP53 gene was also described by predominantly somatic missense mutations (-92%) as 
compared to virtually absent germline missense mutations (<1%).
Not surprisingly, the somatic missense mutations were found to be very likely to 
impair critical domains of the TP53, shown by the preferential location in evolutionarily 
conserved codons. They were also found to be influenced by sequence context, measured by 
disease and non-disease mutability rates. Therefore, the somatic missense mutational
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spectrum in the TP 5 3 gene is influenced by sequence-context, but it is also subject to 
negative selection. Thus, somatic missense mutations were likely to be selected for their 
likely negative impact on the function of the protein. Even although germline missense 
mutations were virtually absent from the missense mutational spectrum, a sizeable proportion 
of shared mutations was observed (-7%). Furthermore, -94% of all germline missense 
mutations were also found in the soma. One could argue that due to the relatively small size 
of TP53 (394 codons) and the large number of somatic mutations (-47% of all possible 
missense mutations, Table 11), shared missense mutations could be due to chance 
occurrence. The results obtained in this chapter have shown that missense mutations found in 
both the soma and the germline were not merely coincidental. In fact, they were extremely 
likely to impair the function of the protein, as compared to potential mutations. They were 
found in evolutionarily conserved sites and mutant amino acids were selected for their greater 
median physicochemical difference, with respect to wild-type amino acids. Additionally, 
shared missense mutations were more likely to be found in evolutionarily conserved sites 
than somatic missense mutations. This suggests that shared missense mutations may be 
more detrimental to protein function than somatic missense mutations. As a result, the 
majority of germline missense mutations are also found in the soma, but more importantly 
these shared lesions also seem to contribute significantly towards tumour development and/or 
progression.
It is well known that TP53 germline mutations are associated with rare dominant 
inherited predisposition syndrome, i.e. Li-Fraumen (Malkin et al. 1990; Varley 2003). Thus, 
germline mutations are known to significantly contribute to cancer development. A closer 
look at the origin of the germline missense mutations in the TP53 gene revealed that -34% 
are derived from Li-Fraumeni syndrome patients (data not presented). Therefore, a logical 
conclusion would be that germline missense mutations are likely to be significantly 
associated not only with Li-Fraumeni syndrome, but may quite possibly play an important 
role in other cancers. A few studies have indicated that this could be so in the case of choroid 
plexus papiloma (Rutherford et al. 2002), glioblastoma and colon cancer (Yamada et al.
2009).
It has been recognized that the occurrence, frequency and distribution of mutations 
are shaped by mutational bias and/or selection. These two processes shape the mutational 
spectrum of TP53 to such an extent that 11 hotspot mutations are found >100 times (Soussi et 
al. 2005). The relative contribution of these processes that shape the occurrence of these 
highly recurrent mutations is relatively unknown. The analysis of recurrent and non-recurrent
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somatic missense mutations presented herein, indicates that selection on the basis of 
functional impact on the protein might play a significant role. The recurrent somatic missense 
mutations were much more likely to be found in evolutionarily conserved codons, than non­
recurrent ones. It is likely that evolutionarily conserved sites bear greater functional 
importance than relatively less conserved sites. Therefore, the recurrence status of somatic 
missense mutations could be linked to their functional importance; hence recurrent mutations 
are very likely to be drivers of tumorigenesis. Nevertheless, these recurrent somatic 
mutations were also found to be influenced to a much greater extent by nucleotide mutability 
rates than non-recurrent mutations. Thus, mutability could also play an important role. 
Furthermore, the great majority of recurrent somatic mutations were found in non-CpG 
dinucleotides (-95%). As a result, the significantly different nucleotide mutability rates 
between recurrent and non-recurrent mutations, could not be attributed to CpG dinucleotides. 
Moreover, the proportions of mutations found in CpG/non-CpG dinucleotides did not differ 
significantly between recurrent and non-recurrent somatic missense mutations; hence the 
mutability differences could not be attributed solely to mutations found in CpG dinucleotides. 
Thus, both nucleotide context and selection play important roles in the recurrence status of 
somatic missense mutations in the TP 5 3 gene. Additionally, it has been suggested that the 
selection criterion is towards gain-of-function mutations, i.e. positive selection (Glazko et al. 
2006). Conversely, the proportion of recurrent somatic mutations that were also found in the 
germline was significantly greater, than the proportion of recurrent non-shared mutations co­
localised within CpG-dinucleotides. In addition, recurrent and shared mutations were 
influenced to a significantly greater extent by nucleotide context than recurrent non-shared 
mutations. Thus, one could argue that recurrent shared missense mutations were more likely 
to be influenced by endogenous mutagenesis (i.e. spontaneous deamination of 5- 
methylcytosine within CpG dinucleotides) than mutations that recur, but are also not found in 
the germline. This is certainly a possibility, although the paucity of mutations and/or no true 
difference, precluded any conclusions for the comparison of recurrent and shared vs. 
recurrent non-shared missense mutations, with respect to both Grantham difference and 
evolutionary conservation.
The fact that shared CpG-located missense mutations were 100% recurrent, would 
suggest that intra-genic CpG methylation of the TP53 gene is a relatively frequent event in 
both the soma and the germline. Indeed, promoter hypermethylation has been observed in 
breast cancer for both invasive and non-invasive lesions (Kang et al. 2001), but also tissue- 
independent complete intra-genic methylation (Tomaletti and Pfeifer 1995). Unfortunately,
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the scarcity of published reports on the intra-genic or promoter methylation status of the 
TP53 gene in the germline precludes the possibility of support the prediction of possible 
germline intra-genic hypermethylation. Nevertheless, Magdinier et al. (2002) have shown a 
relatively high level of methylation of exon 4 of the TP53 gene in blastocysts that supports 
the results and conclusions presented here to some degree.
4.4.7. VHL gene
Germline sequence changes in the VHL gene have been shown in the majority of 
patients with von Hippel-Lindau disease, associated with frequent tumours (Maher and 
Kaelin 1997). It is a tumour suppressor gene that has been shown to be consistent with 
Knudson's two hit hypothesis as point-mutations and deletions have been observed as first- 
second hits (Gnarra et al. 1997).
The somatic mutational spectrum comprises predominantly truncating mutations 
(-73%) as compared to equal proportions of truncating and non-truncating germline 
mutations (52% and 48% non-truncating and truncating mutations respectively). Thus, 
germline missense mutations were found to be a frequent event (-53%) as compared to 
somatic missense mutations (-23%).
Both the germline and the somatic missense mutations were found likely to be 
detrimental to the function of the protein. The germline and somatic missense mutations were 
more likely to be found in evolutionarily conserved codons than potential mutations. 
Moreover, germline missense mutations were also found to exhibit significantly higher 
Grantham differences between mutant and wild-type amino acids. Thus, it would seem that 
both germline and somatic missense mutations are very likely to play an important role in 
tumour development.
Furthermore, the mutational spectrum of the VHL gene was also described by a 
sizeable proportion of shared missense mutations (-24%). These were also found to 
preferentially target evolutionarily conserved codons, as compared to potential mutations. 
What is more, they exhibited a significantly higher median nucleotide disease-associated 
mutability rate when compared to potential mutations. Therefore, one may conclude that 
mutability and selection shape the distribution of missense mutations found in both the soma 
and the germline. Interestingly, both the somatic and germline mutational spectra are very 
likely to have been shaped in a similar way. Evidence comes from the observation that 
neither the somatic nor the germline missense mutations exhibited significant differences
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when compared to shared mutations, with respect to disease-associated mutability rates.
Thus, we may infer that very similar mechanisms operate to influence both the germline and 
somatic missense mutations spectra in the VHL gene.
Reports have indicated an intricate first-hit second-hit relationship in the VHL gene. It 
has been reported that almost exclusively, whenever the inherited hit has been a deletion, the 
second hit is very likely to be a point mutation (Vortmeyer et al. 2002). Vortmeyer et al. 
(2002) have termed the relationship "mutation-deletion sequence”. Furthermore, homozygous 
inactivation of the VHL gene has been reported to lead to embryonic lethality in mice (Gnarra 
et al. 1997). Hence it is likely that homozygous deletions as first and second hits are likely to 
be incompatible with cell survival. It is quite likely that this "mutation-deletion sequence" 
could potentially occur in reverse order. Thus, the germline mutation could be a missense 
mutation and the somatic hit a deletion. This is supported by reports that the second-hit 
usually comprises deletions with variable sizes (Glasker et al. 2006), but more importantly 
both the germline and somatic missense mutations are equally likely to be detrimental to the 
protein function and are influenced by similar mechanisms. In addition, such a scenario has 
been previously described (Wait et al. 2004).
Therefore, an intricate relationship between the germline and somatic mutations could 
play an important role in von Hippel-Lindau disease. In addition, both the germline and 
somatic missense mutations are quite likely to be drivers of tumorigenesis, especially those 
mutations found in both the soma and the germline.
4.4.8. Final conclusions
Despite the absence of other studies to support some of the findings presented in this 
chapter, a number of important conclusions could be drawn. Missense mutations falling into 
different categories can exhibit clear differences in terms of pathogenicity. It would appear 
that germline and missense mutations found in both the soma and the germline may exhibit 
profound effects on tumour development and/or progression as compared to pure somatic 
missense mutations, at least for the TP53 gene and possibly also for CDKN2A. It is quite 
possible that other types of somatic mutation (other than missense) could have a greater 
impact on tumour development in addition to inherited predisposition (e.g. germline missense 
mutations). These include mutations that completely abolish gene structure and/or function, 
such as gross deletions, insertions, indels, gene rearrangements, etc. The data on micro­
lesions (<20bp) in these 17 human tumour suppressor genes partially support such a
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hypothesis. For a number of genes, namely APC, ATM, BRCA2, CDH1, PTCH, PTEN, RBI, 
STK11 and TSC1, the ratio of truncating lesions (i.e. nonsense mutations, micro-deletions, 
micro-insertions and micro-indels) to non-truncating mutations (i.e. missense mutations) 
indirectly indicates that truncating lesions are found relatively more frequently in the soma 
than in the germline. This is further supported by the fact that the combination of lesions in 
the soma for all genes as compared to the combination of lesions in the germline, showed 
significantly more (p-value<2.20E-16, Table 17) truncating lesions than non-truncating ones 
(0.46 and 0.23 for the soma and germline respectively, Table 17). In addition, cancer is 
usually perceived as a disorder of post-reproductive age. Hence, an age-related shift in DNA 
repair mechanisms could potentially indicate the more deleterious impact of somatic lesions 
as compared to germline ones. However, studies on somatic micro-lesions indicate that 
gender, age or tissue-specificity might not play an important role in determining the 
frequency of micro-lesions (Gonzalez et al. 2007). Further analysis could help to resolve the 
relative impact of somatic and germline lesions. One possible way of answering those 
questions is to have matched mutational data (i.e. germline and somatic lesions) from 
tumours (i.e. soma) and normal cells (i.e. germline) from the same individual. This would 
allow a direct comparison between the germline and the soma, with respect to relative impact 
on gene/protein structure and/or function. A slightly different approach is to have mutational 
data of matched DNA from tumour and normal cells from the same individual, for bi-allelic 
inactivation of relevant genes, where there is the presence or absence of a germline hit.
Germline and missense mutations found in both the germline and the soma are 
influenced to a greater extent by the nucleotide context than pure somatic missense 
mutations. Therefore, if missense mutations found in both the soma and germline are the 
result of similar mechanisms, this would indicate that endogenous mutagenesis could have a 
significant impact on tumour development, at least for missense mutations.
Taken together, the results and analysis presented herein strongly suggest that 
algorithms and methods that attempt to predict the relative impact on the function of genes 
and proteins with respect to disease-associated missense mutations, have to take into 
consideration the different mutational categories that these mutations fall into (i.e. somatic, 
germline, shared and recurrent). Thus, some categories of missense mutations are more likely 
to result in a disease phenotype than others.
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Table 8 Possible single base-pair substitutions leading to the non-synonymous change of
Codoa
Pocitioa in the 
codoa
1 2 3
Namber of
All paiitioiu in tkc codon 
pocaiblc nuuense chance*
CTT 3 3 0 6
GCC 3 3 0 6
GGA 2 3 0 5
GTC 3 3 0 6
TGC 3 3 1 7
AGT 3 3 2 8
TGT 3 3 1 7
TCA 3 1 0 4
CGA 1 3 0 4
ATT 3 3 1 7
TAT 3 3 0 6
ATC 3 3 1 7
AAC 3 3 2 8
AGC 3 3 2 8
TAC 3 3 0 6
AAT 3 3 2 8
ACT 3 3 0 6
ACA 3 3 0 6
TCG 3 2 0 5
GAC 3 3 2 8
CAA 2 3 2 7
CCG 3 3 0 6
CTG 2 3 0 5
GGT 3 3 0 6
GCA 3 3 0 6
AAG 2 3 2 7
GTG 3 3 0 6
TCC 3 3 0 6
TTT 3 3 2 8
AGG 2 3 2 7
CAC 3 3 2 8
GTT 3 3 0 6
CGT 3 3 0 6
CGG 2 3 0 5
CAT 3 3 2 8
ATA 3 3 1 7
AGA 1 3 2 6
GGG 3 3 0 6
CCC 3 3 0 6
ACC 3 3 0 6
GAG 2 3 2 7
TTA 2 1 2 5
CCA 3 3 0 6
GAT 3 3 2 8
CTA 2 3 0 5
TCT 3 3 0 6
TGG 3 2 2 7
TTC 3 3 2 8
CGC 3 3 0 6
CTC 3 3 0 6
GCG 3 3 0 6
TTG 2 2 2 6
GGC 3 3 0 6
GAA 2 3 2 7
GCT 3 3 0 6
CAG 2 3 2 7
CCT 3 3 0 6
ACG 3 3 0 6
AAA 2 3 2 7
ATG 3 3 3 9
GTA 3 3 0 6
Total 166 176 50 392
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Table 9 Shared recurrent missense mutations and shared missense mutations found in CpG dinucleotidcs
Mutations
Gene
Shared
I FcpG
CpG-located
F cpg ' F sh F1 REC
Recurrent
F rec ! F sh
Recurrent and CpG-located
F r e c _CpG F r b c _Cpg  /  F sh F r e c _CpG ^FCpG F r e c _ cpg  I F  pec
APC 1 0 0.00 0 0.00 0 0.00 N/A N/A
ATM 0 0 N/A 0 N/A 0 N/A N/A N/A
BRCA1 1 0 0.00 1 1.00 0 0.00 N/A 0.00
BRCA2 1 1 1.00 0 0.00 0 0.00 0.00 N/A
CDH1 1 0 0.00 0 0.00 0 0.00 N/A N/A
CDKN2A 28 7 0.25 1 0.04 0 0.00 0.00 0.00
NFI 0 0 N/A 0 N/A 0 N/A N/A N/A
NF2 0 0 N/A 0 N/A 0 N/A N/A N/A
PTCH 1 0 0.00 0 0.00 0 0.00 N/A N/A
PTEN 22 3 0.14 11 0.50 3 0.14 1.00 0.27
RBI 3 1 0.33 1 0.33 0 0.00 0.00 0.00
STK11 3 1 0.33 0 0.00 0 0.00 0.00 N/A
TP53 88 20 0.23 79 0.90 20 0.23 1.00 0.25
TSC1 0 0 N/A 0 N/A 0 N/A N/A N/A
TSC2 2 2 1.00 1 0.50 1 0.50 0.50 1.00
VHL 45 6 0.13 7 0.16 3 0.07 0.50 0.43
WT1 0 0 N/A 0 N/A 0 N/A N/A N/A
Total 196 41 0.21 101 0.52 27 0.14 0.66 0.27
Ft is the number of mutations, where i E {SH,CpG,REC,REC_CpG}
SH-shared, CpG-CpG-located , /?£C-recurrent, /?£C_ CpG-recurrent and CpG-located
Values marked in red denote genes that made a relatively large contribution to the corresponding mutational spectrum
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Table 10 Species and sequences used to estimate evolutionary conservation
Gene Species cDNA sequence identifier Protein sequence identifier
Xenopus laevis U64442.1 AAB41671.1
APC Bos taurus Rattus norvegicus
XM 865627.1 
NM 012499.1
XP 870720.1 
NP 036631.1
Mus musculus NM_007462.1 NP_031488.1
Gallus gallus XM 417160.1 XP 417160.1
Xenopus laevis AY668954.1 AAT72929.1
ATM Rattus norvegicus XM 236275.3 XP 236275.3Sus scrofa AY587061 AAT01608.1
Canis familiaris XM 845871.1 XP 850964.1
Mus musculus NM_007499 NP_031525.1
Gallus gallus NM 204169.1 NP 989500.1
Xenopus laevis AF416868.1 AAL13037.1
BRCA1 Bos taurus Rattus norvegicus
NM 178573.1 
NM 012514.1
NP 848668.1 
NP 036646.1
Canis familiaris NM 001013416.1 NP 001013434.1
Mus musculus NM 009764.2 NP 033894.2
Gallus gallus NM 204276.1 NP 989607.1
Danio rerio XM  690042.1 XP 695134.1
BRCA2 Bos taurus Rattus norvegicus
XM  583622.2 
NM 031542.1
XP 583622.2 
NP 113730.1
Canis familiaris NM 001006653.4 NP 001006654.2
Mus musculus NM 009765.1 NP_033895.1
Xenopus laevis BC068940.1 AAH68940.1
Danio rerio NM 131820.1 NP 571895.1
CDH1 Bos taurus Rattus norvegicus
NM 001002763.1 
NM 031334.1
NP 001002763.1 
NP 112624.1
Canis familiaris XM  536807.2 XP 536807.2
Mus musculus NM 009864.1 NP 033994.1
Gallus galus NM 204433.1 NP 989764.1
Takifugu rubripes AJ250231.1 CAC12808.1
CDKN2A Bos taurus Rattus norvegicus
XM  868375.1 
NM 031550.1
XP 873468.1 
NP 113738.1
Canis familiaris XM  538685.2 XP 538685.2
Mus musculus AF044336.1 AAC08963.1
Gallus gallus XM 415914.1 XP 415914.1
Takifugu rubripes AF064564.2 AAD15839.1
NF1 Rattus norvegicus NM 012609.1 NP 036741.1
Canis familiaris XM 537738.2 XP 537738.2
Mus musculus NM_010897.1 NP_035027.1
Gallus gallus NM 204497.2 NP 989828.2
Danio rerio NM 212951.1 NP 998116.1
NF2 Bos taurus Rattus norvegicus
XM 611643.2 
XM 341248.2
XP 611643.2 
XP 341249.2
Canis familiaris XM 534729.2 XP 534729.2
Mus musculus NM_010898.2 NP_035028.2
Xenopus laevis AF302765.1 AAK15463.1
Gallus gallus NM 204960.1 NP 990291.1
PTCH Danio rerio Meriones unguiculatus
NM 130988.1 
AB 188226.1
NP 571063.1 
BAE78534.1
Rattus norvegicus NM 053566.1 NP 446018.1
Mus musculus NM_008957.1 NP_032983.1
PTCH Xenopus laevis AF144732.1 AAD46165.1
Gallus gallus XM 421555.1 XP 421555.1
Bos taurus XM 613125.2 XP 613125.2
Canis familiaris NM 001003192.1 NP 001003192.1
Rattus norvegicus NM 031606.1 NP 113794.1
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PTCH Mus musculus NM 008960.2 NP_032986.1
R BI
Gallus gallus 
Rattus norvegicus 
Canis familiaris 
Mus musculus 
Oncorhynchus mykiss 
Notophthalmus viridescens
NM 204419.1 
XM 344434.2 
XM 534118.2 
NM 009029.1 
AF102861.1 
Y09226.1
NP 989750.1 
XP 344435.2 
XP 534118.2 
NP 033055.1 
AAD13390.1 
CAA70428.1
STK11
Xenopus laevis 
Danio rerio 
Rattus norvegicus 
Rtga erinacea 
Canis familiaris 
Mus musculus
U24435.1 
NM 001017839.1 
XM 234900.2 
AF486831.1 
XM 542206.2 
NM_011492.1
AAC59904.1 
NP 001017839.1 
XP 234900.2 
AAL92113.1 
XP 542206.2 
NP_035622.1
TP53
Gallus gallus 
Danio rerio 
Bos taurus 
Rattus norvegicus 
Canis familiaris 
Mus musculus
NM 205264.1 
NM 131327.1 
NM 174201.2 
NM 030989.1 
NM 001003210.1 
NM_011640.1
NP 990595.1 
NP 571402.1 
NP 776626.1 
NP 112251.1 
NP 001003210.1 
NP_035770.1
TSC1
Gallus gallus 
Danio rerio 
Bos taurus 
Rattus norvegicus 
Canis familiaris 
Mus musculus
XM 415449.1 
XM 691747.1 
XM 612846.2 
NM 021854.1 
XM 537808.2 
NM_022887.2
XP 415449.1 
XP 696839.1 
XP 612846.2 
NP 068626.1 
XP 537808.2 
NP_075025.2
TSC2
Gallus gallus 
Takifugu rubripes 
Bos taurus 
Rattus norvegicus 
Canis familiaris 
Mus musculus
XM 414853.1 
AF013614 
XM 581197.2 
NM 012680.2 
XM 537008.2 
NM_011647.2
XP 414853.1 
AAB86682.1 
XP 581197.2 
NP 036812.2 
XP 537008.2 
NP_035777.2
VHL
Gallus gallus 
Danio rerio 
Bos taurus 
Rattus norvegicus 
Canis familiaris 
Mus musculus
XM 414447.1 
XM 681176.1 
XM 613870.2 
NM 052801.1 
NM 001008552.1 
NM_009507.2
XP 414447.1 
XP 686268.1 
XP 613870.2 
NP 434688.1 
NP 001008552.1 
NP_033533.1
WTl
Xenopus laevis 
Gallus gallus 
Rattus norvegicus 
Canis familiaris 
Sus scrofa 
Mus musculus
U42011.1 
NM 205216.1 
NM 031534.1 
XM 846479.1 
NM 001001264.1 
NM 144783.1
AAB53152.1 
NP 990547.1 
NP 113722.1 
XP 851572.1 
NP 001001264.1 
NP 659032.1
Fr
eq
ue
nc
y
Figure 15 Distribution o f nucleotide substitution rates derived from Hess et al. (1994) 
for the somatic missense mutations in the TP53 gene
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Figure 16 Rate of evolution in the studied 17 human tumour suppressor genes
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ML- Maximum likelihood method; NG- Nei and Gojobori (1986) method; LWP85- Li, Wu and Pamillo-Bianchi method; LPB93- Li and 
Pamilo-Bianchi method; ML and NG are part of the PAML software package (Yang 1997); LWP85 and LPB93 are part of the MEGA (Kumar et 
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Table 11 Distribution of somatic and germline missense mutations in the 17 tumour suppressor genes studied
Missense mutations CpG mutations of missense CpG mutations of potential
Recurrent
mutations Shared mutations
Codon*
Possible
missense
mutations
Possible CpG 
mutations Somatic Germline Somatic Germline Somatic Germline Somatic Somatic Germline
Gcae N1 N* N* Freq2 N1 Freq2 N1 Freq2 N* Freq2 N1 Freq2 N* Freq2 N1 Freq2 N1 Freq2 N1 Freq2 N1 Freq2
APC 2844 18727 131 7.00E-03 38 2.03E-03 22 1.17E-03 1 1.67E-02 3 5.00E-02 1 7.63E-03 3 2.29E-02 4 1.05E-01 1 2.63E-02 1 4.55E-02
ATM 3057 20309 118 5.81E-03 11 5.42E-04 75 3.69E-03 1 1.16E-02 6 6.98E-02 1 8.47E-03 6 5.08E-02 1 9.09E-02 0 O.OOE+OO 0 O.OOE+OO
BRCA1 1864 12497 57 4.S6E-03 5 4.00E-04 169 1.35E-02 0 0.00E+00 9 5.17E-02 0 0.00E+00 9 1.58E-01 0 O.OOE+OO 1 2.00E-01 1 5.92E-03
BRCA2 3419 22814 94 4.12E-03 20 8.77E-04 85 3.73E-03 2 1.90E-02 9 8.57E-02 2 2.13E-02 9 9.57E-02 2 1.00E-01 1 5.00E-02 1 1.18E-02
CDH1 883 5840 105 1.80E-02 14 2.40E-03 18 3.08E-03 1 3.13E-02 4 1.25E-01 1 9.52E-03 4 3.81E-02 0 O.OOE+OO 1 7.14E-02 1 5.56E-02
CDKN2A 157 1023 67 6.55E-02 170 1.66E-01 34 3.32E-02 26 1.27E-01 2 9.80E-03 26 3.88E-01 2 2.99E-02 6 3.53E-02 28 1.65E-01 28 8.24E-01
NF1 2819 18723 164 8.76E-03 2 1.07E-04 83 4.43E-03 0 O.OOE+OO 4 4.71E-02 0 O.OOE+OO 4 2.44E-02 0 O.OOE+OO 0 O.OOE+OO 0 O.OOE+OO
NF2 5% 4004 70 1.75E-02 23 5.74E-03 20 5.00E-03 2 4.65E-02 2 4.65E-02 2 2.86E-02 2 2.86E-02 3 1.30E-01 0 O.OOE+OO 0 O.OOE+OO
PTCH 1448 9556 259 2.7 IE-02 13 1.36E-03 23 2.41E-03 2 S.56E-02 2 5.56E-02 2 7.72E-03 2 7.72E-03 0 O.OOE+OO 1 7.69E-02 1 4.35E-02
PTEN 404 2729 19 6.96E-03 201 7.37E-02 23 8.43E-03 4 1.79E-02 1 4.46E-03 4 2.11E-01 1 5.26E-02 47 2.34E-01 22 1.09E-01 22 9.57 E-01
RBI 929 6136 65 1.06E-02 22 3.59E-03 34 5.54E-03 3 5.36E-02 2 3.57E-02 3 4.62E-02 2 3.08E-02 1 4.55E02 3 1.36E-01 3 8.82E-02
STK11 434 2914 102 3.50E-02 17 5.83E-03 27 9.27E-03 4 9.09E-02 2 4.55E-02 4 3.92E-02 2 l.%E-02 2 1.18E01 3 1.76E-01 3 1.11E-01
TP53 394 2604 60 2.30E-02 1138 4.37E-01 6 2.30E-03 30 2.62E-02 0 0.00E+00 30 5.00E-01 0 O.OOE+OO 781 6.86E-01 88 7.73E-02 88 1.47E+01
TSC1 1165 7709 104 1.35E-02 2 2.59E-04 7 9.08E-04 0 0.00E+00 1 1.11E-01 0 O.OOE+OO 1 9.62E-03 0 O.OOE+OO 0 O.OOE+OO 0 O.OOE+OO
TSC2 1808 11880 334 2.81E-02 0 O.OOE+OO 87 7.32E-03 0 O.OOE+OO 13 1.49E-01 0 O.OOE+OO 13 3.89E-02 0 O.OOE+OO 2 O.OOE+OO 2 2.30E-02
VHL 214 1406 69 4.91E-02 43 3.06E-02 98 6.97E-02 4 2.84E-02 2 1.42E-02 4 5.80E-02 2 2.90E-02 5 1.16E-01 45 1.05E+00 45 4.59E-01
WT1 450 3003 101 3.36E-02 1 3.33E-04 39 1.30E-02 0 O.OOE+OO 7 1.75E-01 0 O.OOE+OO 7 693E-02 0 O.OOE+OO 0 O.OOE+OO 0 O.OOE+OO
total 22885 151874 1919 1.26E-02 1720 1.13E-02 850 5.60E-03 80 3.11E-02 69 2.68E-02 80 4.17E-02 69 3.60E-02 852 4.95E-01 196 1.14E-01 196 2.31E-01
-Number of missense mutations
-Frequency
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Tabic 12 Distribution of somatic, germline and shared mutations
Mutations
Gene
Missense
K '
Somatic
F,/F„ FS MT 1
Germline
Fg t Fg /Fgt Fg !Fmt l ' '.ii Fsh>Fm
Shared
Fsh t Fsht Fsh !Fmt
APC 61 38 0.62 0.02 0.01 22 0.36 0.03 0.01 1 0.02 0.01 0.00
ATM 86 11 0.13 0.01 0.00 75 0.87 0.09 0.03 0 0.00 0.00 0.00
BRCA1 175 5 0.03 0.00 0.00 169 0.97 0.20 0.06 1 0.01 0.01 0.00
BRCA2 106 20 0.19 0.01 0.01 85 0.80 0.10 0.03 1 0.01 0.01 0.00
CDH1 33 14 0.42 0.01 0.01 18 0.55 0.02 0.01 1 0.03 0.01 0.00
CDKN2A 232 170 0.73 0.10 0.06 34 0.15 0.04 0.01 28 0.12 0.14 0.01
1SF1 85 2 0.02 0.00 0.00 83 0.98 0.10 0.03 0 0.00 0.00 0.00
NF2 43 23 0.53 0.01 0.01 20 0.47 0.02 0.01 0 0.00 0.00 0.00
PTCH 37 13 0.35 0.01 0.00 23 0.62 0.03 0.01 1 0.03 0.01 0.00
PTE IS 246 201 0.82 0.12 0.07 23 0.09 0.03 0.01 22 0.09 0.11 0.01
RBI 59 22 0.37 0.01 0.01 34 0.58 0.04 0.01 3 0.05 0.02 0.00
STKI1 47 17 0.36 0.01 0.01 27 0.57 0.03 0.01 3 0.06 0.02 0.00
TP53 1232 1138 0.92 0.66 0.41 6 0.00 0.01 0.00 88 0.07 0.45 0.03
TSC1 9 2 0.22 0.00 0.00 7 0.78 0.01 0.00 0 0.00 0.00 0.00
TSC2 89 0 0.00 0.00 0.00 87 0.98 0.10 0.03 2 0.02 0.01 0.00
VHL 186 43 0.23 0.03 0.02 98 0.53 0.12 0.04 45 0.24 0.23 0.02
WT1 40 1 0.03 0.00 0.00 39 0.98 0.05 0.01 0 0.00 0.00 0.00
(^5t ) ( ^ gt) (FSHT)
total 2766 1720 0.62 1.00 0.62 850 0.31 1.00 0.31 196 0.07 1.00 0.07
Ft is the number of mutations, where i E {M,S,G SH,MT,G1r,ST, SHT}
Af-missense, 5-somatic , G-germline , SH-shared, MT-missense total, GT-germline total, ST-somatic total, SHT-shared total 
Marked in red are genes that contribute to a relatively greater extent to the somatic, germline or shared mutational spectrum for all genes 
combined
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Table 13 Summary' of statistically significant results in the studied 17 tumour 
suppressor genes
Soma vs pot
Germ vs pot
I
Shared vs pot
CpG 
Grantham 
Evolution
Obsvs pot
Grantham
Evolution
Soma vs germ
k  raw  c Aik.
I a n t h a m
E v o lu tio n
Soma vs shared
G ran th am
E v o lu tio n
Germ vs shared
G r a n t h a m
E v o lu tion
Grantham
E v o lu tio n
Rec shared vs rec non-shared Hess 
Krawczak 
CpG 
Grantham 
Evolution
N o n -re^ h a g ^ w io jw ey jo f^  
sh ared
Hess 
Krawczak 
CpG 
Grantham
{•so lu tion
Hess 
Krawczak 
CpG 
Grantham 
Evolution
Rec sharet^ j^otwejMioj^
shared
Legend f or J shows the direction of gene- or experiment-wise statistically significant results The direction is with respect to the first group in the comparison shaded box 
represents an experiment-wise statistically significant result, non-shaded arrow (i e f orjjrepresents a gene-wise statistically significant result, shaded box represents *80*/. p 
to detect a statistically significant result for the comparison and associated effect size, ■■fc.hadcd box represents <80% power and experiment-wise statistically significant result. 
Soma- Somatic. Germ- Germline. Obs - Observed (somatic, germline and shared). Pot - Potential. Rec - Recurrent, Non-rec - Non-recurrent,
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Table 14 Gene-wise somatic and germline missense mutations combined for all genes
Mutation rate
Gene Median 
symbol
Disease-associated 
mutation rate
Gene Median 
symbol
Evolutionary 
variation rate
Gene Median 
symbol
Grantham  score
Gene Median 
symbol
CpG-located 
missense 
mutations 
Gene % 
symbol
STK11 1.66 STK11 24CAc_o PTCH 1.06
I3 1  APC W 8.4 CDKN2A 1.01 CDKN2A 0.38 CDKN2A 15
E CDKN2A 7.9 APC 0.83o
e3 PTEN 5.6 PTEN 0.53
E
J TP53 4.6 TP53 0.5 TP53 0.17 RBI 14
VHL k  0.14 BRCA2 10
ATM 9
for all 17 somatic 4.7 somatic 0.53 somatic 0 somatic 78 somatic 5
genes potential 4.1 potential 0.4 potential 0.2 potential 74 potential 1
combined germline 7.2 germline 0.81 germline 0 germline 94 germline 8
TSC2 7.3 TSC2 0
BRCAJ 8.7 BRCA1 5
NF1 7.3 NF1 98 NF1 5
C/l ATM 7.9 ATM 0.79 ATM 0 ATM 98 ATM 8CZ RBI 7.6 BRCAJ 0.81 VHL 0 VHL 99 NF2 10
83 BRCA2 8.7 BRCA2 0.81 BRCA2 11
E PTEN 0.92
_c RBI 0.99
1 NF1 1.03
TSC2 1.03 APC 14
WT1 10.1 WT1 1.22 WT1 0 TSC2 15
CDH1 1.27 BRCAJ 0.14 CDH1 22
CDKN2A 0.29
Legend: Genes exhibiting gene-wise or experiment-wise (shaded in |rey) statistically
significant results for the somatic vs. potential and germline vs. potential missense mutations
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Table 15 Inequalities between somatic, germline and shared missense mutations for all 
genes combined_____________________________________
Parameter
Observed trend 
(p<0.05)
Median mutability rate 
with respect to Hess et al. 
(1994)
shared>germline»somatic 
[8.7] [7.2] [4.7]
Median disease-associated 
mutability rate with 
respect to Krawczak et al. 
(1998)
shared>germline»somatic
[1.06] [0.81] [0.53]
Mean and median 
evolutionary variability
shared «  somatic
[0.10;0] [0.22;0] 
somatic »  germline
[0.22;01 [0.18;0]
Median Grantham score somatic < germline
[78] [94]
Proportion of CpG- 
located mutations
shared»germline>somatic
[0.211 [0.08] [0.051
Legend: »  and « indicate experiment-wise statistical significance; > indicates only gene- 
wise statistical significance; median or median and mean values are presented in square 
brackets
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Table 16 Truncating vs. non-truncating lesions
Geae Miaaeaie Noaaease
Micro-
ddetioaf
Micro-
iaaertioaa
Micro­
in d d i
Non-
truncating Truncating
Noa-
tru  nca tin gATrun eating
APC Somatic 39 79 152 44 3 39 278 0.14
Germline 23 180 299 115 12 23 606 0.04
ATM Somatic 11 7 4 1 0 11 12 0.92
Germline 76 75 122 35 14 76 246 0 31
BRCA1 Somatic 6 9 9 5 0 6 23 0.26
Germline 170 121 259 85 12 170 477 0.36
BRCAJ Somatic 21 1 8 4 0 21 13 1.62
Germline 86 76 247 90 11 86 424 0.20
CDH1 Somatic 15 7 13 2 0 15 22 068
Germline 19 11 12 8 1 19 32 0 59
CDKN2A Somatic 198 18 77 25 8 198 128 1.55
Germline 62 7 11 7 2 62 27 2.30
NF1 Somatic 2 11 16 3 0 2 30 0.07
Germline 83 115 221 105 8 83 449 0 18
NF2
Somatic 23 42 182 28 6 23 258 0.09
Germline 20 43 55 16 2 20 116 0.17
PTCH Somatic 14 9 14 6 1 14 30 0.47
Germline 24 27 42 32 8 24 109 0.22
PTEN
Somatic 226 56 152 51 4 226 263 086
Germline 45 28 29 22 3 45 82 0.55
Somatic 25 27 34 12 3 25 76 0.33
RBI
Germline 37 76 117 53 11 37 257 0 14
S t t l l
Somatic 20 10 5 1 1 20 17 118
Germline 30 27 47 24 3 30 101 0.30
TPS3
Somatic 1229 96 512 238 0 1229 846 1 45
Germline 94 10 16 5 3 94 34 2.76
Somatic 2 1 1 0 0 2 2 1 00TSC1
Germline 7 37 53 25 4 7 119 0.06
TSC2
Somatic 2 1 3 2 1 2 7 0.29
Germline 89 74 110 46 3 89 233 0.38
VHL
Somatic 88 15 180 44 1 88 240 0.37
Germline 143 27 63 37 5 143 132 1 08
Somatic 1 3 4 3 0 1 10 0.10w n
Germline 40 14 8 4 1 40 27 1 48
Total
Somatic 1922 392 1366 469 28 1922 2255 085
Germline 1048 948 1711 709 103 1048 3471 0.30
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Table 17 Truncating vs. non-truncating somatic and germline mutations for all genes 
combined
Son
Truncating 
Number Frequency
atic
N o d - truncating 
Number Frequency
Gen
Truncating 
Number Frequency
iline
Non-truncating 
Number Frequency X2 p-value
1922 0.46 2255 0.54 1048 0.23 3471 0.77 1389.2130 <2.20E-16
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5. Nonsense mutations
5.1. Introduction
5.1.1. Gene expression in eukaryotes
The gene expression pathway in eukaryotes comprises a number of interconnected 
steps. A key player is the mRNA, an intermediate between the genetic information stored in 
DNA and the process of translation into a protein. The mRNA precursor is transcribed from 
DNA and is transformed into a mature mRNA by removal of all or certain introns (alternative 
splicing) and addition of the terminal m(7)GpppN cap (which facilitates ribosome binding) 
and the poly (A) tail. The mature mRNA is then exported to the cytoplasm where it is 
generally translated into protein before ultimately being degraded.
Even although the complexity of the gene expression machinery allows control at 
many different levels, gene expression is susceptible to errors. These errors include mutations 
within the coding regions of the genes via incorrect processing (i.e. splice site mutations), 
ffameshifts (e.g. deletions, insertions and indels) or nonsense mutations (Baker and Parker 
2004; Hilleren and Parker 1999).
5.1.2. Importance of nonsense mutations and their functional 
consequences
An open translational reading frame (ORF) contains a sequence of bases within the 
mRNA that could potentially encode a protein. Generally, ORFs begin with an AUG 
initiation codon and end with a termination (or stop) codon (viz. UAA, UAG, UGA). Apart 
from the ‘naturally-occurring termination codons’ (Mort et al. 2008), various aberrations 
could introduce a premature termination codon (PTC) within the gene coding region thereby 
interrupting the ORF. These include single base-pair substitutions that directly introduce 
termination codons, and intra-genic (i.e. within the gene coding region) ffameshift mutations 
(i.e. insertions, deletions and indels, where the size of the deleted or inserted bases is not 
divisible by three) or mutations that give rise to inefficient or inaccurate intron removal (e.g. 
intron retention) from the pre-mRNA or alternatively spliced mRNAs (Mendell et al. 2004) 
that result in the use of a non-natural termination codon. In addition, a small proportion
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(0.05% to 0.5%) of human mRNA transcripts are estimated to acquire a PTC through various 
transcription errors (Muhlemann et al. 2008).
One commonly occurring mutation is the single base-pair substitution that introduces 
a stop codon (nonsense mutation or premature termination codon) within the coding region of 
a gene that, in a majority of cases, leads to premature translational termination. Nonsense 
mutations (as a result of a single base-pair substitution) are an integral and important part of 
the mutational spectrum associated with inherited disease. In this context, it has been 
estimated that nonsense mutations are twice as likely to come to clinical attention as the most 
extreme missense mutations (extreme in terms of the chemical difference between the 
substituted wild-type and substituting amino acid residues), and three times more likely to 
come to clinical attention than the average amino acid change (Krawczak et al. 1998). 
Numerous inherited diseases have been associated with premature termination codons, 
including cystic fibrosis, Duchenne muscular dystrophy, Hurler syndrome, several types of 
cancer, P-thalassemia, Marfan syndrome, etc (Culbertson 1999; Frischmeyer and Dietz 1999; 
Holbrook et al. 2004). Indeed, they account for -20% of all disease-associated exonic single 
base-pair substitutions logged in the Human Gene Mutation Database (HGMD; 
http://www.hgmd.org: Mort et al. 2008; Stenson et al. 2003). Furthermore, others have 
estimated that 35% of all human alternatively spliced mRNAs harbour a premature 
termination codon (Lewis et al. 2003).
Nonsense mutations are important because they are ‘equivalent to nonsense 
sequences’ (Kuzmiak and Maquat 2006) and generally their occurrence precludes the 
synthesis of a full length protein. If translated (assuming of course that the mRNA is stable 
enough to support translation), these mutant forms (i.e. containing a PTC in the ORF) could 
have very limited or even no function at all (e.g. loss of key domains or amino acids). Thus, 
premature terminational translation could be regarded as a waste of energy expended on non­
functional proteins (Seligmann and Pollock 2004). By contrast, some mutations would lead to 
a ‘gain-of-function’ if they were to give rise to a dominant negative form over the wild-type. 
Dominant negative forms usually arise in dimeric or multimeric proteins, such as that 
encoded by the TP53 gene. Therefore, mutant forms of the protein could heterotetramerize 
(as in the case of TP53) with the wild-type product and exert a dominant negative effect over 
the naturally occurring product. In the given example of TP53, this effect is expressed in 
reduced DNA binding and transactivation of its target genes, CDKN1A, MDM2 and PIG2 
(Willis et al. 2004). It has to be noted that the great majority of tumour suppressor mutations, 
whether inherited or somatic, are loss-of-function mutations (Sherr 2004). Nevertheless,
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numerous studies on tumour suppressor genes have identified mutations that present 
dominant negative effects over the wild-type product. Certain mutant forms of the APC gene 
are shown to exhibit such an effect and the mutant proteins encoded promote proliferation 
and chromosome instability (Dihlmann et al. 1999; Tighe et al. 2004). Other well studied 
tumour suppressor genes, such as the ATM  (Chenevix-Trench et al. 2002; Oguchi et al. 2003; 
Scott et al. 2002), CDH1 (Crane et al. 2004; Pfleger and Kirschner 2000), BRCA1 (Deans et 
al. 2004; Hohenstein and Fodde 2003; Kim et al. 2003), NF2 (Johnson et al. 2002), PTCH 
(Uchikawa et al. 2006), PTEN (Steelman et al. 2008), RBI (Li et al. 2000), TSC2 (Rosner et 
al. 2003) and WT1 (Han et al. 2007) genes, have also been shown to exhibit dominant 
negative forms. Some mutant forms of the ‘guardian of the genome’ (Vousden 2000), the 
TP53 gene, lead to a Toss-of-function’ whereas others give rise to a potent dominant negative 
over the wild-type (Chan and Poon 2007; Hassan et al. 2008; Junk et al. 2008).
5.1.3. CpG dinucleotides and nonsense mutations
Cytosine (C) is subject to a post-replicative covalent modification in the form of 
methylation, converting cytosine into 5-methylcytosine (5mC), mainly in the context of CpG 
dinucleotides (Coulondre et al. 1978; Grippo et al. 1968). Spontaneous deamination of 5mC 
yields the DNA base thymidine (T) (Wang et al. 1982), whereas deamination of 
unmethylated cytosine generates uracil (U), an RNA base, which can be processed and 
removed by uracil DNA glycosylase (Lindahl 1974; Visnes et al. 2008). As is evident from 
numerous studies, this spontaneous deamination of 5mC is largely responsible for a greatly 
increased mutation rate at CpG dinucleotides (Cooper and Youssoufian 1988; Gaffney and 
Keightley 2008; Krawczak et al. 1998). Importantly, key tumour suppressor genes, such as 
TP53 (Greenblatt et al. 1994) and CDKN2A (Pollock et al. 1996), are frequently found to 
exhibit mutations at CpG dinucleotides. Moreover, mutations at CpG sites that are 
compatible with a model of methylation-mediated deamination of 5mC (O T  on the coding 
strand and G>A on the non-coding strand) are found to account for 20-25% of all inherited 
mutations causing human disease (Cooper and Youssoufian 1988). The impact of this 
endogenous mechanism will largely depend, albeit indirectly, on the methylation patterns of 
the DNA sequences in question in the germline or the soma. Some reports suggest that the 
methylation status may differ between the germline and the soma. Indeed, it has been 
suggested that sperm cells may be hypermethylated as compared to oocytes, but both are 
hypomethylated with respect to somatic tissues (Allegrucci et al. 2005). In addition, there
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might be variation in the methylation pattern both within and between individuals (Millar et 
al. 1998) which would make it very difficult to extrapolate from methylation status or 
patterns to mutation rates in specific CpG dinucleotides.
The above notwithstanding, out of the 23 possible single base-pair substitutions that 
could lead to the introduction of a stop codon (as shown in Figure 19), the most frequent 
change is CGA->TGA, converting the arginine codon to a termination codon. Indeed, some 
21% of all nonsense mutations causing human inherited disease logged in HGMD are located 
in CpG dinucleotides (Mort et al. 2008).
5.1.4. Quality control mechanisms and nonsense mutations
Although errors arise in the coding regions of genes and subsequently in the mRNA 
transcripts, it is unwise to assume that such transcripts invariably accumulate to give rise to 
defective or aberrant proteins. Indeed, eukaryotic cells have evolved quality control 
mechanisms to detect and eliminate abnormal mRNA transcripts (Fasken and Corbett 2005). 
Some of these abnormal mRNA transcripts are detected and degraded in the nucleus whereas 
others are degraded in the cytoplasm (Fasken and Corbett 2005). The surveillance 
mechanisms recognise transcripts that lack natural stop codons (Maquat 2002; Vasudevan et 
al. 2002), mRNAs that harbour premature termination codons and other imperfections 
(Gonzalez et al. 2001; Maquat 2004). These imperfections can include incomplete splicing, 
extended 3’ untranslated regions (UTRs) and upstream open reading frames within the 5’ 
UTRs of the genes (Mitrovich and Anderson 2000; Muhlrad and Parker 1999; Ruiz- 
Echevarria and Peltz 2000; Welch and Jacobson 1999).
5.1.5. Nonsense-mediated mRNA decay
One of the most studied quality control mechanisms is nonsense-mediated mRNA 
decay (NMD), which is also known as mRNA surveillance. It generally targets for 
degradation mRNAs that harbour premature termination codons (Baker and Parker 2004; 
Conti and Izaurralde 2005; Fasken and Corbett 2005; Holbrook et al. 2004; Lejeune and 
Maquat 2005; Maquat 2004; Wilkinson 2005; Yamashita et al. 2005).
Even although it may differ between species and is considered non-essential in lower 
eukaryotes such as worms and yeast (Medghalchi et al. 2001), the process and the proteins 
involved generally appear to be evolutionarily conserved and considerable evidence exists to
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suggest that this mechanism is essential for life (Amrani et al. 2004; Behm-Ansmant et al. 
2007; Culbertson 1999; Gatfield et al. 2003; Longman et al. 2007; Maquat 2004).
5.1.5.1. Mechanism of NMD
The ‘unified NMD model’ (Muhlemann et al. 2008) proposes that an initial round of 
translation is required for nonsense codon recognition in which the UAA, UAG or UGA 
codons direct translational termination (Carter et al. 1995; Menon and Neufeld 1994; Qian et 
al. 1993), although PTC recognition entirely by the translating ribosome is insufficient for 
NMD (Zhang and Maquat 1997) and subsequent mRNA degradation. Thus, several lines of 
evidence suggest that the signal which distinguishes premature stop codons from bona fide 
naturally occurring stop codons is the exon junction complex (EJC; Frischmeyer and Dietz 
1999; Hilleren and Parker 1999; Li and Wilkinson 1998). The EJC is a complex of proteins 
that is deposited as a consequence of pre-mRNA splicing (i.e. intron removal) upstream (i.e. 
5’) of the splicing-generated exon-exon junctions. The EJC is deposited 20-24 nucleotides 
upstream of exon-exon junctions after RNA splicing (Tange et al. 2004) in a sequence- 
independent manner (Le Hir et al. 2000; Muhlemann et al. 2008). As such, the EJC maintains 
the position of excised introns in the newly spliced mRNA (Chang et al. 2007). In normal 
mRNA transcripts, the advancing ribosome displaces the exon-exon junction complexes 
(Dostie and Dreyfuss 2002; Lejeune et al. 2002) as they are all deposited upstream of the stop 
codon. By contrast, there is generally at least one EJC downstream (or 3’) of a premature 
termination codon, thereby triggering NMD. There is still an ongoing debate as to whether an 
EJC downstream of a PTC is actually required for PTC recognition or whether it simply 
functions as an NMD enhancer (Buhler et al. 2006; Muhlemann et al. 2008).
5.1.5.2. General rule for triggering NMD
According to the established rule, PTCs that are followed by an intron and are located 
more than 50-55 nucleotides (nt) upstream of the last exon-exon junction (EEJ), would 
generally elicit NMD (Nagy and Maquat 1998). Stated in terms of the spliced mRNA, PTCs 
that are followed by an exon-exon junction (measured after splicing) and which are located 
more than 50-55nt upstream (5’) of the EEJ, would generally elicit NMD (the process is 
illustrated in Figure 17 and Figure 18).
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Figure 17 General mechanism of nonsense-mediated mRNA decay
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Figure 18 NMD elicit by a premature termination codon
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5.1.5.3. Exceptions to the ~55nt boundary rule for triggering NMD
Even although it is commonly accepted that a PTC located more than 50-55nt 
upstream (5’) of the last EEJ would generally elicit NMD, there are a few exceptions to this 
rule. Several studies have indicated that contrary to the ~55nt boundary rule, there could be a 
polar effect with respect to the position of the PTC. Hence, PTCs distal (in a 5’ direction) 
from the last downstream intron trigger robust NMD, whereas proximally located PTCs 
generate a modest NMD response. Such a polar effect has been shown in the T-cell receptor 
beta (TCRB) gene (Wang et al. 2002). Wang et al. (2002) have shown that a distant nonsense 
codon (192nt upstream of the 55th nt upstream of the last intron) results in a -50 fold 
reduction in mRNA level whereas proximally located nonsense codons (91nt and 142nt 
upstream of the 55th nt upstream of the last intron) led to only a 2-4 fold reduction in mRNA 
level. A possible explanation of this polar effect could be that more distal PTCs are 
associated with faster rates of deadenylation, than proximal ones (Cao and Parker 2003).
It has been suggested that introns might not be an absolute requirement for NMD to 
be triggered even although their presence might enhance the process of mRNA degradation.
A transfected intronless HEXA minigene, containing a frame shift mutation or nonsense 
mutation in close proximity to the ffameshift, in Chinese hamster ovary (CHO) cells, has 
been shown to yield half the normal wild-type mRNA level (Rajavel and Neufeld 2001). By 
contrast, the insertion of a spliceable intron downstream of a PTC in the naturally intronless 
HSP70 gene results in the reduction of steady-state mRNA (Maquat and Li 2001). Therefore, 
it is unclear whether or not introns are essential for the triggering of NMD. Danckwardt et al. 
(2002) have suggested that aberrantly spliced mRNA transcripts are not always subject to 
NMD. These authors suggested that some genes contain cis-acting sequences that are 
required for triggering the NMD pathway.
Human p-globin (HBB) mRNAs that harbour nonsense mutations in the 5’ region of 
exon 1 accumulate to levels similar to those of the wild-type mRNA (Inacio et al. 2004; 
Romao et al. 2000). These studies suggest that mRNA transcripts bearing PTCs in close 
proximity to the AUG initiation codon could escape NMD. Similar findings have been 
reported for the TPI mRNA; mRNA transcripts harbouring nonsense mutations are an 
apparent NMD target but yield -84% of the abundance of the wild-type mRNA (Zhang and 
Maquat 1997). Analogous results have been shown for mRNA transcripts from the RBI gene 
(Sanchez-Sanchez et al. 2007) and the BRCA1 gene (Buisson et al. 2006). These studies show 
that when an AUG codon is in close proximity and downstream of the premature termination
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codon, translation re-initiation could occur. Therefore, these apparent targets escape NMD 
and their cellular mRNA abundance is similar to the wild-type product.
Variability in NMD sensitivity has been reported from several studies, indicating that 
a tissue-specific response might exist. CFTR transcripts from different epithelial cell lines 
that carry the same nonsense mutation (W128X) have been shown to display different 
efficiencies in triggering NMD (Linde et al. 2007).
Because exceptions to the ~55nt boundary rule exist, additional and unidentified 
determinants that modulate the NMD sensitivity of these transcripts, might exist. These 
factors have yet to be discovered and our understanding of the mechanism of the NMD made 
more complete.
5.1.6. Why study the role of NMD in cancer?
Cancer is commonly viewed as a genetic disorder since sequence changes in somatic 
DNA are considered causative of neoplasms. Of the three basic types of gene that drive 
tumour development when mutated, i.e. oncogenes, genomic stability genes and tumour 
suppressor genes (Vogelstein and Kinzler 2004), the tumour suppressor genes generally 
require a ‘biallelic gene inactivation’ (Knudson 1971, 1978). Thus, one mutant allele, 
inherited through the germline together with subsequent somatic inactivation of the other 
allele has been the basis of the ‘two-hit’ hypothesis originally proposed by Knudson 
(Knudson 1971, 1978). However, subsequent studies have shown that some tumour 
suppressor genes are ‘haploinsufficient for tumour suppression’ (Payne and Kemp 2005).
That is to say, one allele of the gene is insufficient to restore the function of the two copies of 
the wild-type product. By way of an example, a reduction in TP53 gene dosage could be 
"sufficient to promote tumorigenesis" (Venkatachalam et al. 1998) via reduced level of 
apoptosis (Clarke et al. 1994) and reduced maintenance of genome integrity (Bouffler et al. 
1995). Studies have also shown that some mutant forms of tumour suppressor genes exhibit 
dominant-negative effect over the wild-type product (examples of genes and references listed 
in 5.1.2). In this case, one mutant product of the gene binds to the wild-type protein and 
forms a non-functional complex. Therefore, there is only one mutant allele, but the end result 
is equivalent to a biallelic gene inactivation.
Depending upon the outcome of the NMD pathway (i.e. the decision as to whether or 
not to trigger NMD), nonsense mutations could confer a growth advantage on the cells 
through haploinsufficiency since some of those aberrant alleles, if transcribed (i.e. NMD 
skip), would give rise to protein products with limited or no function at all. By contrast,
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aberrant mRNA transcripts (e.g. harbouring nonsense mutations) could escape degradation 
through NMD, thereby releasing the potential for dominant-negative forms.
In the light of progress being made in the field of nonsense mutation read-through 
therapy (reviewed in Linde and Kerem 2008), exploring the similarities and differences in the 
distribution of potential NMD outcome is particularly timely.
5.1.7. Aims of the analysis
Bearing in mind the importance of nonsense mutations, it is perhaps surprising that 
few attempts have been made to explore the possible role of the NMD machinery in the 
development of cancer and more specifically in the context of tumour suppressor genes and 
their associated nonsense mutational spectrum.
The first and most important question to be addressed in this analysis is the 
involvement of NMD in the process of mutagenesis in a total of 17 different human tumour 
suppressor genes. The main objective of the analysis was to explore any similarities or 
differences that somatic and germline nonsense mutations might exhibit with respect to a 
potential/predicted NMD outcome. To accomplish this objective, a number of tasks were 
performed.
* Definition of predicted NMD outcome
Nonsense mutations were designated as either NMD elicit or NMD skip according to the 
commonly accepted >55nt rule explained in 5.1.5.2
* Calculation of ‘potential nonsense mutations9
Potential nonsense mutations correspond to those codons in a gene coding sequence that 
could potentially give rise to a stop codon via a single base-pair substitution. The 
determination of potential nonsense mutations was performed in order to be able to determine 
whether or not observed nonsense mutations are non-randomly distributed with respect to 
predicted NMD outcome.
* Assessment of the probability of finding nonsense mutations, with respect to 
predicted NMD status, by chance alone
Observed nonsense mutations for each gene were subdivided into four categories. These 
included: exclusively somatic (only found in the soma); exclusively germline (only found in 
the germline); shared (found in both the soma and the germline); a combination of somatic, 
germline and shared. Each of these categories was compared to potential nonsense mutations, 
with respect to predicted NMD outcome. In addition, to assess the overall distribution of
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nonsense mutations (i.e. nonsense mutations in all genes) with respect to predicted NMD 
outcome, within each category, the nonsense mutations were combined for all genes (for 
further explanation, see 5.2.2.3).
* Exploration of the similarities and differences in the positions of somatic and 
germline nonsense mutations with respect to predicted NMD outcome 
For each gene, the proportions of nonsense mutations were compared between the soma and 
the germline with respect to their predicted NMD outcome (i.e. NMD skip and/or NMD 
elicit). In a similar way, the proportions were calculated for the combination of somatic 
nonsense mutations observed for all genes and the corresponding combination of germline 
nonsense mutations for all genes. This was performed in order to assess the overall 
differences and similarities between the somatic and germline nonsense mutations found in 
all genes, with respect to predicted NMD outcome. In addition, for each gene the shared 
nonsense mutations were compared separately to the somatic and germline nonsense 
mutations with respect to predicted NMD outcome. This analysis was also performed for the 
combination of shared nonsense mutations for all genes and the combination of somatic, and 
the combination of germline nonsense mutations, for all genes.
These tasks were performed in order to provide meaningful answers to the following 
questions:
Are there more observed nonsense mutations {viz. somatic, germline and shared; combination 
of somatic, germline and shared nonsense mutations for each gene and all genes) predicted 
to skip or elicit NMD, than by would be expected by chance alone?
How do observed nonsense mutations {viz. somatic, germline and shared) compare to each 
other with respect to predicted NMD outcome?
Are there any differences/similarities between CpG- and non-CpG located nonsense 
mutations between somatic, germline, shared and potential nonsense mutations for each 
tumour suppressor gene and all genes combined?
110
5.2. M aterials and Methods
5.2.1. M ateria ls
5.2.1.1. G enera l definition o f nonsense m uta tions
A nonsense mutation was defined as a single base-pair substitution that was 
responsible for the introduction of a stop codon into the coding region of a gene. Employing 
this definition, there are 23 possible single base-pair substitutions that could lead to the 
introduction of a premature stop codon. These substitutions are shown in Figure 19.
Figure 19 Possible single base-pair substitutions leading to a nonsense mutation 
(adapted from Frank-Kamenetski 1993)
First p o sition  in codon 
S econd position  in codon
Third position  in codon
Single b ase  pair su b stitu tio n  
leading  to  a S top codon
5.2.1.1.1. Labelling of som atic, germ line and shared  nonsense 
m utations
A detailed description of labelling of mutations is given in 3.3. A summary of the 
studied nonsense mutations is given in Table 18 and Table 19.
5.2.1.2. G enera l definition of single base-pa ir substitu tions 
generating  nonsense m uta tions in C pG  dinucleotides
UUA >UAA 
UUA>UGA
UUG >UAG,
UCA >UAA 
UCA >UGA
UCG->UAG UAC >UAA 
SerGlu UAC->UAG
UAUXJAG
UAU-XJAA
c  AGAsp
Tyr
Ala
Stop
UGC>UGA 
Cys UGU->UGA
Val
® .3R
« cU
v . a Leu
UGG >UGA 
UGG >UAG
AGA-XJGA Arg
Ser
AAA >UAA Lys 
AAG >UAG / Pro
Asn
His'AC G AThr
Gin
Arg
CAA>UAA 
CGA XJGA CAG >UAG
1 1 1
CpG nonsense mutations were defined as C->T transitions found in the context of 
CpG-dinucleotides that lead to a stop codon. All observed nonsense mutations were logged 
according to the coding strand of DNA. Hence single base-pair substitutions in CpG 
dinucleotides on the non-coding strand would appear as G->A transitions (as shown in Figure 
20).
Figure 20 Single base-pair substitutions in CpG dinucleotides
change in coding strand C->T
I I
coding strand 5'....,...©G... -3' 5*..... ...... .-3'
1 1 ------► 1 1
non-coding strand 3'..., ... G-C.... -5' 3' ..A-C..... -5*
coding strand 5'..., ...C-G....a a -3' 5' .. C-A.....I | -3'
non-coding strand 3’... ....£4!)... -5* ------► 3'.... .. A-Ti.... -5'
i t
C->T
G->A
change in non-coding strand C->T
5.2.2. M ethods
5.2.2.1. Identification  o f po ten tia l nonsense m uta tions
The identification of potential nonsense mutations and potential nonsense mutations 
in CpG-dinucleotides was accomplished as described in 3.5.
5.2.2.2. Identification  o f nonsense m uta tions th a t could potentially  
reduce m RNA ab u ndance  and  d iscrim ination  from  those th a t 
w ould not
In order to identify mRNA transcripts that would be predicted to be subject to 
degradation by the NMD apparatus, the ^55nt rule (described in 5.1.5.2) was adopted. As a 
result, only those termination codons located ^55nt upstream (viz. 5’; depicted in Figure 17 
and Figure 18) of the most 3’ exon-exon junction (measured after splicing) tend to give rise 
to a marked or complete reduction in mRNA abundance (Nagy and Maquat 1998).
I developed a computer program, which assigns a predicted NMD status (NMD skip 
or NMD elicit) for any given nonsense mutation. The predicted NMD status is based on the 
nucleotide position of the single base-pair substitution leading to a nonsense mutation relative 
to the nucleotide position of the most 3’ exon-exon junction in a gene. Thus, for every
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nonsense mutation {viz. observed and all possible nonsense mutations) in all 17 tumour
suppressor genes, a predicted NMD status was assigned.
5.2.2.3. Comparisons and calculation of statistical significance
In order to answer the questions posed in the aims of the analysis (Section 5.1.7), the 
following tests for each gene were performed:
Soma vs. potential (simulated spectra) nonsense mutations 
Germline vs. potential (simulated spectra) nonsense mutations 
Shared vs. potential (simulated spectra) nonsense mutations
Observed (the combination of numbers of somatic, germline and shared mutations) vs.
potential (simulated spectra) nonsense mutations
Soma vs. germline nonsense mutations
Soma vs. shared nonsense mutations
Germline vs. shared nonsense mutations
Recurrent somatic vs. non-recurrent somatic nonsense mutations
Recurrent somatic shared vs. recurrent somatic non-shared nonsense mutations
Non-recurrent somatic shared vs. non-recurrent somatic non-shared nonsense mutations
Recurrent somatic shared vs. non-recurrent somatic non-shared missense mutations
In addition, the numbers of mutations in all genes were combined, only if nonsense 
mutations had the same label (i.e. somatic, germline, shared) to represent the combination of 
mutations in all genes. The aforementioned tests were also performed for the combination of 
mutations in all genes. Each of these comparisons was performed with respect to predicted 
NMD status (i.e. NMD elicit and NMD skip) and CpG-dinucleotide context. All mutations 
were categorized into two groups, i.e. ‘within CpG dinucleotide’ or not (i.e. not occurring in 
a CpG-dinucleotide); NMD elicit or not (i.e. NMD skip) and the tests were performed using a 
X2 statistic. For each of the tests, a x2 test statistic was calculated (see Chapter 3 (General 
methods) for description) to assess the statistical significance at the chosen alpha level 
( a  -  0.05). To allow for multiple hypothesis testing for the tests performed for each gene, 
10,000 resampling permutations were performed (see Chapter 3 (General methods) for 
description) and corresponding p-value was termed permuted. To allow for multiple 
hypothesis testing, for the tests performed for CpG-dinucleotides and NMD-status analyses, a 
Bonferroni correction was applied. Therefore, each permuted p-value was multiplied by 2
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(gene-wise a  -  0.05/2 or 0.025), to account for different tests within each gene (viz. NMD- 
status and location within CpG-dinucleotides). To allow for multiple hypothesis testing, for 
the tests performed for all genes, a Bonferroni correction was also applied. Therefore, each
gene-wise p-value was multiplied by 17 (overall experiment-wise a  * or 0.0015).
2*17
I designed a computer program that automatically performs the x2 test statistic for 
each test along with the re-sampling permutations and Bonferroni corrections.
5.2.2.4. Calculation of power and effect size
Calculations of the power and associated effect sizes is described in 3.6.3. In order to 
keep the overall a  at the 0.05 level, as multiple statistical tests were performed, the value of 
a  used in the power calculations was set to 0.0001336898 (total number of tests performed 
374; therefore, the Bonferroni-adjusted a , to account for multiple testing, was a  -  0.05/374, 
or 0.0001336898 for test statistic). As Bonferroni correction is considered to be a 
conservative correction for multiple testing, the power calculated for the %2 statistical tests is 
a conservative estimate.
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5.3. Results
The results are presented in comparison-wise fashion. Due to the overwhelming 
quantity of results that were generated during the work described, only summaries of 
statistically significant results are discussed and presented in the form of Tables and Figures 
(Table 23, Table 24 and Figure 21).
Nevertheless, the presented tables capture the results obtained for all comparisons 
performed, along with the directionality of the statistically significant results observed and 
power calculations. For further information, complete results for all comparisons performed 
are to be found in the Supplementary Tables.
In order to facilitate readability, whenever a comparison was statistically significant, 
it was substituted with the words “significant” or “significantly”; gene-wise statistically 
significant p-values were substituted with the symbol pG and experiment-wise statistically 
significant p-values were substituted with the symbol pE. In addition, whenever a 
comparison exhibited gene-wise and experiment-wise statistical significance, only the 
experiment-wise p-values were given and whenever a comparison exhibited only gene-wise 
(but not experiment-wise) statistical significance, only the gene-wise p-value was listed. 
Additionally, all gene-wise and experiment-wise statistically significant results are 
graphically summarized in Figure 21, along with the direction of the result and power 
calculations, but it was not referenced throughout the Results section, in order to reduce 
repetition.
5.3.1. Nonsense mutations and NMD status
5.3.1.1. Somatic vs. potential nonsense mutations
Only the TP 5 3 gene exhibited significantly more (p E<0.0034) NMD-elicit somatic 
nonsense mutations as compared to potential mutations (Table 23). Moreover, all (100%) of 
the TP53 somatic nonsense mutations were predicted to be potential targets of the NMD 
machinery (i.e. NMD elicit). By contrast, significantly fewer potential TP53 nonsense 
mutations were predicted to elicit NMD (-56%). It has to be noted that -74% of all possible 
TP53 nonsense mutations were observed as somatic nonsense mutations. Therefore, while it 
appears that nonsense mutations were a very frequent event in the TP53 gene, all of them 
were predicted to lead to the complete elimination of the mutant copy of the gene.
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5.3.1.2. Germline vs. potential nonsense mutations
Only the APC gene exhibited a significantly higher (p E<0.0034) proportion of 
germline NMD-elicit nonsense mutations, as compared to potential nonsense mutations 
(Table 23). A much higher proportion of germline nonsense mutations in the APC gene were 
predicted to be a target of the NMD machinery (42%), than was predicted for the potential 
nonsense mutations (21%). It is noteworthy that even although there were significantly more 
germline nonsense mutations predicted to be a subject to NMD (compared to the potential 
nonsense mutations), there were more germline nonsense mutations that were predicted to 
skip NMD than those that generally would not (42% predicted to elicit NMD versus 58% 
predicted to skip NMD). This indicates that the predicted outcome for a large proportion of 
the germline nonsense mutations would be NMD skip, but there was an excess of nonsense 
mutations that were predicted to elicit NMD compared to that for potential nonsense 
mutations.
5.3.1.3. Shared vs. potential nonsense mutations
Only the BRCA1 gene exhibited a statistically significant deviation (p G=0.017) in the 
distribution of predicted NMD status, but did not reach experiment-wise significance 
(/?£=0.30), when shared were compared to potential nonsense mutations (Table 23). The 
BRCA1 gene had significantly more shared nonsense mutations predicted to skip NMD 
(33%), than potential nonsense mutations (2%). Further examination of the distribution of 
shared nonsense mutations in the BRCA1 gene showed that there were only 6 shared 
nonsense mutations in total (4 were predicted to elicit NMD and 2 were predicted to skip 
NMD). In addition, there was -85% statistical power to detect an experiment-wise significant 
result. Thus, it is likely that the shared nonsense mutations did not attain experiment-wise 
significance as a result of very small difference in the proportions of predicted NMD status 
between shared and potential nonsense mutations (effect size=0.19).
Even although only the BRCA1 gene showed a trend of more shared mutations 
predicted to skip NMD, the combination of shared nonsense mutations for all genes, showed 
a similar trend in the same direction ( pc=0.0361. More shared mutations were predicted to 
skip NMD (-26%) as compared to potential nonsense mutations (-16%).
Therefore, nonsense mutations found in both the soma and the germline are relatively 
more likely to skip NMD than potential nonsense mutations, at least for the BRCA1 gene. In 
addition, the following genes showed a higher proportion of shared mutations predicted to
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skip NMD: APC (86%), A TM (33%) and VHL (45%) genes, as compared to potential 
nonsense mutations (79%, 2% and 29% for the APC, ATM  and VHL genes respectively), but 
did not exhibit significant results.
5.3.1.4. Somatic vs. germline nonsense mutations
Only the APC gene showed a significant deviation in terms of the distribution of 
somatic and germline nonsense mutations, with respect to predicted NMD outcome 
(p £ <0.0034). An excess of germline nonsense mutations (42%) predicted to elicit NMD was 
noted as compared with the somatic nonsense mutations (6%). This finding is extremely 
interesting as there are reports in the literature that the first hit - the germline mutation in 
familial adenomatosis polyposis (FAP) - may influence and possibly even direct the type and 
position of the somatic hit (second hit; Latchford et al. 2007). For discussion of these results, 
see 5.4.1.1.
5.3.1.5. Germline vs. shared nonsense mutations
No individual gene exhibited a significant result, when germline were compared to 
shared nonsense mutations, with respect to predicted NMD outcome. Nevertheless, the 
combination of germline nonsense mutations for all genes exhibited significantly 
( Pg=0.0074) more mutations predicted to elicit NMD (-87%) as compared to the 
combination of shared mutations for all genes (-74%), even although the result did not attain 
experiment-wise significance ( p E= 0.126). Therefore, a trend was evident in the distribution 
of germline and shared nonsense mutations, with respect to NMD status. Thus, for some 
genes, a higher proportion of germline nonsense mutations was subject to NMD (APC. ATM . 
BRCA1 and PTEN) than was the case with shared nonsense mutations.
5.3.1.6. Combination of somatic, germline and shared nonsense 
mutations in individual genes
The APC and TP53 were the only genes that exhibited a statistically significant 
difference in the distribution of predicted NMD status of observed nonsense mutations (the 
combination of somatic, germline and shared nonsense mutations as described in Section 
5.1.7), when compared to the combination of potential nonsense mutations. A summary of 
the statistically significant results is presented in Table 23. Interestingly, for these genes, a
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significant excess of observed nonsense mutations predicted to elicit NMD was noted by 
comparison to potential nonsense mutations.
The APC gene showed many more observed nonsense mutations predicted to elicit 
NMD (31%) than the potential nonsense mutations (21%). As with the results reported in 
Section 5.3.1.2, even although there were significantly more observed nonsense mutations 
predicted to be subject to NMD (as compared to the potential nonsense mutations), there 
were still more observed nonsense mutations that were predicted to skip NMD than those that 
would not (31% predicted to elicit NMD versus 69% predicted to skip NMD). This indicates 
that the predicted outcome for a large proportion of the observed nonsense mutations would 
be NMD skip. However, there was an excess of nonsense mutations predicted to elicit NMD 
as compared to the potential nonsense mutations.
The TP53 gene showed significantly more observed nonsense mutations predicted to 
elicit NMD (100%) as compared to potential nonsense mutations (56%). Indeed, all 97 TP53 
nonsense mutations (viz. somatic, germline and shared! were predicted to elicit NMD. As a 
result, all TP53 nonsense mutations were very likely to lead to the complete elimination of 
the associated mutant mRNA.
5.3.I.7. Remainder of the comparisons performed
No statistically significant results were obtained for the remainder of comparisons 
performed for both nonsense mutations in individual genes and the combination of mutations 
in all genes. These included:
Somatic vs. shared nonsense mutations.
Recurrent vs. non-recurrent somatic nonsense mutations.
Recurrent and shared vs. recurrent non-shared nonsense mutations.
Non-recurrent and shared vs. non-recurrent non-shared somatic nonsense mutations.
Recurrent and shared vs. non-recurrent non-shared nonsense mutations.
Germline vs. shared nonsense mutations.
It should be noted that none of these comparisons showed enough statistical power (>80%) to 
detect an experiment-wise significant result. Either a small effect size and/or a paucity of 
nonsense mutations must have contributed to these results.
5.3.2. Nonsense mutations in the context of CpG dinucleotides in the 
17 tumour suppressor genes
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5.3.2.1. Germline vs. potential nonsense mutations
A number of genes (viz. APC, ATM, BRCA2, CDH1, NF1, 7SC7 and TSC2) exhibited 
a statistically significant deviation in the distribution of germline CpG-located nonsense 
mutations as compared with the CpG-located potential nonsense mutations ( pG ranging from 
<0.0002 to 0.0062; Table 24). In addition, the results for the ATM  and NF1 genes attained a 
level of experiment-wise statistical significance (p G<0.0034 for both genes). All the above 
genes exhibited an excess of CpG-located germline nonsense mutations as compared to 
potential nonsense mutations. The proportions of the CpG-located germline mutations ranged 
from 5% (APC and BRCA2) to 22% (CDH1 and ATM). By contrast, the proportions of CpG- 
located potential nonsense mutations ranged from ~0% (ATM, BRCA2, CHD1, NF1, TSC1 
and TSC2) to ~1% (APC). Furthermore, the combination of germline nonsense mutations for 
all genes also exhibited an excess of CpG-located mutations (~7% within CpG 
dinucleotides), as compared to the combined CpG-located potential nonsense mutations for 
all genes (~0% within CpG-dinucleotides; pE <0.0034).
Therefore, germline nonsense mutations for a number of genes are very likely to have 
resulted, albeit indirectly, from the heavy intra-genic methvlation of CpG-dinucleotides.
5.3.2.2. Shared vs. potential nonsense mutations
A number of genes (viz. APC, ATM, BRCA1, CDH1, NF1, NF2, PTEN, RBI and 
WT1) exhibited statistically significant deviations in their distributions of shared CpG-located 
nonsense as compared to CpG-located potential nonsense mutations ( pE ranging from 
<0.0034 to 0.0068). All these genes exhibited an excess of CpG-located shared nonsense 
mutations as compared with potential nonsense mutations. The proportions of CpG-located 
shared mutations ranged from 17% (BRCA1) to 100% (WT1). By contrast, the proportions of 
CpG-located potential nonsense mutations ranged from -0%  (ATM, BRCA1, CDH1, NF1, 
PTEN and WT1) to -1%  (APC, NF2 and RBI).
The comparison of shared nonsense mutations, combined for all genes, revealed a 
significantly higher proportion of CpG-located mutations as compared to potential nonsense 
mutations ( p E <0.0034), with -37% of the shared nonsense mutations combined for all genes 
found in CpG-located dinucleotides versus ~0% for the CpG-located potential nonsense 
mutations (Table 24). This result indicates that the preponderance of shared nonsense 
mutations occur within CpG-located dinucleotides.
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5.3.2.3. Somatic vs. shared nonsense mutations
The APC, NF2, PTEN and TP52 genes exhibited preferential location of shared 
nonsense mutations within CpG-dinucleotides ( pG ranging from 0.0104 to 0.0384) as 
compared to somatic CpG-located nonsense mutations, although none of results attained 
experiment-wise significance. Nevertheless, in the case of these genes, none of the somatic 
nonsense mutations (0%) were located in CpG-dinucleotides, whereas the proportions of 
CpG-located shared mutations ranged from 23% (PTEN) to 44% (TP53). Therefore, it would 
seem that CpG-located nonsense mutations are predominantly shared mutations, rather than 
exclusively somatic nonsense mutations. In fact, almost all genes provided examples of 
somatic nonsense mutations that were found in non-CpG dinucleotides (-100%), the 
exception being the PTCH gene with just 1 CpG-located somatic nonsense mutation (-14% 
of PTCH gene mutations). Thus it was not surprising that the combination of somatic 
nonsense mutations for all genes exhibited a significantly smaller proportion of CpG-located 
nonsense mutations (p E <0.0034; -0%) as compared to the combination of shared nonsense 
mutations for all genes (-37% CpG-located).
5.3.2.4. Germline vs. shared nonsense mutations
The APC, NFJ, NF2 and RBI genes exhibited a preferential location of shared 
nonsense mutations within CpG-dinucleotides ( pG ranged from 0.0034 to 0.0384) as 
compared to germline CpG-located nonsense mutations, although none of the results attained 
experiment-wise significance. Nevertheless, all of these genes showed that a substantial 
proportion of the shared nonsense mutations (ranging from 29% to 90% for the APC and NF1 
genes respectively) were located in CpG-dinucleotides, whereas the proportions of CpG- 
located germline mutations ranged from 0% (NF2) to 9% (NF1).
Furthermore, the combination of shared nonsense mutations for all genes were also 
preferentially found within CpG-dinucleotides as compared to the combination of germline 
CpG-located nonsense mutations (p E<0.0034; -37% and -7%  for the shared and germline 
mutations respectively).
5.3.2.5. Recurrent somatic nonsense mutations
Only the NF2 gene exhibited a significant result, when recurrent were compared to 
non-recurrent somatic mutations (p G=0.0376), but this did not attain experiment-wise
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significance ( p E=0.639). The recurrent somatic mutations showed many more CpG-located 
mutations (~33%) as compared to non-recurrent somatic mutations (~0%).
The TPS 3 gene showed a preferential location of recurrent and shared somatic 
mutations within CpG-dinucleotides ( pG=0.0174; 44% within CpG-dinucleotides) as 
compared to recurrent but not shared somatic mutations (0% within CpG-dinucleotides), 
although the result did not attain experiment-wise significance ( pE=0.296).
The NF2 and PTEN genes showed a significantly higher proportion of recurrent and 
shared CpG-located somatic mutations (p G 0.022/0.236 for the NF2/PTEN genes) as 
compared to CpG-located non-recurrent and non-shared somatic nonsense mutations.
Moreover, the combination of recurrent and shared mutations for all genes were found 
to be preferentially located within CpG-dinucleotides as compared to both the combination of 
recurrent, non-shared (p E <0.0034) and the combination of non-recurrent, non-shared 
nonsense mutations for all genes (p E<0.0034). Thus, amongst recurrent somatic nonsense 
mutations, shared mutations were more likely to be found within CpG-dinucleotides (-46%). 
than non-shared mutations (~0%T In addition, among non-recurrent somatic nonsense 
mutations, shared mutations were also more likely to be found within CpG-dinucleotides 
f~31%T than non-shared mutations (~1%T
5.3.2.6. Remainder of comparisons performed
No statistically significant results were obtained for the rest of the comparisons 
performed, for both comparisons in individual genes and the combination of nonsense 
mutations for all genes. These included:
Somatic vs. germline nonsense mutations.
Somatic vs. shared nonsense mutations.
Germline vs. shared nonsense mutations.
Recurrent somatic vs. non-recurrent shared nonsense mutations with respect to CpG- 
located and non-CpG located nonsense mutations.
Recurrent shared vs. non-recurrent shared nonsense mutations with respect to CpG- 
located and non-CpG located nonsense mutations.
Somatic CpG-located vs. shared CpG-located nonsense mutations with respect to 
recurrent and non-recurrent status of nonsense mutations.
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5.4. Discussion
5.4.1. Nonsense mutations and nonsense-mediated mRNA decay 
(NMD)
Considering the importance of nonsense mutations associated with cancer, it is rather 
surprising that the distribution of nonsense mutations within tumour suppressor genes with 
respect to their likely NMD outcome has not so far been explored. This Chapter represents an 
attempt to shed light on the role that NMD might have played in helping to define the 
observed somatic nonsense mutational spectrum in 17 human tumour suppressor genes.
Depending upon whether or not NMD is elicited, any given nonsense mutation will 
have very different consequences for the expression of the gene involved. If elicited, NMD 
will automatically lead to a ‘loss-of-function’ due to the degradation of the affected mRNA 
species (haploinsufficiency). By contrast, a failure to elicit NMD ensures that the mRNA 
escapes NMD potentially resulting in the synthesis of an abnormal prematurely truncated 
protein that could, at least in principle, exert a ‘ gain-of-function’ (dominant-negative) effect.
For the vast majority of reported nonsense mutations in human genes, there are no 
empirical data (e.g. from in vitro assays) that would serve to demonstrate unambiguously 
whether or not these lesions have elicited NMD. However, in the absence of such data, one 
can nevertheless employ the ‘~55nt boundary rule’ (Maquat 2004; Nagy and Maquat 1998), 
by taking account of the relative position of a specific nonsense mutation with respect to the 
position of the last exon of a given gene to predict whether or not NMD is likely to have been 
elicited. In the absence of experimental (laboratory) verification, it is clear that the 
application of the ‘55 nucleotide rule’ has the potential to be over-simplistic and hence 
inaccurate. However, it is clear that the retrospective experimental verification of NMD for 
all the mutations considered here would clearly not be feasible at this juncture.
The above caveat notwithstanding, nonsense mutations from 17 tumour suppressor 
genes were, on the sole basis of their relative genic locations, allocated to two distinct groups 
viz. NMD-elicit and NMD-escape. The relative proportions of the two groups were then 
compared for germline mutations, somatic mutations, mutations present in both the germline 
and the soma (i.e. shared mutations), the germline and somatic mutations combined, and a set 
of ‘potential nonsense mutations’ (codons that could be converted to termination codons by a 
single base-pair substitution). Significant differences were observed for two tumour 
suppressor genes {APC and TP53). These will now be considered separately.
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5.4.1.1. APC
The APC gene encodes a large multidomain protein that plays an important role in 
regulating P-catenin and in mediating intracellular adhesion (Feamhead et al. 2001). It is 
commonly accepted to conform to Knudson’s ‘two-hit’ hypothesis and may therefore be 
regarded as a classical tumour suppressor. The germline and somatic APC mutational spectra 
have been known for some time to be different (Feamhead et al. 2001; Lamlum et al. 1999). 
Over 60% of all somatic APC mutations occur within <10% of the gene coding sequence 
between codons 1281 and 1556 (of the 2843 amino acid-encoding open reading frame) in the 
so-called mutation cluster region (MCR; Beroud and Soussi 1996; Cheadle et al. 2002; 
Miyoshi et al. 1992). The APC somatic mutational spectrum is characterized by ~30% 
nonsense mutations and -60% frameshifts. Within the MCR, there are two hotspots for 
nonsense mutations at codons 1309 and 1450 (Beroud and Soussi 1996). The majority of 
germline APC mutations are nonsense or ffameshift; although fairly uniformly distributed 
between codons 200 and 1460 (Crabtree et al. 2003), hotspots occur at codons 1061 and 1309 
(Leggett et al. 1997) that together account for about a third of inherited APC mutations 
(Beroud and Soussi 1996; Cetta et al. 2000). It is now thought that the type of germline APC 
mutation can play a role in determining the nature of the second (somatic) APC mutation. 
Thus, if the germline mutation occurs outside the region between codons 1194 and 1392, the 
second hit is likely to be a truncating mutation within the MCR (Lamlum et al. 1999). It is 
clear that if the germline APC mutation exerts an influence on the nature and/or location of 
the subsequent somatic APC mutation, the two mutational spectra are likely to be more 
distinct than if there were no such influence. In the context of this study, I was interested in 
assessing whether the differences between the germline and somatic APC mutational spectra 
might help to account for the observed frequency differences in predicted NMD.
Analysis of the APC gene showed that significantly more germline nonsense 
mutations were predicted to elicit NMD (42% NMD elicit) as compared to either the somatic 
(6% NMD elicit) or potential nonsense mutations (21% NMD elicit). Therefore, many more 
inherited APC nonsense mutations would be predicted to result in the degradation of 
nonsense mutation-bearing mRNA transcripts than might be expected by chance alone. 
Indeed, 56% of all germline nonsense mutations were predicted to skip NMD (thereby 
avoiding mRNA degradation and potentially leading to the synthesis of C-terminally 
truncated proteins). This result concurs with those of Mort et al. (2008) who found, in a large
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meta-analysis of some 5316 nonsense mutations in 380 different human genes causing 
inherited disease, that the proportion of disease-causing nonsense mutations predicted to 
elicit NMD was significantly higher than among potential nonsense mutations, implying that 
nonsense mutations that elicit NMD are more likely to come to clinical attention.
By contrast, the vast majority (94%) of somatic nonsense mutations are predicted to 
skip NMD (i.e. potential COOH-terminally truncated proteins). Indeed, only 6% of somatic 
nonsense mutations are predicted to elicit NMD as compared to a proportion of 21% for 
potential nonsense mutations. Thus, in sharp contradistinction to the situation pertaining with 
A PC germline nonsense mutations, APC somatic nonsense mutations appear to exhibit an 
excess of NMD escape (potential gain-of-function) mutations [or put another way, a paucity 
of NMD elicit (potential loss-of-function) mutations]. This suggests that somatic nonsense 
mutations which lead to the synthesis of truncated forms of the APC protein (courtesy of their 
being encoded by mRNAs bearing premature termination codons but which have 
nevertheless escaped NMD) could have been selected for during the process of tumorigenesis 
by dint of their ability to confer a proliferative advantage upon the cells expressing them. One 
way in which this might operate would be if the truncated protein were to exert a dominant 
negative effect, thereby conferring oncogenic properties upon the APC gene. Since the 
oligomerization domain (residues 6-57) is located at the almost invariably included N ik- 
terminal end of the APC protein (Feamhead et al. 2001), some nonsense mutations could 
exert a dominant negative effect via dimerization of the truncated protein product with the 
wild-type protein, thereby reducing the amount of the wild-type product available to the cell. 
Indeed, it has been shown that truncating APC mutations can exert a dominant negative effect 
on the wild-type product (codon 1309; Dihlmann et al. 1999). Two missense variants 
(I1370K and E1317Q) have also been shown a dominant-negative effect (Feamhead et al. 
2001; Frayling et al. 1998). Furthermore, a N-terminal domain, between amino-acids 782- 
1018 immediately adjacent to the armadillo domain, has been shown to interact with the last 
300 C-terminal amino-acids, but also with itself (Li et al. 2008). As a result, amino- 
terminally truncated proteins could interact with full-length APC protein (i.e. heterozygous 
state) and contribute to deregulation of early tumour cells, thus compromising normal 
migration of intestinal epithelial cells (Li et al. 2008).
On the other hand, if dominant-negative APC mutant forms were to play a major role 
in the process of tumorigenesis, it would be logical to suppose that null APC proteins would 
have to be present in a substantial proportion, as these would potentially display an effect on 
the cells similar to dominant-negative protein forms. Instead, homozygous null colon cancers
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are virtually non-existent (McCartney et al. 2006) and mice with one truncated (putative 
dominant-negative) and a wild-type copy, do not present polyps or tumours (Oshima et al. 
1995). Mechanistically, APC plays its tumour suppressor role by binding (and hence down- 
regulating) soluble (3-catenin, the key effector of the Wnt signalling pathway. APC 's P- 
catenin-binding sites are situated within three 15-amino acid repeats (residues 1020-1169) 
and a series of seven 20-amino acid repeats (residues 1265-2035). This means that although 
the majority of truncated mutant APC proteins contain the three 15-amino acid repeats, they 
lack either all or most of the 20-amino acid repeats (Feamhead et al. 2001), implying that the 
loss of P-catenin-binding ability is important for the loss of tumour suppressor function, p- 
catenin is involved in the transcriptional activation of the c-myc (.MYC; He et al. 1998) and 
cyclin D1 (CCDN1; Shtutman et al. 1999; Tetsu and McCormick 1999) oncogenes, both of 
which regulate cell cycle progression. Thus, inactivation of APC is likely to promote cell 
proliferation by indirectly increasing the level of P-catenin (Sieber et al. 2000). Therefore, 
lack of APC null alleles could potentially be explained by "just-right" (Albuquerque et al. 
2002) P-catenin levels, whereby levels above a certain threshold could potentially be lethal to 
cells (McCartney et al. 2006). Indeed, homozygous Ape mutant mice die during gastrulation 
(Moser et al. 1995), although one could argue that a wild-type Ape protein is necessary for 
embryonic development, but may not be lethal in cells of a fully developed organism. It has 
also been suggested that in fruit fly, the armadillo repeat 5 (ARM5) may have a special 
importance and contribute significantly to the overall structure of the arm-repeats 
(McCartney et al. 2006). This is potentially very interesting, as armadillo-repeat 5 (ARM5 
ends at codon 628; ARM6 starts at codon 644; Xing et al. 2004) is N-terminally immediately 
adjacent to the border of a predicted NMD elicit/skip status of the mutant allele (codon 634). 
Whether this is a mere coincidence or whether it bears any functional relevance to humans 
with respect to potential involvement of the NMD machinery, remains to be addressed.
An alternative model to explain how truncated protein products might confer a 
cellular proliferative advantage would be if the NH2-terminal end of the APC protein were to 
contain domains that promote cell division, whilst the C-terminal end of the protein contained 
domains that repress cell division. C-terminally truncated proteins (i.e. nonsense mutations at 
codons 750 and 1309, both at a considerable distance from the ~55nt boundary) have been 
shown to have a ‘profound proliferation effect’ (Tighe et al. 2004). Furthermore, full length 
APC protein inhibits DNA replication, by directly binding to DNA through a region that 
maps between codons 2140 and 2421 (Qian et al. 2008). Both the somatic nonsense
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mutations in the MCR region (codons 1281-1556) and most germline nonsense mutations 
(codons 200-1460) would potentially result in C-terminally truncated proteins that 
completely lack this region. Thus, C-terminally truncated proteins, as a result of the most 
common nonsense mutations, would potentially be insufficient to inhibit DNA replication, 
hence are very likely to promote cellular proliferation.
5.4.1.2. TP53
The TP 5 3 gene, also commonly referred to as the ‘guardian of the genome’ (Vousden 
2000), is a multifunctional transcription factor that among many other functions regulates cell 
cycle progression, targets for apoptosis cells with an unacceptable amount of DNA damage, 
interacts with key proteins responsible for DNA transcription, replication and repair (Levine 
1997; Vogelstein and Kinzler 2004). The key role of TP53 is shown by the fact that -50% of 
all human cancers harbour mutations in the TP53 gene (Soussi and Beroud 2001). 
Interestingly, in contrast to other tumour suppressor genes, the majority (>80%) of lesions in 
TP53 are missense mutations (The UMDp53 mutation 'database, http://p53.free.fr/ Soussi 
and Beroud 2001). Therefore, most of the inactivating mutations in the TP53 gene are 
associated with a full-length gene product. p53 contains several domains: activation domain 1 
(residues 1-42), activation domain 2 (residues 43-63), proline-rich domain (64-91), DNA- 
binding domain (residues 100-300), domain responsible for nuclear localization and 
containing the export signal (residues 316-325), tetramerization domain (residues 326-356) 
and C-terminal basic domain (residues 364-393 Zhu et al. 2000). The majority of mutations 
found in TP53 are localized in the DNA-binding domain, and these serve to modify the 
protein’s contact with its target DNA sequence. Even although >80% of the lesions found are 
missense variants (Soussi and Beroud 2001), nonsense mutations and ffameshiffc mutations 
still comprise -8%  and -11% of lesions, respectively.
The above analysis of the TP53 gene has shown that there were significantly more 
somatic nonsense mutations predicted to elicit NMD (100% NMD elicit) than would be 
expected on the basis of a comparison with the potential nonsense mutations (56% NMD 
elicit). Therefore, it would appear that, during tumorigenesis, somatic nonsense mutations in 
the TP53 gene that would trigger NMD (leading to degradation of the TP53 mRNA from the 
mutation-bearing allele) have been selected for. Indeed, a total of 87 observed somatic 
nonsense mutations were predicted to elicit NMD and none were predicted to escape NMD. 
This is a rather surprising finding, as there are numerous reports that mutant TP53 forms
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could exert a dominant-negative effect over the wild-type or exhibit a gain-of-function. Even 
though these dominant-negative forms reported involve missense variants exclusively, it is 
perhaps surprising that there are no truncating nonsense mutations that could potentially give 
rise to dominant-negative-forms.
One possible explanation may be provided by animal studies, which show that, TP5S'
' mice (i.e. mice with both alleles inactivated) do not develop carcinomas with particularly
, • , j  . rr,n c o  missense variant/- ,  -missense variant/+ /T . ihigh frequency as compared to TP53 or TP53 mice (Lang et al.
2004; Olive et al. 2004). These authors suggested that inactivation of TP53 is insufficient for 
tumour progression and that a gain-of-function is actually required. In addition, during 
tumour progression, TP53 has been suggested to 'evolve' under strong positive selection 
(Glazko et al. 2004). Generally, in an evolutionary context, evidence of positive selection is 
taken as being indicative of the acquisition of new functions (Koonin et al. 2005). Thus far, 
no studies have ever reported a potential gain-of-function (i.e. dominant-negative effect over 
the wild-type) associated with any of the nonsense mutations found in TP53.
One plausible explanation of the spectrum of somatic nonsense mutations with respect 
to predicted NMD outcome is that gene-dosage may affect the selection of nonsense 
mutations. A reduction in gene-dosage (i.e. inactivation of one of the TP53 alleles) has been 
shown to be sufficient for tumour development (Venkatachalam et al. 1998). Furthermore, 
mice with constitutive TP53 deletions have been shown to be insufficient for apoptosis 
(Clarke et al. 1994) and maintenance of genome integrity (Bouffler et al. 1995).
Alternatively, most truncated p53 proteins (made possible as a consequence of NMD 
skipping) would ultimately retain several functionally important domains, due to the fact that 
the last exon, that bears functional importance to the NMD pathway, is only 81 bp in length. 
Thus, potentially only the tetramerization domain and the C-terminal basic domain would be 
functionally compromised in a truncated, mutant form of the p53 protein. Therefore, it seems 
plausible that a potentially truncated protein could be partially functional, assuming the 
existence of a sufficiently stable product that could support transcription and translation. It 
would seem that such truncated proteins are not selected during tumorigenesis, as none of the 
somatic nonsense mutations present in the TP53 gene were predicted to skip NMD. Indeed, a 
truncated p53 protein bearing an unusual 7bp insertion in a choroid plexus tumour, has been 
shown to have completely lost transactivation and transrepression of target genes, such as 
CDKNJA and CDKN2A, but has nevertheless partially (-65% of wild-type protein) retained 
the ability to induce apoptosis in lymphocytes (Rutherford et al. 2002).
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It should be noted that the mere prediction of potential NMD-elicit nonsense 
mutations would not necessarily mean that mutant protein would be completely removed 
from the cell. Although, the product of the mutant p53 allele, comprising the 7bp insertion, 
reported by Rutherford et al. (2002), could not be detected as an expressed protein, the 
mechanism responsible for the partially retained ability to induce apoptosis remains 
unknown. In addition, a mutant p53 protein comprising 770delT, was surprisingly reported to 
be as abundant as a wild-type copy (Anczukow et al. 2008), although its abundance was 
markedly increased when NMD was inhibited. Furthermore, a correlation has been reported, 
of increased expression levels of CDK inhibitor p2 icn>1/WAF1 and nonsense mutations in the 
TP53 gene (Mousses et al. 2001). The CDK inhibitor p2 iCIP1/WAF1 is part of the /753- 
dependent DNA damage response pathway; thus, it is likely that some transcriptional 
activation function was retained in these mutant TP53 alleles that comprised nonsense 
mutations.
5.4.2. Nonsense mutations in the context of CpG dinucleotides
The enzymatic methylation of cytosine to 5-methylcytosine constitutes an epigenetic 
modification which is associated with a variety of different biological processes including 
gene regulation (i.e. gene expression), X-chromosome inactivation, genomic imprinting and 
development (Pfeifer 2000). DNA methylation occurs predominantly at CpG dinucleotides, 
which have been known for some time to be a mutational hotspot in both the germline and 
the soma (Cooper et al. 1995; Krawczak et al. 1998). Their hypermutability is estimated to be 
6-7 times the base mutation rate (Cooper et al. 1995). Their hypermutability is largely 
dependent upon the methylation status of CpG dinucleotides, even although some reports 
have suggested a limited correlation (Millar et al. 1998). Therefore, patterns of methylation 
may influence the location and frequency of both somatic and germline nonsense mutations 
in the context of CpG dinucleotides. Furthermore, hypermethylation has been shown in 
sperm cells as compared to oocytes, but both are hypomethylated by comparison to somatic 
tissues (Allegrucci et al. 2005). However, CpG dinucleotides have been found to exhibit 
differences in their methylation status both within and between individuals (Millar et al.
1998).
The analysis of CpG-located nonsense mutations demonstrated that virtually all 
(98%) somatic CpG-located nonsense mutations (Table 21) were also found in the germline, 
as compared to -33% of somatic nonsense mutations (irrespective of whether or not they
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occur in a CpG-dinucleotide; Table 20) and ~23% of the somatic non-CpG-located mutations 
(Table 22). As a result, CpG-located nonsense mutations are more likely to be shared 
between the soma and the germline, than non-CpG-located nonsense mutations. This was 
further confirmed, by the comparison with potential nonsense mutations, which indicated that 
shared nonsense mutations were more likely to be found within CpG-dinucleotides. This 
observation was made not only for the combination of nonsense mutations in all genes, but 
also in a number of individual genes (viz. APC, ATM , BRCA1, CDH1, NF1, NF2, RBI and 
077). Moreover, for some genes (viz. BRCA1, CDKN2A, PTEN, STK11, 7P55, TZ/I and 
WT1), all possible CpG-located nonsense mutations were present in either the germline 
and/or the soma. Additionally, for the CDKN2A, PTEN, TP53, VHL and WT1, all possible 
CpG-located nonsense mutations were present in both the soma and the germline. This 
indicates that mutation hotspots are commonly shared between the germline and the soma 
and a sizeable proportion of these are located in CpG dinucleotides. In addition, no 
significant differences were observed between the germline and the soma with respect to 
CpG-located nonsense mutations for all genes, implying that the methylation status of these 
genes is likely to be very similar between the germline and the soma. However, insufficient 
statistical power meant that we could not rule out the possibility that a paucity of mutation 
could have contributed for the observed results.
Conversely, more than 81% of all possible nonsense mutations within CpG 
dinucleotides were present among the observed germline nonsense mutations (viz. germline 
and shared) as opposed to 36% in the soma (viz. somatic and shared). Therefore, one 
conclusion that can be drawn is that CpG sites in the germline are relatively more methylated 
than in the soma. This contrasts with at least one study which appears to show precisely the 
opposite, i.e. that the germline is hypomethylated by comparison to the soma (Allegrucci et 
al. 2005). An alternative explanation may however be that the smaller proportion of somatic 
CpG-located nonsense mutations could be due to the smaller number of somatic nonsense 
mutations examined as compared to the numbers of germline nonsense mutations.
Somatic nonsense mutations were found to be randomly distributed (as determined by 
reference to potential nonsense mutations) with respect to their occurrence in CpG and non- 
CpG-dinucleotides. Nevertheless, there was not enough statistical power to detect an 
experiment-wise significant result, due to the fact that there was only 1 CpG-located 
nonsense mutation (PTCH) and the great majority of somatic nonsense mutations (-99.6%) 
were non-CpG located. Furthermore, the great majority of somatic CpG-located nonsense 
mutations (98%) were also found in the germline, hence they were labelled shared. In
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addition, germline nonsense mutations were preferentially found within CpG-dinucleotides 
{APC, BRCA2, CDH1, NF1, PTCH, TSC1 and TSC2).
We may infer that highly methylated CpG dinucleotides are present in both the 
germline and the soma, since if these CpG dinucleotides were not methylated, they would be 
no more mutable than any other dinucleotide. These results indicate that for some genes, 
specific CpG sites might be hypermethylated in the germline as compared to the soma, but 
for others the methylation status is potentially very similar. In addition, as reported 
previously, some variation of methylation levels in both the germline and the soma is evident 
(Millar et al. 1998; Trasler 1998).
The analysis of CpG-located nonsense mutations demonstrated that all CpG-located 
recurrent somatic nonsense mutations (i.e. those nonsense mutations that have been reported 
more than once) were also found in the germline. Conversely, all CpG-located shared 
nonsense mutations were found to be recurrent. Not only do somatic nonsense mutations 
recur in CpG-located dinucleotides, but all (100%) of these recurrent somatic CpG-located 
nonsense mutations have also been noted in the germline. Thus, CpG dinucleotides are 
generalized mutational hotspots due to methylation-mediated deamination, and their 
hypermutability is evident not only on account of their giving rise to recurrent somatic 
mutations but also because they give rise to germline mutations.
Taking the observed results altogether, one could pose a few additional questions for 
the future: why are virtually all somatic CpG-located nonsense mutations also found in the 
germline? Is endogenous mutagenesis the most important factor responsible for the high 
proportion of CpG-dinucleotides amongst nonsense mutations? Are exogenous factors also 
responsible for non-CpG located nonsense mutations?
The above findings could in principle be explicable at the level of the individual CpG 
dinucleotide, if data on the methylation status of all CpG sites were available. At present, 
data on the methylation status of only a few of the 17 human tumour suppressor genes are 
available and most of the published studies relate solely to CpG-dinucleotides located in 
promoter regions. Nevertheless, CpG-dinucleotides in exons 5-8 in the TP53 gene have been 
shown to be completely methylated in all tissues and cells examined by Tomaletti and Pfeifer 
(1995), but also exon 4 (Magdinier et al. 2002). In addition, codon 248 in the TP53 gene, a 
mutation hotspot in both the soma and the germline, has been shown to be methylated in all 
tissues and cells examined (Magewu and Jones 1994). Similarly, the promoter region and 
exon 1 of the WT1 gene have also been shown to be extensively methylated (Laux et al.
1999). In addition, a number of genes have been shown to exhibit promoter
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hypeimethylation, such as BRCA1 (Baldwin et al. 2000; Esteller et al. 2000; Radpour et al. 
2009), CDKN2A (Radpour et al. 2009; Wang et al. 2009), PTEN (Montiel-Duarte et al. 2008; 
Zhu ct al. 2009). Since most of these studies only involve methylation patterns in relation to 
tumour tissues (i.e. somatic tissues), it is difficult to extrapolate intra-genic methylation 
patterns in the germline. Nevertheless, these studies provide support, in the case of a few 
genes, of a likely heavy intra-genic methylation in at least somatic tissues.
As mentioned earlier, CpG-located nonsense mutations in both the soma and the 
germline are very likely to have resulted from methylation-mediated deamination. 
Nevertheless, a number of studies have shown that epigenetic modifications could be 
modulated by exogenous factors. Specifically, these include tobacco smoke, metals, arsenic, 
ionizing UVA & UVB radiation, aflatoxin B l, alcohol, etc. (Fleming et al. 2008). In 
particular, human non-melanoma cancers have been shown to exhibit UV-specific mutational 
patterns. These patterns comprise C->T transitions at methyl CpG-associated dipyrimidine 
sites (Ikehata and Ono 2007). Therefore, it is likely that some of the CpG-located nonsense 
mutaiions could be due to exogenous factors, such as UV light. Some reports suggest that 
environmental factors, such as aflatoxin Bl increase mutation frequency in some codons, but 
not others (Chan et al. 2003); thus, structural sequence context may play an important role. 
Furthermore, G->T transversions at CpG-dinucleotides are very likely to be a mutational 
signature associated with exposure to tobacco smoke (Yoon et al. 2001). However, a closer 
look at the CpG-located nonsense mutations in the 17 tumour suppressor genes studied, 
revealed that no G->T transversions at CpG-dinucleotides were observed. Furthermore, only 
3 such transversions would potentially lead to the introduction of a stop codon out of 23 
possible (Figure 19). Thus, one could only speculate as to the importance of these G->T 
transversions, with respect to CpG-located nonsense mutations.
It has to be noted that the increased mutation frequency in CpG-dinucleotides as a 
result of carcinogens is largely dependent on the methylation status of the CpG-dinucleotides. 
As a result, methylation is required for the mutational-signature patterns associated with 
carcinogens (Pfeifer 2006).
Similar methylation patterns between the soma and the germline could potentially be 
explained by inherited epigenetic modifications, whereby a "hypothetically1’ heavy intra­
genic germline methylation is transmitted to somatic cells. Such methylated CpG- 
dinucleotides, present in both the soma and the germline would be substrates for both 
spontaneous endogenous deamination and carcinogens. Indeed, CpG methylation has been 
shown to be heritable in Mendelian and non-Mendelian fashion (Fleming et al. 2008).
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Mendelian inherited modifications are very likely to be result from incomplete epigenetic re­
programming in the germline and have been shown in hereditary nonpolyposis colorectal 
cancer (Chan et al. 2006). Nevertheless, such "transgenerational" inheritance of epigenetic 
events could be also due to carcinogens (Anway et al. 2005; Chang et al. 2006; Fleming et al. 
2008). Therefore, both endogenous mechanisms and carcinogens are quite likely to play an 
important role in determining methylation patterns in both the soma and the germline and 
hence ultimately, the mutability of methylated cytosines in both cell lineages.
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Table 18 Distribution of germline and somatic nonsense mutations in the 17 human tumour suppressor genes
Gene
Codons
Number
Possible
missense
mutations
Fp
Possible CpG 
mutations
FpcpG
Fpq>G FP ' v Fm FW
Somatic
F±
FP
FjCpG
Fs
FjCpG
Fpcpo
Fa
Fs
Fsh
Fs ' FoCpG Fgh
Germline
Fq Fqq^
FP F0
Focpo
Fpcpo
Fgh
Fg
APC 2844 1278 27 0.02 79 8 35 28 0.06 0.10 0.30 0.44 035 180 16 28 0.14 0.09 0.59 0.16
ATM 3057 1480 21 0.01 7 2 0 3 0.00 0.29 0.10 0.00 0.43 75 18 3 0.05 0.24 0.86 0.04
BRCA1 1864 803 4 0.00 9 1 0 6 0.01 0.11 0.25 0.00 0.67 121 4 6 0.15 0.03 1.00 0.05
BRCA2 3419 1594 5 0.00 1 0 0 0 0.00 0.00 0.00 0.00 0.00 76 4 0 0.05 0.05 0.80 0.00
CDH1 883 263 4 0.02 7 1 0 2 0.03 0.14 0.25 0.00 0.29 11 3 2 0.04 o n 0.75 0.18
CDKN2A 157 27 2 0.07 18 2 3 5 0.67 0.11 1.00 0.17 0.28 7 2 5 0.26 0.29 1.00 0.71
NF1 2819 1089 19 0.02 14 9 0 10 0.01 0.64 0.47 0.00 0.71 115 18 10 0.11 0.16 0.95 0.09
NF2 596 251 7 0.03 42 6 18 18 0.17 0.14 0.86 0.43 0.43 43 6 18 0.17 0.14 0.86 0.42
PTCH 1448 480 5 0.01 9 1 0 2 0.02 0.11 0.20 0.00 0.22 27 2 2 0.06 0.07 0.40 0.07
PTEN 404 183 3 0.02 56 3 19 13 0.31 0.05 1.00 0.34 0.23 28 3 13 0.15 0.11 1.00 0.46
RBI 929 420 14 0.03 27 7 9 15 0.06 0.26 0.50 0.33 0.56 76 11 15 0.18 0.14 0.79 0.20
STK11 434 143 1 0.01 10 0 1 3 0.07 0.00 0.00 0.10 0.30 27 1 3 0.19 0.04 1.00 0.11
TP53 394 129 4 0.03 96 4 85 9 0.74 0.04 1.00 0.89 0.09 10 4 9 0.08 0.40 1.00 0.90
TSC1 1165 439 7 0.02 1 0 0 0 0.00 0.00 0.00 0.00 0.00 37 6 0 0.08 0.16 0.86 0.00
TSC2 1808 551 7 0.01 1 0 0 1 0.00 0.00 0.00 0.00 1.00 74 6 1 0.13 0.08 0.86 0.01
VHL 214 73 0.03 15 2 4 11 0.21 0.13 1.00 0.27 0.73 27 2 11 0.37 0.07 1.00 0.41
WT1 450 161 3 0.02 3 3 0 3 0.02 1.00 1.00 0.00 1.00 14 3 3 0.09 0.21 1.00 0.21
Total 22885 9364 135 0.01 395 49 174 129 0.04 0.12 0.36 0.44 0.33 948 109 129 0.10 0.11 0.81 0.14
Ft is the number of mutations, where i E  {P,PCpG,S,SCpG,SR,SH,G,GCpG,GH}
P -possible, PCpG-possible CpG-located , S-somatic , SCpG-somatic CpG-located, SP-somatic recurrent, SH-somatic shared, G-germline, 
GCpG-germline CpG-located, GH -germline shared
Values marked in red denote those genes that made a relatively large contribution to the corresponding mutational spectrum
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Table 19 Shared recurrent nonsense mutations and shared nonsense mutations found in CpG-dinucleotides
Mutations
Gene
Shared
F 1 •//
CpG-located
FcpG FCpG I F sH F1 KK
Recurrent
F rec ! F sh F1 REC _CpG
Recurrent and CpG-located
F r e c_cpg !  F sh  F rec _CpG I F CpC F reC_CPG I F  pec
APC 28 8 0.29 17 0.61 6 0.21 0.75 0.35
ATM 3 2 0.67 0 0.00 0 0.00 0.00 N/A
BRCA1 6 1 0.17 0 0.00 0 0.00 0.00 N/A
BRCA2 0 0 N/A 0 N/A 0 N/A N/A N/A
CDH1 2 1 0.50 0 0.00 0 0.00 0.00 N/A
CDKN2A 5 2 0.40 2 0.40 1 0.20 0.50 0.50
NF1 10 9 0.90 0 0.00 0 0.00 0.00 N/A
NF2 18 6 0.33 10 0.56 6 0.33 1.00 0.60
PTCH 2 0 0.00 0 0.00 0 0.00 N/A N/A
PTEN 13 3 0.23 8 0.62 3 0.23 1.00 0.38
RBI 15 7 0.47 7 0.47 5 0.33 0.71 0.71
STK11 3 0 0.00 1 0.33 0 0.00 N/A 0.00
TP53 9 4 0.44 9 1.00 4 0.44 1.00 0.44
TSC1 0 0 N/A 0 N/A 0 N/A N/A N/A
TSC2 1 0 0.00 0 0.00 0 0.00 N/A N/A
VHL 11 2 0.18 3 0.27 1 0.09 0.50 0.33
WT1 3 3 1.00 0 0.00 0 0.00 0.00 N/A
Total 129 48 0.37 57 0.44 26 0.20 0.54 0.46
Fi is the number of mutations, where i E {SH,CpG,REC,REC _ CpG}
SH-shared, CpG- CpG-located , EEC-recurrent, REC_CpG-recurrent CpG-located
Values marked in red denote genes that made a relatively large contribution to the corresponding mutational spectrum
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Table 20 Distribution of somatic, germline and shared nonsense mutations
Mutations
Gene
Nonsense
Fs Fs Fs 'Fn
Somatic
Fs IF& l \  I', , fgif n
Germline
fg/ fct Fg ! Fnt F Fsh !Fn
Fsh 
Fsh + Fs
Shared
Fsh 
Fsh + Fg Fsh  ^FSht Fsh !Fnt
APC 231 51 0.221 0.192 0.042 152 0.658 0.186 0.125 28 0.35 0.35 0.16 0.217 0.023
ATM 79 4 0.051 0.015 0.003 72 0.911 0.088 0.059 3 0.04 0.43 0.04 0.023 0.002
BRCA1 124 3 0.024 0.011 0.002 115 0.927 0.140 0.095 6 0.05 0.67 0.05 0.047 0.005
BRCA2 77 1 0.013 0.004 0.001 76 0.987 0.093 0.063 0 0.00 0.00 0.00 0.000 0.000
CDH1 16 5 0.313 0.019 0.004 9 0.563 0.011 0.007 2 0.13 0.29 0.18 0.016 0.002
CDKN2A 20 13 0.650 0.049 0.011 2 0.100 0.002 0.002 5 0.25 0.28 0.71 0.039 0.004
NF1 119 4 0.034 0.015 0.003 105 0.882 0.128 0.086 10 0.08 0.71 0.09 0.078 0.008
NF2 67 24 0.358 0.090 0.020 25 0.373 0.031 0.021 18 0.27 0.43 0.42 0.14 0.015
PTCH 34 7 0.206 0.026 0.006 25 0.735 0.031 0.021 2 0.06 0.22 0.07 0.016 0.002
PTEN 71 43 0.606 0.162 0.035 15 0.211 0.018 0.012 13 0.18 0.23 0.46 0.101 0.011
RBI 88 12 0.136 0.045 0.010 61 0.693 0.074 0.050 15 0.17 0.56 0.20 0.116 0.012
STK11 34 7 0.206 0.026 0.006 24 0.706 0.029 0.020 3 0.09 0.30 0.11 0.023 0.002
TP53 97 87 0.897 0.327 0.072 1 0.010 0.001 0.001 9 0.09 0.09 0.90 0.070 0.007
TSC1 38 1 0.026 0.004 0.001 37 0.974 0.045 0.030 0 0.00 0.00 0.00 0.000 0.000
TSC2 74 0 0.000 0.000 0.000 73 0.986 0.089 0.060 1 0.01 1.00 0.01 0.008 0.001
VHL 31 4 0.129 0.015 0.003 16 0.516 0.020 0.013 11 0.36 0.73 0.41 0.085 0.009
WT1 14 0 0.000 0.000 0.000 11 0.786 0.013 0.009 3 0.21 1.00 0.21 0.023 0.002
total
NT
1214
ST
266 0.219 1.000 0.219
GT
819 0.675 1.000 0.675
SET
129 0.11 0.33 0.14 1.000 0.106
F. is the number of mutations, where i E {N,S,G,GT,NT,SH,SHT\
/V-nonsense, S- somatic , G-germline , GT-germline total, AT-nonsense total, SH-shared, SHT-shared total 
Values marked in red denote genes that made a relatively large contribution to the corresponding mutational spectrum
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Table 21 Distribution of CpG-located somatic, germline and shared nonsense mutations
Codons
Possible
nonsense
mutations
Possible nonsense 
CpG mutations Somatic Germline Shared
Recurrent
somatic
non-shared
Recurrent
somatic
shared
FpCpG Fs Fa Fsh Fsh Fsh F rs F rsh
Gene Number FP FpCfG fp Fs Fg Fsh FRS F rsh FpcpG Fpcpo FpcpG Fs h + FS F sh  + F g Fsh F sh
APC 2844 1278 27 0.02 0 8 8 0 6 0.00 0.30 0.30 1.00 0.50 N/A 0.75
ATM 3057 1480 21 0.01 0 16 2 0 0 0.00 0.76 0.10 1.00 0.11 N/A 0.00
BRCA1 1864 803 4 0.00 0 3 1 0 0 0.00 0.75 0.25 1.00 0.25 N/A 0.00
BRCA2 3419 1594 5 0.00 0 4 0 0 0 0.00 0.80 0.00 N/A 0.00 N/A N/A
CDHl 883 263 4 0.02 0 2 1 0 0 0.00 0.50 0.25 1.00 0.33 N/A 0.00
CDKN2A 157 27 2 0.07 0 0 2 0 1 0.00 0.00 1.00 1.00 1.00 N/A 0.50
NF1 2819 1089 19 0.02 0 9 9 0 0 0.00 0.47 0.47 1.00 0.50 N/A 0.00
NF2 596 251 7 0.03 0 0 6 0 6 0.00 0.00 0.86 1.00 1.00 N/A 1.00
PTCH 1448 480 5 0.01 1 2 0 0 0 0.20 0.40 0.00 0.00 0.00 0.00 N/A
PTEN 404 183 3 0.02 0 0 3 0 3 0.00 0.00 1.00 1.00 1.00 N/A 1.00
RBI 929 420 14 0.03 0 4 7 0 5 0.00 0.29 0.50 1.00 0.64 N/A 0.71
STKll 434 143 1 0.01 0 1 0 0 0 0.00 1.00 0.00 N/A 0.00 N/A N/A
TP53 394 129 4 0.03 0 0 4 0 4 0.00 0.00 1.00 1.00 1.00 N/A 1.00
TSC1 1165 439 7 0.02 0 6 0 0 0 0.00 0.86 0.00 N/A 0.00 N/A N/A
TSC2 1808 551 7 0.01 0 6 0 0 0 0.00 0.86 0.00 N/A 0.00 N/A N/A
VHL 214 73 2 0.03 0 0 2 0 1 0.00 0.00 1.00 1.00 1.00 N/A 0.50
WT1 450 161 3 0.02 0 0 3 0 0 0.00 0.00 1.00 1.00 1.00 N/A 0.00
total 22885 9364 135 0.01 1 61 48 0 26 0.01 0.45 0.36 0.98 0.44 0.00 0.54
P -possible, PCpG- possible CpG-located , S-somatic, G-germline, SH-shared, R S-recurrent somatic non-shared, RSH -recurrent somatic 
shared
Values marked in red denote genes that made a relatively large contribution to the corresponding mutational spectrum
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Table 22 Distribution of non-CpG located somatic, germline and shared nonsense mutations
Codons
Possible
nonsense
mutations
Possible nonsense 
CpG mutations Somatic Germline Shared
Recurrent
somatic
non-shared
Recurrent
somatic
shared
pPCpG Fs Fc Fsh Fsh Fsh Frs Frsh
Gene Number Fp FpcpG Fp F s Fg Fsh Frs Frsh Fp Fp Fp Fs h + F s Fsh +Fg Fsh Fsh
APC 2844 1278 27 0.02 51 144 20 18 11 0.04 0.11 0.02 0.28 0.12 0.35 0.55
A TM 3057 1480 21 0.01 4 56 1 0 0 0.00 0.04 0.00 0.20 0.02 0.00 0.00
BRCA1 1864 803 4 0.00 3 112 5 0 0 0.00 0.14 0.01 0.63 0.04 0.00 0.00
BRCA2 3419 1594 5 0.00 1 72 0 0 0 0.00 0.05 0.00 0.00 0.00 0.00 N/A
CDH1 883 263 4 0.02 5 7 1 0 0 0.02 0.03 0.00 0.17 0.13 0.00 0.00
CDKN2A 157 27 2 0.07 13 2 3 1 1 0.48 0.07 0.11 0.19 0.60 0.08 0.33
NF1 2819 1089 19 0.02 4 96 1 0 0 0.00 0.09 0.00 0.20 0.01 0.00 0.00
NF2 596 251 7 0.03 24 25 12 8 4 0.10 0.10 0.05 0.33 0.32 0.33 0.33
PTCH 1448 480 5 0.01 6 23 2 0 0 0.01 0.05 0.00 0.25 0.08 0.00 0.00
PTEN 404 183 3 0.02 43 15 10 11 5 0.23 0.08 0.05 0.19 0.40 0.26 0.50
R B I 929 420 14 0.03 12 57 8 2 2 0.03 0.14 0.02 0.40 0.12 0.17 0.25
STK11 434 143 1 0.01 7 23 3 0 1 0.05 0.16 0.02 0.30 0.12 0.00 0.33
TP53 394 129 4 0.03 87 1 5 76 5 0.67 0.01 0.04 0.05 0.83 0.87 1.00
TSC1 1165 439 7 0.02 1 31 0 0 0 0.00 0.07 0.00 0.00 0.00 0.00 N/A
TSC2 1808 551 7 0.01 0 67 1 0 0 0.00 0.12 0.00 1.00 0.01 N/A 0.00
VHL 214 73 2 0.03 4 16 9 1 2 0.05 0.22 0.12 0.69 0.36 0.25 0.22
WT1 450 161 3 0.02 0 11 0 0 0 0.00 0.07 0.00 N/A 0.00 N/A N/A
total 22885 9364 135 0.01 265 758 81 117 31 0.03 0.08 0.01 0.23 0.10 0.44 0.38
Ff is the number of mutations, where i E  {P,PCpG,S,G,SH,RS,RSH}
P-possible, PCpG- possible CpG-located , 5-somatic , G-germline, S/Z-shared, RS -recurrent somatic non-shared, RSH -recurrent somatic 
shared
Values marked in red denote genes that made a relatively large contribution to the corresponding mutational spectrum
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Table 23 Summary of statistically significant results for nonsense mutations, with respect to NMD status
Group 1 vs. 
Group 2 Gene
Group 1
NMD elicit NMD skip 
N1 F2 N1 F2
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NMD elicit NMD skip 
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shared vs. pot ALL 96 0.74 33 0.26 6879 0.84 1271 0.16 9.54 2.01E-03 1.78E-02 3.56E-02 6.05E-01 0.034 23.26
germ vs. shared ALL 710 0.87 109 0.13 96 0.74 33 0.26 13.18 2.83E-04 3.70E-03 7.40E-03 1.26E-01 0.118 42.50
germ vs. pot APC 64 0.42 88 0.58 225 0.21 822 0.79 30.84 2.81E-08 <1.00E-04 <2,00E-04 <3.40 E-03 0.160 95.85
obs vs. pot APC 71 0.31 160 0.69 225 0.21 822 0.79 9.09 2.57E-03 1.96E-02 3.92E-02 6.66E-01 0.084 21.06
soma vs. germ APC 3 0.06 48 0.94 64 0.42 88 0.58 22.66 1.93E-06 <1.00E-04 <2.00 K-04 <3.40E-03 0.334 82.66
shared vs. pot BRCA1 4 0.67 2 0.33 664 0.98 15 0.02 23.81 1.07E-06 8.70E-03 1.74E-02 2.96E-01 0.186 85.53
soma vs. pot TP53 87 1.00 0 0.00 18 0.56 14 0.44 43.14 5.10E-11 <1.00E-04 <2.00E-04 <3.40E-03 0.602 99.70
obs vs. pot TP53 97 1.00 0 0.00 18 0.56 14 0.44 47.60 5.22E-12 <1.00E-04 <2.00E-04 <3.401-03 0.607 99.90
- Number; -Frequency; Gene-wise or experiment-wise statistically significant results are marked in red; Pot.- Potential, Obs.- Observed, Soma - Somatic
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Table 24 Summary' of statistically significant results for nonsense mutations, with respect to CpG-dinucleotidcs
Group 1 vs. Group 2 Gene
Group 1
In CpG Not in CpG 
N1 F2 N1 F2
Group 2
In CpG Not in CpG 
N1 F2 N1 F2
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germ vs. pot ALL 61 0.07 758 0.93 25 0.00 8125 1.00 399.66 6.54E-89 <1.00E-04 <2.00E-04 <3.40 E-03 0.211 100.00
shared vs. pot ALL 48 0.37 81 0.63 25 0.00 8125 1.00 1978.72 -0.00E+O <1.00E-04 <2.00F.-04 <3.40 E-03 0.489 100.00
obs vs. pot ALL n o 0.09 1104 0.91 25 0.00 8125 1.00 569.88 -0.00E+O <1.00E-04 <2.00F.-04 <3.40 E-03 0.247 100.00
soma vs. germ ALL 1 0.00 265 1.00 61 0.07 758 0.93 18.64 1.58E-05 5.00E-04 1.001-03 1.70E-02 0.131 69.07
soma vs. shared ALL 1 0.00 265 1.00 48 0.37 81 0.63 108.46 2.13E-25 <1.00E-04 <2.00 E-04 <3.40 E-03 0.524 100.00
germ vs. shared ALL 61 0.07 758 0.93 48 0.37 81 0.63 97.01 6.92E-23 <1.00E-04 <2.001:04 <3.40 E-03 0.320 100.00
Rec shared vs. rec non-shared 
Non-rec shared vs. non-rec non-
ALL 26 0.46 31 0.54 0 0.00 117 1.00 62.74 2.35E-15 <1.00E-04 <2.00E-04 <3.40E-03 0.600 100.00
shared ALL 22 0.31 50 0.69 1 0.01 148 0.99 46.50 9.18E-12 <1.00E-04 <2.00 E-04 <3.40 E-03 0.459 99.86
Rec shared vs. non-rec non-shared ALL 26 0.46 31 0.54 1 0.01 148 0.99 73.12 1.22E-17 <1.00E-04 <2.00E-04 <3.40 E-03 0.5% 100.00
germ vs. pot APC 8 0.05 144 0.95 11 0.01 1036 0.99 15.10 1.02E-04 5.80E-03 1.16E-02 1.97E-01 0.112 52.66
shared vs. pot APC 8 0.29 20 0.71 11 0.01 1036 0.99 118.96 1.07E-27 <1.00E-04 <2.00F.-04 <3.40 E-03 0.333 100.00
obs vs. pot APC 16 0.07 215 0.93 11 0.01 1036 0.99 31.59 1.90E-08 4.00E-04 8.00 E-04 1.36 E-02 0.157 96.42
soma vs. shared APC 0 0.00 51 1.00 8 0.29 20 0.71 16.21 5.66E-05 5.20E-03 1.04E-02 1.77E-01 0.453 58.20
germ vs. shared APC 8 0.05 144 0.95 8 0.29 20 0.71 15.86 6.82E-05 5.20E-03 1.04E-02 1.77E-01 0.297 56.48
Rec shared vs. non-rec non-shared APC 6 0.35 11 0.65 0 0.00 33 1.00 13.24 2.75E-04 7.70E-03 1.54E-02 2.62E-01 0.514 42.80
germ vs. pot ATM 16 0.22 56 0.78 3 0.00 1398 1.00 260.51 1.33E-58 <1.00E-04 <2.00 E-04 <3.40 E-03 0.421 100.00
shared vs. pot ATM 2 0.67 1 0.33 3 0.00 1398 1.00 372.53 5.26E-83 <1.00E-04 <2.00 E-04 <3.40 E-03 0.515 100.00
obs vs. pot ATM 18 0.23 61 0.77 3 0.00 1398 1.00 272.36 3.47E-61 <1.00E-04 <2.00 E-04 <3.40 E-03 0.429 100.00
shared vs. pot BRCA1 1 0.17 5 0.83 0 0.00 679 1.00 113.33 1.83E-26 <1.00E-04 <2.00 E-04 <3.40E-03 0.407 100.00
germ vs. pot BRCA2 4 0.05 72 0.95 1 0.00 1516 1.00 62.48 2.69E-15 3.10E-03 6.20E-03 1.05E-01 0.198 100.00
obs vs. pot BRCA2 4 0.05 73 0.95 1 0.00 1516 1.00 61.65 4.1 IE-15 3.10E-03 6.20E-03 1.05E-01 0.197 100.00
germ vs. pot CDH1 2 0.22 7 0.78 1 0.00 246 1.00 35.69 2.31E-09 8.40E-03 1.68E-02 2.86E-01 0.373 98.44
shared vs. pot CDH1 1 0.50 1 0.50 1 0.00 246 1.00 61.25 5.04E-15 1.00E-03 2.00E-03 3.40 E-02 0.496 100.00
obs vs. pot CDHl 3 0.19 13 0.81 1 0.00 246 1.00 33.76 6.22E-09 8.40E-03 1.68E-02 2.86E-01 0.358 97.68
germ vs. pot NFI 9 0.09 % 0.91 1 0.00 969 1.00 73.73 8.98E-18 <1.00E-04 <2.00E-04 <3.40 E-03 0.262 100.00
shared vs. pot NF1 9 0.90 1 0.10 1 0.00 969 1.00 791.98 -0.00E+0 <1.00E-04 <2.00 E-04 <3.40 E-03 0.899 100.00
obs vs. pot NFI 18 0.15 101 0.85 1 0.00 969 1.00 139.55 3.34E-32 <1.00E-04 <2.00 E-04 <3.40 E-03 0.358 100.00
germ vs. shared NFI 9 0.09 96 0.91 0.90 1 0.10 45.86 1.27E-11 1.70E-03 3.40E-03 5.78E-02 0.631 99.84
shared vs. pot NF2 6 0.33 12 0.67 1 0.01 183 0.99 52.70 3.89E-13 <1.00E-04 <2.00F.-04 <3.40E-03 0.511 99.97
obs vs. pot NF2 6 0.09 61 0.91 1 0.01 183 0.99 12.82 3.43E-04 1.04E-02 2.08E-02 3.54E-01 0.226 40.55
soma vs. shared NF2 0 0.00 24 1.00 6 0.33 12 0.67 9.33 2.25E-03 1.92E-02 3.84 E-02 6.53E-01 0.471 22.23
germ vs. shared NF2 0 0.00 25 1.00 6 0.33 12 0.67 9.68 1.86E-03 1.92E-02 3.84E-02 6.53E-01 0.475 23.%
rec vs. non-rec NF2 6 0.33 12 0.67 0 0.00 24 1.00 9.33 2.25E-03 1.88E-02 3.76E-02 6.39E-01 0.471 22.23
Rec shared vs. non-rec non-shared NF2 6 0.60 4 0.40 0 0.00 16 1.00 12.48 4.1 IE-04 1.04E-02 2.08 E-02 3.54E-01 0.693 38.71
shared vs. pot PTEN 3 0.23 10 0.77 0 0.00 112 1.00 26.48 2.66E-07 2.00E-04 4.00 E-04 6.80 E-03 0.460 90.77
soma vs. shared PTEN 0 0.00 43 1.00 3 0.23 10 0.77 10.48 1.20E-03 1.25E-02 2.50E-02 4.25E-01 0.433 28.04
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Rec shared vs. non-rec non-shared PTEN 3 0.38 5 0.62 0 0.00 32 1.00 12.97 3.16H-04 1.2 5 E-02 2.50 E-02 4.25E-01 0.569 41.38
shared vs. pot RBI 7 0.47 8 0.53 3 0.01 329 0.99 107.39 3.66E-25 <1.00E-04 <2.00 E-04 <3.40 E-03 0.556 100.00
obs vs. pot RBI 11 0.12 77 0.88 3 0.01 329 0.99 29.03 7.12E-08 3.00E-04 6.00 E-04 1.02 E-02 0.263 94.16
germ vs. shared RBI 4 0.07 57 0.93 7 0.47 8 0.53 15.65 7.64E-05 7.10E-03 1.42 E-02 2.41E-01 0.454 55.41
soma vs. shared TP53 0 0.00 87 1.00 4 0.44 5 0.56 40.35 2.13E-10 6.80E-03 1.36 E-02 2.31E-01 0.648 99.43
Rec shared vs. rec non-shared TP53 4 0.44 5 0.56 0 0.00 76 1.00 35.45 2.62E-09 6.80E-03 1.36 E-02 2.31E-01 0.646 98.36
germ vs. pot TSC1 6 0.16 31 0.84 1 0.00 400 1.00 54.91 1.26E-13 1.51 E-02 3.02 E-02 5.13E-01 0.354 99.98
obs vs. pot TSCI 6 0.16 32 0.84 1 0.00 400 1.00 53.42 2.69E-13 1.51 E-02 3.02 E-02 5.13E-01 0.349 99.98
germ vs. pot TSC2 6 0.08 67 0.92 1 0.00 476 1.00 32.32 1.31E-08 1.15E-02 2.30 E-02 3.91E-01 0.242 96.90
obs vs. pot TSC2 6 0.08 68 0.92 1 0.00 476 1.00 31.86 1.65E-08 1.15E-02 2.30 E-02 3.91E-01 0.240 96.60
shared vs. pot WTI 3 1.00 0 0.00 0 0.00 147 1.00 150.00 1.73E-34 <1.00E-04 <2.00 E-04 <3.40 E-03 1.000 100.00
obs vs. pot WTI 3 0.21 11 0.79 0 0.00 147 1.00 32.10 1.47E-08 1.10E-03 2.20 E-03 3.74E-02 0.447 96.76
- Number; :-Frequency; Gene-wise or experiment-wise statistically significant results are marked in red; Pot.- Potential, Obs - Observed, Soma - Somatic, Rec.- Recurrent, Non-rec - Non-recurrent
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Figure 21 Summary of statistically significant results for nonsense mutations, with 
respect to CpG-dinuc eotides and NMD status
Soma vs pot N M D
Germ vs pot
Shared vs pot NMD ! I
Obs vs pot NMD
r t
NMDSoma vs germ
Soma vs shared N M D
Germ vs shared N M D
Rec vs non-rec N M D
Rec shared vs. rec non- NMD shared
Non-rec shared vs non- NMD rec non-shared
Rec shared vs non-rec non-shared NM1)
Legend: t  or |  denotes the direction of the gene- or experiment-wise statistically significant 
result. The direction is with respect to the first group in the comparison. A Grey shaded box 
represents a experiment-wise statistically significant result, a non-shaded arrow (i.e. f or | )  
represents a gene-wise statistically significant result, a Gree( shaded box represents ^80% 
power to detect a statistically significant result for the comparison and associated effect size, 
I ^ H frh a d e d  box represents <80% power and experiment-wise statistically significant 
result. Soma- Somatic, Germ- Germline, Obs.- Observed (somatic, germline and shared). 
Pot.- Potential, Rec.- Recurrent, Non-rec.- Non-recurrent;
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6. Micro-lesions
6.1. Introduction
6.1.1. Importance of micro-lesions and their functional consequences
Cancer is perceived as a genetic disorder because DNA sequence changes are 
considered causative of neoplasms. Mutations in three basic types of gene drive tumour 
development: oncogenes, genomic stability genes and tumour suppressor genes (Vogelstein 
and Kinzler 2004). Generally ‘biallelic gene inactivation’ is required for tumour suppressor 
gene inactivation (Knudson 1971). Thus, one mutant allele, inherited through the germline, 
and subsequent inactivation of the other allele in the soma has been the basis of the ‘two-hit’ 
hypothesis originally proposed by Knudson (Knudson 1971, 1978).
Micro-deletions, micro-insertions and micro-indels (inserted and/or deleted 
nucleotides <20bp) are an important part of the mutational spectrum associated with cancer 
predisposition and tumour development. When causing ffameshifts within the coding 
sequence of genes (i.e. when the length in base-pairs of the deleted or inserted bases is not 
divisible by three), these lesions invariably have drastic consequences for the function of the 
protein. Abrupt termination of translation would be expected when the reading frame is 
changed, due to the triplet nature of the genetic code (Crick et al. 1961; Yanofsky 2007). 
Thus, ‘hidden’ (out-of-frame) stop codons terminate mRNA translation (Seligmann and 
Pollock 2004). Seligmann and Pollock (2004) have proposed an ‘ambush hypothesis’, 
suggesting that ‘hidden’ stop codons (stop codons in -1 and +1 shifted reading frames) are 
frequently selected for, depending on adjacent codons and the synonymous codon state.
These authors have suggested that codons with increased potential to form ‘hidden’ stops 
have greater usage frequency. The latter finding is compatible with the fact that translation 
termination following a ffameshift would be likely to be beneficial to the cell, by reducing 
the energy waste on non-functional proteins or by reducing a cytotoxic effect (Seligmann and 
Pollock 2004). Indeed, it has been estimated that translation would be terminated on average 
~15 codons following a ffameshift (Itzkovitz and Alon 2007). Additionally, mRNAs with 
potential premature termination codons would be subject to quality control mechanisms that 
could potentially reduce or even eliminate the production of faulty proteins through the rapid 
degradation of the affected mRNA (Gonzalez et al. 2001; Holbrook et al. 2004; Lejeune and 
Maquat 2005; Maquat 2002, 2004; Vasudevan et al. 2002; Wilkinson 2005). Thus, the
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functional consequence of most ffameshifts would be a truncated protein: truncated protein 
with markedly decreased concentration or no protein altogether. These types of mutations are 
often termed ioss-of-ftmction’ mutations (Haber and Harlow 1997). Alternatively, some 
mutations could lead to a ‘gain-of-fimction’ where they give rise to dominant negative forms 
over the wild-type. Certain mutant forms of the APC gene could exert a dominant negative 
effect over the wild-type product (Dihlmann et al. 1999). By way of example, some mutant 
forms of TP53 gene lead to a ‘loss-of-function’ whereas others give rise to a potent dominant 
negative over the wild-type forms (Junk et al. 2008).
On the other hand, in-frame (i.e. the number of added or subtracted nucleotides is 
divisible by 3) micro-deletions, micro-insertions and micro-indels would be expected to have 
less severe consequence for the function of the protein. In support of this assertion, a 
comprehensive meta-analysis of micro-deletions and micro-insertions causing inherited 
human genetic disease (Ball et al. 2005) revealed that the in-frame lesions of size 3bp and 
6bp exhibit markedly lower frequencies than expectation. Since such mutations appear to 
come to clinical attention less frequently, it may be inferred that such micro-lesions are less 
likely to cause human disease. This notwithstanding, adding or subtracting amino acids, 
termed ‘protein tinkering’, could play an important role in carcinogenesis (Gonzalez et al. 
2007). In support, all recorded mutations associated with non-small lung cancer in the 
Epidermal Growth Factor Receptor Mutation Database are in-frame (EGFR Database: 
http://www.citvofhope.org/mdl/egfr/Pages/default.aspx: Gu et al. 2007).
6.1.2. E ndogenous m utagenesis
6.1.2.1. D irec t repeats
Several lines of evidence are supportive of the non-random occurrence of micro­
lesions (viz. micro-deletions, micro-insertions and micro-indels) and the potential 
involvement of endogenous mechanisms of mutagenesis. Early work by Efstratiadis et al. 
(1980) identified short (2-8bp) direct repeats (Figure 22a) around the endpoints of deletions. 
Efstratiadis et al. (1980) hypothesised a ‘slipped mispairing’ mechanism to explain the role of 
direct repeats in the process of mutagenesis, as depicted in Figure 23. The presence of such 
sequences could facilitate ‘slipped mispairing’ and thus promote deletions. This model could 
explain deletions of one copy of the repeat and the intervening sequence between the repeats.
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Figure 22 Examples of repetitive elements: direct repeat (a); inverted repeat (b); mirror 
repeat (c); G-quartet (d); runs of identical nucleotides (e)
a) AGTGG ACAGA 3’CTACCG CTACCG
direct repeat
b) 5 ’ GGCTG
c) 5 ’ ACGTC
AGTGCACTAAT ATTAGT
inverted repeat
CTTGCGTCAGA AGACTG
GATTG 3’
CACTT 3 ’
mirror repeat
d) TCTCT AGGA TTAAGGG GGG GGGGGG
G quartet
e) 5’ GGCATTACAGG AAAAAAAAAA GGTGTCAGTCA 3’
run of identical nucleotide
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Figure 23 The ‘slipped mispairing mechanism’ for generation of micro-lesions during
DNA replication (adapted from Cooper and Krawczak 1993; Efstratiadis et al. 1980)
-IGATGGC
Double stranded DNA 
containing a direct 
repeat (R1 and R2)
Single stranded DNA
R2 repeat mispairs with 
the complementary R1 
repeat, producing single 
stranded loop
Single stranded loop 
containing repeat R1 
excised and repaired by 
DNA repair enzymes
End of DNA replication. 
As a result only one of 
the newly derived 
double stranded DNA 
contains the full 
sequence of the repeat 
(R1 and R2). The 
second daughter 
double stranded DNA 
lacks sequence R1 and 
intervening sequence 
between R1 and R2
It has been noted that the proposed ‘slipped mispairing’ mechanism could not readily explain 
a number of deletions, where apparent involvement of direct repeats is noticeable. Thus, a 
modified version of the ‘slipped mispairing’ has been proposed (Cooper and Krawczak , 
depicted in Figure 24). This modified model suggests that the mispairing is only an 
intermediate and the deletion of one copy of the repeat as proposed in the original model does 
not occur. The intermediate is proposed only to last long enough to promote formation of a 
second copy repeat, followed by excision of the intervening sequence and subsequent end 
joining. Studies on triplet repeat expansion show that both insertions (expansions) and
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deletions (contractions) are extremely likely and are mediated by the repeats (Bowater and 
Wells 2001; Sinden et al. 2002; Wells et al. 2005). These studies have also suggested that 
expansions and contractions of repeats are dependent upon the replication origin. Expansions 
are generated when more stable slipped structures are formed on the newly synthesized 
Okazaki fragments (Hebert et al. 2004; Wells et al. 2005). Contractions on the other hand are 
generated when slipped structures are formed on the template strand for replication. The 
triplet repeats could be considered as simple short (3bp) direct repeats; thus, direct repeats 
may not only promote deletions, but also insertions (Wells et al. 2005), as shown in Figure 
26. The slipped mispairing mechanism could also account for insertion events of one base 
frameshifts (Cooper and Krawczak 1993; Kunkel 1990; Ripley 1990).
6.1.2.2. Inverted repeats
Inverted repeats (Figure 22b) have the intrinsic property of forming secondary 
structures, such as hairpins in single-stranded DNA and cruciforms in double-stranded DNA 
(Bzymek and Lovett 2001; Wells 2007). An inverted repeat has self-complementarity within 
the same DNA strand, which allows the strand to fold back on itself and form a hairpin 
secondary structure (as shown in Figure 27a). Following the self-complementarity of the 
DNA code, palindromes could also be formed (two symmetrical hairpin structures on both 
sides of the DNA molecule, Figure 27b). A mechanism has been proposed that could explain 
deletions promoted by ‘quasi-palindromic’ sequences facilitated by inverted repeats (Figure 
25; Ripley 1982). These ‘quasi-palindromic’ sequences represent imperfect inverted repeats, 
where there are extra nucleotides in one of the strands in the hairpin formation (Figure 25, 
region B).
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Figure 24 Modified version of the ‘slipped mispairing mechanism’ for generation of
deletions during DNA replication (adapted from Cooper and Krawczak 1993)
CTACCG
i i i i i r
GATGGC
CTACCG
Double stranded DNA 
containing a direct 
repeat (R1) and 
homologous interrupted 
sequence (R2a and 
R2b)
Single stranded DNA
R2a and R2b 
sequences mispair with 
the complementary R2' 
repeat, producing single 
stranded loop
Single stranded loop, 
containing intervening 
sequence between R2a 
and R2b is excised and 
repaired by DNA repair 
enzymes
End of DNA replication. 
As a result only one of 
the newly derived 
double stranded DNA 
contains the original 
sequence (R1 and R2a 
+ R2b). The second 
daughter double 
stranded DNA lacks the 
intervening sequence 
between R2a and R2b
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Figure 25 Deletions and insertions mediated by quasi-palindromic sequences (modified 
after Cooper and Krawczak 1993; Ripley 1982)
A
5’
addition  in A
5'—
Figure 26 Triplet repeat expansion and contraction
a)
5’ Ic a g c a g c a g c a g c a g [$ ^  
J  11 111111.111111 
3- IGTCGTCGTCGTCGTC
b)
5' ICTGCTGCTGCTGCTG
I I I I I 1 I I 1 I 11
3’ iGACGACGACGACGAC
a) Deletion event in the newly 
synthesized lagging strand, due 
to a stable hairpin loop 
structure in the template strand
b) Expansion event due to a 
hairpin loop structure in the 
newly synthesized lagging 
strand
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Figure 27 Palindromes and hairpins and inverted repeats (adapted from Bzymek and 
Lovett 2001)
a) AGTGC GATTG 3’ACTAAT ATTAGT
inverted repeat
g t g
5’ GGCTG GATTG 3’
hairpin structure
b)
3’ CCGAC
ACTAAT AGTGC ATTAGT
a t  lit? TTTnrr
TGATTA TCACG TAATCA
X I
g t g
CTAAC 5’
cruciform structure
lATTG 3’
CCGAC CTAAC 5’
T G 
C C 
A
This model provides a mechanistic explanation for both deletion and insertion events. 
Exonucleolytic removal of unpaired bases in region B followed by DNA repair synthesis 
templated by region A (rather than region B on the complementary strand) would lead to 
deletion of the unpaired bases (Figure 24). Removal of region A and subsequent DNA repair
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synthesis is templated by region B (rather than region A on the complementary strand) would 
result in insertion of the mispaired nucleotides (Figure 25, region A). These events may not 
only be limited to enzymatic repair, but slipped mispairing could potentially also be involved 
during DNA replication. If, during DNA replication, the primer strand dissociates from the 
template, a hairpin structure could form and subsequent extension would lead to a mutation. 
Replication slipped mispairing on the lagging strand could also form after stalling at a hairpin 
and subsequent misalignment at a direct repeat nearby. Perfect hairpin DNA structures placed 
between direct repeats increase the deletion rate by up to fourfold when compared to tandem 
direct repeats alone (Bzymek and Lovett 2001). Furthermore, Bzymek et al. (2001) have 
shown that defects in the polymerase unit of DNA polymerase III increase the mutation rate 
mediated by inverted repeats by up to 100 times.
An alternative mechanism (i.e. "strand-switching") has been proposed which explains 
the same deletions and insertion events (Ripley 1982). The ‘strand-switching’ model shows 
that during DNA replication the displaced DNA strand (complementary to the template 
strand) could itself become a template. Thus, DNA synthesis continues, templated by the 
displaced DNA strand. Resolution or repair of the ‘branched’ DNA (Ripley 1982), could be 
accomplished by hairpin removal, and hence no mutation occurs. If quasi-palindromic 
sequences take part, or the ‘strand-switching’ occurs not exactly between the two inverted 
repeats, then deletions or insertions could result by incorrect use of template.
6.1.2.3. Mirror repeats
Sequence motifs termed ‘symmetric elements’ (mirror repeats) have also been noted 
around breakpoint ends (Krawczak and Cooper 1991). These authors proposed that these 
repeated elements could promote deletion events through an intermediate Mobius loop-like 
structure, where one DNA strand dissociates and twists through a half-turn and then re­
anneals to the complementary strand in reverse orientation (Figure 29). Possible mismatches 
in the mirror repeats could promote deletion events in a similar way to the ‘quasi- 
palindromic’ sequences described above (see 6.1.2.2). Mirror repeats could adopt 
‘intramolecular triplexes’ or a H-DNA secondary structure (Htun and Dahlberg 1988). These 
triplexes have been shown to form in vitro (Lyamichev et al. 1985) and in vivo (Kohwi et al. 
1992; Kohwi and Panchenko 1993; Lee et al. 1989; Ussery and Sinden 1993). The triplexes 
affect replication fidelity, as DNA polymerase stalls at these secondary structures. In addition 
it has been shown that they stimulate homologous recombination by bringing direct repeats 
closer together (Kohwi and Panchenko 1993; Rooney and Moore 1995). It has also been
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shown that H-DNA could induce double-strand breaks in DNA, thereby increasing genomic 
instability (mutation frequencies) by up to 20-fold (Wang and Vasquez 2004).
6.1.2.4. C/G quartets
It has been shown that closely spaced runs of Gs could adopt unusual non B-DNA 
conformations (Bacolla et al. 2001). They are commonly termed G-quartets, ‘tetraplexes’ or 
‘tetrads’ (Bacolla et al. 2001; Wells 2007). These tracts of G-quartets could be brought close 
together in a single stranded DNA and could form a four-stranded DNA secondary structure 
(Figure 28).
Figure 28 G-quartets (modified after Wells 2007)
It has been shown that the non-B DNA secondary structures (i.e. triplexes) are responsible for 
mutagenesis rather than the sequence per se (Wells 2007; Wojciechowska et al. 2006). They 
could also bring together direct repeats that could be present on both sides of the triplex 
structure (Shukla and Roy 2006). This could potentially lead to ‘slipped mispairing’ and 
might also induce homologous recombination between the direct repeats (Shukla and Roy 
2006). In addition, these unusual structures could be recognized by nucleotide excision 
repair, causing double-strand breaks and replication fork collapse. Nucleotide excision repair 
enzymes recognize distortions in the DNA duplex and also chemical modification of single­
stranded DNA (Luo et al. 2000). This would also result in recognition and removal of 
secondary DNA structures and subsequent repair of the gaps by the mismatch repair pathway
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(Wells et al. 2005). It has been shown that repair of these gaps by the mismatch repair 
pathway could lead to deletions in triplet repeat sequences (Jaworski et al. 1995).
Figure 29 Mobius loop-like DNA structure (modified after Cooper and Krawczak 1993)
6.I.2 .5 . R uns of identical nucleotides
Studies have shown that runs of identical nucleotides are a major factor contributing 
to endogenous mutagenesis (Ball et al. 2005; Cooper and Krawczak 1993; Greenblatt et al. 
1996; Kondrashov and Rogozin 2004). The ‘slipped mispairing’ mechanism has been 
proposed to explain why these monotonic sequences are mutagenic (see ‘slipped mispairing’ 
mechanism in direct repeats, 6.1.2.1). It has been noted that runs of identical nucleotides are 
mostly involved in small deletions and insertions (l-2bp). Monotonic runs of 2-5bp account 
for 83% of all lbp deletions and insertions (Greenblatt et al. 1996). In another study, a 
considerable proportion (59/84; -1 frameshifts) were found to occur within monotonic 
sequences (Cooper and Krawczak 1993).
6.1.3. Exogenous m echanism s o f m utagenesis
The human genome is constant subject to a variety of modifying agents (mutagens or 
toxins; Hagan and Sharrocks 2002). These include oxidation (e.g. reactive oxygen species), 
radiation (e.g. UV light, gamma and X rays), a plethora of chemicals (e.g. nitrosamines, 
aromatic amides, polycyclic hydrocarbons, etc.) and food toxins (i.e. aphlatoxin Bl; Pineau et 
al. 2008), to name a few. These mutagens have an enormous impact on the integrity of the 
DNA. Reactive oxygen species, as a result of normal metabolic processes and numerous 
external sources (Bertram and Hass 2008), could directly attack DNA thereby generating a 
variety of mutagenic lesions; including oxidized bases, abasic sites, single-strand breaks 
(SSBs) and double-strand-breaks (DSBs; Breen and Murphy 1995; Sankaranarayanan and 
Wassom 2005). Ionizing radiation could also produce reactive oxygen species as well as 
directly induce SSBs, DSBs, DNA-DNA and DNA-protein links (Sankaranarayanan and
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Wassom 2005). A variety of repair mechanisms are involved in the repair process of DNA 
lesions. These include homologous recombination (HR) and non-homologous recombination 
repair pathways to repair DSBs (Haber 2000; Jackson 2002; Takata et al. 1998). Non- 
homologous recombination repair, also known as non-homologous end joining (NHEJ), is the 
mechanism predominantly involved in DSB repair (Honma et al. 2003). NHEJ requires a 
short sequence (1-1 Obp) or no sequence homology at all (Critchlow and Jackson 1998; 
Pfeiffer et al. 2000; Tsukamoto and Ikeda 1998).
In addition, special DNA polymerases could bypass DNA lesions (‘translesion 
synthesis’) that block and stall DNA replication (Pages and Fuchs 2002). The repair 
mechanisms involved in the repair of mutagenic lesions are efficient, but also error-prone. 
Nucleotides are often lost, when broken DNA ends are modified in order to be joined by the 
NHEJ repair mechanism (Ferguson and Alt 2001; Lieber et al. 2003; Pfeiffer et al. 2000). 
‘Translesion synthesis’ could potentially lead to ffameshift mutations (Pages and Fuchs 
2002). Figure 30 depicts the steps involved in ‘translesion synthesis’ and its potential to 
introduce ffameshift mutations. The mechanism mainly comprises two steps: insertion and 
extension. When the DNA polymerase encounters an unusual base (e.g. abasic site, 8-oxo- 
guanine, B(a)P-N2-dG, dG-C8-AAF, dG-C8-AF, dG-NyAFBl, etc.), it will experience 
difficulty in finding a complementary deoxyrbonucleotide (dNTP) to incorporate. Thus, 
addition of an incorrect nucleotide is not uncommon. Moreover, if the neighbouring 
nucleotide on the opposite strand is complementary to the incorrectly added one, slippage 
may occur resulting in a -1 ffameshift mutation (deletion of lbp; Pages and Fuchs 2002).
6.1.4. Exogenous versus endogenous mechanisms of mutagenesis
The distinction between the action of environmental agents and an endogenous cause 
of DNA damage may not be so clear. In particular, some exogenous mutagens could induce 
slippage mutations in tetranucleotide repeats; thus, some sporadic mutations might reflect 
DNA damage caused by carcinogens (Slebos et al. 2002). Also the introduction of abasic 
sites in triplet-repeat tracts or the presence of mutagens (e.g. mitomycin C, 
cyclophosphamide and radiation) induces a higher rate with respect to triplet-repeat 
expansion (Lyons-Darden and Topal 1999; Pineiro et al. 2003; Zhang et al. 2002). In 
addition, similarities have been noted between radiation-induced mutations and spontaneous 
mutation slippage (Niwa 2006).
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Figure 30 ‘Translesion synthesis’ mechanism and its potential capacity to introduce 
frameshift mutations (after Pages and Fuchs 2002)
B iu  substitution
error free
6.1.5. Som atic and  germ line m uta tions in tu m o u r-su p p resso r genes
It is evident that endogenous mechanisms and various mutagens from endogenous or 
exogenous sources operate to influence the mutation spectra {viz. micro-deletions, micro­
insertions and micro-indels). It has also been shown that mutational spectra resulting from the 
action of environmental mutagens can exhibit marked similarities with mutation spectra 
considered to be caused by endogenous mechanisms (Lyons-Darden and Topal 1999; Pineiro 
et al. 2003; Slebos et al. 2002; Zhang et al. 2002). Therefore, mutations could be caused by 
endogenous mutational mechanisms and exogenous mutagens with or without the interaction 
between them.
Mutations associated with the malignant transformation of normal cells could arise 
somatically or be inherited through the germline (Marshall et al. 1997). Germline mutations 
are generally meiotic in nature, whereas somatic mutations occur predominantly during 
mitosis. Despite the difference of origin, they often both exhibit similar repeat instability 
(Sturzeneker et al. 2000; Tijsterman et al. 2002) as well as a similar frequency of 
homozygosity (Assie et al. 2008). In response to ionizing radiation, both the germline and the 
soma show similar damage rates (Vilenchik and Knudson 2000). In addition, a review by 
Erickson (2003) suggests that mutations in genes other than cancer-associated genes might
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exhibit frequencies similar in the germline and the soma. Then again, it has been shown that 
the germline exhibits extreme minisatellite instability, whereas this mutational mechanism is 
rare in the soma (Buard et al. 2000). Also, there might be a direct relationship between the 
first (i.e. germline) hit and the second (somatic) hit. This relationship could be expressed in 
terms of the position of the germline hit influencing the position of the second, somatic, hit 
(Tijsterman et al. 2002).
It is quite surprising that relatively few studies have sought to compare the germline 
and somatic mutational spectra associated with micro-lesions (viz. micro-deletions, micro­
insertions and micro-indels). When they have been performed, similarities but also 
differences in their relative frequency of occurrence and putative mechanisms have been 
found. In a meta-analysis, Marshall et al. (1997) found many more somatic lbp deletions 
(22.3%) as compared to the germline (5.7%). This notwithstanding, no difference was found 
in any other group of mutations (i.e. insertions and deletions >2bp). Marshall et al. (1997) 
explored this question further by suggesting that the differences might be due to exposure to 
different environmental mutagens or differences in efficiency of DNA repair enzymes. 
Nevertheless, remarkable similarities shared between the soma and the germline have been 
shown in terms of micro-indels (Gonzalez et al. 2007), suggesting the predominant role of 
endogenous mechanisms operating to influence both the germline and somatic occurrence of 
micro-indels (i.e. strand switching and slippage caused by translesion DNA synthesis 
polymerases).
Clearly the mutational spectrum associated with the neoplastic transformation of 
normal cells is likely to be a consequence of both endogenous mechanisms and exogenous 
mutagens. Studying putative mechanisms underlying somatic and germline mutational 
spectra are thus extremely important since it could lead not only to earlier diagnosis but also 
to a better understanding of mechanisms underlying tumour progression. In addition, any 
similarities or differences in the germline and somatic mutational spectra could shed new 
light on the relative importance of exogenous and endogenous mutagenesis.
6.1.6. Aims of the analysis
The first and most important question addressed in this analysis is the involvement of 
repetitive elements in the process of mutagenesis in the 17 human tumour suppressor genes 
studied. The main objective of the analysis was to explore any similarities or differences that 
somatic and germline micro-lesions (viz. micro-deletions, micro-insertions and micro-indels)
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might exhibit with respect to their occurrence in repetitive elements. To accomplish this 
objective, a number of tasks were performed.
* Analysis of the repetitivity of the studied tumour suppressor genes 
Repetitive elements, the most commonly implicated in the process of endogenous 
mutagenesis were sought in the extended cDNA sequences of the studied genes. These 
repetitive elements included repeats (i.e. direct, inverted and mirror), C/G quartets and runs 
of identical nucleotides (RINS).
* Assessment of the probability of finding micro-lesions in the vicinity of repetitive 
elements by chance alone.
Observed micro-lesions for each gene were subdivided into three categories. These included: 
exclusively somatic (only found in the soma); exclusively germline (only found in the 
germline); shared (found in both the soma and the germline). For each of these categories, a 
spectrum of micro-lesions was simulated. This simulated spectrum was used to assess the 
distribution of micro-lesions with respect to their occurrence in repetitive sequence elements 
in randomly selected mutations. In addition, to assess the overall distribution of micro-lesions 
(i.e. micro-lesions in all genes) with respect to their occurrence in repetitive elements, within 
each category, the micro-lesions were combined for all genes.
* Explore the similarities and differences of somatic and germline micro-lesions 
with respect to their occurrence in repetitive elements.
For each gene, the proportions of micro-lesions found in the vicinity of repetitive elements 
were compared between the soma and the germline. In addition, for each gene the shared 
micro-lesions were compared separately to the somatic and germline micro-lesions with 
respect to the positions of repetitive elements.
These analyses were designed to provide meaningful answers to the following questions:
Are there more observed mutations (viz. somatic, germline and shared; combination of 
somatic, germline and shared micro-lesions for each gene and all genes) found in the 
vicinity of repetitive elements, than would be expected by chance alone?
How do observed mutations (viz. somatic germline and shared) compare with each other with 
respect to their occurrence in the vicinity of repeats?
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6.2. Materials and Methods
6.2.1. Materials
6.2.1.1. Labelling of micro-lesions
For detailed description of labelling of mutations, see 3.3. A summary of the studied 
micro-lesions is shown in Table 44.
Micro-deletions were defined by the positions of two breakpoints in the gene 
sequence and deleted bases between these two breakpoints (as shown in Figure 31). The 
distance D between the two breakpoints was set to ^20 base-pairs (bp) and ranged from 1- 
20bp. For each gene, the micro-deletions were assigned a label (i.e. somatic, germline and 
shared).
Figure 31 Example of a micro-deletion
Micro-insertions were defined by the position of a single breakpoint and inserted 
bases of size <20bp (ranging from 1-20), as shown in Figure 32. For the purposes of the 
analysis, the inserted bases were not taken into consideration, only the positions of the 
breakpoint.
Figure 32 Example of a micro-insertion
6.2.1.2. Micro-deletions
Size of deletion-3 bases (ATC)
5’-ACTGTGACTG ATC ACGGTGTATC -3’
nucleotide position 109 114
6.2.I.3. Micro-insertions
Size of insertion-3 bases (ATC)
5’-ACTGTGACTG ATC ACGGTGTATC-3’
nucleotide position 109 110
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6.2.1.4. Micro-indels
Micro-indels were defined by the positions of two breakpoints and inserted bases 
between the breakpoints. The lengths of both the deleted and the inserted bases were set to 
<20bp (ranging from 1-20), as shown in Figure 33. For the purposes of the analysis, the 
inserted bases were not taken into consideration, only the positions of the breakpoints.
Figure 33 Example of a micro-indel
Size of deletion- 4 bases (ATC) 
Size of insertion-1 base (G)
5’-ACTGTGACTG G ACGGTGTATC -3
nucleotide position 109 114
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6.2.2. Methods
6.2.2.1. General definitions of repetitive elements
A DNA pattern or DNA substring is a sequence of nucleotides \A, C, G ,r}  with an 
arbitrary length. Repetitive DNA sequence refers to a DNA substring or DNA pattern that is 
found multiple times (at least twice) throughout the sequence in question. Most frequent 
repetitive elements associated with mutagenesis are: repeats (viz. direct, inverted and mirror 
repeats), C/G quartets and runs of identical nucleotides (RINS).
6.2.2.1.1. Repeats
Repeats are defined by a pair of DNA substrings (5’ and 3’ parts) of length (m) and 
distance (D) between the parts of the repeats. Both parts of the repeat are found on the same 
strand of DNA. The length m of the 5’ and 3’ parts of the repeats was set to be >6bp, >7bp, 
and >8bp. The distance (D) between the 5’ and 3’ parts of the repeats was set to be <20bp 
(ranging from 0-20bp; Obp when one part of the repeat abuts the other part). In addition to the 
aforementioned sizes, the number of mutations within regions that include the repeats 
themselves and ±5bp of flanking sequences away from the repeats were also considered. 
These included >6±5bp, >7±5bp, and >8±5bp regions.
6.2.2.1.1.1. Direct repeats
A direct repeat was defined as a DNA substring or a DNA pattern that is found twice 
on the same strand of DNA with an arbitrary distance between them. A direct repeat used in 
this analysis was defined as two copies of exactly the same DNA pattern/sequence (Figure 
22a) that are found in the extended cDNA of the studied genes. When the repeats are entirely 
the same (e.g. CAGTTTA and CAGTTTA), they are said to be exact repeats. Only exact 
direct repeats were considered in this analysis. Multiple instances of exactly the same DNA 
patterns were considered as separate direct repeats (as shown in Figure 22a). Thus, each 
direct repeat consists of a pair of exactly the same DNA patterns (5’ and 3’ parts) of the same 
length (m) and distance (D) between the parts.
6.2.2.1.1.2. Inverted repeats
An inverted repeat was defined in a similar way to a direct repeat (see 6.2.2.1.1.1), 
with the exception that the second copy of the repeat (3’ part) is the reverse complement of
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the first DNA pattern or substring (5’ part; Lang 2007). Both parts of the inverted repeat are 
found on the same DNA strand (Figure 22b). Only exact inverted repeats were considered in 
this analysis (i.e. one copy of the inverted repeat is an exact reverse complement of the other; 
e.g. CAGTTA and TAACTG). Multiple instances were treated in an analogous way as 
explained in direct repeats (see 6.2.2.1.1.1). Inverted repeats that were also found to be direct 
repeats were excluded from the list of repeats. For example, an inverted repeat ATAT-ATAT 
is also a direct repeat. Thus, only the direct repeat was considered.
6.2.2.1.1.3. Mirror repeats
A mirror repeat was defined in an analogous way to a direct repeat (6.2.2.1.1.1), with 
the exception that the second copy of the repeat (3’) is a mirror reflection of the first copy 
(5’). It is said that both parts of the mirror repeat have a centre of symmetry on a single strand 
of DNA (Figure 22c; Cooper and Krawczak 1991). Only exact mirror repeats were 
considered in the analysis (i.e. one copy of the mirror repeat is an exact mirror image of the 
other copy e.g. CAGTTA and ATTGAC). Mirror repeats that were also found to be direct 
repeats were excluded from the list of repeats. For example, a mirror repeat ATATA-ATATA 
is also a direct repeat. Thus, only the direct repeat was considered.
6.2.2.1.1.4. C/G quartets
C/G-quartets (Bacolla et al. 2004) were defined using the following equation: 
Equation 5 C/G-quartets
S(3-5)N(1_5)S(3_5)Ar(1_5)S(3_5)Ar(1_5)S(3_5), where S  could be either G or C and A = {A,C,G,T}.
An example of a G-quartet is given in Figure 22d.
6.2.2.1.1.5. Runs of identical nucleotides
Runs of identical nucleotides (RINS), also known as ‘homonucleotide runs’ 
(Kondrashov and Rogozin 2004) or ‘contiguous sequence’ (Cooper and Krawczak 1993), 
were defined as non-interrupted sequence comprising the same nucleotide of length >4bp 
(e.g. AAAA, AAAAA, TTTT, etc.).
6.2.2.2. Simulation of potential micro-lesions
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The number of breakpoints differs between the 3 types of lesions (i.e. micro-deletions 
and micro-indels having 2 breakpoints and micro-insertions having 1 breakpoint). It is logical 
that micro-deletions and indels would have a slightly better chance of coinciding with 
repetitive elements than micro-insertions on the basis that micro-deletions and indels have 2 
breakpoints versus 1 breakpoint for the micro-insertions. Thus, the number of the different 
types of mutation (being micro-deletions, micro-insertions and indels) has to be known a 
priori in order to generate potential micro-lesions. By default, all positions in the cDNA 
sequence of the genes could serve as breakpoints of mutations {viz. micro-deletions, micro­
insertions and micro-indels). The distance between the breakpoints in accordance with the 
already collected micro-lesions, could be l-20bp for micro-deletions and micro-indels and 
Obp for micro-insertions.
Some breakpoints could extend into the introns of the genes; thus, the leftmost or 
rightmost positions for a mutational breakpoint in the introns must be determined.
In order to calculate the leftmost or rightmost positions that a mutational breakpoint could 
extend into an intron, the most extreme case possible must be considered (leftmost position; 
Figure 34).
Figure 34 An example of the most extreme case of a micro-deletion with respect to a 
mutational breakpoint in the intron (micro-deletion in lower case)
__________ 30nt____________
20nt y 10nt j
GCTTACAGTAgtgtgcgctgttcttattggATCCACAGAA_l7E8_A
v__________________^ ^
Intron
The leftmost position of a mutational breakpoint that could occur in an intron is between 
nucleotide positions 30-31 (see Figure 36). A mutation in the vicinity of a repeat is defined in 
such a way that a breakpoint of the mutation has to overlap with the repeat (the repeat itself 
or between the repeats). Thus, the furthest position that a mutational breakpoint (for micro- 
deletions and micro-indels) could extend into an intron is:
10bp DNA reference + max 20bp deletion = 30bp (breakpoint between nucleotide positions 
31-30), as shown in Figure 35 and Figure 36.
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For micro-insertions:
lObp (breakpoint between nucleotide positions 10-11)
The furthest (viz. leftmost and rightmost) positions where breakpoints of micro-deletions and 
micro-indels could extend into an intron could be split into two case scenarios:
An exon followed by an intron:
In this case, the first breakpoint could potentially occur anywhere in the exon and the first 10 
nucleotides into the intron (breakpoint between nucleotides 10 and 11, Figure 35). The 
second breakpoint (towards the 3’ end of the gene with respect to the first breakpoint) could 
potentially occur up to 30bp in the intron (breakpoint between nucleotides 30 and 31, Figure 
35). The distance between these breakpoints is set to range from 1-20 nucleotides.
Figure 35 Potential breakpoints in micro-deletions and micro-indels (an exon followed 
by an intron)
distance between the breakpoints ranging form 1-20bp
Intron 1
Exon 1
utmost position of the second breakpoint
utmost position of the first breakpoint
breakpoint breakpoint
An intron followed by an exon:
In this case, the first breakpoint could occur anywhere in the exon and the first lOnt of the 
intron (counting from the beginning of the exon into the intron). The leftmost position of the 
second breakpoint (towards the 5’ end of the gene with respect to the first breakpoint) is the 
30th nt (breakpoint between nucleotide positions 30-31) with a distance from the first 
breakpoint ranging from 1-20 nucleotides (as shown in Figure 36).
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Figure 36 Potential breakpoints in micro-deletions and micro-indels (an intron followed 
by an exon)
Intron 1
>
distance be tween the breakpoints ranging form 1 - 9 n ----------- -----------------------------------
utmost position of the second breakpoint
utmost position of the first breakpoint ^  ~ ~ ► ----------------------------rr—-------------------- —-------< ------------------------- ► /
Exon 2
31 30 11 10 1
breakpoint breakpoint
For micro-insertions, the furthest (leftmost or rightmost) position into an intron where a 
breakpoint could potentially occur is between nucleotides 10-11, counting from the end of an 
exon into an intron and between nucleotides 10-11, counting from the beginning of an exon 
into the intron to account for the end of the intron (Figure 37).
Figure 37 Potential breakpoints in micro-insertions
Intron 1
Exon 2Exon 1
10bp, counting from end of 
Exon 1 into the intron
10bp, counting from beginning 
of Exon 2 into the intron
V '
any position between 2 nucleotides in 
this interval could be a potential 
breakpoint
J
---------------,' V ' --------------
any position between 2 nucleotides in 
this interval could be a  potential 
breakpoint
Micro-insertions - 0 bases (by default, micro-insertions have only one breakpoint, hence the 
distance between the breakpoints is 0 bases).
6.2.2.3. Generation of extended cDNA sequences
As described in 6.2.2.2, the leftmost or rightmost breakpoint positions that a potential 
micro-lesion could extend into an intron is between nucleotides 30 and 31. Thus, the 
extended cDNA sequence needed for each intron is:
Equation 6 Extended cDNA sequence
REF{l0bp) + max(del) + Rl + max(D) + /^  -  65bp,
where REF is lObp DNA reference, max(del) is the maximum length of the sequence 
deleted, is the size of the first part of the repeat (7bp, allowing for lbp overlap), max(D)
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is the maximum distance in the repeat (20bp), It, is the size of the second part of the repeat 
(8bp).
The actual size of the repeat could be bigger than the size found by the above formula, 
as one part of the repeat could abut the other. Thus, the actual combined size of both parts of 
the repeat could not extend more than 65bp + 20bp (no distance in the repeat). Thus, the 
extended cDNA sequence needed for each intron is 65+20=85bp. These 85bp of intronic 
sequence would also cover runs of identical nucleotides (defined as >4bp) and C/G quartets 
(maximum size of C/G quartets is 35bp, see Equation 5).
Generation of extended cDNA sequences is described in 3.4.
6.2.2.4. Generation of simulated spectra
In order to find out how many micro-lesions would be found in the vicinity of 
repetitive elements by chance alone, simulated spectra were used. I devised a computer 
program that automatically generates simulated spectra. For each gene, the number of micro­
deletions, micro-insertions and indels were counted. Since the sizes of deleted bases in micro­
deletions and indels are not uniformly distributed (as shown in Figure 39 - many more 
mutations are found with small lengths of deleted bases), the lengths of deleted bases could 
not be randomly chosen (i.e. simulate uniform distribution of lengths of deleted bases). 
Therefore for each gene, the distribution of lengths of deleted bases was assessed. The 
numbers of mutations within each size category of deleted bases (e.g. lbp, 2bp, 3bp, up to the 
maximum size of the deleted bases) were counted and this represented the distribution of 
deleted bases. This distribution was used for choosing the size of the deleted bases for the 
generation of the simulated spectra. For each gene, on the basis of the number of mutations in 
each mutation category (i.e. somatic, germline and shared) and the distribution of sizes of 
deleted bases, mutational spectra were simulated. Thus, the positions of micro-lesions were 
chosen completely randomly and the distribution of sizes of deleted bases followed the 
distribution of the original micro-lesion spectra (for a flow chart, see Figure 38). This process 
of generating micro-lesion spectra was repeated 10,000 times as described above (i.e. 10,000 
simulations). After each simulation, the number of mutations that occur either in repeats or in 
the vicinity of repetitive elements (as described above) was counted. After 10,000 
simulations, the average number of mutations that occur either in the repeats or in the vicinity 
of the repetitive elements was calculated. These numbers were used to compare the observed 
number of mutations in the vicinity of repetitive elements with simulated spectra. In fact, the
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simulated spectra represent the number of mutations that would be found in the vicinity of 
repetitive elements if there were no association between micro-lesions and repetitive 
elements (i.e. that expected by chance alone).
Figure 38 Example of the process of generating simulated spectra
T ype m icro­
le s io n s
M icro-d eletion s  
and m icro -in d els
M icro-
insertions
D istribution  o f  s iz e s  o f  deleted  bases  
(m icro -d e le tio n s an indels)
Ibp) 1 2 3 4 5
Somatic 10 5 7 1 0 1 1
Gcrmlinc IS 7 10 4 1 0 0
Shared 4 1 3 0 0 1 0
Observed 29 13 20 5 1 2 1
R andom ly ch o o se  the p osition s o f  the 
m icro-lesion s; c h o o se  lengths o f  
d eleted  b ases accord in g  to the observed  
distribution o f  d eleted  bases
T ype m icro­
les io n s
M icro-d eletion s  
and m icro -in d els
M icro­
insertions
D istribution o f  s iz e s  o f  deleted  bases  
(m icro -d e le tio n s an indels)
(bp) 1 2 3 4 5
Somatic 10 5 7 1 0 1 1
(icrmlinc 15 7 10 4 1 0 0
Shared 4 1 3 0 0 1 0
Observed 29 13 20 5 1 2 1
Count the number of micro-lesion* in the 
vicinity of repetitive dementi.
Repeat 10,000 tiroes
Calculate average number o f micro-lesions in the 
vicinity of repetitive dements
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Figure 39 Distribution of lengths of micro-lesions (micro-deletions and indels)
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6.2.2.5. S earch  fo r repetitive  elem ents in the extended cDNA
6.2.2.5.I. R epeats
A novel algorithm to search for repeats was devised. The algorithm consists of three 
steps: pre-processing, search for repeats of fixed length L and extension of the repeats.
6 .2 .2 .5 .I.I. P re-P rocessing
A substring, such that aiaM..Jai+l_1 of string a]a2..jaI}s  termed an oligonucleotide or /- 
gram (Shannon 1948), where a,, is a nucleotide (i.e. A,C,G or T) within the oligoneucleotide.
Thus, in a given gene sequence with a length L and a fixed size of the /-grams / ( /  ^ L), there 
are (L-/+1) /-grams. The extended cDNA sequence for each gene was used to generate all /- 
grams with a fixed size (viz. 6bp, 7bp and 8bp), as shown in Figure 40. For each gene, a tree­
like structure also known as a trie-structure (Knuth 1973) was generated from the /-grams. A 
trie structure is a tree structure that is used to store strings (e.g. /-grams). It consists of 
numbered nodes and leaves (leaf is used to denote end-nodes or arcs). Trie has one node 
called a root node. Each arc is labelled by a symbol from /-gram. If several /-grams share a 
common prefix, then there is only one path leading from the root node to the node 
corresponding to the common prefixes; /-grams are represented and stored in end-nodes or 
leaves. An example of a trie-structure is given in Figure 41. The construction of the trie- 
structure was as follows:
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Consecutively for each symbol of the /-gram starting from the root node (node 0 in 
Figure 41) for every /-gram, search the trie-structure until a mismatch is found or an end node 
is reached. The search was performed using a goto function that returns a success if a 
transition to a successive node is possible or a failure if no transition is possible. If no 
transition is possible, then a new arc labelled with the current symbol from the current node is 
created. Alternatively, if an end node is reached, the output function is updated with the 
number of the /-gram and positions of their occurrence. I devised a computer program that 
takes the extended cDNA sequence as well as the mapping file associated with the extended 
cDNA (both described in 6.2.2.3) and consecutively for all extended exons (85bp intronic 
sequence + exonic sequence + 85bp intronic sequence), generates the trie-based structure.
The computer program was constructed in such a way that only three parameters are needed: 
extended cDNA, mapping file and size of the /-grams. Thus, for each gene, trie-based 
structures were generated (size of /-grams 6bp, 7bp and 8bp). A combination of an array and 
a hash was used to implement the trie-based structure. The array indices comprised the 
numbers of the nodes in the trie structure and each element in the array pointing to a hash 
comprising DNA symbols (A, C, G and T). The transition from a node to node (goto 
function) was implemented by assigning a pointer for each DNA symbol in the hash to an 
index in the array. The output function was implemented by using a hash. The keys in the 
hash represented the end nodes. Each number of end node (keys in the hash) pointed to an 
array with the positions of /-grams in the extended cDNA sequence
Figure 40 Example of generation of /-grams with a size 4bp and a sliding window of lbp
C’TjCTfcAlTGGATCTGATGGG
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Figure 41 Example of a trie-based structure
root node nodes end nodes output function
Sequence:
3GATCTGATGGG
/-grams: 1---------- CTC'I 2---------- TCTG 3-----------CTGA 4-----------TGAT 5-----------GATG 6---------- ATGG 7---------- TGGA 8-----------GGAT 9-----------GATC
1 0-------- ATCT
1 1-------- TCTG
1 2-------- CTGA
1 3-------- TGAT
1 4---------GATG
1 5-------- ATGG
1 6-------- TGGG
.........
--------------^  /-grams: 3 ,1 2
o
Transitions
using goto 
function
-►I /-grams: 2, 11
/-grams: 4 ,1 3
►I /-grams
^ 0 —  -►| /-grams: 16
-►{ /-grams: 5. 14
/-grams: 9
^   H  /-grams:~8~
►01 * 0 - - -►| /-grams: 10
6.2.2.5.2. Search  fo r rep ea ts  w ith  a fixed length L
I devised a computer program that searches the trie-based structure (as described in 
6.2.2.5.1.1) for repeats (viz. direct, inverted and mirror repeats). For each gene, it takes the 
trie-based structure as an input and sequentially generates a list of the positions where repeats 
are found in the extended cDNA.
6 .2 .2 .5 .2 .I.I. D irec t repea ts
Finding direct repeats from the trie-based structures is straightforward. Direct repeats 
are found where the output function for a given end node produces positions of two or more 
/-grams (as seen in Table 25 and Figure 42).
T a b le  25 D ire c t  r e p e a t s  fo u n d  a t  e n d  n o d es
P o s it io n s  o f  2 o r  m o r e  /- 
g r a m s  fo u n d  a t  a n  e n d  n o d e
G e n e  p o s i t io n s S e q u e n c e
3 3-6 CTGA12 12-15
2 2-5 TCTG11 11-14
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4 4-7 TGAT13 13-16
5 5-8 GATG14 14-17
6 6-9 ATGG15 15-18
Figure 42 Schematic representation of direct repeats found in the gene sequence
1 2 3 4 5 6 7 CD00 10 11 12 13 14 15 16 17 18 19
C T C T G A T G j G A T C T G A T G G G
Multiple instances of /-grams found at a given end node were considered as separate direct 
repeats (as described in 6.2.2.1.1.1).
6.2.2.5.2.I.2. Inverted repeats
Finding inverted repeats was performed by searching the already generated trie-based 
structure (/-gram sizes: 6bp, 7bp and 8bp) with the reverse complement of the extended 
cDNA. Thus, L-grams were generated from the reverse complement (the reverse complement 
of the extended cDNA sequence was used as an input to the trie-based structure) with sizes: 
6bp, 7bp and 8bp. The search procedure for every /-gram was as follows:
Start from the initial state (0) and /-gram i
Using the goto function, compare DNA symbols from the /-gram until a mismatch is found or 
an end node is reached.
If a mismatch is found, restart the search from the initial state (0) and /-gram i+l
If an end node is reached, output i and the positions found at the end node
Where inverted repeats were found, the actual genic position where the inverted repeat starts
and ends were calculated using the following formulae:
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Equation 7 Start position of inverted repeats 
Pm - L - K - 2 ,
where Pstart is the position where an inverted repeat starts, L is the gene size in bp and K  is the 
number of the /-gram
Equation 8 End position of inverted repeats
^end  “  &  start +  ^ ^ »
where / is the fixed minimum size of the /-grams.
The first part of the inverted repeat (5’) is the /-gram that is found at a given end node. 
Multiple instances of /-grams found at a given end node were considered as separate direct 
repeats (as described in 6.2.2.1.1.1).
6.2.2.5.2.1.3. Mirror repeats
The search for mirror repeats was performed in the same way as inverted repeats 
(described in 6.2.2.5.2.1.2), with the exception that the trie-based structure was searched 
using the reverse of the extended cDNA.
6.2.2.5.2.1.4. Extension of repeats
As shown in Figure 42, there were longer repeats than the fixed minimum size of /- 
grams exist. Thus, it was necessary to generate the longest possible repeats. I wrote a 
computer program that takes a list of repeats {viz. direct, inverted and mirror repeats) and 
generates the longest possible repeats. The program uses the following algorithm:
For /-grams found at end nodes, with a frequency >2, all possible pairs of /-grams were 
generated. These pairs of /-grams represent repeats, one /-gram the 5’ part and the other /- 
gram in the pair the 3’ part of the repeat. The so formed pairs were numerically sorted in 
ascending order by the position of the first part of the repeat. Consecutively, every pair of /- 
grams was compared with the rest of the pairs.
If P denotes the genic positions where /-grams start and end, 
thenPs -  start and PE -  e n d . If G is an /-gram pair, then Gu is the 5’ part of the repeat and 
Gj2 is the 3* part of the repeat in the /-gram pair and the positions in an /-gram pair are: 
Ps-Gih Pe-Gh, Ps.Gn and Pe-Gu(as shown in Figure 43). Let the distances D;,L>2, P>3, D4be 
as follows:
Dx -  Ps .Gn —Ps .G2i „
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D2 ^ P E-Gn Pe .G2i ,
A  ™ PS *^12 — *^22 
D< -P E &\2 ” *^ 22 *
The following rules were used for extending the length of repeats:
Form a new repeat, if the following conditions are met:
Di~ Z>3 and Df= D4 for direct repeats or
D]= \Ds\ and Dr= \D4\ for inverted and mirror repeats,
[min(Ps .G12,Ps '@22 )_ niax^/^.G^,PE.G21 )]> 0 , and
Ps- G21 > Ps- Gj] and Pe- G2 1 < Pe- Gu 
Extension of repeats:
Ps .Gn ■ m i n ^ . G u j . G 21 )
PE .Gn ■ max(P£ .Gn, PE .G21) 
PS.G12 ■ min(P5.G12,Pj.G22) 
PE 'G 2^ ■ max(P£ .G12, PE -G^ )
If a new repeat is formed:
Then, the newly formed extended repeat is added to the pool of /-gram pairs and the pair of /- 
grams that formed this repeat are deleted from the list of -/-gram pairs. Continue the 
comparisons with the newly formed extended repeat.
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Figure 43 Extension of repeats
1 2 3 I 4 5 | 6 7 | 8 9 10 11 12 13 14 15 16 | 17 18 19
c T C j T G ; A H O G A T C T G A T ; G G G
Ps ' G 11 • ---
G. Ps • G, PE ’ G 12 
 ►
P q ' G ,
Dt
PE ’ G21 
 ►
P* • G, Pe ’ G22 
 ►
D 2 * < ^
If D1= D3 and D2= D4 for direct repeats or 
D 1 - \D3\ and D2= \D4\ for inverted and mirror repeats, 
min(P§ ■ G 12, P$ 1 G 2 2 ) ~ max(P^ • G ii, Pg • G2 1 ) > 0 
and PS.G21 >PS.G 11  and PE.G21 <PE.G11
TCTGAT TCTGAT
new direct repeat derived
6.2.2.5.3. Search for C/G quartets
I designed a computer program that automatically searches the extended cDNA of 
each gene for C/G quartets. Starting from the beginning of the extended cDNA and 
sequentially for each extended exonic sequence (85bp intronic sequence around each exon 
and including the exonic sequence itself), the program finds stretches of Cs and Gs that are 
>3bp according to Equation 5. Then, if stretches of Cs and separately for Gs did not satisfy 
the criteria listed in Equation 5, they were removed from the list of C/G quartets.
6.2.2.5.4. Search for runs of identical nucleotides
In a similar fashion to that described in 6.2.2.5.3, a search for stretches of 
mononucleotides (viz. A, C, G and T) of length >4bp was performed. I designed a computer 
program that takes the extended cDNA as an input and generates the positions of all runs of 
identical nucleotides. In consecutive manner, the program reads the extended cDNA and 
records the positions and the lengths of stretches of mononucleotides.
6.2.2.6. Labelling micro-lesions with respect to their occurrence in 
repetitive elements
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Every micro-lesion (viz. micro-deletions, micro-insertions and micro-indels) in each 
gene was labelled according to their occurrence in repetitive elements. Two labels were used:
1 if there is a repetitive element in the vicinity of the micro-lesion and 0 if there is no 
repetitive element in the vicinity of the micro-lesion. I designed a computer program such 
that when supplied with a list of micro-lesions with positions of the breakpoints and a list of 
repetitive elements with their positions, it automatically assigns appropriate labels (i.e. 1 or 0 
as described above). Both lists are tab-delimited text files. The program works in an iterative 
way. Thus, for every micro-lesion, it scans the list of repeats and checks whether a mutational 
breakpoint occurs in the vicinity of a repetitive element or within repeats themselves (for 
description see 6.2.2.6.1 and 6.2.2.6.2).
6.2.2.6.1. Micro-lesions and repeats
Micro-lesions such that at least one breakpoint is found to coincide with repeats were 
labelled in the vicinity of repeats. To coincide with a repeat, a breakpoint had to overlap with 
any part of the repeat (i.e. 5’ or 3’ part) or lie in between the parts of the repeat (for repeat 
sizes of >6bp, >7bp and >8bp). In addition, for repeats ±5bp (i.e. >6±5bp, >7±5bp, >8±5bp), 
micro-lesions were considered to be in the vicinity of repeats if a mutational breakpoint is 
within 5bp of a repeat, but also including the rules for repeat sizes of >6bp, >7bp and >8bp.
6.2.2.6.2. Micro-lesions and runs of identical nucleotides
Micro-lesions were labelled in the vicinity of runs of identical nucleotides in the same 
way as described in 6.2.2.6.1. Instead of using the positions of repeats, the positions of runs 
of identical nucleotides were used. In addition, micro-lesions were considered to be in the 
vicinity of runs of identical nucleotides if a mutational breakpoint was within 5bp of a run, in 
addition to the rules for runs o f identical nucleotides.
6.2.2.7. Comparisons and statistical significance
In order to answer the questions set out in the aims of the analysis (see Section 6.1.6), 
for each group of the studied repetitive elements (viz. repeats and runs of identical 
nucleotides) the following comparisons for each gene were performed:
Soma vs. simulated micro-lesions 
Germline vs. simulated micro-lesions
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Shared vs. simulated micro-lesions
Observed (viz. somatic, germline and shared mutations) vs. simulated micro-lesions 
Soma vs. germline 
Soma vs. shared 
Germline vs. shared
For each of the tests, a x2 test statistic was calculated (see Chapter 3 (General 
methods) for description) to assess the statistical significance at the chosen significance level 
(a  -  0.05). To allow for multiple hypothesis testing for the tests performed for each gene, 
10,000 resampling permutations were performed (see Chapter 3 (General methods) for 
description) and corresponding p-value was termed permuted. To allow for multiple 
hypothesis testing, for the tests performed for all repeat/runs of identical nucleotide sizes, a 
Bonferroni correction was applied. Therefore, each permuted p-value, associated with repeats 
was multiplied by 6 (repeat-wise a  -  0.05/6 or 0.0083), to account for different repeat sizes 
(viz. repeat sizes of >6bp, >7bp, >8bp, >6±5bp, >7±5bp and >8±5bp). In addition, each 
permuted p-value, associated with RINS, was multiplied by 2 (experiment-wise a  -  0.05/2 
or 0.025), to account for the different RINS sizes (i.e. run sizes >4bp and >4±5bp). To allow 
for multiple hypothesis testing, for the tests performed for all genes, a Bonferroni correction 
was also applied. Therefore, each repeat-wise p-value was multiplied by 17 (overall
experiment-wise a  -  or 0.00049) and each run-wise p-value was multiplied by 2
(overall experiment-wise a  -  or 0.0015).
I designed a computer program that automatically performs the x2 test statistic for 
each test along with the re-sampling permutations and Bonferroni corrections.
Furthermore, the numbers of mutations in all genes were combined, only if micro­
lesions had the same label (i.e. somatic, germline, shared) to represent the combination of 
mutations in all genes. The aforementioned tests were also performed for the combination of 
mutations in all genes. Additional tests were performed for the combination of recurrent 
somatic mutations for all genes:
Somatic recurrent vs. somatic non-recurrent micro-lesions
Somatic recurrent and shared vs. somatic recurrent non-shared micro-lesions
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Somatic non-recurrent and shared vs. somatic recurrent non-shared micro-lesions Somatic 
recurrent and shared vs. somatic non-recurrent non-shared micro-lesions
The combination of micro-lesions for all genes and the comparisons performed for 
those were considered as separate from the comparisons in individual genes. Therefore, to 
allow for multiple hypotheses testing, for the tests performed for all repeat/runs of identical 
nucleotide sizes, a Bonferroni correction was applied. Therefore, each permuted p-value 
associated with repeats/RINS was multiplied by 11 (repeat-wise a  -  0.05/11 or 0.0045), to 
account for different tests (see above, the test also included the comparisons for recurrent 
micro-lesions). To allow for multiple hypothesis testing, for the different sizes of repetitive 
elements performed, a Bonferroni correction was also applied. Therefore, each repeat-wise p-
value was multiplied by 6 (overall experiment-wise a  -  or 0.00076) and each run-wise
p-value was multiplied by 2 (overall experiment-wise a  -  — or 0.0023).
11*2
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6.3. Results
6.3.1. Repetitive elements in the studied genes
6.3.1.1. Repeats
Direct, mirror and inverted repeats and C/G-quartets were sought in the extended 
cDNA sequences of the 17 human tumour suppressor genes. The sizes of the repeats were as 
follows: >6bp, >7bp and >8bp; the distance between the repeats was set to <20bp (ranging 
from 0 to 20bp). A summary of the number and type of repeats found within the specified 
parameters in the studied genes is presented in Table 26 and Table 27. In total, 3591 repeats 
of size >6bp, 1179 repeats of size >7bp, and 499 repeats of size >8bp were found in all genes. 
These results clearly show that the smaller the minimum repeat size, the more repeats are 
found (Pearson’s p=-0.95). At first glance, the number of repeats found varies between the 
genes (for repeats of size >6bp, the number ranged from 22 for the CDKN2A gene to 646 for 
the A TM  gene).
However, there is very strong correlation between the size of the genes (bp j and the 
number of repeats (repeat size >6bp p=0.97. >7bp p=0.93 and >8bp p=0.81i. These results 
show that despite the different absolute number of repeats in the different genes, the number 
of repeats relative to the gene size (bp) remains relatively similar in the different genes. In 
support of this finding, a recent study (Lawson and Zhang 2008) has revealed that the relative 
number of simple sequence repeats per sequence distance (i.e. megabase) is very similar 
between housekeeping and tissue-specific genes. It is evident that the repeats constitute a 
large proportion of the coding sequence of the genes. Repeats of size >6bp (excluding the 
distance between the two parts constituting a repeat) make up on average -23% of the total 
length of the genes (results presented in Table 28 and Table 29). With increasing repeat size, 
the proportion of the gene length made up of repeats decreases, due to the smaller number of 
repeats. In other words, smaller repeats take up a larger proportion of the genes, due to the 
relatively larger number of repeats found. Thus, repeats with a size of >7bp constitute only 
-9%, while repeats with a size of >8bp only encompass -4%  of the total length of the genes 
(Table 29).
By contrast, C and G quartets on average comprise only -0.5% of the total length of 
the genes if the distance between the quartets is excluded and —0.6% if the distance between 
the quartets is included. Despite the small proportion of the total gene length, there were 2
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genes that had substantially more C/G quartets. These were the STK11 gene with 46 C/G 
quartets (-3% of the extended cDNA sequence) and TP53 with 90 C/G quartets respectively 
(-4% of the extended cDNA sequence). For the rest of the genes, the number of C/G quartets 
ranged from 0 to 18 (TSC2 gene; ~0.77% of the extended cDNA sequence). Even though the 
C/G quartets encompass a relatively high proportion of the extended gene sequences in the 
STK11 and TPS3. none of the quartets is exonic (i.e. found in the exons of the genesT In fact, 
out of all 165 C/G quartets in all genes, only 7 were found in the exons of the genes (4.24%) 
and 6 out of those 7 exonic C/G quartets were found in the TSC2 gene (-86%).
There was no apparent correlation between repeat length and the distance between the 
repeats (as shown in Figure 44). One apparent feature of all repeat sizes and repeat types is 
the most frequent distance within the repeats, which is Obp. The two parts of these repeats 
abut each other.
6.3.I.2. Runs of identical nucleotides
In total, 2949 runs of mononucleotides of size >4bp in all genes were identified.
These mononucleotides represent -10% (ranging from 7.13% to 14.11%) of the total length 
of the genes (as shown in Table 30). Even though the number of mononucleotide runs varies 
between the different genes, there is a very strong correlation between the numbers of 
mononucleotide runs and the gene sizes in bp /Pearson’s p=0.97T These results show that 
despite the different absolute number of mononucleotide runs in the different genes, the 
number of mononucleotide runs relative to the gene size (bp) remains constant. This finding 
is similar to the uniform distribution of repeats (number of repeats relative to the gene size, 
measured in bp) in these 17 human tumour suppressor genes (see 6.3.1.1). In support, it is 
considered that4 single-amino-acid tandem repeats’ (repeated amino acids encoded by a 
single nucleotide- AAA AAA AAA) are abundant in mammalian proteins (Mularoni et al. 
2007). In addition, Mularoni et al. (2007) have shown that proteins under strong selective 
constraints (i.e. highly conserved proteins) contain surprisingly high numbers of repeats. The 
most frequent mononucleotide runs are of size 4-7bp (Figure 45) and a negative correlation 
was observed between the frequency and size of the mononucleotide runs (Pearson’s p—- 
0.471. Most frequent are runs of As and Ts. On average, for mononucleotides in all genes, 
runs of As account for 3.39% of the total gene length, whereas runs of Ts comprise 4.62%. 
On the other hand, runs of Cs and Gs are 3-4 times less frequently observed. Runs of Cs on 
average comprise 1.26% of the total gene length, whereas runs of Gs account for 1.04%.
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6.3.2. Micro-lesions and repetitive elements
6.3.2.1. Micro-lesions and repeats
The positional co-localisation or co-occurrence of micro-lesions (viz. micro-deletions, 
micro-insertions and micro-indels) and repeats (viz. direct, inverted and mirror repeats and 
C/G quartets) with varying sizes (>6bp, >7bp, >8bp, >6±5bp, >7±5bp, >8±5bp) and distance 
between comprising the repeats (ranging from 0 to 20bp) were analysed. The distribution of 
the micro-lesions with respect to their occurrence in repeats is detailed in Table 32. For all 
genes, on average ~35% of the micro-lesions were found in the vicinity of repeats of size 
>6bp. Interestingly, almost half (46.36%, Table 32) of the mutations were found to be in the 
vicinity of repeats when repeats of size >6±5bp were considered. In addition, there is an 
inverse relationship between the number of mutations and the minimum size of the repeats 
(Pearsons p=-0.97T Thus, increasing the minimum repeat size (e.g. >6bp vs. >7bp), results in 
a lower number of mutations found in the vicinity of repeats. This shows that more mutations 
are found in the vicinity of repeats when a smaller minimum repeat size is chosen.
Nevertheless, there is also a positive correlation between the number of repeats in a 
particular repeat size ranee (i.e. >6bp. >7bp and >8bp) and the number of mutations found in 
the vicinity of the repeats (Pearson’s p=0.99). This implies that the proportions of mutations 
found in the vicinity of repeats is very similar to the total number of repeats, with respect to 
different repeat sizes. In addition, as shown in 6.3.1.1, the number of repeats decreases with 
increasing minimum repeat size. Thus, mutations are found less frequently in the vicinity of 
repeats when the minimum repeat sizes are increased. Nevertheless, the number of mutations 
found in the vicinity of repeats is proportional to the number of repeats. Interestingly, the 
proportion of mutations found in the vicinity of repeats in this analysis is relatively low as 
compared to reports by other authors. Ball et al. (2005) reported that 92% of the studied 
micro-deletions and micro-insertions co-localised with different types of repeats, namely 
direct, inverted, mirror and inversions of inverted repeats. It has to be said that Ball et al. 
(2005) studied >400 genes (micro-deletions) and >300 genes (micro-insertions). Similarly, in 
another study by Cooper and Krawczak (1993), all micro-deletions were found to be flanked 
or to lie within direct repeats. It should be noted that in contrast to this analysis, these studies 
have additionally searched repeats of sizes <6bp (i.e. 2, 3, 4 and 5bp), even although Cooper 
and Krawczak (1993) reported that direct repeats of size 2 and 3bp are underrepresented.
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Thus, it could be speculated, as these repeats (i.e. <5bp) are underrepresented, that 
they might not mediate the occurrence of micro-lesions and their observation is due to chance 
occurrence. Alternatively, this particular dataset of 17 human tumour suppressor genes might 
not follow the same pattern observed in previous studies.
6.3.2.2. Micro-lesions and runs of identical nucleotides
The distribution of micro-lesions (viz. micro-deletions and micro-insertions) with 
respect to their occurrence in runs of mononucleotides was analysed. Micro-indels were 
excluded from this analysis as they are potentially mediated by different mechanisms than the 
micro-deletions and micro-insertions (Chuzhanova et al. 2003). The minimum size of the 
runs of mononucleotides was set to be >4bp. In addition, the numbers of mutations that 
occurred within regions comprising runs of mononucleotides themselves and ±5bp of 
flanking regions were also analysed. On average, -11%  (ranging from -2.9% for the VHL 
gene to -24.7% for the BRCA2 gene) of the micro-lesions (viz. micro-deletions and micro- 
insertions) were found to be in the vicinity of runs of mononucleotides (Table 43). In 
addition, when runs of mononucleotides with ±5bp of flanking regions were also considered, 
the number of micro-lesions found in the vicinity of runs of identical nucleotides increased to 
-24%  (ranging from 6.8% for the VHL gene to -40%  for the BRCA2 gene). Different types of 
micro-lesions (viz. somatic, germline and shared) for each genes were also analysed with 
respect to runs of identical nucleotides.
6.3.2.3. Somatic vs. simulated micro-lesions
For all repeat sizes, only 4 genes (CDKN2A, PTEN, TP53 and VHL) exhibited 
statistically significant results, when somatic were compared to simulated micro-lesions. A 
summary of all significant results for somatic vs. simulated micro-lesions is presented in 
Table 34. There were many more somatic mutations (proportions of mutations found within 
or in the vicinity of repeats ranged from -44%  to -67%) found in the vicinity of repeats 
(repeat sizes of >6bp, >7bp, >6±5bp and >7±5bp) for the CDKN2A gene, when compared to 
simulated (proportions of simulated mutations found within or in the vicinity of repeats 
ranged from -23%  to -37%) micro-lesions ( pG ranged from 0.048 to 0.0012; pE= 0.02 for 
repeat size >6±5bp). The PTEN gene only showed significantly more somatic micro-lesions 
in the vicinity of repeats for repeat size >6±5bp ( pG =0.0096), with 54% and 36% for the 
somatic and simulated micro-lesions respectively. Interestingly, the TP53 and VHL genes
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exhibited a significantly lower number of somatic mutations (~13% and -3%  found in the 
vicinity of repeats for the TP53 and VHL respectively) in the vicinity of repeats (repeat size 
>7±5bp for both genes, pG =0.0096 and 0.0114 for TP53 and VHL respectively), as compared 
to simulated mutations (-20% and -13%  found in the vicinity of repeats for the TP53 and 
VHL respectively).
Nevertheless, significantly more somatic mutations were found in the vicinity of 
repeats when somatic mutations were combined for all genes and compared to the simulated 
spectra ( p£=0.035 for repeat size of >6±5bp), with -45%  and 39% of the somatic and 
simulated micro-lesions found in the vicinity of repeats respectively. It is of note that only the 
repeat size of >6±5bp exhibited a significant result. In addition, none of the remainder of the 
comparisons had enough statistical power to detect an experiment-wise significant result.
Additionally, the somatic micro-lesions in the A PC, NF2, PTEN, TP53 and VHL 
genes comprised -86%  of all somatic mutations in all genes, with the somatic mutations in 
the TP53 representing -44%  of the somatic mutations in all genes. Therefore, it is evident 
that there is a strong association of somatic micro-lesions and repeats in some genes (i.e. APC 
and CDKN2A). but for others (i.e. TP53 and VHP  micro-lesions were less likely to be found 
in repeats than simulated mutations.
With respect to RINS, only the APC gene exhibited statistically significant result 
(RINS size >4±5bp; pG =0.0158). Significantly more somatic micro-lesions (-40%) were 
noted in the vicinity of RINS, when compared to simulated mutations (-24%).
Therefore, these results suggest that in the case of somatic mutations the involvement 
of repeats is much more significant than runs of identical nucleotides.
6.3.2.4. Germline vs. simulated micro-lesions
Only the BRCA2 gene exhibited a statistically significant result (repeat size >6±5bp, 
pE=0.0204). Many more germline mutations (-56%) were found in the vicinity of repeats 
than simulated mutations (-42%). A summary of all significant results for germline vs. 
simulated micro-lesions is presented in Table 35. As with the somatic mutations, the germline 
micro-lesions combined for all genes exhibited many more mutations (-48%) in the vicinity 
of repeats (repeat size >6±5bp; pE =0.00000005) than simulated mutations (-39%).
Furthermore, the germline micro-lesions in the APC, BRCA1, BRCA2 and NF1 genes 
comprised -60%  of all germline micro-lesions. As a result, it is likely that germline micro­
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lesions are strongly associated with repeats, not only in the BRCA2 gene, but quite possibly to 
some degree in others, such as APC . BRCA1 and NF1.
The BRCA1 and BRCA2 genes showed significantly more germline micro-lesions 
(-24% for RINS size in BRCA1 >4bp; -35%  and —44% for RINS sizes >4bp and >4±5bp in 
the BRCA2) found both within and in the vicinity of RINS ( /?c=0.0206 RINS size >4±5bp 
BRCA1 gene; pG= 0.013 and pG=0.0072 for the BRCA2 gene for RINS sizes >4bp and 
>4±5bp respectively), as compared to simulated micro-lesions (-14% and for RINS size in 
BRCA1 >4bp; -24%  and -32%  for RINS sizes >4bp and >4±5bp n the BRCA2). Furthermore, 
the combination of germline micro-lesions for all genes showed significantly more micro­
lesions (-12% and -29%  for RINS sizes >4bp and >4±5bp respectively) found in the vicinity 
of RINS ( pc =0.0474 and pE=0.000031 for RINS sizes >4bp and >4±5bp respectively), as 
compared to simulated micro-lesions (-10% and -24%  for RINS sizes >4bp and >4±5bp 
respectively). Therefore. RINS are very likely to plav a significant role in the positional 
occurrence of germline micro-lesions in at least two genes (i.e. BRCA1 and BRCA2). but they 
are also likely to plav some part in other genes as well.
6.3.2.5. Shared vs. simulated micro-lesions
With respect to repeats, no statistically significant difference was noted in any of the 
tests performed, although none of the comparisons had enough statistical power. It is very 
likely that lack of power was due to the paucity of shared mutations. Indeed, on average, 
shared mutations comprised only -1.8% of the observed micro-lesions (viz. somatic, 
germline and shared).
No individual gene exhibited a significant difference between the proportions of 
shared and simulated micro-lesions, with respect to occurrence within or in the vicinity of 
RINS. It should be noted that there was not enough statistical power for any of the 
comparisons performed, with respect to RINS. Nevertheless, the combination of shared 
micro-lesions for all genes exhibited significantly ( p E=0.0223) more micro-lesions within 
RINS (-27%) as compared to simulated mutations (-7%). A summary of significant results 
for shared vs. simulated micro-lesions is presented in Table 36.
Thus, it mav be concluded that the positional occurrence of shared micro-lesions is 
significantly influenced bv runs of mononucleotides.
6.3.2.6. Somatic vs. germline micro-lesions
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Only the APC  gene exhibited a statistically significant result, when somatic were 
compared to germline micro-lesions. Significantly more somatic micro-lesions ( p E=0.0102 
and pG =0.0088 for RINS sizes >4bp and >4±5bp respectively) were noted within or in the 
vicinity of RINS (~19% and —40% for RINS sizes >4bp and >4±5bp respectively) as 
compared to germline micro-lesions (-8% and -26%  for RINS sizes >4bp and >4±5bp 
respectively). A summary of all significant results for somatic vs. germline micro-lesions is 
presented in Table 38.
Interestingly, the combination of germline micro-lesions for all genes was 
significantly ( pE =0.00162) more likely to be found in the vicinity of RINS (-24%), than 
somatic micro-lesions (-30%).
Thus, it is evident that relatively more somatic mutations are found in the vicinity of 
RINS in comparison to germline micro-lesions for the APC gene. This notwithstanding, 
relatively more germline micro-lesions (i.e. the combination of germline micro-lesions for all 
genes) were found in the vicinity of RINS as compared to somatic micro-lesions. This result 
suggests that the difference in the distribution of mutations with respect to positions of RINS 
in the germline and in the soma may be widespread across a number of genes.
6.3.2.7. Somatic vs. shared micro-lesions
The TP53 gene showed significantly more shared mutations (-50% and -58% for 
RINS of sizes >4bp and >4±5bp respectively) found in the vicinity of RINS (RINS size >4bp 
pE =0.0102 and RINS >4±5bp pG =0.0416) as compared to somatic micro-lesions (-8%  and 
-24%  for RINS of sizes >4bp and >4±5bp respectively). A summary of all significant results 
for somatic vs. shared micro-lesions is presented in Table 39.
Furthermore, the combination of shared micro-lesions showed significantly 
( pE=0.0000572 and pG=0.0471 for RINS of sizes >4bp and >4±5bp respectively) more 
mutations (-27%  and -39%  for RINS of sizes >4bp and >4±5bp respectively) found in the 
vicinity of RINS than somatic micro-lesions (-10%  and -24%  for RINS of sizes >4bp and 
>4±5bp respectively).
Thus, the shared mutations are much more likely to be found in the vicinity of RINS than the 
somatic micro-lesions in all genes and in particular the TP53 gene.
6.3.2.8. Germline vs. shared micro-lesions
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The NF1 gene showed significantly more shared mutations (-67%) found in the 
vicinity of RINS of size >4bp ( pc =0.0238) as compared to somatic micro-lesions (-7%). 
Furthermore, the combination of shared micro-lesions showed significantly (p E=0.0049) 
more mutations (-27%) found in the vicinity of RINS of size >4bp than somatic micro­
lesions (-12%). A summary of all significant results for germline vs. shared micro-lesions is 
presented in Table 40.
Thus, the shared mutations are much more likely to be found in the vicinity of RINS 
than the germline micro-lesions in all genes and in particular the NF1 gene.
6.3.2.9. Recurrent somatic micro-lesions
The combination of recurrent somatic micro-lesions for all genes exhibited a 
significantly higher number (-14%) of micro-lesions found in RINS of size >4bp 
( pc=0.0393), as compared to non-recurrent somatic micro-lesions (-9%).
Furthermore, the combination of somatic recurrent and shared micro-lesions for all genes 
showed many more mutations (-29%) found in RINS of size >4bp (p G =0.0361) than somatic 
non-recurrent and non-shared micro-lesions (-9%). A summary of significant results for 
recurrent somatic micro-lesions is presented in Table 41.
Therefore, somatic micro-lesions recur in runs of identical nucleotides, but those are 
also shared between the germline and the soma.
6.3.2.10. Observed vs. simulated
The results for the combination of micro-lesions in the individual 17 genes were very 
much dependent on the number of somatic, germline and shared mutations. Thus, the 
mutational spectra in these genes could be separated into several groups: predominantly 
somatic micro-lesions (CDKN2A, NF2, PTEN, TP53 and VHL); predominantly germline 
micro-lesions (.APC, ATM, BRCA1, BRCA2, NF1, PTCH, RBI, STKJJ, TSC1, TSC2 and 
WT1); similar proportions of somatic and germline micro-lesions (CDH1). The results for the 
combination of observed micro-lesions exhibited very similar patterns (e.g. direction of 
results and statistical significance) to the comparisons of the largest proportion of mutations 
in the individual genes. A summary of all significant results for observed vs. simulated 
micro-lesions is presented in Table 37.
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6.4. Discussion
Numerous studies have reported the non-random occurrence of mutations. Indeed, 
sequence context has been shown to influence the specificity of insertions and deletions 
(Kunkel 1990; Ripley 1990). In addition, various studies have shown the relative importance 
of repetitive elements in the process of mediating endogenous mechanisms of mutagenesis 
(Ball et al. 2005; Chuzhanova et al. 2003; Cooper and Krawczak 1993; Greenblatt et al.
1996; Kondrashov and Rogozin 2004). The analysis in this chapter was designed to 
investigate the contribution of the local sequence environment (i.e. repetitive elements) in 17 
human tumour suppressor genes to the associated micro-lesion spectra in the germline and 
the soma.
The extended cDNA sequences of the genes were searched for repetitive elements. 
This was accomplished by using a custom built novel computer algorithm. It allowed the 
identification and localisation of various types of repetitive element. These repetitive 
elements included direct repeats; inverted repeats; mirror repeats; C/G-quartets; and runs of 
identical nucleotides (RINS). The sizes of the repeats were >6bp, >7bp, >8bp, >6±5bp, 
>7±5bp, >8±5bp (maximum distance within the repeat <20bp) and the sizes of the runs of 
identical nucleotides were >4bp and >4±5bp. The repeats and runs of identical nucleotides 
were analysed separately so as to avoid overlap, but also to allow recognition of potential 
differences. The analysis showed that on average -23%  of the studied genes comprise repeats 
(repeat size >6bp). On the other hand, runs of identical nucleotides on average comprise 
-10%  of the total length (bp) of the studied tumour suppressor genes. These results are 
broadly consistent with those of a previous study which showed that -9%  of >22000 human 
genes studied comprise simple sequence repeats (di-, tetra-, penta-simple sequence repeats of 
<8 repeated units; Loire et al. 2009). Thus, the repetitive elements examined comprise a 
relatively large proportion of the studied genes. The analysis shows that the abundance of 
repetitive elements is related to gene size. Thus, the bigger the gene, the more repetitive 
elements it should have, but the relative length of the repetitive elements, with respect to 
individual gene sizes, is relatively similar between the different genes (-23% for repeats of 
size >6bp, ranging from -17%  for the NF2 gene to -26%  for the TP53 gene; —10% for runs 
of identical nucleotides >4bp, ranging from -5%  for the VHL gene to -14%  for the PTEN 
gene). Micro-lesions were analysed with respect to the positions of the repetitive elements.
An initial exploratory analysis revealed that a relatively large proportion of the micro-lesions 
could be accounted for by repetitive elements. It was discovered that on average for all genes,
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-35%  of micro-lesions are found in the vicinity of repeats (repeat size >6bp), whereas a much 
smaller proportion of the micro-lesions was accounted for by runs of identical nucleotides 
(-11%). These proportions increased considerably when micro-lesions were analysed ±5bp 
away from repeats and runs of identical nucleotides (-46 and -24%  for the repeats and runs 
of identical nucleotides respectively). In contrast to other studies, the proportions of micro­
lesions found in the vicinity of repeats in this study, appear relatively small. Ball et al. (2005) 
reported that 92% of all studied micro-deletions and micro-insertions could be accounted for 
by various types of repeats. It has to be noted however that Ball et al. studied >300 genes. 
Therefore, it is likely that a smaller proportion of micro-lesions in the 17 human tumour 
suppressor genes studied are accounted for by repetitive elements. Similarly, in another study 
Cooper and Krawczak (1993) suggest that all studied micro-lesions were flanked or resided 
within repeats. Cooper and Krawczak (1993) however noted an under-representation of 
repeats of smaller sizes (i.e. 2 and 3bp) in association with the occurrence of micro-lesions. 
The findings presented here suggest that the lower the repeat size, the larger the number of 
repeats that will be found in the studied genes. Several studies have shown that the frequency 
of micro-lesions increases with the size of repetitive elements (Greenblatt et al. 1996; 
Kondrashov and Rogozin 2004; Vogler et al. 2006). Therefore, selecting a minimum repeat 
size of 6bp and a minimum mononucleotide run of 4bp could potentially explain the 
relatively smaller proportion of micro-lesions found within, or in the vicinity of, repetitive 
elements.
Taking into consideration the relatively large proportion of repetitive elements found 
in the studied 17 human tumour suppressor genes, it is inevitable that some of the micro­
lesions would coincide with repetitive elements just by chance alone. Thus, finding repetitive 
elements in the vicinity of micro-lesions would not necessarily indicate that the micro-lesions 
were caused/mediated by repetitive elements. The approach applied in this analysis allows 
one to deduce whether the positional occurrence of micro-lesions is due simply to chance or 
whether micro-lesions indeed co-localise with repetitive elements (micro-lesions found in the 
vicinity of repetitive elements). In addition, the analysis was performed on somatic and 
germline micro-lesion spectra, thus allowing inference, but also a comparison and a contrast 
of the potential involvement of endogenous mechanisms of mutagenesis in both the soma and 
the germline.
The presented results showed that in the CDKN2A and the PTEN genes, many more 
somatic micro-lesions were found to be in the vicinity of repeats. Thus, it is very likely that 
endogenous mutagenesis, mediated by repeats, significantly influences the somatic micro­
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lesion spectrum in the CDKN2A and PTEN genes. Quite the opposite was found for the TP53 
and the VHL genes, with significantly fewer somatic mutations being found in the vicinity of 
repeats. This latter finding contrasts with various studies, which have shown that the majority 
of the micro-lesions in the TP53 gene could be explained by the ‘slipped mispairing’ 
mechanism (Greenblatt et al. 1996; Tang et al. 2001). Therefore, it appears that mechanisms 
not involving repetitive elements are more likely to play an important part in shaping the 
somatic micro-lesion mutational spectrum in the TP53 and VHL genes. These mechanisms 
could be exogenous in origin and hence could involve environmental carcinogens, such as 
reactive oxygen species, exposure to tobacco smoke, aflatoxin B l, environmental factors 
such as UV light and ionizing radiation (Barbour et al. 2006). It is noteworthy that the TP53 
extended cDNA gene sequence comprises ~4% C/G-quartets. All of these C/G-quartets were 
located within the intronic parts of the extended cDNA sequence. Furthermore, none of the 
micro-lesions were located in or within these C/G-quartets. Thus, it is likely that these 
repetitive elements could slightly increase the frequency of simulated micro-lesions and 
contribute to the overall results, at least for the TP53 gene. In addition, tissue specificity has 
been reported to be a property of mutational spectra in the TP53 gene (Glazko et al. 2004) 
and this specificity will be ignored when the micro-lesion spectrum is analysed as a whole.
Tissue specificity has been also shown in spontaneous micro-deletions and micro­
insertions in the Big Blue transgenic mouse mutation detection system {lad  gene; Halangoda 
et al. 2001). The spectrum of these micro-lesions (i.e. pattern and size of distribution of 
micro-lesions) was found to be very similar to that of the TP53 gene and the majority of these 
occur within mononucleotide runs. Thus, tumours with a different tissue origin may well 
have a different ratio of micro-lesions caused by environmental carcinogens and endogenous 
mechanisms. Furthermore, a recent study (Scaringe et al. 2008) has proposed a ‘Tarzan’ 
model of mutagenesis (see Figure 46). This model is reminiscent of the translesional 
synthesis mechanism, in that a large DNA adduct blocks the advancing replication. It 
suggests that the helicase unwinds nucleotides on the nascent strand, thereby allowing the 
translesion polymerase to synthesize additional nucleotides on the nascent strand. These 
additional nucleotides may be copied from either the nascent strand or the template strand 
and could serve to by-pass the DNA adduct. As a result some nucleotides will be incorrectly 
missed and others incorrectly added, giving rise to a micro-indel. Even though this 
mechanism only explains micro-indels, similar or other endogenous mechanisms [e.g. variety 
of error-prone polymerases, relaxed version o f ‘slipped mispairing’ model (Kondrashov and
186
Rogozin 2004) or carcinogens may influence the mutational spectra in these two particular 
genes (i.e. TP 5 3 and VHL)}.
The germline micro-lesions showed preferential co-localisation both within (and in the 
vicinity of) repetitive elements (repeats and RINS), as compared to simulated mutations. This 
was the case for the BRCA2 gene and for the combination of germline micro-lesions for all 
genes. It is clear that the occurrence of germline micro-lesions is very likely to be influenced 
by endogenous mechanisms of mutagenesis, mediated by repetitive elements.
Despite the fact that the somatic micro-lesions in the TP53 and VHL genes were less 
likely to be found in repetitive elements, shared micro-lesions (the combination of shared 
micro-lesions for all genes) were generally found to occur preferentially within RINS. As a 
result, micro-lesions found in both the soma and the germline were associated with runs of 
mononucleotides. Furthermore, the shared mutations in the TP53 and VHL genes comprised 
~34% of the shared micro-lesions in all genes. Therefore, runs of mononucleotides were very 
likely to play an important role in somatic and germline mutagenesis, as shared mutations are 
found in both the soma and the germline. In addition, some similarities between the 
mechanisms that generate germline and somatic mutations were evident. This finding concurs 
with a study that shows very similar frequencies between micro-insertions and micro- 
deletions in the mouse soma and the human germline (Gonzalez et al. 2007). It should be 
noted that frequency analysis can only indicate similarities or differences in the underlying 
mechanisms of mutagenesis.
Our results clearly demonstrate the relative importance of repeats in the process of 
mutagenesis, but also reveal the similarities in the underlying mechanisms between the 
somatic and germline mutational spectra.
Shared micro-lesions were also found to be more likely to be co-localised within RINS than 
the somatic TP53 micro-lesions. Furthermore, shared mutations were preferentially found 
within RINS as compared to both the somatic and the germline mutations combined for all 
genes. As a result, mutational mechanisms appear to be shared between the germline and the 
soma. Additionally, a significant part of these shared mutational mechanisms were mediated 
through runs of identical nucleotides. Hence, it would appear that endogenous mutagenesis is 
an important factor in influencing the positional occurrence of both the somatic and germline 
micro-lesions.
The results presented herein, also indicated that somatic recurrent micro-lesions are 
more likely to be found within RINS than non-recurrent mutations. One could speculate that 
recurrent somatic mutations are more likely to be involved in tumour development than non­
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recurrent ones, due to the multiple independent observations. This would suggest that those 
micro-lesions mediated by RINS are more likely to play a role in tumour development than 
those micro-lesions that are not mediated by RINS. Bacolla and Wells (2009) have argued 
that recurrent mutations whose genes are involved in tumour development are more likely to 
contain repetitive elements. These repetitive elements have been shown to be associated with 
specific functions of the genes. Thus, C/G-quartets are involved in transcriptional initiation 
(Du et al. 2008; Huppert and Balasubramanian 2007), and RINS and simple sequence repeats 
are predominantly found in genes responsible for regulation of transcription and various 
cellular activities (Alba and Guigo 2004; Faux et al. 2005; Karlin et al. 2002). Furthermore, 
homopolymeric runs (e.g. runs of glutamic acid, alanine and leucine) have been associated 
with proteins responsible for DNA-binding, as well as transmembrane receptors and 
transcription factors (Alba and Guigo 2004). A few of the studied 17 human tumour 
suppressor genes are involved in DNA-binding (TP53 and WT1); protein-protein and protein- 
DNA interactions (BRCA2); transcriptional activation and regulation (BRCA1, APC and 
TP53); interaction with cell-surface proteins (NF2); transcription factors (TP53 and WT1) and 
cell receptors (PTCH) (Futreal et al. 2004; Knudson 2002; Sherr 2004; Vogelstein and 
Kinzler 2004). As a result, repetitive elements are likely to be involved in important functions 
of the genes, but nevertheless are also likely to be responsible or involved in the process of 
mutagenesis.
It was also found that not only were somatic recurrent mutations more likely to be 
found in RINS as compared to non-recurrent mutations, but they were also more likely to be 
found in the germline. Thus, somatic micro-lesions do not only recur in repetitive elements, 
such as RINS, but somatic recurrent micro-lesions that are also found in the germline have an 
even higher proportion of micro-lesions found in repetitive elements (i.e. RINS). Therefore, 
this indicates that RINS are likely to be a shared mutational hotspot for both the soma and the 
germline on the basis that they recurred in the soma, but were also noted in the germline.
Even although mutational mechanisms involving RINS appear to be shared between the 
germline and the soma, some differences were also noted. When micro-lesions were analysed 
with respect to positions of runs of identical nucleotides, a number of interesting findings 
were discovered. The APC gene exhibited many more somatic mutations within (or in the 
vicinity of) runs of identical nucleotides than the germline micro-lesions. This observation 
could perhaps be due to impaired mismatch repair. Patients with hereditary non-polyposis 
colorectal cancer and impaired mismatch repair genes exhibit a substantial excess of 
frameshift mutations (predominantly lbp deletions; Huang et al. 1996) with a significant
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proportion (49%) of those are found in polyA runs. In addition, both sporadic and inherited 
gastrointestinal cancer associated with somatic or germline mutations in mismatch repair 
genes (hMSH2 and hMLHl) display increased somatic frameshifts in polyC and poly A runs 
(Ohmiya et al. 2001). Inactivation of mismatch repair genes (MSH-2 and MSH-6) in C. 
elegans suggests that spontaneous mutagenesis is increased in both the germline and the 
soma (Tijsterman et al. 2002). On the other hand, a closer look into the somatic and germline 
micro-lesions revealed that the distribution of lbp deletions did not differ between the soma 
and the germline (~50% for both the somatic and germline micro-lesions). Hence, it is 
unlikely that impairment of mismatch repair could explain the difference between germline 
and somatic micro-lesions with respect to co-localisation within RINS, although this cannot 
be ruled out. An alternative mechanism that could potentially explain the difference between 
the somatic and germline micro-lesions, with respect to RINS, is a potential age-related shift 
in the efficacy of DNA-repair mechanisms. Indeed, such an age-related shift has been 
reported in unilateral sporadic vestibular schwannoma (Evans et al. 2005). Thus, in older 
patients, a higher proportion of frameshifts has been observed as compared to younger 
patients. Evans et al. (2005) have argued that this is most likely due to reduced mutation 
repair efficiency than an increased rate of mutagenesis.
By contrast, the combined germline mutations for all genes were more likely to be 
found in the vicinity of RINS as compared to somatic micro-lesions. It would appear that the 
occurrence of germline micro-lesions is more likely to be influenced by RINS than somatic 
mutations. One potential explanation could be that the proportion of somatic micro-lesions 
consequent to exogenous mutagenesis is higher as compared to the germline. Indeed, 
chemical carcinogens have been shown to be able to induce frameshifts (Lambert et al. 1992; 
Ripley 1990). Alternatively, the spectrum of somatic micro-lesions could be the result of 
more complex endogenous mutational mechanisms. These include the formation of quasi- 
palindromic loops, palindromic dyads and imperfect repetitive elements (Greenblatt et al. 
1996). On the other hand, the combination of germline micro-lesions for all genes were more 
likely to be found in the vicinity in both repeats and RINS, where the combination of somatic 
micro-lesions were preferentially found only in the vicinity of repeats. Thus, defects in 
mutation-repair mechanisms (i.e. mismatch repair, non-homologous end joining, base- 
excision repair, etc. (Evans et al. 2005) are likely to influence the difference between the 
soma and germline with respect to RINS. A potentially impaired mismatch repair gene in the 
soma, could perhaps slightly increase the frequency of micro-lesions associated with repeats, 
but not runs of mononucleotides. Indeed, the proportion of somatic micro-lesions found
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within (or in the vicinity of) repeats was in almost all cases (all repeat sizes except >6bp) 
higher than the corresponding micro-lesions found in the germline. It is notable that none of 
the comparisons of somatic and germline micro-lesions exhibited statistically significant 
results, although insufficient statistical power to detect a difference could have contributed to 
the observed results.
It is evident that repetitive elements (i.e. repeats and runs of identical nucleotides) 
play an important role in the process of mutagenesis in these 17 tumour suppressor genes, 
when the mutational micro-lesion spectra are analysed as a whole. When analysed separately, 
the germline and the soma exhibit great similarities but also differences. Thus, it is important 
to distinguish between the two types of micro-lesions when analysing mechanisms that 
influence the process of mutagenesis. This finding appears not to concur with studies that 
have shown the importance of runs of identical nucleotides in the process of mutagenesis. In 
fact, most studies do not distinguish between somatic and germline micro-lesions, reporting 
only the effect of the runs of mononucleotides on the combined spectrum of germline and 
somatic mutations. In support, our results show that the combination of germline mutations 
for all genes reveal many more mutations found in the vicinity of runs of identical 
nucleotides and in the vicinity of repeats, as is the case with the combination of observed 
mutations for all genes. Furthermore, the combination of somatic micro-lesions revealed 
many more mutations found in the vicinity of repeats which was also noted in the 
combination of observed mutations for all genes.
The fact that most of the significant results are predominantly observed with shorter 
repeat sizes (e.g. minimum repeat size of 7bp would not include repeats of size 6bp) indicates 
that mutations are predominantly associated with short repeats rather than long repeats. Then 
again, there are more repeats with shorter sizes than longer ones. Thus, the difference in the 
distribution of mutations as compared to chance alone would be relatively small and would 
not yield statistically significant results. It is also intriguing that a relatively stronger 
association was observed of mutations found in the vicinity of repeats (i.e. ±5bp) in 
comparison to mutations found within repeats (e.g. a micro-lesions overlaps with a repeat). 
This is potentially quite interesting, as the ‘slipped mispairing mechanism’ would not readily 
explain this observation. Thus, it is possible that a proportion of the mutations mediated by 
repeats might be due to a mechanism that is similar to, but nevertheless distinct ffom,
‘slipped mispairing’. A literature search did not yield mechanisms that could explain how 
repeats in close proximity to mutations could mediate mutations, although one report noted 
that most ffameshift mutations in the human ubiquitin-B (UBB) and amyloid precursor
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protein (APP) genes were in close proximity to short simple repeats, but these were attributed 
to molecular misreading at the mRNA level (van Den Hurk et al. 2001). Then again, distant 
direct repeats (distance between repeats >20bp) could be brought closer together by flanking 
inverted repeats; thus, the involvement of the ‘slipped mispairing’ mechanism could not be 
ruled out in the cases of mutations found in the vicinity of repeats (i.e. ±5bp).
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Table 26 Number and type of repeats found in the studied tumour suppressor genes (C 
and G quartets excluded)_______________________________________________________
N um ber o f d irect N um ber o f N um ber o f m irro r
Gene
repeats invei•ted re| >eats repeats al 1 repeats
size
Gene (bp) 6bp ?bp 8bp 6bp 7bp 8bp 6bp 7bp 8bp 6bp 7bp 8bpAPC 11082 115 35 15 89 31 9 95 31 12 299 97 36ATM 19711 269 85 32 199 61 22 178 52 23 646 198 77BRCA1 9332 107 38 20 45 13 3 78 33 13 230 84 36BRCA2 14677 146 45 12 126 29 13 144 34 10 416 108 35CDH1 5369 58 15 4 31 5 1 33 11 3 122 31 8CDKS2A 981 11 4 2 3 0 0 8 3 1 22 7 3SF1 18147 210 86 48 125 41 13 163 58 27 498 185 88NF2 4508 31 9 3 23 7 0 25 6 3 79 22 6PTCH 8254 89 23 9 37 15 5 58 22 10 184 60 24PTEN 2742 33 17 11 16 4 0 33 13 8 82 34 19RBI 7377 123 51 40 74 22 9 94 44 19 291 117 68STKll 2832 41 10 4 17 4 0 22 9 1 80 23 5TP53 2882 50 27 21 12 3 1 22 6 1 84 36 23TSC1 7065 94 45 29 25 8 0 50 16 7 169 69 36TSC2 12394 111 32 9 74 17 5 93 23 8 278 72 22VHL 1152 18 8 2 4 0 0 8 1 1 30 9 3WT1 3050 33 15 7 23 6 1 25 6 2 81 27 10
Total 131555 1539 545 268 923 266 82 1129 368 149 3591 1179 499
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Table 27 Number and type of G and C quartets found in the studied tumour suppressor
genes ________________________________________________________________________
Gene Number C quartets 
C(3) C(4) C(5)
Number G quartets 
G(3) CG(4) G(5)
Number total quartets 
C G C/G 
quartets quartets quartets
Number Total 
quartets 
In In 
introns exons
APC 0 0 0 0 0 0 0 0 0 0 0
ATM 0 0 0 0 0 0 0 0 0 0 0
BRCAI 0 0 0 0 0 0 0 0 0 0 0
BRCA2 0 0 0 0 0 0 0 0 0 0 0
CDH1 0 0 0 0 0 0 0 0 0 0 0
CDKN2A 0 0 0 0 0 0 0 0 0 0 0
NF1 4 0 0 0 0 0 4 0 4 4 0
NF2 0 0 0 0 0 0 0 0 0 0 0
PTCH 3 0 0 0 0 0 3 0 3 3 0
PTEN 0 0 0 0 0 0 0 0 0 0 0
RBI 0 0 0 0 0 0 0 0 0 0 0
STK11 0 0 0 46 0 0 0 46 46 46 0
TP53 80 8 0 2 0 0 88 2 90 90 0
TSC1 4 0 0 0 0 0 4 0 4 3 1
TSC2 6 0 0 12 0 0 6 12 18 12 6
VHL 0 0 0 0 0 0 0 0 0 0 0
WT1 0 0 0 0 0 0 0 0 0 0 0
Total 97 8 0 60 0 0 105 60 165 158 7
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Table 28 Length of repeats including the distance between the repeats)
Repeats
Geae
Geae
size
IbpJ
>6bp 
Ibpl %
>7bp 
Ibpl %
>8 bp
ibpl %
>6±5bp 
ibp] %
>7±5bp 
Ibp] %
>8±5bp 
Ibp] %
C qaartets
Ibp] %
G qaartets 
Ibpl %
C qaartets
±5bp
Ibpl %
G qaartets
±5bp
Ibpl %
APC 11082 4113 37.11 1681 15.17 749 676 5408 48.80 2303 20.78 1032 9.31 0 0.00 0 0.00 0 0.00 0 0.00
ATM 19711 7359 37.33 2917 14.80 1189 6.03 9616 48.78 3993 20.26 1661 8.43 0 0.00 0 0.00 0 0.00 0 0.00
BRCA1 9332 2986 32.00 1153 12.36 478 5.12 3968 42.52 1558 16.70 648 6.94 0 0.00 0 0.00 0 0.00 0 0.00
BRCA2 14677 5970 40.68 2167 14.76 839 5.72 7691 52.40 2937 20.01 1140 7.77 0 0.00 0 0.00 0 0.00 0 0.00
CDH1 5369 1582 29.47 471 8.77 131 2.44 2125 39.58 661 12.31 191 3.56 0 0.00 0 0.00 0 0.00 0 0.00
CDKN2A 981 339 34.56 181 18.45 76 7.75 411 41.90 240 24.46 96 9.79 0 0.00 0 0.00 0 0.00 0 0.00
NF1 18147 6261 34.50 2593 14.29 1146 6.32 8282 45.64 3575 19.70 1556 8.57 36 0.20 0 0.00 56 0.31 0 0.00
NF2 4508 1255 27.84 399 8.85 109 2.42 1684 37.36 562 12.47 159 3.53 0 0.00 0 0.00 0 0.00 0 0.00
PTCH 8254 2311 28.00 810 9.81 292 3.54 3109 37.67 1130 13.69 406 4.92 20 0.24 0 0.00 30 0.36 0 0.00
PTEN 2742 939 34.25 450 16.41 271 9.88 1217 44.38 588 21.44 371 13.53 0 0.00 0 0.00 0 0.00 0 0.00
RBI 7377 3142 42.59 1347 18.26 554 7.51 4027 54.59 1818 24.64 735 9.96 0 0.00 0 0.00 0 0.00 0 0.00
STKII 2832 1104 38.98 497 17.55 137 4.84 1472 51.98 683 24.12 187 6.60 90 3.18 0 0.00 130 4.59 0 0.00
TP53 2882 1075 37.30 513 17.80 210 7.29 1369 47.50 650 22.55 260 9.02 73 2.53 40 1.39 103 3.57 60 2.08
TSC1 7065 2275 32.20 1009 14.28 353 5.00 3011 42.62 1376 19.48 483 6.84 22 0.31 0 0.00 32 0.45 0 0.00
TSC2 12394 4409 35.57 1605 12.95 627 5.06 5768 46.54 2157 17.40 837 6.75 95 0.77 0 0.00 145 1.17 0 0.00
VHL 1152 410 35.59 161 13.98 69 5.99 545 47.31 211 18.32 89 7.73 0 0.00 0 0.00 0 0.00 0 0.00
WTl 3050 1078 35.34 454 14.89 171 5.61 1405 46.07 614 20.13 221 7.25 0 0.00 0 0.00 0 0.00 0 0.00
Total 131555 46608 35.43 18408 13.99 7401 5.63 61108 46.45 25056 19.05 10072 7.66 336 0.26 40 0.03 496 0.38 60 0.05
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Table 29 Length of repeats (excluding the distance between the repeats)
■ is  repeat 
size
Geae
Geae size 
Ibpl
>6 bp 
Ibp] %
>7 bp 
[bpj %
>8 bp
[bp] %
>6±5bp
Ibp] %
>7±5bp 
[bp] %
>8±5bp 
[bp] %
C qaartets
[bp] %
C qaartets
±5bp
[bp] %
G qaartets
[bp] %
G qaartets 
±5 bp
Ibp] %
APC 11082 2675 24.14 1091 9.84 509 4.59 4274 38.57 1762 15.90 799 7.21 0 0.00 0 0.00 0 0.00 0 0.00
ATM 19711 4862 24.67 2027 10.28 887 4.50 7612 38.62 3185 16.16 1376 6.98 0 0.00 0 0.00 0 0.00 0 0.00
BRCA1 9332 1955 20.95 791 8.48 344 3.69 3119 33.42 1234 13.22 519 5.56 0 0.00 0 0.00 0 0.00 0 0.00
BRCA2 14677 3744 25.51 1348 9.18 534 3.64 5894 40.16 2169 14.78 840 5.72 0 0.00 0 0.00 0 0.00 0 0.00
CDH1 5369 1062 19.78 346 6.44 110 2.05 1702 31.70 553 10.30 170 3.17 0 0.00 0 0.00 0 0.00 0 0.00
CDKN2A 981 243 24.77 131 13.35 67 6.83 334 34.05 195 19.88 87 8.87 0 0.00 0 0.00 0 0.00 0 0.00
NF1 18147 4082 22.49 1744 9.61 794 4.38 6509 35.87 2798 15.42 1217 6.71 26 0.14 0 0.00 46 0.25 0 0.00
NF2 4508 786 17.44 274 6.08 86 1.91 1285 28.50 443 9.83 136 3.02 0 0.00 0 0.00 0 0.00 0 0.00
PTCH 8254 1490 18.05 561 6.80 217 2.63 2408 29.17 898 10.88 331 4.01 14 0.17 0 0.00 24 0.29 0 0.00
PTEN 2742 578 21.08 300 10.94 188 6.86 918 33.48 448 16.34 292 10.65 0 0.00 0 0.00 0 0.00 0 0.00
RBI 7377 2091 28.34 930 12.61 393 5.33 3246 44.00 1450 19.66 589 7.98 0 0.00 0 0.00 0 0.00 0 0.00
STK11 2832 732 25.85 313 11.05 84 2.97 1148 40.54 508 17.94 134 4.73 66 2.33 0 0.00 109 3.85 0 0.00
TP53 2882 751 26.06 371 12.87 171 5.93 1130 39.21 528 18.32 231 8.02 52 1.80 36 1.25 88 3.05 56 1.94
TSC1 7065 1398 19.79 636 9.00 241 3.41 2246 31.79 1034 14.64 371 5.25 14 0.20 0 0.00 24 0.34 0 0.00
TSC2 12394 2793 22.54 997 8.04 412 3.32 4426 35.71 1563 12.61 622 5.02 68 0.55 0 0.00 118 0.95 0 0.00
VHL 1152 282 24.48 121 10.50 55 4.77 452 39.24 187 16.23 90 7.81 0 0.00 0 0.00 0 0.00 0 0.00
WT1 3050 686 22.49 280 9.18 119 3.90 1090 35.74 444 14.56 165 5.41 0 0.00 0 0.00 0 0.00 0 0.00
Total 131555 30210 22.96 12261 9.32 5211 3.96 47793 36.33 19399 14.75 7969 6.06 240 0.18 36 0.03 409 0.31 56 0.04
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Figure 44 Distribution of lengths of repeats (direct, inverted and mirror) and the 
distance between repeats
Distribution of Isngths of repeats (26bp) and distance between the 
repeats
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Distribution of lengths of repeats (27bp) and distance between the 
repeats
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D istance  be tw een  th e  re p e a ts  [bp]
Distribution of lengths of repeats (28bp) and distance between the 
repeats
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Table 30 Distribution of runs of identical nucleotides in the 17 tumour suppressor genes
Geae
G«ae size 
Ibp] N
raaa of A 
I^eagtb
Ibp] % N
raasofC '
l*agtli
Ibpl % N
n u  of G 
U a f tk
ibp] % N
m as of T 
1 / l f l k
ibp] % N
Total raas 
U ig tk
Ibp] %
APC 11082 126 571 5.15 16 66 0.60 7 31 0.28 90 401 3.62 239 1069 965
ATM 19711 172 767 3 89 14 58 0.29 8 32 0.16 308 1499 7.60 502 2356 11.95
BRCAI 9332 80 356 3 81 22 92 0.99 9 39 0.42 82 375 4.02 193 862 9.24
BRCA2 14677 214 997 6.79 16 65 0.44 6 26 0.18 173 807 5.50 409 1895 12.91
CDH1 5369 20 88 1.64 33 144 2.68 18 73 1.36 41 178 3.32 112 483 9.00
CDKN2A 981 0 0 0.00 4 18 1 83 12 53 5.40 2 8 0.82 18 79 8.05
NF1 18147 151 690 3.80 21 99 0.55 21 86 0.47 239 1164 6 41 432 2039 11.24
NF2 4508 19 80 1.77 12 54 1.20 19 80 1.77 23 115 2.55 73 329 7.30
PTCH 8254 27 124 1.50 40 178 2.16 28 121 1.47 49 215 2.60 144 638 7.73
PTEN 2742 28 129 4.70 1 4 0.15 3 13 0.47 46 241 8.79 78 387 14.11
RBI 7377 81 391 5.30 11 49 0.66 8 34 0.46 108 557 7.55 208 1031 13.98
STK1I 2832 4 17 0.60 23 102 3.60 42 182 6.43 2 8 0.28 71 309 10.91
TP53 2882 9 50 1.73 36 157 5.45 16 76 2.64 15 62 2.15 76 345 11.97
TSCI 7065 29 131 1.85 19 85 1.20 10 41 0.58 55 278 3.93 113 535 7.57
TSC2 12394 7 33 0.27 83 351 2.83 100 426 3.44 16 74 0.60 206 884 7.13
VHL 1152 2 10 0.87 4 16 1.39 2 8 0.69 6 27 2.34 14 61 5.30
WT1 3050 7 29 0.95 26 115 3.77 12 51 1.67 16 70 2.30 61 265 8.69
Total 131555 976 4463 3.39 381 1653 1.26 321 1372 1.04 1271 6079 4.62 2949 13567 10.31
N- Number of runs
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Figure 45 Distribution of mononucleotides in all 17 tumour suppressor genes
D istribu tion  of ru n s  of id en tica l n u c le o tid e s
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Table 31 Distribution of micro-lesions in the 17 tumour suppressor genes studied
Number of micro-lesions
Gene
Somatic Germline Shared
_*J£___________  FSiL _
Total
T—
G
T
SH SH
SH
_T
Tr
A PC
A TM
BRCAl
BRCA2
CDH1
CDKN2A
N F /
NF2
PTCH
P TE N
R B I
STK I1
TPS3
TSC1
TSC2
VHL
WT1
184
5 
9 
9
15 
108
16 
210
21
1%
44
4
738
1
6 
210
7
411
171
350
342
21
18
331
68
82
44
175
71
14
82
159
91
13
15
0
5
3
0
2
3
5
0
10
5
3
12
0
0
14
0
610
176
364
354
36
128
350
283
103
250
224
78
764
83
165
315
20
0.30
0.03
0.02
0.03
0.42
0.84
0.05
0.74
0.20
0.78
0.20
0.05
0.97
0.01
0.04
0.67
0.35
0.67
0.97
0.96
0.97
0.58
0.14
0.95
0.24
0.80
0.18
0.78
0.91
0.02
0.99
0.96
0.29
0.65
0.02
0.00
0.01
0.01
0.00
0.02
0.01
0.02
0.00
0.04
0.02
0.04
0.02
0.00
0.00
0.04
0.00
0.10
0.00
0.01
0.01
0.01
0.06
0.01
0.12
0.01
0.11
0.02
0.00
0.41
0.00
0.00
0.12
0.00
0.17
0.07
0.14
0.14
0.01
0.01
0.14
0.03
0.03
0.02
0.07
0.03
0.01
0.03
0.07
0.04
0.01
0.19
0.00
0.06
0.04
0.00
0.03
0.04
0.06
0.00
0.13
0.06
0.04
0.16
0.00
0.00
0.18
0.00
0.14
0.04
0.08
0.08
0.01
0.03
0.08
0.07
0.02
0.06
0.05
0.02
0.18
0.02
0.04
0.07
0.00
1783
Tout
2443
To
77 4303
l_SH_ Tr
Ft is the number o f micro-lesions, where i E  {S,G,S//}
7] is the total number o f micro-lesions, where i E  {S,G,S//,7’}, and 
S-somatic, G-germline , SH -shared , T -total (somatic, germline and shared) 
Values marked in red denote genes that made a relatively large contribution to the 
corresponding mutational spectrum
Table 32 Number of mutations (micro-deletions, micro-insertions and micro-indels)
found in the vicinity of repeats (direct, inverted and mirror repeats and C/G quartets)
Size o f
M utati ons found in t tie vicinity o f re peats
repeats >6 bp > ' bp >8 bp >6±5 bp >7±5 bp >8±5 bp
Gene N N % N % N % N % N % N %APC 610 245 40.16 109 17.87 41 6.72 311 50.98 146 23.93 55 9.02ATM 176 67 38.07 24 13.64 10 5.68 81 46.02 33 18.75 16 9.09BRCAl 364 110 30.22 39 10.71 13 3.57 160 43.96 58 15.93 22 6.04BRCA2 354 153 43.22 39 11.02 17 4.80 199 56.21 65 18.36 24 6.78CDH1 36 10 27.78 6 16.67 2 5.56 12 33.33 8 22.22 2 5.56CDKN2A 128 73 57.03 53 41.41 17 13.28 84 65.63 63 49.22 20 15.63NF1 350 103 29.43 44 12.57 16 4.57 134 38.29 54 15.43 22 6.29NF2 283 77 27.21 22 7.77 3 1.06 109 38.52 38 13.43 7 2.47PTCH 103 40 38.83 10 9.71 4 3.88 53 51.46 14 13.59 4 3.88PTEN 250 107 42.80 43 17.20 17 6.80 133 53.20 55 22.00 29 11.60RBI 224 82 36.61 36 16.07 20 8.93 107 47.77 52 23.21 30 13.39STK1 78 26 33.33 16 20.51 4 5.13 38 48.72 21 26.92 5 6.41TP53 764 236 30.89 76 9.95 34 4.45 316 41.36 96 12.57 43 5.63TSC1 83 30 36.14 19 22.89 14 16.87 44 53.01 29 34.94 16 19.28TSC2 165 72 43.64 16 9.70 4 2.42 91 55.15 25 15.15 7 4.24VHL 315 81 25.71 9 2.86 1 0.32 116 36.83 11 3.49 1 0.32WT1 20 8 40.00 1 5.00 0 0.00 8 40.00 1 5.00 0 0.00
T otal 4303 1520 35.31 562 13.05 217 5.04 1996 46.36 769 17.86 303 7.04
N- Number of micro-lesions
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T a b le  33  S u m m a ry  o f  s ta t is t ic a l ly  s ig n if ic a n t  r e s u lts ,  d i r e c t io n a li ty  a n d  p o w e r  
c a lc u la t io n s
vs
i
1 cgcnd t or 1 denoces the direction of the gene- or experiment-wise statistically significant result The direction is with respect to the first 
group in the comparison A grey shaded box represents an experiment-wise statistically significant result, a non-shaded arrow (i.e. T or i )  
represents a gene-wise statistically significant result, a H  shaded box represents *80% power to detect a statistically significant result for 
the comparison and associated effect si/e, ■ ■ s h a d e d  box represents <80% power and experiment-wise statistically significant result. 
Soma- Somatic. Germ- Germline, Obs - Observed (somatic, germline and shared). Pot - Potential. Rec - Recurrent, Non-rec.- Non-recurrent,
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Table 34 Summary of statistically significant results for somatic vs. simulated micro-
lesions, with respect to repetitive elements_______________
G ear
ALL
CDKS2A
TPSJ
VHL
Parameter
Somatic [%]
Simulated [%]
Gene-wive p-value 
Expen ment-wise p-value 
Effect size 
Power [%J
Somatic (%)
Simulated [%]
Gene-wise p-value 
Expenmem-wisc p-value 
Effect turn 
Power [H]
Somatic [%]
Simulated [%]
Gene-wise p-vaiue 
Experiment-wise p-value 
Effect size 
Power [S]
Somatic [%]
Simulated [%]
Gene-wise p-vahte 
Experiment-wise p-value 
Effect size 
Power (%]
Somatic [%]
Simulated [%] 
Gene-wise p-value 
Experiment-wise p-value 
Effect size 
Power [HI
>6bp >7bp
Repeats 
>8bp >6±5bp >7±5bp >8±5bp
33.60 
31.74 
1 OOE+OO 
1 OOE+OO 
002  
143
1239 
13.40 
1 00E+00 
1 00E+00 
002  
0.68
466 
5.89 
LOOE+OO 
1 OOE+OO 
0.03 
428
45 09 
3932 
5.26E-03 
3.15E-02 
0.06 
54 96
16.55 
17.39 
LOOE+OO 
1 OOE+OO 
0.01 
0.35
6.39 
7.91 
8.72E-01 
1 OOE+OO 
0.03 
5.34
58 33 
37 04 
2.94E-42 
500E-01 
021 
3621
43 52 
23 15 
4.80E-02 
8 16E-01 
0 22 
37 80
15 74 
11.11 
1 OOE+OO 
I OOE+OO 
0.07 
064
66.67 
36.11 
1.20E-0J 
2.04E-02 
031 
84 29
51.85
23.15
4.20E-03
7.14E-42
0.30
8081
17.59 
1389 
1 OOE+OO 
1.OOE+OO 
0.05 
0.31
4235 
30.61 
369E-01 
1 OOE+OO 
0.12 
14.17
16.33 
11.73 
1 OOE+OO 
1 OOE+OO 
0.07 
1.47
6.12 
7.65 
1 OOE+OO 
1 OOE+OO 
0.03 
0.20
53.57
35.71
9.60E-03
163E-01
0.18
52.79
2092 
1378 
1 OOE+OO 
LOOE+OO 
0.09 
528
969 
10.71 
1 OOE+OO 
1 OOE+OO 
0.02 
0.09
30.76 
32.11 
1 OOE+OO 
1 OOE+OO 
0.01 
0.17
10.03 
14.63 
1 91E-01 
1 OOE+OO 
0.07 
2135
4.47 
6.37 
1 OOE+OO 
I.OOE+OO 
0.04 
3.03
4 1 4 6
41.33 
1 OOE+OO 
1 OOE+OO 
0.00 
0.05
12.74
19.92
9.60E-03
1.63E-01
0.10
59.73
5.69 
8.13 
lOOE+OO 
1 OOE+OO 
0.05 
5.06
23 81 
34 76 
343E-01 
1 OOE+OO 
0.12 
1539
286 
10.00 
109E-01 
1 OOE+OO 
0.15 
30 79
000 
3.81 
2.04E-01 
1 OOE+OO 
0.14 
26 42
35.71 
40 95 
1 OOE+OO 
1.OOE+OO 
005 
086
333 
1333 
1.14E-02 
1 94E-01 
0.18 
5876
0.00 
5.24 
7.32E-02 
1 OOE+OO 
0.16 
45.02
RINS 
>4bp >4±5bp
9.73 
888 
1 OOE+OO 
1 OOE+OO 
0.01 
1.46
900 
10.00 
1.OOE+OO 
1 OOE+OO 
0.02 
0.20
15.10 
1198 
LOOE+OO 
1 OOE+OO 
0.05 
1.12
786 
9.49 
1 OOE+OO 
1 OOE+OO 
0.03 
1.92
3.35
3.35
1 OOE+OO 
lOOE+OO 
0.00 
0.15
24.13
22.54
100E+00
lOOE+OO
0.02
2.65
27.00
28.00 
LOOE+OO 
LOOE+OO
0.01
0.17
2813
21.88
9.30E-01
LOOE+OO
0.07
3.87
23 85 
26.29 
LOOE+OO 
LOOE+OO 
0.03 
1.79
6.22 
909 
LOOE+OO 
LOOE+OO 
0.05 
1 89
Table 35 Summary' of statistically significant results for germline vs. simulated micro-
Gene Parameter -Obp >7bp
Repeats
>8bp >6t5bp >7±5bp
RINS 
-4 bp '4i5bp
Germline [%] 36 55 1363 540 47.52 19.03 7.70 1225 29.71
Simulated [%] 31.03 1293 524 3880 1662 7.16 9.65 23.47
ALL Gene-wise p-vaiue 4 89E-04 LOOE+OO LOOE+OO
8.40E-09 3.02E-01 LOOE+OO 4 74E-02 1.52E-05
Experiment-wise p-value 2 94E-03 LOOE+OO LOOE+OO 5.04E-08 LOQE+OO LOOE+OO 9.47E-02 3.05E-05
Effect size 006 0.01 000 0.09 003 0.01 004 0.07
Power 1S1 7628 040 0.11 99 73 1225 039 42.15 96.21
Germline [H] 29 43 10.57 3.43 43 71 16.00 600 12.43 34 62
Simulated [H] 3000 11.43 400 38.57 1400 600 8 88 23.67
BRCAl Gene-wise p-value 1 OOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO
5.67E-01 2.06E-02
Experiment-wise p-value LOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO 3 5(®-01
Effect size 0.01 0.01 002 0.05 003 000 0.06 0.12
Power fS l 006 0.10 O il 1.77 0.30 005 4.61 48.06
202
BMCA2
Germline [%] 42 98 11.40 497 55.83 18.42 7.02 24.10 43 98
Simulated [%] 33 04 14.04 5.26 41.81 18.42 6.73 13.86 31.93
Gene-wise p-value 169E-01 1 OOE+OO lOOE+OO 1.20E-03 lOOE+OO lOOE+OO 1.30E-02 7.20E-03
Experiment-wise p-value 1 OOE+OO lOOE+OO lOOE+OO 2.04E-02 1 OOE+OO 1 OOE+OO 2.21E-01 1.22E-01
Effect size 0.10 004 0.01 0.14 0.00 0.01 0.13 0.12
Power fS l 20 96 0.71 0.06 57.36 0.05 0.06 57.32 50.74
Table 36 Summary' o f statistically significant results for shared vs. simulated micro­
lesions, with respect to repetitive elements_______________
Gene
Shared [%]
Simulated [%]
Gene-wise p-value 
Experiment-wise p-value 
Effect size
_=Z£e_
Repeats
^ 7* 5bP ^ ?b P
3766
3247
1169
11.69
3.90 
S. 19
42.86
40.26
14.29
1688
3.90
649
1 00E+00 1 OOE+OO 1 OOE+OO 1 OOE+OO I OOE+OO 1 OOE+OO
1 OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO l.OOE+OO 1 OOE+OO
0 .0 5
036
000
008
0.03
0.13
0.03
013
0.04 
0 18
006
0.41
RINS 
>4bp >4±5bp
26.67
667
0.27 
59 26
3867
21.33
I.12E-02 2.25E-01
2.23E-02 4 51E-01
0.19
23.09
Table 37 Summary o f statistically significant results for observed vs. simulated micro-
Gene i - ., r,< >7bo
Repeat]
>8bp >6±5bp >7±Sbp >8±Jbo
RINS 
>4bp >4n5bp
Observed [H] 35.35 1308 5.07 4643 17.92 7.09 11.45 27.52
Simulated (%] 31J3 13.08 562 39.07 16.96 7.44 9.29 23.07
ALL Gene-wise p-value 8.38E-04 1 OOE+OO 1 OOE+OO 5.44E-11 1 OOE+OO 1 OOE+OO IJ6E-02 3.UE-OS
Expcnment-wise p-value 5.03E-03 1 OOE+OO 1 OOE+OO 3.26E-I0 lOOE+OO 1.OOE+OO 2.71E-02 6.22E-05
Effect size 004 0.00 0.01 0.07 0.01 0.01 0.04 0.05
Power fS l 72.17 0.08 1.33 99 98 1.38 0.31 57 08 94.85
Observed [%] 4016 17.87 6.72 50 98 23.93 9.02 11.76 30.59
Simulated [H] 33.11 1492 6.72 40 00 19.84 902 9.92 24.54
APC Gene-wise p-value 2.75E-01 1 OOE+OO
1 OOE+OO 3.00E-03 1 OOE+OO 1 OOE+OO 1 OOE+OO 1.55E-01
Experiment-wise p-value 1 OOE+OO 1 OOE+OO 1 OOE+OO 5.10E-02 1 OOE+OO 1 OOE+OO 100E+00 1 OOE+OO
Effect size 0.07 004 0.00 0.11 0.05 0.00 0.03 0.07
Power fS l 1759 181 0.05 6428 396 005 1.56 19.91
Observed [56] 3022 10.71 3.57 43 96 15.93 604 1222 34 38
Simulated [%] 30 22 1126 4.12 3846 13.74 6.04 9.09 23 58
BJtCAl Gene-wise p-value 1 OOE+OO 1 OOE+OO 1 OOE+OO
1 OOE+OO 1.OOE+OO 1. OOE+OO 9.33E-01 1.S2E-02
Experiment-wise p-value 1 OOE+OO 1 OOE+OO I OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO 309E-01
Effect size 000 0.01 001 006 0.03 0.00 005 0.12
Power f%l 005 0.07 0.10 238 040 0.05 3.31 49.06
Observed [%J 43 22 11.02 4.80 5621 18 36 6.78 24.71 44 48
Simulated [%] 33 05 1384 5.37 4181 18.36 678 13.66 3198
BMCAJ Gene-wise p-vaiue 1 08E-01
1 OOE+OO 1 OOE+OO 0. OOE+OO 1 OOE+OO 1 OOE+OO 8.00E-03 5.20E-03
Experiment-wise p-value 1 OOE+OO 1 OOE+OO 1 OOE+OO 0. OOE+OO 1 OOE+OO 100E+00 1.36E-01 8.84 E-02
Effect size 0.10 004 0.01 0.14 0.00 0.00 0.14 0.13
Power fS l 24 18 095 009 63 61 005 0.05 69 10 57.66
CDK.S2A Observed [H] 57.03 41.41 1328 6563 4922 15.63 7.63 27.12
Simulated [%) 37.50 23 44 11.72 35.94 23 44 1406 9.32 27.97
Gene-wise p-value 2.44E-02 S.88E-62 1 OOE+OO 0. OOE+OO 4.20E-03 1 OOE+OO 1 OOE+OO 1.OOE+OO
Experiment-wise p-value SOOE-Ol 1 OOE+OO 1 OOE+OO OOOE+OO 7.14E-02 1 OOE+OO 1 OOE+OO 1.OOE+OO
203
Effect size 020 0.19 002 0.30 0.27 0.02 0.03 0.01
Power [%] 36 08 3391 0 10 89 70 78 88 0.09 0.35 0 16
Observed [%] 42 80 1750 680 5350 2200 11.60 14.40 28.40
Simulated [V.] 3010 11.60 760 35.60 1400 10.80 11.93 21.81
PTES Gene-wise p-value 1 28E-01 1 OOE+OO 1 OOE+OO 5.40E-03 492E-01 1 OOE+OO 1 OOE+OO 6.32E-01
Experiment-wise p-value 1 OOE+OO 1 OOE+OO 1 OOE+OO 9 18E-02 1 OOE+OO 1 OOE+OO lOOE+OO 1 OOE+OO
Effect sue 0.12 006 002 0.18 0.10 0.01 004 0.08
Power f%l 24 07 443 009 6824 12.34 008 0 88 6.60
Observed (%] 3089 995 4.45 41.36 12.57 5.63 854 24.57
Simulated [%] 3220 1466 6.41 41.36 1990 8.12 946 26 28
TPSJ Gene-wise p-value 1 OOE+OO 1 57E-01 1 OOE+OO 1 OOE+OO S.40E-03 lOOE+OO 1 OOE+OO l.OOE+OO
Experiment-wise p-value 1 OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO 143E-01 1 OOE+OO 1 OOE+OO 1 OOE+OO
Effect size 001 0.07 004 000 0.10 0.05 0.02 0.02
Power f%l 0.17 24 75 365 005 6551 588 054 0.79
Observed (%] 25 71 286 0.32 36 83 3.49 0.32 2.91 680
Simulated [%] 34.29 10.16 3.81 4063 1353 508 324 9.06
VHL Gene-wise p-value 4 68E-01 I.92E-02 1.52E-01 1 OOE+OO I.20E-03 3.54E-02 1 OOE+OO 1 OOE+OO
Experiment-wise p-value 1 OOE+OO 3 26E-01 1 OOE+OO 1 OOE+OO 2.041.-02 6 02E-01 1 OOE+OO 1 OOE+OO
Effect size 009 0.15 0.12 0.04 018 0.15 0.01 0.04
Power f%l 12.74 59 05 34 34 0.61 83 23 58.01 0.19 1.63
Table 38 Summary of statistically significant results for somatic vs. germline micro-
Gene Parameter >6 bp >7bp
Repeats 
>8bp >6±5bp >7±5bp >8±5bp
RINS 
>4bp >4±5bp
Somatic [H] 3360 1259 466 4509 16.55 6 39 9.73 24.13
Germline [S ] 36 55 13.63 540 47.52 19.03 770 12.25 29.71
ALL Gene-wise p-value 5.16E-01 1 OOE+OO 1 OOE+OO 1 OOE+OO 4.12E-01 1 OOE+OO 1 2SE-01 S.12E-04
Experiment-wise p-value 1 OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO 2 50E-01 1.62E-03
Effect size 003 002 002 0.02 003 0.02 004 006
Power r%l 8.37 142 1.15 3.57 990 405 30 14 8190
Somatic [H] 3641 17.93 815 53 80 27.72 1304 19.89 39.78
Germline [%] 4161 1776 584 49 88 2238 7.06 7.52 26.07
APC Gene-wise p-value 1 OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO 4.97E-01
6.00E-04 8.S0E-03
Experiment-wise p-value 1 OOE+OO 1 OOE+OO 1 OOE+OO l.OOE+OO l.OOE+OO 1 OOE+OO 1.02E-02 1 50E-01
Effect size 005 000 0.04 0.04 006 0.10 018 0.14
Power [%1 1.10 005 0.75 0.47 1 88 13.21 87 83 55 89
Table 39 Summary of statistically significant results for somatic vs. shared micro-
Gene Parameter >7bp
Repeats 
>8bp >6±5bp >7±5bp >8±5bp
RINS 
-4bp +4*5b£_
Somatic [%] 33 60 1259 466 45.09 16.55 6.39 9.73 24.13
Shared [%] 37.66 11.69 3.90 4286 1459 3.90 26.67 3867
ALL Gene-wise p-value 1 OOE+OO lOOE+OO 1 OOE+OO
1 OOE+OO 1 OOE+OO 1 OOE+OO 2.S6E-05 4.71 E-02
Experiment-wise p-value 1 OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO 5.72E-05 9 42E-02
Effect nze 002 0.00 0.01 0.01 0.01 0.02 0.11 0.07
Power fHl 043 009 0 12 015 0.23 0.65 95.03 42 28
TPSJ Somatic [%] 30.76 10.03 4.47 41.46 12.74 569 7.86 23.85
Shared (%] 3353 8.33 0.00 3353 8.33 000 50.00 58.33
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Gene-wise p-vaiue 1 OOE+OO LOOE+OO l.OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO 6.00 f.-04 4.I6E-02
Experiment-wise p-vaiue 1 OOE+OO 1 OOE+OO 1 OOE+OO 1 OOE+OO l.OOE+OO 1 OOE+OO I.02E-02 7.07E-01
Effect size 001 0.01 0.03 0.02 0.02 0.03 0.19 0.10
Power fS l 006 006 021 0.18 0.13 0.42 97 74 33.68
Table 40 Sum mary o f statistically significant results for germ line vs. shared micro-
Gene Parameter >6bp >7bp
Repeats 
>8bp >6±5bp >7±5bp ■Hi 5 b p
RINS 
>4bp >4±5bp
Germline [SJ 3655 1363 5.40 47.52 1903 7 70 12.25 29.71
Shared [S ] 3766 1169 390 42 86 1429 3.90 26 67 3867
ALL Gene-wise p-value 100E+00 LOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO 2.45E-03 LOOE+OO
Experiment-wise p-value 100E+00 LOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO 4.90E-03 LOOE+OO
Effect size 000 0.01 0.01 002 0.02 002 008 0.03
Pow erful 009 021 027 052 102 1.67 73 88 821
Germline [S] 3021 1329 483 38 67 16.31 6.65 7.12 21.98
Shared [S ] 000 000 0.00 3323 000 0.00 66.67 66.67
NF1 Gene-wise p-value lOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO 228E-02 4 78E-01
Experiment-wise p-value 1 OOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO 4.05E-01 1.00E+00
Effect size 006 004 002 0.01 004 0.03 021 0.10
Power fS] 094 025 0.10 006 0.33 0.13 75.10 9 14
Table 41 Sum m ary o f statistically significant results for recurrent somatic micro 
lesions, with respect to repetitive elements____________________________________
Gene Parameter -ebp >7bp
Repeats 
>8bp >6±5bp >7±5bp >S±5bp
RINS 
>4bp >4±5bp
Somatic recurrent [%] 35.11 12.54 3.45 45.45 15.99 5.96 14 11 26 96
Somatic non-recurrent [%] 3327 12.36 492 45.01 16.67 649 8 76 23.50
ALL Gene-wise p-value 1 OOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO
3.93E-02 LOOE+OO
Experiment-wise p-value LOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO 7.86E-02 1.00E+00
Effect size 0.01 0.01 003 0.00 0.01 0.01 0.07 0.03
Power [SI 046 031 1.26 009 0.12 0.21 44 49 4.03
Somatic recurrent non-ahared [SJ 36 08 13.06 344 47 08 1684 6.19 12.71 26.12
Somatic recurrent shared [%) 25 00 7.14 3.57 28.57 7.14 3.57 28.57 35.71
ALL Gene-wise p-value LOOE+OO LOOE+OO LOOE+OO 6.63E-01
1.00E+00 LOOE+OO 442E-01 LOOE+OO
Experiment-wise p-value 1 OOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO 8 84E-01 LOOE+OO
Effect size 007 0.07 0.00 0.11 0.07 003 0.13 006
Power [S ] 193 141 008 682 2.11 0.37 22.67 2.51
Somatic recurrent non-ahared [SJ 36 08 13.06 344 47 08 16.84 6.19 12.71 26.12
Somatic non-recurrent shared [S] 44 90 1429 408 51.02 1827 408 25 53 40.43
ALL Gene-wise p-value LOOE+OO LOOE+OO
LOOE+OO LOOE+OO LOOE+OO LOOE+OO 2.27E-01 4 72E-01
Experiment-wise p-value 1 OOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO LOOE+OO 4 53E-01 9.43E-01
Effect size 006 0.06 0.01 003 0.01 0.03 0.13 0.11
Power [S I 197 143 0.10 022 0.11 039 23 08 15 22
Somatic non-recurrent non-shared [S ] 33.11 1227 489 44 71 16.49 6.43 9 14 23.74
Somatic recurrent shared [SJ 25 00 7.14 3.57 28.57 7.14 3.57 28.57 35.71
ALL Gene-wise p-value LOOE+OO 1.00E+00
LOOE+OO 9.74E-01 LOOE+OO LOOE+OO 3.61 E-02 LOOE+OO
Ex pen mem-wise p-value LOOE+OO LOOE+OO LOOE+OO LOOE+OO 1 OOE+OO LOOE+OO 7.21E-02 LOOE+OO
Effect size 002 0.02 0.01 0.04 0.03 0.02 009 0.04
Power fS l 0.97 069 0.13 4.79 2.06 044 66 30 569
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Table 42 Repeats and recurrent somatic mutations
mutations Total
*6
In repeats 
N %
bp
not in repeats 
N %
In repeats 
N %
Ibp
not in repeats
N %
In repeats 
N %
Observed
8bp
not in repeats 
N •/.
mutations
•61
In repeats 
N %
5bp
not in repeats 
N %
-7
In repeats 
N %
5bp 
not in repeats 
N %
>8
In repeats 
N %
±5bp
not in repeats 
N •/.
somatic 1783 599 33 60 1184 66 40 221 1239 1562 87 61 83 4 66 1700 95.34 804 4509 979 5491 295 1655 1488 83 45 114 639 1669 9361
germline 2443 893 36 55 1550 63 45 333 13 63 2110 8637 132 5 40 2311 94.60 1161 47 52 1282 5248 465 19 03 1978 80 97 188 7 70 2255 92 30
shared 77 29 37 66 48 62 34 9 II 69 68 88 31 3 3 90 74 96 10 33 4286 44 57 14 11 14 29 66 85 71 3 3 90 74 96 10
observed 4305 1521 35 35 2782 64 65 563 13 08 3740 86 92 218 5 07 4085 94 93 1998 4643 2305 53 57 771 17 92 3532 82 08 305 709 3998 92.91
somatic
recurrent 347 119 34 3 228 65 71 42 12 1 305 87 9 12 3 46 335 96 54 153 44.1 194 55 91 53 15 3 294 84.73 20 5 76 327 94.24
somatic
non
recurrent 1436 480 334 956 66 57 179 12 5 1257 87 53 71 4.94 1365 95.06 651 45.3 785 5467 242 169 1194 83 15 94 6 55 1342 93.45
N- Number of micro-lesions
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Table 43 Distribution of micro-deletions and micro-insertions and runs of mononucleotides
Somatic matatioas Germliae matatioas Shared matatioas Observed matatioas
M atatioas ia Matatioas aot ia Matatioas ia M atatioas aot ia Matatioas ia Matatioas aot Matatioas ia Matatioas aot ia
Matatioas Raas raaa ra a t raas raas raas ia raas raas raas
Gene N N N % N % N % N % N % N % N % N %
APC 595 677 36 19.89 145 80.11 30 7.52 369 92.48 4 26.67 11 73.33 70 11.76 525 88.24
A TM 162 1352 1 20.00 4 80.00 31 19.75 126 80.25 0 0.00 0 0.00 32 19.75 130 80.25
B R C A l 352 584 0 0.00 9 100.00 42 12.43 296 87.57 1 20.00 4 80 00 43 12.22 309 87.78
BRCA2 344 1054 3 33.33 6 66.67 80 24.10 252 75.90 2 66.67 1 33.33 85 24.71 259 75.29
CDH1 35 328 1 6.67 14 93.33 7 35.00 13 65.00 0 0.00 0 0.00 8 22.86 27 77.14
CDKN2A 118 61 9 9.00 91 91.00 0 0.00 16 100.00 0 0.00 2 100.00 9 7.63 109 92.37
NF1 342 1195 2 12.50 14 87.50 23 7.12 300 92.88 2 66.67 1 33.33 27 7.89 315 92.11
NF2 275 248 13 6.37 191 93.63 2 3.03 64 96.97 0 0.00 5 100.00 15 5.45 260 94.55
PTCH 94 492 4 20.00 16 80.00 13 17.57 61 82.43 0 0.00 0 0.00 17 18.09 77 81.91
PTEN 243 197 29 15.10 163 84.90 5 12.20 36 87.80 1 10.00 9 90.00 35 14.40 208 85.60
R B I 211 545 6 14.29 36 85.71 22 13.33 143 86.67 1 25.00 3 75.00 29 13.74 182 86.26
S T K Il 75 185 1 25.00 3 75.00 9 13.04 60 86.96 2 100.00 0 0.00 12 16.00 63 84.00
TP53 761 184 58 7.86 680 92.14 1 9.09 10 90.91 6 50.00 6 50.00 65 8.54 696 91.46
TSC1 79 393 0 0.00 1 100.00 8 10.26 70 89.74 0 0.00 0 0.00 8 10.13 71 89.87
TSC2 161 727 0 0.00 5 100.00 12 7.69 144 92.31 0 0.00 0 0.00 12 7.45 149 92.55
VHL 309 66 7 3.35 202 96.65 1 1.16 85 98.84 1 7.14 13 92.86 9 2.91 300 97.09
W Tt 19 176 1 14.29 6 85.71 1 8.33 11 91.67 0 0.00 0 0.00 2 10.53 17 89.47
Total 4175 8464 171 9.73 1586 90.27 287 12.25 2056 87.75 20 26.67 55 73.33 478 11.45 3697 88.55
N- Number of micro-lesions
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Table 44 Micro-deletions, micro-insertions and micro-indels
Gene
Typ*
Ittioa
N M kro- 
ddetioaa
P repon iM  of micro- 
dd ttioaa  of total
NM icro-
iaaertioas
Proportion of micro- 
iaeertioaa of total
N Micro- 
ie d d i
Proportion of micro- 
indd r of total
Total
N
soma 137 74 46 44 23 91 3 1 63 184
APC germ 284 69 10 115 27 98 12 2.92 411
shared 15 100 00 0 000 0 0.00 15
soma 4 80 00 1 20 00 0 0.00 5
ATM germ 122 71 35 3$ 2047 14 8 19 171
shared 0 000 0 000 0 000 0
6 66 67 3 33 33 0 000 9
BXCAJ germ 25$ 72 86 83 23 71 12 3 43 350
shared 3 60 00 2 40 00 0 000 5
7 77 78 2 22 22 0 000 9
BJtCAl germ 244 71 3$ 88 25 73 10 292 342
shared 1 33 33 2 66 67 0 000 3
ioma 13 86 67 2 13 33 0 000 15
CDH1 germ 12 57 14 8 38 10 1 476 21
shared 0 0 00 0 000 0 0.00 0
soma 76 7037 24 22 22 8 741 108
CDES2A germ 10 5$ 56 6 33 33 2 1111 18
shared 1 50 00 1 50 00 0 000 2
soma 13 81 25 3 18 75 0 000 16
SF1 germ 218 65 86 105 31 72 8 2.42 331
shared 3 100 00 0 000 0 000 3
soma 176 83 81 28 13 33 6 2.86 210
SF1 germ 50 73 53 16 23 53 2 294 68
shared 5 100 00 0 000 0 0.00 5
soma 14 66 67 6 28 57 1 4.76 21
PTCH germ 42 51 22 32 39 02 8 976 82
shared 0 0 00 0 000 0 000 0
fOfp j 14$ 73 98 47 23 98 4 2.04 196
PTES germ 23 52 27 18 40 91 3 682 44
shared 6 60 00 4 40 00 0 0.00 10
soma 30 68 18 12 27 27 2 455 44
RBI germ 112 64 00 $3 30 29 10 5 71 175
shared 4 80 00 0 000 1 20.00 5
soma 3 75 00 1 25 00 0 0 00 4
STKU germ 45 63 38 24 33 80 2 2.82 71
shared •> 66 67 0 000 1 33 33 3
soma 504 68 29 234 31 71 0 000 738
TPSJ germ 8 57 14 3 21 43 3 21 43 14
shared 8 66 67 4 3333 0 000 12
soma 1 100 00 0 000 0 000 1
TSC1 germ 53 64 63 2$ 30 49 4 488 82
shared 0 0 00 0 000 0 000 0
somi 3 $0 00 2 33 33 1 1667 6
TSC3 genu 110 69 18 46 28 93 3 1 89 159
(hared 0 0 0 0 0 000 0 000 0
tome 171 81 43 38 18 10 1 048 210
VHL genu 5$ 60 44 31 3407 5 $49 91
(hared 8 $7 14 6 42 86 0 000 14
(oma 4 57 14 3 42 86 0 000 7
WTI germ 8 61 54 4 30 77 1 769 13
0 000 0 000 0 000 0
(oma 1307 73 30 450 25 24 26 1 46 1783
Total germ 1651 67 58 692 28 33 100 409 2443
$6 72 73 19 24 68 2 2.60 77
G raad
3014 70 04 1161 26 98 128 297 4303
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F ig u re  46  M e c h a n is m  o f  g e n e ra t io n  o f  m ic ro - in d e ls  (m o d if ie d  a f te r  S c a r in g e  e t a l. 2 0 0 8 )
%
DNA adduct
DNA
polymerase
Helicase
Translesion
polymerase
Micro-indel
3 ’
■5’
5 ’ A  o. 5 ’
5' 4 lK /
3 ’
■5’
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7. General discussion
7.1. Objectives
The main objective of this PhD project was to compare the known somatic and 
germline mutational spectra of 17 human tumour suppressor genes, and to explore the 
similarities and differences that these spectra might exhibit, with respect to various 
parameters. These parameters comprised: mutations within CpG dinucleotides, disease and 
non-disease associated nucleotide substitution rates, physicochemical differences between 
wild-type and mutant amino-acids, the evolutionary conservation of affected codons, the role 
of nonsense-mediated mRNA decay and the potential involvement of repetitive sequence 
elements. The questions to be addressed were posed in such a way as to provide a glimpse of 
the mechanisms that might influence the somatic and germline mutational spectra and their 
relative involvement in the process of tumour initiation and/or development. Thus, this work 
represents a formal attempt to try to shed some light on the relative importance of exogenous 
and endogenous mechanisms of mutagenesis that have influenced the occurrence of both 
somatic and germline mutations in the 17 tumour suppressor genes studied. Further, since 
some types or classes o f mutations, either germline and/or somatic might be relatively more 
likely to drive tumorigenesis than others, some additional questions were also posed e.g. do 
such mutations exist and if so, are these mutations more likely to be found in the soma or the 
germline? Moreover, are they likely to recur?
To accomplish the main objective, the mutational spectra of 17 human tumour 
suppressor genes (i.e. A PC, ATM, BRCA1, BRCA2, CDH1, CDKN2A, NF1, NF2, PTCH, 
PTEN, RBI, STK11, TP53, TSC1, TSC2, VHL and WT1) were sought, at the beginning of this 
PhD work (end of 2005). The selection of these 17 genes was based on their being known at 
the time to exhibit somatic mutations in one or more types of human cancer as well as 
germline mutations conferring an inherited predisposition to cancer. It should be noted that a 
considerable number of mutations in a given gene does not necessarily imply the significant 
involvement of that particular gene in tumour development. Nevertheless, for all these 17 
genes, a sufficient body of biologically plausible evidence had been amassed to denote their 
involvement in tumorigenesis when mutated either in the germline or the soma. Because 
these genes are also some of the most commonly mutated genes in human cancers, the 
number of mutations available to study would be maximized. For example, ~50% of all
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studied cancers have been found to exhibit mutations in the TP 5 3 gene, indicative of its 
pivotal role of suppressing tumour development (Soussi and Beroud 2001).
The mutation spectra comprised single base-pair substitutions that introduced 
missense and nonsense mutations; and micro-lesions (viz. micro-deletions, micro-insertions 
and micro-indels; length of deleted and/or inserted nucleotides <20bp) within the coding 
regions of the genes. These sequence changes comprised both somatic and germline 
mutations. The germline mutations were obtained from the Human Gene Mutation Database 
(HGMD; http://www.hgmd.org: Stenson et al. 2003) whereas the somatic mutations were 
derived from literature searches, via PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez) and 
various somatic mutational databases (for detailed information see Chapter 2; General 
materials). In addition, somatic mutations that were reported more than once were recorded 
as being recurrent. Once the germline and somatic mutational spectra were directly compared 
for a particular gene, some mutations were found in both the soma and the germline. 
Therefore, in order to recognise the existence of such mutations, all mutations that were 
found in both the soma and the germline, in a particular gene, were removed and a single 
entry with the label ‘shared’ was created.
Overall, >4000 somatic and >4000 germline mutations were collected (summary of 
the collected mutations is presented in Table 45 and Table 46). Thus, the known mutations 
from the 17 human tumour suppressor genes under study, at the time of start of this PhD 
project (i.e. end of 2005), comprised >8000 mutations in total. With such a large number of 
mutations overall, it came as something of a surprise to find that some of the analyses 
undertaken exhibited relatively low statistical power to detect a significant difference (i.e. 
<80%). It should however be made clear that -50%  of all the collated somatic mutations (i.e. 
-25%  of all the mutations collected) were from the TP53 gene. As a result, for some genes, a 
paucity of lesions was observed which limited the statistical power available in some cases. 
Therefore, for some of the comparisons performed, only a limited number of conclusions 
could be drawn. This notwithstanding, most of the analyses performed yielded some 
interesting findings. Some of these results confirmed the findings of previous research, 
whereas other results were relatively novel.
7.2. S u m m a ry  o f m ain  conclusions
Some genes exhibited almost a complete absence of somatic mutations (i.e. ATM , 
BRCA1, BRCA2, NF1, TSC1 and TSC2). In some of these cases evidence was presented that
211
the paucity of somatic mutations could well be a consequence of mechanisms other than 
inactivation via somatic mutations, e.g. potential promoter hypermethylation for the BRCA1 
gene and dominant-negative effect of germline missense mutations in the case of the ATM  
gene. By contrast, only the TP53 gene exhibited a paucity of germline mutations.
A small proportion of the combined mutations for all genes (-5%) were found to be 
shared between the germline and the soma, although the numbers slightly ranged between the 
different type of mutations. Thus, relatively greater proportions of the shared mutations were 
found amongst nonsense (-11%; ranged from 0% to 35%) and missense mutations (-7%; 
ranged from 0% to 12%), as compared to micro-deletions (-3%; ranged from 0% to 4%), 
micro-insertions (-2% ; ranged from 0% to 8%) and micro-indels (-1%; ranged from 0% to 
33%). Shared missense mutations were not merely coincidental. The shared missense 
mutations were found to be more likely to be drivers o f tumorigenesis than either exclusively 
somatic or exclusively germline missense mutations. This was the case not only for the 
combined shared mutations across genes but also for individual genes, such as the CDKN2A, 
TP53 and VHL.
A relatively large proportion of the combined somatic mutations for all genes (-33%; 
ranged from 0% to 53%) were found to have been independently observed more than once 
(i.e. they were found to recur), although the proportions ranged considerably between the 
different types of mutations. Thus, the largest proportions o f recurrent mutations were found 
amongst the missense (—44%; ranged from 0% to 64%) and nonsense mutations (-43%; 
ranged from 0% to 89%), followed by micro-deletions (-20%; ranged from 0% to 32%), 
micro-insertions (-18% ; ranged from 0% to 31%) and micro-indels (no mutations were found 
to recur). It is o f note that the proportion of recurrent somatic mutations were mainly 
influenced by the numbers o f recurrent mutations in the TP53 gene, comprising -78%  of all 
recurrent mutations for all genes. The recurrence status o f the somatic missense mutations 
was found to be heavily influenced by nucleotide context, but they were also likely to have 
been selected for their functional importance.
For some genes, it was found that intra-genic CpG-methylation was likely to have 
been frequently responsible for methylation-mediated deamination of 5-methylcytosine in 
CpG dinucleotides in both the soma and the germline (e.g. TP53). In addition, the CpG- 
dinucleotides comprised only —1% of the extended cDNA sequence lengths combined for all 
genes, but missense and nonsense mutations found within CpG-dinucleotides comprised —8% 
of all single base-pair substitutions for all genes. Even more, —27 % of shared missense and 
nonsense mutations were found within CpG-dinucleotides, significantly more as compared to
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~4% and ~8% for the somatic and germline mutations respectively (for more details see 
Chapter 5). Furthermore, CpG-located mutations were found to be more likely to be shared 
between the germline and the soma than non-CpG located mutations. Thus, for a number of 
genes, all possible CpG-located nonsense mutations were present in either the germline or the 
soma (i.e. BRCA1, CDKN2A, PTEN, STK1 / , TP53, VHL and WT1). This is likely to be 
consistent with the operation of this endogenous mutational mechanism in both the germline 
and the soma for the genes under study.
A significantly higher proportion (-34%) of the micro-lesions (both somatic and 
germline; repeats o f size ^6±5bp) combined for all genes were found within repetitive 
elements as compared to simulated micro-lesions (-32%; for more details see Chapter 6). 
Furthermore, shared micro-lesions were significantly more likely to be found in repetitive 
elements (i.e. runs o f identical nucleotides) than both somatic and germline micro-lesions. 
Thus, it is likely that the mutational mechanisms responsible for these micro-lesions are 
shared between the germline and the soma and have probably been mediated by repetitive 
elements. Intriguingly, germline micro-lesions were found to be more likely to be influenced 
by repetitive elements than somatic micro-lesions. This could be a reflection of the probable 
higher proportion of mutations arising from the action of endogenous mutational mechanisms 
in the germline, as the germline is likely to be relatively protected from the action of 
exogenous mutagens compared to the soma.
7.3. Exogenous vs. endogenous mechanisms of mutagenesis
It is evident from numerous studies that the mutational spectrum in both the germline 
and the soma is influenced by the action of both endogenous mutational mechanisms and 
exogenous mutagens (e.g. carcinogens).
A similar mutational spectrum in the soma to that in the germline would argue 
strongly that the mechanisms that influence the spectra are very likely to be shared. Thus, the 
relatively large proportion of identical (i.e. in terms of the genic position and type of 
sequence change) mutations in both the soma and the germline (i.e. shared mutations) would 
suggest that those mutations are quite likely to have originated through the action of very 
similar mechanisms.
On average for all 17 genes studied, -21%  of shared missense mutations and -37%  of 
shared nonsense mutations were found within CpG dinucleotides (i.e. C->T on the coding 
and G->A on the non-coding DNA strand; for more details see Chapters 4 and 5). Therefore,
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a relatively large proportion of the single base-pair substitutions are quite likely attributable 
to endogenous deamination of 5-methylcytosine within CpG-dinucleotides (Pfeifer 2006) 
without having to invoke the action of exogenous mutagens or carcinogens. However, Pfeifer 
and Besaratinia (2009) have shown that methylated CpG-dinucleotides are a preferential 
target o f various physical and chemical genotoxic agents (e.g. nitric oxide, benzo[a]pyrene, 
aflatoxin B1, etc.), at least in the context of the TP 5 3 gene. Thus, some of the mutations at 
CpG dinucleotides could well have resulted from the action of exogenous genotoxic agents or 
carcinogens as well as from the action of endogenous mechanisms. Their relative 
contribution is however as yet largely unknown.
It should be said that the TP53 gene is likely to be a unique gene, in the sense that the 
majority of observed mutations are non-truncating mutations (i.e. missense) as opposed to 
other tumour-suppressor genes, where this is relatively uncommon. In addition, the analysis 
of micro-lesions suggested that observed micro-lesions combined for all genes were very 
likely to be associated with repetitive elements. Hence, it is likely that a relatively large 
proportion of the observed micro-lesions (both somatic and germline) are also likely to have 
resulted from endogenous mutagenesis, such as ‘ slipped-mispairing’, ‘quasi-palindromic’ 
sequences, ‘strand-switching’ etc. (Bacolla and Wells 2009; Cooper and Krawczak 1993; 
Efstratiadis et al. 1980; Wells 2007; Wells et al. 2005). By contrast, the somatic micro­
lesions in the TP53 gene showed a trend in the opposite direction, i.e. relatively few somatic 
mutations were observed in repetitive elements. One could argue that relatively more somatic 
micro-lesions in the TP53 gene are result of the actions of exogenous mutagenesis, in 
comparison to most of the tumour suppressor genes studied. Indeed, mutagens, such as 
reactive oxygen species, ionizing radiation, a variety of chemicals, food toxins, etc., have 
been shown to induce ffameshiffcs, and both double and single-strand DNA breaks (Bertram 
and Hass 2008; Bertram et al. 2001; Breen and Murphy 1995; Sankaranarayanan and 
Wassom 2005). Nevertheless, shared micro-lesions in the TP53 gene were preferentially 
found in runs of identical nucleotides, as compared to somatic micro-lesions. Thus, some 
TP53 micro-lesions are likely to be the result of endogenous mechanisms and these are also 
likely to be found in both the soma and the germline.
It has to be said that a clear-cut distinction between carcinogens or toxins of 
endogenous origin (e.g. oxyradicals, nitric oxide, etc.) and exogenously derived carcinogens 
(e.g. cigarette and tobacco smoke, heavy metals, asbestos fibres, etc.) is probably untenable 
(Morley and Turner 1999; Valavanidis et al. 2009). Furthermore, the relative exposure of the 
germline and soma to environmental carcinogens is often largely unknown. One exception is
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UV light in skin cancer, where the relative contribution can be ascertained since it is unlikely 
that UV light makes a significant contribution to the observed germline mutational spectrum 
because the germline is relatively well protected from exposure to UV light as compared to 
the soma. On the other hand, the somatic mutational spectrum of skin cells is very likely to 
be influenced by sunlight - indeed, it contains high frequency CC->TT tandem mutations 
(genome-wide CC->TT mutations; HPLC method; Mouret et al. 2008) - but it is relatively 
unlikely that UV light could directly induce mutagenic DNA damage (e.g. cyclobutane 
pyrimidine dimers and pyrimidine-pyrimidone photoproducts) in other tissues, mainly due to 
the absorption of the energy levels of U V light by the upper epidermal layers of the skin 
(Javeri et al. 2008). Nevertheless, the relative incidence of cyclobutane pyrimidine dimers, 
characteristic o f UVC light, has not been found to correlate with the frequency of the most 
common mutations (Vreeswijk et al. 2009) and could be independent of the clinical 
phenotype (i.e. basal cell carcinoma; Heitzer et al. 2007). On the other hand, carcinogens are 
more likely to be found in various tissues, transported mainly via the blood stream, such as 
nitrosamines, heavy metals, alkaloids, etc. (Hoffmann et al. 2001; Taioli 2008). There has 
even been some evidence that air pollution could elevate germline mutation frequencies at 
expanded simple tandem repeats in mice, but whether these represent a good marker for other 
genomic regions or the cells of the human germline is largely unknown (Somers and Cooper 
2009).
7.4. Structural characteristics of individual genes and observed 
mutational spectra
Private characteristics o f individual genes are likely to influence the observed 
mutational spectrum. Thus, it is likely that certain features o f a gene could influence the 
selection of the type and position of mutations. For example, the somatic and germline 
mutational spectra in the A PC gene have been known for some time to be different 
(Feamhead et al. 2001; Lamlum et al. 1999). It has also been shown that the type of the 
inherited (germline) mutation in the APC  gene could play a role in determining the position 
and/or nature of the second (somatic) hit. Thus, if the germline mutation occurs outside the 
region between codons 1194 and 1392, the second hit is likely to be a truncating mutation 
within the Mutation Cluster Region (MCR; Lamlum et al. 1999). Furthermore, our analysis 
indicated that the majority of somatic and germline nonsense mutations in the APC  gene are 
quite likely to have been selected for the loss of p-catenin-binding ability of the mutant
215
protein product. Thus, specific sequence and structural characteristics o f the APC  gene (i.e. 
p-catenin-binding sites) are likely to play an important part in influencing the mutational 
spectrum of both the germline and somatic mutations.
The TP53 gene is another gene in which gene-specific characteristics could well play 
an important role in shaping the mutational spectrum. Unlike any other tumour suppressor 
gene, the majority of lesions comprise missense mutations. These also cluster in the DNA- 
binding region of the gene (Soussi et al. 2005). It has been previously shown that mutations 
in the TPS3 gene are selected for the disruption of DNA-binding ability, i.e. the majority of 
mutations are located in the DNA-binding domain of the gene (Soussi and Beroud 2001; 
Soussi et al. 2005; Soussi and Wiman 2007). In addition, complete inactivation of the protein 
could be insufficient for tumorigenesis (Lang et al. 2004; Olive et al. 2004), hence the 
majority of lesions are non-truncating mutations (i.e. missense mutations). These 
observations have led to the idea that the TP53 gene might be different from other tumour 
suppressor genes, not only because of its mutational spectrum, but also because it might not 
be a true tumour suppressor gene in the traditional sense. Tumour suppressor genes are 
generally regarded as sustaining a ioss-of-function’ mutations during tumour development, 
i.e. mutations are selected for their ability to partially or completely inactivate the wild-type 
protein product. Several studies have suggested a possible ‘gain-of-function’ or acquisition of 
oncogenic properties o f the TP53 (Kawamata et al. 2007; Strano et al. 2007), exemplifying 
this unusual tumour suppressor gene. It appears that TP53 exhibits some duality with respect 
to oncogenic and tumour suppressor functions (Strano et al. 2007). Nevertheless, although 
nonsense mutations in the TPS3 gene are relatively uncommon (-8%), all were highly likely 
to have been selected for the complete inactivation of the protein. Therefore, not all 
mutations in the TPS3 gene are selected for a ‘gain-of-function’.
It would seem that such private characteristics are confined to individual genes and 
are not commonly shared in the rest of the tumour suppressor genes studied. None of the 
other genes showed such extreme differences in their mutational spectrum. One could 
speculate that such private characteristics might be important in the context of other tumour 
suppressor genes, but for some of those, an insufficient number o f mutations was observed. 
Thus, no definitive conclusions could be made, with respect to such private characteristics in 
other tumour suppressor genes.
7.5. Selection and mutability
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As pointed out above, selection of the types and positions of mutations is likely to 
play a very important part in shaping the mutational spectrum. Nevertheless, in order for 
these mutations to be selected for their functional impact or consequences, the pool of 
mutations that selection exerts its influence upon, is likely to be critically dependent on 
mutability.
A study by Walter et al. (1998) have suggested that mutation frequencies in the germ 
cells (spermatogenic cells o f all types) are relatively lower, as compared to somatic tissues. 
Thus, at least in mice, the spontaneous mutation frequency in male germ cells is likely to be 
lower than in somatic cells. Walter et al. (1998) have also suggested that the lower 
spontaneous frequency could be due to additional quality control mechanisms or checkpoints 
that could induce apoptosis within spermatogonic cells. Moreover, no increase in mutation 
frequencies in spermatogonia in mice, following ionizing irradiation, has been observed (Xu 
et al. 2008). Thus, differences in the mutation frequencies and hence corresponding 
mutational spectrum might differ between the soma and the germline, with respect to both 
spontaneous and induced mutations (e.g. environmental factors). Nevertheless, some 
similarities are also observed. Among others, an age-related shift in mutation frequency is 
observed in both somatic and germline cells in humans (Evans et al. 2005; Walter et al. 1998) 
and in mice (Walter et al. 1998). Evans et al. (2005) have argued that it could be mainly due 
to increasingly dysfunctional repair mechanisms with increase of age.
Throughout this PhD work, the 17 genes studied were regarded as, and assumed to be, 
classical tumour suppressor genes. As such, bi-allelic inactivation is required for tumour 
initiation and/or development, following Knudson's two-hit hypothesis (Knudson 1971,
1978). In addition, one functional allele of the tumour suppressor genes is likely to be 
sufficient for tumour suppression. Cancer is a somatic disorder, mainly occurring in post- 
reproductive age. On this basis, a major distinction between germline and somatic mutations 
may be made. Thus, germline mutations are very likely not selected against, due to the fact 
that selection has not yet acted upon the predisposing germline mutations, whereas somatic 
mutations are selected for their 'Ioss-of-function' effect on a cellular level (Stratton et al. 
2009). Quite the opposite was found when somatic and germline missense mutations were 
analysed. Germline missense mutations were indeed more likely to have negative impact on 
the function of the proteins for the combined mutations in all genes (in comparison with 
somatic missense mutations) and specifically in the ATM, BRCA1 and VHL genes. As a 
result, it seems that germline missense mutations are selected for their relatively more drastic 
consequences, than somatic missense mutations. Alternatively, germline missense mutations
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could have come to clinical attention, because these mutations could have given a 
predisposition or inherited risk, through various potential mechanisms. These mechanisms, 
include: haploinsufficiency, gene-dosage effect, increased somatic mutation frequency, etc. 
Further, the fact that one allele copy of the gene has already been inactivated, results in one 
less somatic hit required for tumour development. Furthermore, relatively fewer somatic 
mutations were observed in the A TM (-6%  somatic mutations) and BRCA1 (-3%  somatic 
mutations) genes, as compared to other tumour suppressor genes.
Due to the relative paucity of second (somatic) hits in these genes, at least with the 
mutations analysed, one way to inactivate them is via germline bi-allelic inactivation. This is 
not likely in the case o f tumour-suppressor genes. Furthermore, heterozygous BRCA1 
primary mammary epithelial cells have been shown to exhibit increased clonal growth and 
proliferation (Burga et al. 2009). Thus, one could speculate that a gene-dosage effect may 
exist for the BRCA1 gene by which one functional allele is insufficient for tumour 
suppression. A TM  knockout mice display a gene dose-dependent effect of the embryopathic 
effects of ionizing radiation (Bhuller and Wells 2006). Further, somatic LOH in the ATM  
gene is likely to be present in mammary carcinoma, but germline missense mutations occur 
with similar frequencies, whether somatic LOH is present or not (Feng et al. 2003). Thus, 
Feng et al. (2003) have suggested that LOH as a second (somatic) hit might not be a crucial 
step, at least in mammary carcinoma. Alternative mechanisms to bi-allelic inactivation also 
comprise dominant-negative effect over the wild-type product. Reports have suggested that 
some heritable missense mutations in the A TM  gene could exhibit a dominant-negative effect 
over the wild-type protein product (Bakkenist and Kastan 2003; Gatti et al. 1999). Such 
germline mutations, displaying a dominant-negative effect could potentially explain the 
paucity of somatic mutations in the A TM  gene.
Even although there is some evidence that the A TM  and BRCA1 genes may display 
duality with respect to their tumour suppressor functions, additional evidence supports their 
role as true tumour suppressor genes. Thus, A TM  ' mice are viable, although with impaired 
cel 1-cycle arrest, increased chromosome breaks and are radiosensitive (Gurley and Kemp 
2001). In addition, A TM  haploinsufficiency has been shown to exhibit little or no effect on 
the somatic or germline mutation rates (expanded simple tandem repeats; ESTR) in mice, 
although it is difficult to extrapolate intra-genic mutation rates from ESTRs (Somers and 
Cooper 2009). Since mice heterozygous for either BRCA1 or ATM  do not show increased 
susceptibility to mammary tumour development (Karabinis et al. 2001), the second somatic
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hit could be loss-of-heterozygosity. Further, somatic LOH or somatic bi-allelic deletions of 
the BRCA1 gene have been shown in sebaceous gland carcinoma (Becker et al. 2008).
Further support for a tumour suppressor role for the A TM  and BRCA1 genes comes 
from the fact that the majority of germline mutations are truncating mutations (-74% and 
-73%  for the ATM  and BRCA1 genes respectively). Therefore, the majority of germline 
mutations are selected for their ‘loss-of-function effect’. Thus, it is likely that a second hit 
could comprise LOH, gross gene rearrangement or suppression of gene expression through 
promoter hypermethylation.
Duality o f tumour suppression and oncogenic functions are best exemplified by the 
mutational spectra in the TP53 gene. As mentioned earlier, the majority of lesions are 
missense mutations. Thus, the selection of mutations is not only towards loss-of-function 
mutations (e.g. deletions, insertions, indels and nonsense mutations), but also gain-of- 
function mutations. This is supported by studies that have suggested that the loss-of-function 
mutations might not give sufficient enough growth advantage over the cells, and gain-of- 
function mutations are required (reviewed in Brosh and Rotter 2009). Thus, 77\55-null mice 
have not shown an increased ability to form tumours (Brosh and Rotter 2009; Dittmer et al. 
1993; Shaulsky et al. 1991; Wolf et al. 1984).
The fact that -50%  of all the somatic mutations studied herein were TP53 mutations 
is likely to have influenced the overall result o f -55%  of the combined somatic mutations in 
all genes being truncating lesions (i.e. nonsense mutations, micro-deletions, micro-insertions 
and micro-indels). Thus, a significantly higher proportion of germline mutations (-80%) are 
truncating mutations as compared to somatic mutations (-55%). It seems that most of the 
germline mutations are selected for their negative impact on the function on the protein and 
somatic mutations to some extent are not selected against. In addition, when TP53 mutations 
are excluded, the proportion of somatic truncating mutations rises to -68%, as compared to 
-80%  for the germline mutations, but still significantly more germline truncating mutations 
were observed. As a consequence, the relatively high proportion of TP53 mutations that make 
up the somatic mutational spectrum have not skewed the overall results observed for the 
combined mutations for all genes. In addition, -39%  of all recurrent somatic micro-lesions 
combined for all genes are truncating mutations. When TP53 recurrent mutations were 
excluded, -77%  of the recurrent somatic mutations were truncating. Thus, for most genes, 
but with the exception of TP53, most of the somatic mutations that recur are selected for their 
negative impact on the function of the protein.
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It is well known that CpG dinucleotides are a mutational hotspot, mainly due to the 
spontaneous deamination of 5-methylcytosine (Pfeifer and Besaratinia 2009). In addition, 
estimates show that their hypermutability is 5 times the base mutation rate (Krawczak et al.
1998). Therefore, one would expect to observe a high proportion of CpG-located missense 
and nonsense mutations. Indeed, —7% and —9% of all missense and nonsense mutations 
respectively (combined for all genes) showed CpG-located mutations. It has to be said that 
not all CpG-located mutations are going to have the same impact on the function of the 
genes. It is likely that selection would also play an important part in the occurrence of CpG- 
located mutations. Both missense and nonsense germline mutations (combined for all genes) 
exhibited a relatively higher proportion of CpG-located mutations (-8%  and -7%  for 
germline missense and nonsense mutations respectively) as compared to somatic mutations 
(-5%  and <1% for the somatic missense and nonsense mutations). One explanation includes 
different methylation status o f CpG-dinucleotides in the germline and the soma.
Alternatively, in case o f similar methylation status, it is likely that selectional forces 
against CpG-located somatic mutations could have contributed to a lower proportion as 
compared to germline CpG-located mutations. This is further supported by the even lower 
proportion of recurrent somatic CpG-located missense mutations (-3%). Conversely, CpG- 
located recurrent nonsense mutations are selected for (-15%) as compared to exclusively 
somatic CpG-located nonsense mutations (<1%). In addition, mutability is likely to play 
equally important role in both the germline and the soma. This was supported by the 
observation that the highest proportion of CpG-located missense and nonsense mutations 
were found in shared mutations (-21%  and -37%  for the missense and nonsense mutations 
respectively), as compared to exclusively somatic and exclusively germline mutations.
Surprisingly, very few mutations were shared between the soma and the germline 
with respect to micro-deletions, micro-insertions and micro-indels. One potential explanation 
includes the fact that micro-lesions could occur throughout the gene sequence with varying 
lengths (0-20bp) of affected nucleotides. Therefore, the number of possible mutations is 
much greater for micro-lesions than for missense and nonsense mutations; hence the 
probability o f a micro-lesion to be found in both the soma and the germline is much lower 
than for shared missense and nonsense mutations.
Taking these results altogether, selection and mutability are the main forces that 
influence the mutational spectra in the germline and soma. As a result, some of the 
similarities, but also the differences between the germline and the somatic mutations are
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likely to be a result of differences or similarities in selection and/or mutability that operate on 
the mutational spectra in the 17 studied human tumour suppressor genes.
7.6. Contributions/Benefits of the PhD work with respect to cancer 
genetics
The presented herein PhD work is relevant to a number o f mainstream hypotheses or
ideas.
Some mutations are likely to confer relatively greater cellular growth and/or 
proliferative advantages, hence are more likely to contribute towards tumorigenesis, than 
others. As a result, mutations could be described as either being more likely to be ‘drivers’ of 
tumour development or more likely to be ‘passengers’ (Stratton et al. 2009). Thus, somatic 
cells could acquire ‘passenger’ mutations relatively early during clonal expansions that would 
then come to be present in a majority, or even all, cells in a tumour. Alternatively, cells that 
acquire ‘passenger’ mutations relatively late during clonal expansion, would display 
mosaicism when tumours are analysed. Most o f these mutations would not confer growth 
and/or a proliferative advantage over the cells harbouring them. Hence, it is very likely that 
they are neither selected for, nor against. Consequently, ‘passenger’ mutations are very likely 
to be randomly distributed along the sequence of the cancer genes. On the other hand,
‘driver’ mutations confer growth and/or a proliferative advantage during clonal expansion 
and as such are very likely to be selected for. Identifying such mutations plays "a central role 
of cancer genome analysis" (Stratton et al. 2009). As a consequence, a great deal of effort by 
the whole cancer genetics community has been put into distinguishing such ‘drivers’ from 
‘passenger’ mutations. Functional assays could help, by providing an insight into the 
functional consequences of a particular mutation, but are expensive (e.g. in terms of cost and 
labour) or do not exist for every mutation (Chan et al. 2007). As a consequence, a number of 
in silico algorithms have been designed, which are relatively inexpensive, to help to identify 
‘passenger’ from ‘drivers’ mutations. These algorithms involve a number of parameters, such 
as physicochemical difference between wild-type and mutant amino acids, evolutionary 
conservation of affected codons, etc.
Our analysis, using some of these parameters suggests that some mutations are indeed 
more likely to have greater functional consequences than others. Thus, shared missense 
mutations displayed relatively greater functional impact than either somatic or germline 
missense mutations. In addition, germline missense mutations were more likely to confer
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more severe functional consequences than somatic mutations. One could rank these classes of 
mutations, with respect to their functional importance during tumour development. Shared 
missense mutations are more likely to be ‘drivers’ of tumorigenesis than germline mutations, 
which in turn are more likely to be of functional importance than somatic missense 
mutations. These results are further supported by studies showing that some or most of the 
somatic micro-lesions found in cancer genes are indeed ‘passenger’ mutations (Greenman et 
al. 2007).
On the other hand, nonsense mutations are generally considered to be detrimental to 
the gene function. Our analysis suggests that some additional factors play a role in 
determining the impact of nonsense mutations and not all mutations will have a similar 
functional impact. Nonsense mediated mRNA decay could be attributed to one of these 
factors. In most cases, mRNAs harbouring a stop codon would be degraded and their 
consequence would be similar to a null allele. Nevertheless, some nonsense mutations could 
escape degradation (e.g. nonsense mutations in the last exon or in close proximity to the 
AUG initiation codon), leading to a truncated protein product. Furthermore, these truncated 
products in some instances could be functionally intact (assuming stable and functional 
mRNA). Indeed, such mutations have been shown for the RBI and BRCA1 genes (Buisson et 
al. 2006; Sanchez-Sanchez et al. 2007). In addition, it is likely that selection and functional 
characteristics o f individual genes (e.g. the position of p-catenin binding sites in the APC 
gene) could also play an important role in distinguishing the functional importance of 
nonsense mutations. Similar reasoning could be applied to the functional consequences of 
micro-lesions (i.e. deletions, insertions and indels), where a stop codon, on average -15 
codons following a frameshift, is the likely consequence (Itzkovitz and Alon 2007).
This PhD work is particularly timely with respect to the whole-genome sequencing of 
cancer genomes (Greenman et al. 2007; Stratton et al. 2009). Thus, special attention has to be 
attributed to some classes or types of mutations (e.g. shared mutations), as these would be 
more likely to be relevant in tumour development and/or progression than others, at least 
within tumour suppressor genes.
7.7. Shortcomings
With hindsight, some shortcomings of the work have become evident.
The power analysis for all tests performed suggested that some of the comparisons 
had insufficient statistical power to detect an experiment-wise significant result. For some of
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these tests, a relatively small effect size was noted (i.e. <0.1). For others, the effect size was 
relatively large, but due to the paucity of mutations the comparisons did not reach statistical 
significance. It has to be said that -50% of all somatic mutations were derived from the TP 5 3 
gene and the TP53 mutations comprised -25%  of all mutations for all genes. Therefore, with 
hindsight, the analyses performed in this PhD work should perhaps have been performed with 
a smaller number of genes, thereby reducing the number of tests performed. Such a scenario 
would have been more likely to yield greater statistical power; hence for some of the tests, 
conclusions could perhaps have been derived where it was not possible in this analysis. 
Nevertheless, the presented comparison of somatic and germline micro-lesions is the first of 
its kind and as such we could only make power calculations post hoc or retrospectively, 
rather than a priori. Thus, the power calculations and effect sizes could be used as a basis for 
future comparison of somatic and germline micro-lesions.
In Chapter 4, a number of parameters were used. These included Grantham 
physicochemical difference, disease and non-disease associated mutability rates and 
evolutionary conservation measures. The Grantham amino-acid difference, also known as the 
amino-acid physicochemical difference (Grantham 1974), is based on the difference of side- 
chain atomic composition, polarity and volume of two amino acids. Based only on a few 
parameters, the Grantham difference is likely to be an oversimplification. Indeed, other 
mathematically more complex scores have been created, such as MAPP (multivariate 
analysis of protein polymorphism; Stone and Sidow 2005) that combines amino-acid 
properties with multiple sequence alignments. Additionally, the AAindex database 
(http://www.genome.ip/dbget-bin/wvvw bfind?aaindex) has >500 indices that describe the 
individual amino acids (Kawashima et al. 2008). Thus, more accurate representation of 
amino-acid differences could be derived, although it would most likely involve 
mathematically and/or statistically more complicated calculations.
In a similar way to the Grantham difference, both the disease (Krawczak et al. 1998) 
and non-disease (Hess et al. 1994) associated nucleotide substitution rates used in the 
analysis of missense mutations are not likely to be completely accurate in representing the 
relative substitution rates. Some of the disease-associated single base-pair substitutions used 
by Krawczak et al. (1998) could be neutral or nearly neutral mutations with respect to 
functional/clinical importance. In addition, the non-disease associated substitution rates 
derived by Hess et al. (1994) were calculated using 311 aligned gene-pseudogene pairs of 
sequences. Sequence changes in pseudogene are commonly assumed to be biologically 
neutral. Nevertheless, some studies have suggested that some pseudogenes might be under
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some form of purifying selection; hence some of these pseudogenes could bear functional 
importance. Indeed, a pseudogene in mice (Oct4 pseudogene; Lin et al. 2007) has been 
shown to be functional (i.e. expressed as mRNA) and displays a function in stem cell 
regulation. Therefore, some of the sequence changes in the gene-pseudogene pairs used in the 
calculation of the non-disease nucleotide substitution rates could potentially harbour changes 
that are non-neutral and bear functioned importance or clinical relevance.
Only orthologous sequences from vertebrate species were used to derive evolutionary 
conservation estimates for every codon along the sequences of the 17 human tumour 
suppressor genes. Only sequences from vertebrate species were chosen to avoid amino-acid 
variation that could be correlated with functional differences of the associated products from 
relatively more phylogenetically distant species from humans (Miller and Kumar 2001).
Thus, limiting ourselves to vertebrate species could have introduced chance variation into the 
values for the evolutionary variation measure. As a consequence, some codons would appear 
as evolutionary conserved solely because of the limited number of sequences sampled. 
Calculations for the BRCA1 gene suggest that when 7 species were used (mammals through 
fish; Abkevich et al. 2004; Tavtigian et al. 2008), up to 1 in 4 o f the fully evolutionarily 
conserved positions may be invariant, simply due to chance.
The repetitive elements searched for in the extended cDNA sequences of the 17 
human tumour suppressor genes studied, were defined a priori based on existing evidence 
that showed that these were the most common sequence elements found in and around the 
breakpoints of, and most likely to mediate the occurrence of, micro-lesions. During the 
micro-lesion analysis, no micro-lesions were noted in any of the discovered C/G-quartets. It 
is quite likely that most of these C/G quartets do not play a major role in mediating the 
occurrence of at least the studied micro-lesions that is micro-deletions, micro-insertions and 
micro-indels. Further, it is likely some potential micro-lesions could be positioned in these 
C/G-quartets and be counted as within, or in the vicinity of, repeats; hence could have 
contributed towards the observed results. Nevertheless, if we had post factum  excluded those 
from the initial hypothesis and subsequently re-analysed the micro-lesions, it would have 
been tailoring the initial hypothesis according to the observed results. Therefore, those C/G- 
quartets were left in the group of repetitive elements studied, although it is likely that those 
could have slightly increased the proportion of potential micro-lesions found in or in the 
vicinity of repeats.
By analysing all repetitive elements and all observed micro-lesions in one 
homogenous sample, some important characteristics of specific sequence elements, such as
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mediating different type of micro-lesions, could have been missed. Thus, the different types 
of repetitive elements, that is direct, inverted and mirror repeats, could mediate and/or 
influence the occurrence of the different types of micro-lesions (i.e. micro-deletions, micro­
insertions and micro-indels) with a different propensity. However, splitting the repetitive 
elements and micro-lesions into their counterparts, and analysing them separately, would 
have introduced 9 times as many statistical tests (3 types of repeats times 3 types of micro­
lesions). This undoubtedly would have decreased the statistical power even further, although 
the effect sizes could well have been greater, thereby compensating for the increased number 
of statistical tests.
It has to be said that not all possible repetitive elements were analysed with respect to 
micro-lesions. It is possible that some other types of sequence elements are also likely to be 
involved in mediating the occurrence of micro-lesions. These sequence elements include di- 
and tri-nucleotide tandem repeats, various motifs (e.g. heptanucleotides CCCCCTG, 
TGRRKM, etc.), micro-indel hotspots (GTAAGT and its complement ACTTAC), etc. 
(Bacolla et al. 2004; Bacolla and Wells 2009; Ball et al. 2005; Cooper and Krawczak 1993; 
Wells 2007). As these sequence elements are not part of those most commonly found in or 
around breakpoints of micro-lesions, it is likely that their effect size is quite possibly smaller 
than the repetitive elements analysed here. Nevertheless, some of these elements could be 
involved in mediating the occurrence of micro-lesions.
With respect to the NMD analysis, the ‘55-nucleotide rule’ (Nagy and Maquat 1998) 
is quite possibly oversimplified and is not representative of the biological fate of some of the 
mRNAs harbouring nonsense mutations. Mechanisms, such as translational re-initiation 
(Sanchez-Sanchez et al. 2007), polar effect (Wang et al. 2002), failure to trigger NMD 
(Inacio et al. 2004), are very likely to have been missed, by using the ‘55-nucleotide rule’ 
(Nagy and Maquat 1998). It is of note that these mechanisms are very likely to be exceptions 
and have to be treated on an individual basis. Further, with advances in our understanding of 
NMD and similar mechanisms, a more complete picture is likely to emerge that will better 
describe the mechanisms that operate to influence the functionality of the protein products of 
genes harbouring premature stop codons.
7.8. Future work
Any study that sets out to compare mutational mechanisms underlying germline and 
somatic mutational spectra has to have a sufficient number of mutations. This PhD work was
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initiated at the end of 2005. Since then, numerous studies have reported additional mutations 
(both somatic and germline) that have been observed in tumour samples. As a consequence, 
any subsequent studies are likely to have increased statistical power (i.e. >80%) with which 
to derive relatively conclusive results. This applies especially to micro-lesions, that is micro­
deletions, micro-insertions and micro-indels.
Recent, along with past, research suggests that soma-germline mutational interplay 
(Campbell 2009; Lamlum et al. 1999; Vortmeyer et al. 2002) could well be more widespread 
than anticipated. Such intricate interplay happens within the individuals, hence mutational 
spectra that is derived from different tumours (i.e. within separate individuals) and normal 
cells/tissues, is only a proxy to the actual mechanisms that operate within the cells of 
individual people. Therefore, one way to investigate the actual relationships is to have 
matched mutational data (i.e. somatic and germline mutational data) from tumours and 
normal cells/tissues from the same individual. A variation of such matched mutational data 
also includes a somatic bi-allelic inactivation. This would allow a direct comparison between 
the germline and the soma, with respect to relative impact on gene/protein structure and/or 
function.
A different aspect of the functional impact o f somatic and germline mutations could 
involve secondary structure analysis of the affected protein products and mRNA. It is likely 
that different mutations would exhibit different effects on the secondary structure of proteins 
(Ng and Henikoff 2001; Wang and Moult 2001). Some amino-acids are crucial for the protein 
stability, such as ‘buried residues’ (Chen and Zhou 2005), whereas others, even large 
deletions, could be relatively tolerated within the protein (Khan and Vihinen 2007). Many of 
the proteins are fully functional in dimers or multimers, such as the TP53 gene (Webber et al. 
2009). Therefore, mutations in different positions would potentially have different functional 
consequences, with respect to protein folding and secondary structure.
Further to the secondary structure analysis, certain parts of the proteins (e.g. a-helices 
and p-sheets; Bhattachaijee and Biswas 2009) could be used to define clustering of 
mutations. Thus, mutations could be classified on their functional impact on the protein 
function, through disruption of secondary or tertiary structures.
Overall, the work presented herein has shown a glimpse of the similarities and 
differences between the germline and somatic mutational spectrum in the 17 human tumour 
suppressor genes studied. Some differences were found to be gene-specific, but some shared
226
by all genes. In addition, the similarities that were found are likely to reflect mutational 
mechanisms that are shared between the germline and the soma.
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Table 45 Summary of the mutations in the 17 human tumour suppressor genes studied
M atatieru
Mtmewe N a aim er M kre-dtltrteat
M kre-
iaaertieai
mmi--- -a a.lU K fM N M Tetal T ra  Beating
Nm Nm
T
SLl
N0
Nu
Nor
N„
T
Hjl
No
N„
Nor
No NjlT
Njl
No
Njl.
Nor
Ntt NjlT
Njl
No
Njl .
Not
Nm Nm
T
Nm
No
Njjl
Nor
No
N0
Nqt Nr
Nj.
No
Somatic 38 62 30 13 92 4 10 51 22 08 1868 5 51 137 31 42 50 18 14 79 44 2767 16 12 4 75 3 769 1 10 032 273 29 48 235 13 92
Germline 22 36 07 361 238 152 65 80 24 96 1641 284 65 14 46 63 3067 115 T i n 1888 12 42 36 9231 591 3 89 609 65 77 587 361
APC Shared 1 1 64 227 0 11 28 12 12 63 64 302 15 344 34 09 1 62 0 000 000 000 0 000 000 000 44 475 43 227
Recurrent 4 10 26 526 043 35 44 30 46 05 378 33 21 71 43 42 3 56 4 909 526 043 0 000 000 000 76 27.84 72 526
Total
( T ) 61 10000 659 659 231 10000 24 95 24 95 436 100 00 47 08 47 08 159 100 00 17 17 17 17 39 10000 421 421
926
IN") 865 6 59
Somatic 11 12 79 5500 3 23 4 506 20 00 1 17 4 3 17 20 00 1 17 1 278 500 029 0 000 000 000 20 5 87 9 5500
Germline 75 8721 23 58 21 99 72 91 14 22 64 21 11 122 96 83 38 36 3578 35 97 22 11 01 1026 14 10000 440 4 11 318 93 26 243 23 58
ATM Shared 0 000 000 000 3 3 80 100 00 088 0 000 000 000 0 000 000 000 0 000 000 000 3 0 88 3 000
Recurrent 1 909 10000 029 0 000 000 000 0 000 000 000 0 000 0.00 000 0 N/A 000 000 1 500 0 10000
Total
( T  ) 86 100 00 25 22 25 22 79 10000 23 17 23 17 126 100 00 36 95 36.95 36 100 00 1056 1056 14 100 00 4 11 4 11
341
( Ngr) 255 25 22
Somatic 5 2 86 29 41 075 3 242 1765 045 6 227 35 29 090 3 3 41 17 65 045 0 000 000 000 17 256 12 29 41
Germline 169 9657 26 66 2549 115 92 74 18 14 1735 255 96 59 40 22 3846 83 94.32 1309 1252 12 10000 1 89 1 81 634 95 63 465 26 66
BKCAl Shared 1 057 833 0 15 6 484 50 00 090 3 1 14 25 00 045 2 2.27 1667 030 0 000 000 000 12 181 11 833
Recurrent 0 000 000 0.00 0 0.00 0.00 000 2 22.22 100 00 0 30 0 000 000 000 0 (KDFV/O! 000 000 2 690 2 000
Total 
( T ) 175 100 00 26 40 26 40 124 100 00 18.70 18 70 264 10000 39.82 39 82 88 100.00 13 27 13.27 12 100 00 1 81 1 81
663 
( N or)
488 26.40
Somatic 20 1887 66 67 372 1 1 30 333 0.19 7 278 23.33 1 30 2 2 17 667 037 0 000 000 000 30 5.59 10 66 67
Germline 85 80 19 1690 15 83 76 98 70 15.11 14 15 244 96.83 4851 45.44 88 95 65 17.50 1639 10 100 00 1.99 1 86 503 93 67 418 16.90
BRCA2 Shared 1 094 25 00 0 19 0 0.00 000 000 1 0.40 25.00 0 19 2 2.17 50.00 037 0 000 000 000 4 0 74 3 25 00
Recurrent 2 9 52 66.67 037 0 0.00 0.00 0.00 1 12.50 33.33 0 19 0 0.00 000 0.00 0 N/A 000 0.00 3 882 1 66.67
Total
( T ) 106 100 00 19.74 1974 77 10000 14.34 1434 252 100 00 46.93 46.93 92 100.00 17.13 17 13 10 100.00 1 86 1.86
537
( N m ) 431 19.74
Somatic 14 42.42 41 18 16.47 5 31 25 14.71 588 13 52.00 3824 15.29 2 20.00 588 2.35 0 0.00 0.00 0.00 34 40.00 20 41.18
Germline 18 54 55 37.50 21 18 9 56.25 1875 1059 12 48.00 25.00 14.12 8 80.00 16.67 9 41 1 100.00 2.08 1 18 48 56.47 30 37.50
CD HI Shared 1 3 03 33.33 1 18 2 12.50 66.67 2.35 0 0.00 0.00 0.00 0 0.00 0.00 0.00 0 000 0.00 000 3 3.53 2 33.33
Recurrent 0 0.00 N/A 0.00 0 0.00 N/A 0.00 0 0.00 N/A 0.00 0 0.00 N/A 000 0 N/A N/A 000 0 0.00 0 N/A
Total
( T ) 33 10000 3882 3882 16 100.00 18.82 1882 25 100.00 29.41 29.41 10 100.00 11.76 11 76 1 100.00 1.18 1.18
85
(AU) 52 38.82
CDKN2A Somatic 170 73.28 5842 44.74 13 65.00 4.47 3.42 76 87.36 26.12 20.00 24 77.42 8.25 6.32 8 80 00 2.75 2 11 291 76.58 121 58.42
228
Gennlioe 34 14 66 62 96 8 95 2 10 00 3 70 0 53 10 II 49 18 52 263 6 19 35 1111 I 58 2 20 00 3 70 0 53 54 1421 20 62 96
Shared 28 12 07 80 00 737 5 25 00 14 29 1 32 1 1 15 286 026 1 3 23 286 026 0 000 000 000 35 921 7 80 00
Recurrent 6 3 03 28 57 1 58 3 16 67 14 29 079 9 11 69 42 86 2 37 3 1200 1429 079 0 000 000 000 21 644 15 28 57
Total
( T  ) 232 10000 61 05 61 05 20 100 00 526 526 87 10000 22 89 22 89 31 100 00 8 16 8 16 10 10000 2 63 2 63
380
( Nor )
148 61 05
Somatic 2 235 909 036 4 336 18 18 072 13 556 5909 235 3 2 78 1364 054 0 000 000 000 22 3 97 20 909
Germline S3 97 65 1599 14 98 105 88 24 20 23 1895 218 93 16 4200 3935 105 97 22 20 23 18 95 8 10000 1 54 1 44 519 93 68 436 1599
NFl Shared 0 000 000 000 10 840 76 92 1 81 3 1 28 23 08 054 0 000 000 000 0 000 000 000 13 235 13 000
Recurrent 0 000 000 000 0 000 000 000 1 625 10000 018 0 000 000 000 0 N/A 000 000 1 286 1 000
Total
( T  ) 8$ 10000 1534 15 34 119 10000 21 48 21 48 234 100 00 4224 4224 108 100 00 1949 1949 8 10000 I 44 1 44
554
(* < * )
469 1534
Somatic 23 5349 895 5 85 24 35 82 934 6 11 176 76 19 68 48 44 78 28 63 64 10 89 7 12 6 75 00 233 1 53 257 65 39 234 895
Gennlioe 20 46 51 17 70 509 25 37 31 22 12 6 36 50 21 65 44 25 1272 16 36 36 14 16 407 2 25 00 1 77 051 113 28 75 93 17 70
NF2 Shared 0 000 000 000 18 26 87 78 26 4 58 5 2 16 21 74 1 27 0 000 000 000 0 000 000 000 23 5 85 23 000
Recurrent 3 13 04 968 0 76 18 4286 58 06 458 8 442 25 81 204 2 7 14 645 051 0 000 000 000 31 11.07 28 968
Total
( T  ) 43 10000 1094 1094 67 100 00 17 05 17 05 231 10000 58 78 5878 44 100 00 11 20 11.20 8 10000 204 204
393 
( N ot )
350 1094
Somatic 13 35 14 31 71 747 7 20 59 17 07 402 14 25 00 34 15 805 6 15 79 1463 345 1 11 11 244 057 41 23 56 28 31 71
Gennlioe 23 62 16 1769 13 22 25 73 53 1923 1437 42 75 00 32 31 24 14 32 84 21 24 62 1839 8 88 89 6 15 460 130 74 71 107 17 69
PTCH Shared 1 270 33 33 057 2 588 6667 115 0 000 000 000 0 000 000 000 0 0.00 000 0.00 3 1 72 2 33 33
Recurrent 0 000 N/A 000 0 000 N/A 000 0 0.00 N/A 000 0 0.00 N/A 000 0 000 N/A 000 0 000 0 N/A
Total
( T ) 37 10000 21 26 21 26 34 100.00 1954 1954 56 10000 32 18 32.18 38 100.00 21 84 21 84 9 10000 5 17 5.17
174 
( N or )
137 21 26
Somatic 201 81 71 4568 3545 43 60.56 977 758 145 83.33 32.95 25.57 47 68 12 10.68 829 4 57 14 091 071 440 77 60 239 45 68
Germline 23 935 28 05 406 15 21 13 1829 265 23 13 22 28.05 4.06 18 26 09 21 95 3 17 3 4286 366 0.53 82 14.46 59 28.05
PTEN Shared 22 8.94 48 89 3.88 13 1831 28 89 2.29 6 3.45 1333 1.06 4 5 80 889 071 0 000 000 0.00 45 794 23 48 89
Recurrent 47 21 08 3701 8.29 19 33 93 1496 335 45 29 80 35.43 7.94 16 31.37 12.60 2 82 0 0.00 000 0.00 127 26.19 80 37.01
Total
(T  ) 246 10000 43 39 43 39 71 10000 12.52 1252 174 10000 30.69 30 69 69 100.00 12 17 12 17 7 10000 1 23 1.23
567
321 43.39
Somatic 22 37 29 28 21 593 12 13 64 1538 3.23 30 20.55 38.46 809 12 18.46 15.38 323 2 15 38 256 054 78 21.02 56 28.21
Germline 34 57 63 12 59 9.16 61 6932 22.59 16.44 112 76.71 41.48 30.19 53 81.54 19.63 1429 10 76.92 3.70 2.70 270 72.78 236 12.59
RBI Shared 3 508 1304 0.81 15 17.05 65.22 4.04 4 2.74 17.39 1.08 0 0.00 0.00 0.00 1 7.69 435 0.27 23 6.20 20 13.04
Recurrent 1 4.00 833 0.27 9 33.33 75.00 243 2 588 16.67 0 54 0 0.00 0.00 000 0 0.00 000 0.00 12 11.88 11 8.33
Total
( T ) 59 10000 15.90 15.90 88 10000 23.72 23 72 146 100.00 39.35 39.35 65 100.00 17.52 17 52 13 10000 3 50 3 50
371
( N „ ) 312 15.90
STK11 Somatic 17 36.17 6071 1069 7 20.59 25.00 4.40 3 6.00 10.71 1.89 1 4.00 3.57 0.63 0 0.00 0.00 0.00 28 17.61 11 60 71
229
Germline 27 57 4$ 22 13 16 98 24 70 59 19 67 1509 45 90 00 36 89 28 30 24 96 00 19 67 1509 2 66 67 1 64 1 26 122 76 73 95 22 13
Shved 3 6 38 33 33 1 89 3 882 33 33 1 89 2 4 00 22 22 1 26 0 000 000 000 1 33 33 11 11 0 63 9 566 6 33 33
Recurrent 2 10 00 50 00 1 26 1 1000 25 00 0 63 1 20 00 25 00 0 63 0 000 000 000 0 N/A 000 000 4 1081 2 50 00
Total 
(7- ) 47 100 00 29 56 29 56 34 10000 21 38 21 38 50 10000 31 45 3145 2$ 100 00 15 72 15 72 3 100 00 1 89 1 89
159
( Nf f f ) 112 29 56
Somatic 1138 92 37 $7 97 54 37 87 89 69 443 4 16 504 96 92 25 67 24 08 234 97 10 11 92 11 IS 0 000 000 000 1963 93 79 825 $7 97
Germline 6 0 49 28 57 029 1 103 4 76 005 8 1 54 38 10 038 3 1 24 14 29 0 14 3 10000 1429 0 14 21 1 00 15 28 57
TPSJ Shved n 7 14 80 73 420 9 928 826 0 43 8 1 54 7 34 0 38 4 166 3 67 0 19 0 000 000 000 109 521 21 80 73
Recurrent 781 63 70 71 98 37 31 85 88 54 783 406 162 31 64 1493 774 57 23 95 525 272 0 N/A 000 000 1085 52 36 304 71 98
Total
( T ) 1232 100 00 58 86 5886 97 10000 463 4 63 520 10000 24 84 24 84 241 100 00 II 51 11 51 3 100 00 014 0 14
2093
( Nor )
861 5886
Somatic 2 22 22 50 00 1 54 1 2 63 25 00 077 1 1 85 25 00 0 77 0 000 000 000 0 000 000 000 4 3 08 2 50 00
Gennlioe 7 77 78 5 56 5 38 37 97 37 29 37 28 46 53 98 15 4206 40 77 2$ 100 00 1984 19 23 4 10000 3 17 3 08 126 96 92 119 556
TSCI Shared 0 000 N/A 000 0 000 N/A 000 0 000 N/A 000 0 000 N/A 000 0 000 N/A 000 0 000 0 N/A
Recurrent 0 000 N/A 000 0 000 N/A 000 0 000 N/A 000 0 N/A N/A 000 0 N/A N/A 000 0 000 0 N/A
Total
( T ) 9 100 00 692 692 38 10000 29 23 29 23 54 100 00 41.54 41 54 25 100 00 19 23 1923 4 10000 308 3 08
130
( N ot)
121 692
Somatic 0 000 000 000 0 000 000 000 3 265 50 00 091 2 4 17 33 33 061 1 25 00 1667 0 30 6 1 83 6 000
Gennlioe 87 97 75 27.27 2652 73 98 65 22 88 22 26 110 9735 34 48 33 54 46 95 83 1442 1402 3 75 00 094 091 319 97 26 232 27 27
TSC2 Shved 2 225 66 67 061 1 1 35 33 33 030 0 000 000 000 0 000 000 000 0 000 000 000 3 091 1 66 67
Recurrent 0 N/A N/A 000 0 N/A N/A 000 0 000 N/A 000 0 000 N/A 000 0 000 N/A 000 0 000 0 N/A
Total
( T ) 89 10000 27 13 27 13 74 10000 22 56 22 56 113 10000 3445 34.45 48 100.00 1463 14 63 4 100.00 1 22 1 22
328 
( Not )
239 27 13
Somatic 43 23 12 1673 808 4 12.90 1.56 075 171 73 08 66.54 32 14 38 50.67 14.79 7 14 1 1667 039 019 257 48.31 214 16 73
Gennlioe 98 5269 47 80 1842 16 5161 780 301 55 23 50 26 83 10.34 31 41.33 15 12 583 5 8333 244 094 205 3853 107 47.80
VHL Shared 45 24 19 64 29 846 11 3548 1571 207 8 3 42 11 43 1.50 6 8.00 8 57 1.13 0 000 000 000 70 13 16 25 64 29
Recurrent 5 012 20 00 094 4 1 00 1600 0.75 14 008 56.00 2.63 2 0.05 8.00 0.38 0 000 000 000 25 9.73 20 20.00
Total
( T ) 186 10000 34 96 34.96 31 10000 583 583 234 10000 43 98 43.98 75 100.00 14 10 14 10 6 10000 1 13 113
532
( N ot)
346 34 96
Somatic 1 2.50 12 50 1 35 0 000 0.00 0.00 4 33.33 50 00 5.41 3 42.86 37 50 4.05 0 000 0.00 000 8 10.81 7 12.50
Gennlioe 39 97 50 61 90 52.70 11 78.57 17.46 1486 8 66.67 12.70 10.81 4 57.14 6.35 541 1 10000 1 59 1 35 63 85 14 24 61 90
WT1 Shared 0 000 000 000 3 2143 100.00 405 0 0.00 0.00 0.00 0 0.00 000 0.00 0 000 0.00 000 3 4.05 3 0.00
Recurrent 0 000 N/A 0.00 0 N/A N/A 0.00 0 0.00 N/A 0.00 0 0.00 N/A 0.00 0 N/A N/A 000 0 0.00 0 N/A
Total
( T  ) 40 100.00 54.05 54.05 14 10000 18.92 18.92 12 100.00 16.22 16.22 7 100.00 9.46 9.46 1 100.00 1 35 1 35
74
( N ot)
34 54.05
ALL Somatic 1720 62.18 45 55 20 69 273 22 36 7.23 3.28 1307 43.36 3461 15.72 450 38.76 11 92 541 26 17 11 0.69 0.31 3776 45.42 2056 45.55
230
GermliDe 850 JO 73 20 55 10 22 819 67 08 19 80 9 85 1651 54 78 39 92 1986 692 59 60 16 73 8 32 124 81 58 300 1 49 4136 49 75 3286 2055
Shared 1% 709 48 76 2 36 129 10 57 3209 1 55 56 1 86 13 93 0 67 19 1 64 4 73 0 23 2 I 32 050 0 02 402 484 206 48 76
Recurrent 852 44 47 61 38 1025 174 43 28 12 54 209 278 20 40 20 03 3 34 84 1791 605 1 01 0 000 000 000 1388 33 22 536 61 38
Total
( T ) 2766 10000 33 27 33 27 1221 100 00 1469 1469 3014 100 00 3625 36 25 1161 100 00 1396 13% 152 10000 1 83 1 83
8314
( N, „ ) 5548 33 27
/D-micro-indels, O-sum of somatic, germline, shared or recurrent, GT -grand total 
T -total (somatic, germline and shared)
All calculations for recurrent mutations are with respect to the numbers of somatic and shared mutations
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Table 46 Summary of the CpG-located missense and nonsense mutations in the 17
human tumour suppressor genes studied_____________________________________
M im n»t
N„
Miwenie within CpG- 
diandeotidei
NucrQ NucfcNu
Nonsense N onsense within C'pG-dinucleotide*
NsCfG Nmqo
Somatic 38 1 263 51 0 0.00
Germline 22 3 1364 152 8 5 26
APC Shared 1 0 000 28 8 28 57
Recurrent 4 0 000 35 6 17.14
Total ( T  ) 61 4 6 56 231 16 693
Somatic 11 1 909 4 0 0.00
Germline 75 6 800 72 16 22.22
ATM Shared 0 0 N/A 3 2 66.67
Recurrent 1 1 100 00 0 0 N/A
Total ( T  ) 86 7 8 14 79 18 22.78
Somatic 5 0 0.00 3 0 0.00
Germline 169 9 5 33 115 3 2.61
BRCAI Shared 1 0 0.00 6 1 1667
Recurrent 0 0 N/A 0 0 N/A
Total ( T  ) 175 9 5 14 124 4 3.23
Somatic 20 2 10.00 1 0 0.00
Germline 85 9 10 59 76 4 5.26
BMCA2 Shared 1 1 100.00 0 0 N/A
Recurrent 2 0 000 0 0 N/A
Total ( T  ) 106 12 11.32 77 4 5 19
Somatic 14 1 7.14 5 0 0.00
Germline 18 4 22.22 9 2 22.22
CDH1 Shared 1 0 000 2 1 50 00
Recurrent 0 0 N/A 0 0 N/A
Total ( T  ) 33 5 15 15 16 3 1875
Somatic 170 26 1529 13 0 0 00
Germline 34 2 5 88 2 0 0.00
CDXN2A Shared 28 7 25 00 5 2 40 00
Recurrent 6 0 000 3 1 33.33
Total ( T  ) 232 35 1509 20 2 10.00
Somatic 2 0 0.00 4 0 0.00
Germline 83 4 4 82 105 9 8 57
NF1 Shared 0 0 N/A 10 9 90.00
Recurrent 0 0 N/A 0 0 N/A
Total ( T  ) 85 4 471 119 18 15 13
Somatic 23 2 8 70 24 0 000
Germline 20 2 1000 25 0 0 00
SF2 Shared 0 0 N/A 18 6 33 33
Recurrent 3 1 33 33 18 6 33.33
Total (T  ) 43 4 930 67 6 8.96
Somatic 13 2 15 38 7 1 14.29
Germline 23 2 8 70 25 2 800
PTCH Shared 1 0 000 2 0 0.00
Recurrent 0 0 N/A 0 0 N/A
Total ( T  ) 37 4 10.81 34 3 8 82
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Somatic 201 4 1 99 43 0 0.00
Germline 23 1 4.35 15 0 0.00
PTEN Shared 22 3 13 64 13 3 23.08
Recurrent 47 3 638 19 3 15.79
Total ( T  ) 246 8 3.25 71 3 4.23
Somatic 22 3 1364 12 0 0.00
Germline 34 2 5 88 61 4 6.56
RBI Shared 3 1 33 33 15 7 46.67
Recurrent 1 0 000 9 5 55 56
Total ( T  ) 59 6 10 17 88 11 12 50
Somatic 17 4 23 53 7 0 0.00
Germline 27 2 741 24 1 4 17
STK ll Shared 3 1 33.33 3 0 000
Recurrent 2 1 50 00 1 0 0.00
Total (7* ) 47 7 1489 34 1 2.94
Somatic 1138 30 264 87 0 0.00
Germline 6 0 000 1 0 00 0
TPS3 Shared 88 20 22.73 9 4 44 44
Recurrent 781 23 294 85 4 4.71
Total ( T  ) 1232 50 406 97 4 4 12
Somatic 2 0 000 1 0 0.00
Germline 7 1 14.29 37 6 16.22
TSC1 Shared 0 0 N/A 0 0 N/A
Recurrent 0 0 N/A 0 0 N/A
Total ( T  ) 9 I t i l l 38 6 15.79
Somatic 0 0 N/A 0 0 N/A
Germline 87 13 1494 73 6 8.22
TSC3 Shared 2 2 100 00 1 0 0.00
Recurrent 0 0 N/A 0 0 N/A
Total ( T  ) 89 15 16.85 74 6 8 11
Somatic 43 4 930 4 0 0.00
Germline 98 2 2.04 16 0 000
VKL Shared 45 6 13 33 11 2 18.18
Recurrent 5 0 0.00 4 1 25 00
Total ( T  ) 186 12 645 31 2 6.45
Somatic 1 0 0 00 0 0 N/A
Germline 39 7 1795 11 0 0 00
WT1 Shared 0 0 N/A 3 3 100.00
Recurrent 0 0 N/A 0 0 N/A
Total ( T  ) 40 7 17 50 14 3 21 43
Somatic 1720 80 465 273 1 0.37
Germline 850 69 8 12 819 61 7.45
ALL Shared 196 41 20 92 129 48 37.21
Recurrent 852 29 3 40 174 26 14.94
Total ( T  ) 2766 190 687 1221 110 9.01
iC pG  is the number o f CpG-located mutations, where i and A/-missense, N  -nonsense
T -total (somatic, germline and shared)
All calculations for recurrent mutations are with respect to numbers o f somatic and shared mutations
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